Nivolumab Clinical Trials (2026): 1,624 Studies for Melanoma & Metastatic Melanoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1,624 Nivolumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 718 indications (including Melanoma & Metastatic Melanoma) and 236,575 total planned enrollment. 137 Phase 3 Nivolumab trials and 732 Phase 2, 15 Phase 4 are listed. 291 Nivolumab clinical trials are actively recruiting at 4,858 U.S. sites across 51 states. Most recent activity: NCT05732389 (Feb 2052).
Where to Participate: All Nivolumab Trial Sites in the U.S. (4,858 sites across 51 states)
Every actively recruiting Nivolumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT04546399 | Map |
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT05675410 | Map |
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT06064097 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06364917 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06618287 | Map |
| AL | University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) | Birmingham35294-3300 | NCT07246863 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05112601 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT04511013 | Map |
| AL | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham35294 | NCT02693535 | Map |
| AL | Southern Cancer Center, PC | Daphne36526 | NCT06646276 | Map |
| AL | Thomas Hospital | Fairhope36532 | NCT04511013 | Map |
| AL | Mobile Infirmary Medical Center | Mobile36607 | NCT04511013 | Map |
| AL | USA Health Strada Patient Care Center | Mobile36604 | NCT04546399 | Map |
| AL | USA Health Strada Patient Care Center | Mobile36604 | NCT05675410 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT05647265 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT05677490 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT05647265 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT05677490 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05647265 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05677490 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT04511013 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT05647265 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT05677490 | Map |
| AK | Anchorage Oncology Centre | Anchorage99508 | NCT04511013 | Map |
| AK | Anchorage Radiation Therapy Center | Anchorage99504 | NCT04511013 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT04511013 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT05647265 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT05677490 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT04511013 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05647265 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05675410 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05677490 | Map |
| AK | Fairbanks Memorial Hospital | Fairbanks99701 | NCT04511013 | Map |
| AZ | Pioneer Research Center, LLC | Bullhead City86442 | NCT06463665 | Map |
| AZ | Ironwood Cancer & Research Centers | Chandler85224 | NCT06246916 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05266612 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT06246916 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT06264180 | Map |
| AZ | CTCA at Western Regional Medical Center | Goodyear85338 | NCT05675410 | Map |
| AZ | I-Mab Site 1016 | Goodyear85338 | NCT07432295 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05647265 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05677490 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT04546399 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT05675410 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT05987241 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT06632327 | Map |
| AZ | Cancer Treatment Centers of America-Phoenix | Phoenix85338 | NCT02693535 | Map |
| AZ | Exelixis Clinical Site #67 | Phoenix85054 | NCT05176483 | Map |
| AZ | Mayo Clinic | Phoenix85054 | NCT05223816 | Map |
| AZ | Mayo Clinic | Phoenix85054 | NCT05919264 | Map |
| AZ | Mayo Clinic | Phoenix85054 | NCT06743126 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05136196 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT03866382 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05647265 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05987241 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT06632327 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT04546399 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT05675410 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT06064097 | Map |
| AZ | Honor Health | Scottsdale85258 | NCT05919264 | Map |
| AZ | Honor Health Research Institute | Scottsdale85258 | NCT06743126 | Map |
| AZ | HonorHealth Research Insisute | Scottsdale85258 | NCT06581406 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT03866382 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT03017820 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT05647265 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT07226856 | Map |
| AZ | Arizona Cancer Center at University of Arizona | Tucson85719 | NCT05919264 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT04546399 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT05987241 | Map |
| AZ | Exelixis Clinical Site #1 | Tucson85711 | NCT05176483 | Map |
| AZ | Southern Arizona VA Health Care System | Tucson85723 | NCT06561386 | Map |
| AZ | University of Arizona | Tucson85720 | NCT06112314 | Map |
| AZ | University of Arizona Cancer Center | Tucson85719 | NCT05901285 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT05987241 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT05987241 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT07383441 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT04511013 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT05677490 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT06632327 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT06632327 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT07383441 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT04546399 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT05675410 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT06064097 | Map |
| AR | Baptist Health Medical Center - Little Rock | Little Rock72205 | NCT06203600 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT05677490 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT06632327 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05136196 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05327686 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06203600 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06246916 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT05987241 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT07383441 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT05987241 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT07383441 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT04546399 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT05987241 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT06203600 | Map |
| CA | Kaiser Permanente-Deer Valley Medical Center | Antioch94531 | NCT05677490 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT06632327 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05327686 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05647265 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05677490 | Map |
| CA | Sutter Auburn | Auburn95602 | NCT02693535 | Map |
| CA | Sutter Auburn Faith Hospital | Auburn95602 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT05677490 | Map |
| CA | Kaiser Permanente - Baldwin Park | Baldwin Park91706 | NCT06534983 | Map |
| CA | Kaiser Permanente-Baldwin Park | Baldwin Park91706 | NCT05987241 | Map |
| CA | Kaiser Permanente-Baldwin Park | Baldwin Park91706 | NCT06203600 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT05987241 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT06203600 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT05677490 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT07166406 | Map |
| CA | Sutter Alta Bates | Berkeley94705 | NCT02693535 | Map |
| CA | Precision NextGen Oncology | Beverly Hills90212 | NCT06047379 | Map |
| CA | Tower Cancer Research Foundation | Beverly Hills90211 | NCT05136196 | Map |
| CA | Tower Cancer Research Foundation | Beverly Hills90211 | NCT06203600 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT04511013 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT05647265 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT05677490 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT05327686 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT07166406 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT05675410 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT06632327 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT05675410 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT06632327 | Map |
| CA | Eden Hospital Medical Center | Castro Valley94546 | NCT05677490 | Map |
| CA | Enloe Medical Center | Chico95926 | NCT06632327 | Map |
| CA | City of Hope Corona | Corona92882 | NCT05675410 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT05675410 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT05677490 | Map |
| CA | Sutter Davis Hospital | Davis95616 | NCT05677490 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT04546399 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT05675410 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT06064097 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT05272384 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT05675410 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT04561206 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06399419 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07128680 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT05361720 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT06743126 | Map |
| CA | I-MAB Site 1005 | Duarte91010 | NCT07432295 | Map |
| CA | Epic Care-Dublin | Dublin94568 | NCT04511013 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT05675410 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT05677490 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT05987241 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT06029270 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT06203600 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT05675410 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT06632327 | Map |
| CA | Bay Area Breast Surgeons Inc | Emeryville94608 | NCT04511013 | Map |
| CA | Epic Care Partners in Cancer Care | Emeryville94608 | NCT04511013 | Map |
| CA | UC San Diego Health System - Encinitas | Encinitas92024 | NCT05327686 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT04546399 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT05987241 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT06203600 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT05675410 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT05677490 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT05987241 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT06029270 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT06203600 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT07166406 | Map |
| CA | ClinRé 001-022 (Premier Cancer Care and Infusion Center) | Fresno93710 | NCT07195695 | Map |
| CA | Fresno Cancer Center | Fresno93720 | NCT05677490 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT05677490 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT05987241 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT06029270 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT06203600 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT05675410 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT05677490 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT05987241 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT06029270 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT06203600 | Map |
| CA | Providence Medical Foundation | Fullerton92835 | NCT06246916 | Map |
| CA | OPN Healthcare, Inc | Glendale91203 | NCT06047379 | Map |
| CA | OPN Healthcare, Inc. | Glendale91203 | NCT07195695 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT05987241 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT06203600 | Map |
| CA | City of Hope Seacliff | Huntington Beach92648 | NCT05675410 | Map |
| CA | City of Hope | Irvine92618 | NCT06053658 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT05675410 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT05987241 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT06203600 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05136196 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05327686 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05675410 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05677490 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT07166406 | Map |
| CA | University of California, Irvine | Irvine92868 | NCT06624475 | Map |
| CA | University of California, Irvine (UCI) Health - UC Irvine Medical Center | Irvine92612 | NCT06697197 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05327686 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92037 | NCT06581406 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05647265 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05896839 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05987241 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06203600 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92037 | NCT06264180 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06632327 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06743126 | Map |
| CA | University of California - San Diego | La Jolla92093-0698 | NCT06112314 | Map |
| CA | University of California San Diego | La Jolla92093 | NCT05502315 | Map |
| CA | University of California San Diego | La Jolla92093 | NCT06863311 | Map |
| CA | University of California, San Diego Moores Cancer Center | La Jolla92093 | NCT06624475 | Map |
| CA | City of Hope Antelope Valley | Lancaster93534 | NCT05675410 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT04546399 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT05675410 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT06064097 | Map |
| CA | City of Hope at Long Beach Elm | Long Beach90813 | NCT05675410 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT04546399 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT05675410 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT06246916 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT04609046 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05136196 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT04546399 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05675410 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06203600 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT04546399 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT05675410 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT06064097 | Map |
| CA | ESC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06112314 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT05987241 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT06203600 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT05987241 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT06203600 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT03866382 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05677490 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05896839 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT06029270 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT06203600 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05327686 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05677490 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05896839 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT06029270 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT06203600 | Map |
| CA | Mattel Children's Hospital UCLA | Los Angeles90095 | NCT04546399 | Map |
| CA | Site 03 | Los Angeles90025 | NCT07276373 | Map |
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT06581406 | Map |
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT05533697 | Map |
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT06264180 | Map |
| CA | The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles90025 | NCT05136196 | Map |
| CA | The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles90025 | NCT06697197 | Map |
| CA | The Angeles Clinic and Research Institute- West Los Angeles | Los Angeles90025 | NCT06112314 | Map |
| CA | The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles90025 | NCT02693535 | Map |
| CA | The Angeles Clinic at Cedars Sinai | Los Angeles90025 | NCT05428007 | Map |
| CA | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles90095 | NCT04511013 | Map |
| CA | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles90095 | NCT05987241 | Map |
| CA | UCLA Department of Medicine - Hematology/Oncology | Los Angeles90095 | NCT06264180 | Map |
| CA | UCLA Hematology/Oncology | Los Angeles90095 | NCT06112314 | Map |
| CA | UCLA Hematology/Oncology | Los Angeles90024 | NCT06743126 | Map |
| CA | University of California Los Angeles | Los Angeles90095 | NCT06581406 | Map |
| CA | University of California Los Angeles | Los Angeles90024 | NCT06246916 | Map |
| CA | University of California, Los Angeles (UCLA) | Los Angeles90095 | NCT05919264 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT06047379 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05327686 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05677490 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05896839 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06029270 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06203600 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06264180 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT07246863 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT04546399 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT06064097 | Map |
| CA | Contra Costa Regional Medical Center | Martinez94553-3156 | NCT04511013 | Map |
| CA | Fremont - Rideout Cancer Center | Marysville95901 | NCT06632327 | Map |
| CA | Mercy Cancer Center | Merced95340 | NCT06632327 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT05677490 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT05987241 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT06029270 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT06203600 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT05675410 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT05677490 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT05987241 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT06029270 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT06203600 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT05327686 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT07166406 | Map |
| CA | Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View94040 | NCT05677490 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT04511013 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT05647265 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT05677490 | Map |
| CA | City of Hope Newport Beach | Newport Beach92660 | NCT05675410 | Map |
| CA | USC Newport Beach | Newport Beach92663 | NCT06624644 | Map |
| CA | USC Norris Oncology/Hematology-Newport Beach | Newport Beach92663 | NCT05677490 | Map |
| CA | USC Norris Oncology/Hematology-Newport Beach | Newport Beach92663 | NCT06029270 | Map |
| CA | USC Norris Oncology/Hematology-Newport Beach | Newport Beach92663 | NCT06203600 | Map |
| CA | Sutter Cancer Research Consortium | Novato94945 | NCT05677490 | Map |
| CA | Bay Area Tumor Institute | Oakland94609 | NCT04511013 | Map |
| CA | Kaiser Permanente - Oakland Medical Center | Oakland94611 | NCT02693535 | Map |
| CA | Kaiser Permanente Oakland-Broadway | Oakland94611 | NCT05677490 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT04546399 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT05675410 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT05677490 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT05987241 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06029270 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06064097 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06203600 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT06064097 | Map |
| CA | Kaiser Permanente-Ontario | Ontario91761 | NCT05987241 | Map |
| CA | Kaiser Permanente-Ontario | Ontario91761 | NCT06203600 | Map |
| CA | Chao Family Comprehensive Cancer Center | Orange92868 | NCT05361720 | Map |
| CA | Chao Family Comprehensive Cancer Center, University | Orange92868 | NCT05733689 | Map |
| CA | Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange92868 | NCT04472767 | Map |
| CA | Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange92868 | NCT06682728 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT04546399 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT05675410 | Map |
| CA | St. Joseph Hospital Orange | Orange92868 | NCT06246916 | Map |
| CA | Stern Center for Cancer Clinical Trials and Research | Orange92868 | NCT04900818 | Map |
| CA | UC Irvine Health, Chao Family Comprehensive Cancer Center | Orange92868 | NCT06264180 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05136196 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05327686 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05675410 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05677490 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT07166406 | Map |
| CA | University of California Irvine | Orange92868 | NCT05655312 | Map |
| CA | University of California Irvine, UCI Medical Center | Orange92868 | NCT06246916 | Map |
| CA | University of California, Irvine | Orange92868 | NCT03259867 | Map |
| CA | University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange92868 | NCT07221149 | Map |
| CA | Exelixis Clinical Site #123 | Palo Alto94304 | NCT05176483 | Map |
| CA | Lucile Packard Children's Hospital Stanford University | Palo Alto94304 | NCT04546399 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT07166406 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304 | NCT06581406 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304 | NCT06264180 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT05987241 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT06029270 | Map |
| CA | Stanford Cancer Institute, Stanford University | Palo Alto94304 | NCT05919264 | Map |
| CA | Stanford University | Palo Alto94304 | NCT06712927 | Map |
| CA | Sutter Palo Alto Medical Foundation: Palo Alto | Palo Alto94301 | NCT02693535 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT05987241 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT06203600 | Map |
| CA | Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova95670 | NCT05677490 | Map |
| CA | Eisenhower Medical Center | Rancho Mirage92270 | NCT05677490 | Map |
| CA | Emad Ibrahim, MD, Inc. | Redlands92373 | NCT06246916 | Map |
| CA | Kaiser Permanente- Marshall Medical Offices | Redwood City94063 | NCT05677490 | Map |
| CA | Kaiser Permanente-Richmond | Richmond94801 | NCT05677490 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT05987241 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT06203600 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT05675410 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT06632327 | Map |
| CA | Rohnert Park Cancer Center | Rohnert Park94928 | NCT05677490 | Map |
| CA | Kaiser Permanente - Roseville Medical Center | Roseville95661 | NCT02693535 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT05677490 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT05987241 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT06029270 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT06203600 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT05327686 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT07166406 | Map |
| CA | Sutter Roseville | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT05327686 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT05677490 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT07166406 | Map |
| CA | The Permanente Medical Group-Roseville Radiation Oncology | Roseville95678 | NCT05677490 | Map |
| CA | Kaiser Permanente - Sacramento Medical Center | Sacramento95814 | NCT02693535 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT05675410 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT05677490 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT05987241 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT06029270 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT06203600 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT05675410 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT05677490 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT05987241 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT06029270 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT06203600 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT05675410 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT06632327 | Map |
| CA | South Sacramento Cancer Center | Sacramento95823 | NCT05677490 | Map |
| CA | Sutter Health | Sacramento95816 | NCT06246916 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT04546399 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT05327686 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT05677490 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT07166406 | Map |
| CA | Sutter Sacramento | Sacramento95816 | NCT02693535 | Map |
| CA | University of California Davis (UC Davis) Comprehensive Cancer Center | Sacramento95817 | NCT06561386 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT03816345 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT04546399 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05272384 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05987241 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06029270 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06632327 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT07166406 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT04546399 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT05987241 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT06203600 | Map |
| CA | Naval Medical Center -San Diego | San Diego92134 | NCT05675410 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT04546399 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT05675410 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT06064097 | Map |
| CA | Sharp Memorial Hospital | San Diego92123 | NCT04511013 | Map |
| CA | UC San Diego Medical Center - Hillcrest | San Diego92103 | NCT05327686 | Map |
| CA | California Pacific Medical Center Research Institute | San Francisco94115 | NCT02693535 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT05677490 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT07166406 | Map |
| CA | Kaiser Permanente - San Francisco Medical Center | San Francisco94115 | NCT02693535 | Map |
| CA | Kaiser Permanente - South San Francisco Medical Center | San Francisco94080 | NCT02693535 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT05675410 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT05677490 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT05987241 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT06029270 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT06203600 | Map |
| CA | San Francisco Oncology Associates | San Francisco94115 | NCT06561386 | Map |
| CA | San Francisco Oncology Associates | San Francisco94115 | NCT06264180 | Map |
| CA | Sutter Cancer Research Consortium | San Francisco94115 | NCT02693535 | Map |
| CA | UCSF | San Francisco94143 | NCT06624644 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94158 | NCT04665206 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT05533697 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06264180 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06743126 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT04546399 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT05327686 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT06064097 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT04609046 | Map |
| CA | University of California San Francisco | San Francisco94143 | NCT07195695 | Map |
| CA | University of California San Francisco (UCSF) | San Francisco94143 | NCT06246916 | Map |
| CA | University of California San Francisco, Helen Diller Family Comprehensive Cancer Center | San Francisco94158 | NCT05919264 | Map |
| CA | University of California, San Francisco | San Francisco94158 | NCT06624475 | Map |
| CA | Kaiser Permanente - San Jose Medical Center | San Jose95119 | NCT02693535 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT05675410 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT05677490 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT05987241 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT06029270 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT06203600 | Map |
| CA | Kaiser Permanente - San Leandro Medical Center | San Leandro94577 | NCT02693535 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT05675410 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT05677490 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT05987241 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT06029270 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT06203600 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT06632327 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT05987241 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT06203600 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT05327686 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT05677490 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT05675410 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT05677490 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT05987241 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT06029270 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT06203600 | Map |
| CA | Exelixis Clinical Site #59 | Santa Barbara93463 | NCT05176483 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT05327686 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT05677490 | Map |
| CA | Sansum Clinic | Santa Barbara93105 | NCT06246916 | Map |
| CA | Santa Barbara Cottage Hospital | Santa Barbara93102 | NCT05675410 | Map |
| CA | Sutter Sansum Clinic | Santa Barbara93105 | NCT02693535 | Map |
| CA | Kaiser Permanente - Santa Clara Medical Center | Santa Clara95051 | NCT02693535 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT05677490 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT05987241 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT06029270 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT06203600 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT05677490 | Map |
| CA | Santa Cruz Radiation Oncology Medical Group | Santa Cruz95065 | NCT05677490 | Map |
| CA | Sutter Palo Alto Medical Foundation: Fremont | Santa Cruz994538 | NCT02693535 | Map |
| CA | Sutter Palo Alto Medical Foundation: Santa Cruz | Santa Cruz95065 | NCT02693535 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT06632327 | Map |
| CA | Saint John's Health Center - John Wayne Cancer Institute (JWCI) | Santa Monica90404 | NCT06112314 | Map |
| CA | Sant P Chawla | Santa Monica90403 | NCT04535713 | Map |
| CA | Sarcoma Oncology Center | Santa Monica90403 | NCT03886311 | Map |
| CA | Sarcoma Oncology Center | Santa Monica90403 | NCT05919264 | Map |
| CA | Sarcoma Oncology Research Center | Santa Monica90403 | NCT03138161 | Map |
| CA | St John's Cancer Institute | Santa Monica90404 | NCT06246916 | Map |
| CA | UCLA Hematology/Oncology - Santa Monica | Santa Monica90404 | NCT06561386 | Map |
| CA | University of California Los Angeles | Santa Monica90404 | NCT07195695 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT05675410 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT05677490 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT05987241 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT06029270 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT06203600 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT04511013 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT05647265 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT05677490 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT04511013 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT05647265 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT05677490 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT05327686 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT05677490 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT07166406 | Map |
| CA | City of Hope South Pasadena | South Pasadena91030 | NCT05675410 | Map |
| CA | Kaiser Permanente Cancer Treatment Center | South San Francisco94080 | NCT05677490 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT05675410 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT05677490 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT05987241 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT06029270 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT06203600 | Map |
| CA | Stanford | Stanford94305 | NCT06624644 | Map |
| CA | Stanford Cancer Center | Stanford94305 | NCT06743126 | Map |
| CA | Stanford Cancer Institute | Stanford94305 | NCT03686124 | Map |
| CA | Kaiser Permanente-Stockton | Stockton95210 | NCT05677490 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT06632327 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT07166406 | Map |
| CA | Sutter Palo Alto Medical Foundation: Sunnyvale | Sunnyvale94086 | NCT02693535 | Map |
| CA | City of Hope South Bay | Torrance90503 | NCT05675410 | Map |
| CA | City of Hope Upland | Upland91786 | NCT05675410 | Map |
| CA | Kaiser Permanente Medical Center-Vacaville | Vacaville95688 | NCT05677490 | Map |
| CA | Kaiser Permanente - Vallejo Medical Center | Vallejo94589 | NCT02693535 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT05675410 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT05677490 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT05987241 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT06029270 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT06203600 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT05677490 | Map |
| CA | Epic Care Cyberknife Center | Walnut Creek94597 | NCT04511013 | Map |
| CA | Kaiser Permanente - Walnut Creek Medical Center | Walnut Creek94596 | NCT02693535 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT05675410 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT05677490 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT05987241 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT06029270 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT06203600 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT05675410 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT06632327 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT05987241 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT06203600 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT04546399 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT05675410 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06064097 | Map |
| CO | Rocky Mountain Cancer Centers-Aurora | Aurora80012 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Aurora80012 | NCT07392892 | Map |
| CO | Rocky Mountain Regional VA Medical Center | Aurora80045 | NCT06246916 | Map |
| CO | UCHealth Cancer Care - Anschutz Medical Campus | Aurora80045 | NCT04900818 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05327686 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05675410 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05987241 | Map |
| CO | University of Colorado | Aurora80045 | NCT05919264 | Map |
| CO | University of Colorado Anschutz | Aurora80045 | NCT06624644 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT05533697 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT06246916 | Map |
| CO | University of Colorado Cancer Center | Aurora84005 | NCT06362369 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT04511013 | Map |
| CO | University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora80045 | NCT06264180 | Map |
| CO | University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) | Aurora80045 | NCT06581406 | Map |
| CO | University of Colorado, Anschutz Medical Campus | Aurora80045 | NCT03686124 | Map |
| CO | University of Colorado, Anschutz Medical Campus | Aurora80045 | NCT06112314 | Map |
| CO | University of Colorado, Anschutz Medical Campus | Aurora80045 | NCT06743126 | Map |
| CO | Boulder Community Foothills Hospital | Boulder80303 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Boulder | Boulder80304 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Boulder80303 | NCT07392892 | Map |
| CO | Intermountain Health Platte Valley Hospital | Brighton80601 | NCT05677490 | Map |
| CO | Rocky Mountain Cancer Centers - Centennial | Centennial80112 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Centennial80112 | NCT07392892 | Map |
| CO | Memorial Hospital North | Colorado Springs80920 | NCT05136196 | Map |
| CO | Memorial Hospital North | Colorado Springs80920 | NCT05675410 | Map |
| CO | Memorial Hospital North | Colorado Springs80920 | NCT06203600 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT06632327 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT06632327 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Colorado Springs80907 | NCT07392892 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Colorado Springs80923 | NCT07392892 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT06632327 | Map |
| CO | UCHealth Memorial Hospital Central | Colorado Springs80909 | NCT05136196 | Map |
| CO | UCHealth Memorial Hospital Central | Colorado Springs80909 | NCT05675410 | Map |
| CO | UCHealth Memorial Hospital Central | Colorado Springs80909 | NCT06203600 | Map |
| CO | Cancer Center of Colorado at Sloan's Lake | Denver80204 | NCT05677490 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT04511013 | Map |
| CO | Kaiser Permanente-Franklin | Denver80205 | NCT05987241 | Map |
| CO | National Jewish Health-Main Campus | Denver80206 | NCT05677490 | Map |
| CO | Presbyterian - Saint Lukes Medical Center - Health One | Denver80218 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Midtown | Denver80218 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Rose | Denver80220 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Denver80218 | NCT07392892 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Denver80220 | NCT07392892 | Map |
| CO | Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center | Denver80218 | NCT04546399 | Map |
| CO | Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center | Denver80218 | NCT05675410 | Map |
| CO | Saint Joseph Hospital - Cancer Centers of Colorado | Denver80218 | NCT05677490 | Map |
| CO | Sarah Cannon Research Institute at HealthONE | Denver80218 | NCT05901285 | Map |
| CO | The Melanoma & Skin Cancer Institute | Denver80222 | NCT06112314 | Map |
| CO | The Women's Imaging Center | Denver80209 | NCT04511013 | Map |
| CO | UCHealth - Cherry Creek | Denver80206 | NCT05327686 | Map |
| CO | University of Colorado | Denver80204 | NCT06624644 | Map |
| CO | CommonSpirit Cancer Center Mercy | Durango81301 | NCT06632327 | Map |
| CO | Mercy Medical Center | Durango81301 | NCT06632327 | Map |
| CO | Mountain Blue Cancer Care Center - Swedish | Englewood80113 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers - Swedish | Englewood80113 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Englewood80113 | NCT07392892 | Map |
| CO | Swedish Medical Center | Englewood80113 | NCT04511013 | Map |
| CO | The Melanoma & Skin Cancer Institute | Englewood80113 | NCT06581406 | Map |
| CO | The Melanoma and Skin Cancer Institute | Englewood80113 | NCT04511013 | Map |
| CO | The Melanoma and Skin Cancer Institute | Englewood80113 | NCT06264180 | Map |
| CO | The Melanoma And Skin Cancer Institute | Englewood80113 | NCT06246916 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05136196 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05327686 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05675410 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05677490 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05987241 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT06203600 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT07166406 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05136196 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05327686 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05675410 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05677490 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05987241 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT06203600 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT07166406 | Map |
| CO | Lutheran Hospital - Cancer Centers of Colorado | Golden80401 | NCT05677490 | Map |
| CO | National Jewish Health-Western Hematology Oncology | Golden80401 | NCT05677490 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT05677490 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT07166406 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05136196 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05327686 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05675410 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05677490 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05987241 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT06203600 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT07166406 | Map |
| CO | UCHealth Highlands Ranch Hospital | Highlands Ranch80129 | NCT05327686 | Map |
| CO | UCHealth Highlands Ranch Hospital | Highlands Ranch80129 | NCT05987241 | Map |
| CO | Good Samaritan Hospital - Cancer Centers of Colorado | Lafayette80026 | NCT05677490 | Map |
| CO | Kaiser Permanente-Rock Creek | Lafayette80026 | NCT05987241 | Map |
| CO | CommonSpirit Saint Anthony Hospital Cancer Center | Lakewood80228 | NCT06632327 | Map |
| CO | Rocky Mountain Cancer Centers-Lakewood | Lakewood80228 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Lakewood80228 | NCT07392892 | Map |
| CO | Exelixis Clinical Site #87 | Littleton80124 | NCT05176483 | Map |
| CO | Rocky Mountain Cancer Centers-Littleton | Littleton80120 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Littleton80120 | NCT07392892 | Map |
| CO | Kaiser Permanente-Lone Tree | Lone Tree80124 | NCT05987241 | Map |
| CO | Rocky Mountain Cancer Centers-Sky Ridge | Lone Tree80124 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Lone Tree80124 | NCT07392892 | Map |
| CO | UCHealth Lone Tree Health Center | Lone Tree80124 | NCT05327686 | Map |
| CO | UCHealth Lone Tree Health Center | Lone Tree80124 | NCT05987241 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT06632327 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Longmont80504 | NCT07392892 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05136196 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05327686 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05675410 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05677490 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05987241 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT06203600 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT07166406 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Pueblo81003 | NCT07392892 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT06632327 | Map |
| CO | National Jewish Health-Northern Hematology Oncology | Thornton80260 | NCT05677490 | Map |
| CO | Rocky Mountain Cancer Centers-Thornton | Thornton80260 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Thornton80260 | NCT07392892 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT06632327 | Map |
| CO | Intermountain Health Lutheran Hospital | Wheat Ridge80401 | NCT05677490 | Map |
| CT | Hartford HealthCare - Avon | Avon06001 | NCT05677490 | Map |
| CT | Hartford HealthCare - Avon | Avon06001 | NCT05987241 | Map |
| CT | Hartford HealthCare - Saint Vincent's Medical Center | Bridgeport06606 | NCT05987241 | Map |
| CT | Saint Vincent's Medical Center (SVMC) | Bridgeport06606 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT07166406 | Map |
| CT | Hartford Healthcare - Fairfield | Fairfield06824 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Hamden Care Center | Hamden06518 | NCT07166406 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT04546399 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT05675410 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT06064097 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT02693535 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT05677490 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT07166406 | Map |
| CT | Hartford HealthCare - Manchester | Manchester06042 | NCT05677490 | Map |
| CT | Hartford HealthCare - Manchester | Manchester06042 | NCT05987241 | Map |
| CT | Midstate Medical Center | Meriden06451 | NCT05677490 | Map |
| CT | Midstate Medical Center | Meriden06451 | NCT05987241 | Map |
| CT | Midstate Medical Center (MSMC) | Meriden06451 | NCT02693535 | Map |
| CT | The Hospital of Central Connecticut | New Britain06050 | NCT05677490 | Map |
| CT | The Hospital of Central Connecticut | New Britain06050 | NCT05987241 | Map |
| CT | The Hospital of Central Connecticut (HOCC) Cancer Center | New Britain06053 | NCT02693535 | Map |
| CT | Exelixis Clinical Site #62 | New Haven06510 | NCT05176483 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT03816345 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT07166406 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT06246916 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT06743126 | Map |
| CT | Yale University | New Haven06520 | NCT03816345 | Map |
| CT | Yale University | New Haven06520 | NCT05272384 | Map |
| CT | Yale University | New Haven06511 | NCT05317000 | Map |
| CT | Yale University | New Haven06520 | NCT05675410 | Map |
| CT | Yale University | New Haven06520 | NCT05987241 | Map |
| CT | Yale University | New Haven06520 | NCT06203600 | Map |
| CT | Yale University | New Haven06510 | NCT06963905 | Map |
| CT | Yale University | New Haven06520 | NCT07166406 | Map |
| CT | Yale University School of Medicine | New Haven06520 | NCT05919264 | Map |
| CT | Yale-New Haven Hospital - Yale Cancer Center | North Haven06473 2195 | NCT07527858 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT05675410 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT05987241 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT06203600 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT07166406 | Map |
| CT | William W. Backus Hospital | Norwich06360 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT07166406 | Map |
| CT | Charlotte Hungerford | Torrington06790 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT05675410 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT05987241 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT06203600 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT07166406 | Map |
| CT | VA Connecticut Healthcare System West Haven Campus, West Haven, CT | West Haven06516-2770 | NCT06275360 | Map |
| CT | Windham Hospital (WH) | Willimantic06226 | NCT02693535 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT05327686 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT05677490 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT06632327 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT05327686 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT05677490 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT06203600 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT06632327 | Map |
| DE | Christiana Care Health System- Site Number : 8400011 | Newark19713-2072 | NCT05584670 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT05327686 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT05677490 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT06632327 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05136196 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05327686 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05677490 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05987241 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06203600 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06632327 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05136196 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05327686 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05677490 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05987241 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06203600 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06632327 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT05327686 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT05677490 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT06203600 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT06632327 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT04546399 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT05675410 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT06064097 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT05327686 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT05677490 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT06632327 | Map |
| DC | Children's National Hospital | Washington D.C.20010 | NCT07017816 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT04546399 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT05675410 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT06064097 | Map |
| DC | George Washington University | Washington D.C.20037 | NCT05533697 | Map |
| DC | George Washington University | Washington D.C.20052 | NCT05901285 | Map |
| DC | George Washington University Medical Center | Washington D.C.20037 | NCT05677490 | Map |
| DC | George Washington University Medical Center | Washington D.C.20037 | NCT05987241 | Map |
| DC | Georgetown Lombardi Comprehensive Cancer Center | Washington D.C.20007 | NCT06015724 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT06112314 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT06581406 | Map |
| DC | Johns Hopkins University, Sibley Memorial Hospital | Washington D.C.20016 | NCT05919264 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT03816345 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT03866382 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT05675410 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT05677490 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT05987241 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06203600 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06632327 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT05677490 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT05987241 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT06264180 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT06632327 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05677490 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05896839 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05987241 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT07293351 | Map |
| DC | VA Central Office, Washington, DC | Washington D.C.20420-0001 | NCT06275360 | Map |
| FL | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05327686 | Map |
| FL | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05677490 | Map |
| FL | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05987241 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05896839 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Aventura | Aventura33180 | NCT02693535 | Map |
| FL | Schulze Family Foundation Cancer Clinic - Bonita Health Center | Bonita Springs34135 | NCT05677490 | Map |
| FL | Exelixis Clinical Site #48 | Celebration34747 | NCT05176483 | Map |
| FL | Clermont Oncology Center | Clermont34711 | NCT06246916 | Map |
| FL | Clermont Oncology Center | Clermont34711 | NCT06463665 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05896839 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05987241 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Lennar | Coral Gables33146 | NCT02693535 | Map |
| FL | Oncology & Hematology Associates of West Broward | Coral Springs33065 | NCT06463665 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05896839 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05987241 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Deerfield Beach | Deerfield Beach33442 | NCT02693535 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT05675410 | Map |
| FL | Helios Clinical Research | Fort Lauderdale33316 | NCT06463665 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT03866382 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT02693535 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT05677490 | Map |
| FL | Florida Cancer Specialists - South | Fort Myers33901 | NCT06646276 | Map |
| FL | Florida Cancer Specialists - South | Fort Myers33901 | NCT07221149 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT04546399 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT05675410 | Map |
| FL | Regional Cancer Center-Lee Memorial Health System | Fort Myers33905 | NCT05677490 | Map |
| FL | Exelixis Clinical Site #11 | Gainesville32610 | NCT05176483 | Map |
| FL | Malcom Randall Veterans Administration Medical Center | Gainesville32610 | NCT05987241 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT04546399 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT05675410 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT05987241 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06064097 | Map |
| FL | University of Florida Health | Gainesville32610 | NCT02693535 | Map |
| FL | Bioresearch Partner | Hialeah33013 | NCT06463665 | Map |
| FL | Memorial Cancer Institute at Memorial Regional Hospital | Hollywood33021 | NCT06264180 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT04546399 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05327686 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05675410 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05677490 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05987241 | Map |
| FL | Baptist MD Anderson Cancer Center | Jacksonville32207 | NCT06264180 | Map |
| FL | Cancer Specialist of North Florida | Jacksonville32256 | NCT06246916 | Map |
| FL | Exelixis Clinical Site #78 | Jacksonville32224 | NCT05176483 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT05655312 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT05919264 | Map |
| FL | Mayo Clinic - Jacksonville FL | Jacksonville32224 | NCT06581406 | Map |
| FL | Mayo Clinic Florida | Jacksonville32224 | NCT05223816 | Map |
| FL | Mayo Clinic Florida | Jacksonville32224 | NCT06112314 | Map |
| FL | Mayo Clinic Florida | Jacksonville32224 | NCT06246916 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05136196 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05327686 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05675410 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT06265285 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT07226856 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT04546399 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT05675410 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT06064097 | Map |
| FL | Jupiter Medical Center | Jupiter33458 | NCT05677490 | Map |
| FL | Orlando Health Cancer Institute - Lake Mary | Lake Mary32746 | NCT06632327 | Map |
| FL | The Watson Clinic | Lakeland33805 | NCT05677490 | Map |
| FL | Bioresearch Partner | Miami33155 | NCT06463665 | Map |
| FL | Exelixis Clinical Site #47 | Miami33136 | NCT05176483 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05327686 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05987241 | Map |
| FL | Miami Cancer Institute at Baptist Health | Miami33176 | NCT05317858 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT05675410 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT06064097 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT06581406 | Map |
| FL | Sylvester Comprehensive Cancer Center - Miami | Miami33136-1002 | NCT05267626 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05896839 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05987241 | Map |
| FL | University of Miami | Miami33136 | NCT05655312 | Map |
| FL | University of Miami | Miami33136 | NCT06889493 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Cente | Miami33136 | NCT06743126 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Center | Miami33136 | NCT06463665 | Map |
| FL | University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami | Miami33136 | NCT06112314 | Map |
| FL | University of Miami Hospital and Clinics | Miami33136 | NCT03686124 | Map |
| FL | University of Miami Hospital and Clinics, Sylvester Cancer Center | Miami33136 | NCT06561386 | Map |
| FL | University of Miami Hospital and Clinics, Sylvester Cancer Center | Miami33136 | NCT06618287 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04609046 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05675410 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05896839 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05987241 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Alex's Place | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Kendall | Miami33176 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Sole Mia | Miami33181 | NCT02693535 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT05327686 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT05675410 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT05677490 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT04609046 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT05896839 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT05987241 | Map |
| FL | Health Central | Ocoee34761 | NCT06632327 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT06463665 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT06646276 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT07195695 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT04546399 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT05675410 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT05987241 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT06203600 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT04546399 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT05675410 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT06064097 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT04546399 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT05675410 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT06064097 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT03866382 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT04511013 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT06632327 | Map |
| FL | Orlando Health UF Health Cancer Center | Orlando32806 | NCT05533697 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05327686 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT06561386 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05677490 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05987241 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT04546399 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT05675410 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT06064097 | Map |
| FL | BRCR Medical Center, Inc. | Plantation33322 | NCT06463665 | Map |
| FL | Exelixis Clinical Site #61 | Plantation33322 | NCT05176483 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05896839 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05987241 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Plantation | Plantation33324 | NCT02693535 | Map |
| FL | Sarasota Memorial Hospital | Sarasota34239 | NCT05655312 | Map |
| FL | Florida Cancer Specialists - North | St. Petersburg33705 | NCT06561386 | Map |
| FL | Florida Cancer Specialists - North | St. Petersburg33705 | NCT06646276 | Map |
| FL | Florida Cancer Specialists - North | St. Petersburg33701 | NCT07221149 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT04546399 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT05675410 | Map |
| FL | Boca Raton Clinical Research (BRCR) Global | Tamarac33321 | NCT06246916 | Map |
| FL | Exelixis Clinical Site #8 | Tampa33612 | NCT05176483 | Map |
| FL | H. Lee Moffitt Cancer Center | Tampa33612 | NCT06246916 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04741997 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05076760 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04511013 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04562129 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05317858 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05681780 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06264180 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06295159 | Map |
| FL | Moffitt Cancer Center | Tampa87535 | NCT06624644 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06743126 | Map |
| FL | Moffitt Cancer Center - McKinley Campus | Tampa33612 | NCT04511013 | Map |
| FL | Moffitt Cancer Center-International Plaza | Tampa33607 | NCT04511013 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT04546399 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT05675410 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT06064097 | Map |
| FL | Tampa General Hospital | Tampa33606 | NCT04546399 | Map |
| FL | Tampa General Hospital | Tampa33606 | NCT05675410 | Map |
| FL | Florida Cancer Specialists - East | West Palm Beach33401 | NCT06561386 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT04546399 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT05675410 | Map |
| GA | University Cancer & Blood Center | Athens30607 | NCT06246916 | Map |
| GA | Cancer Treatment Centers of America - Atlanta | Atlanta30265 | NCT02693535 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT04546399 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT05675410 | Map |
| GA | Emory Proton Therapy Center | Atlanta30308 | NCT05675410 | Map |
| GA | Emory Proton Therapy Center | Atlanta30308 | NCT07166406 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05039073 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05675410 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05987241 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06203600 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06495125 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT07166406 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT03690986 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT03866382 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT05675410 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT05987241 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06029270 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06203600 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06731270 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT07166406 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT03866382 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05039073 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05675410 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05987241 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06203600 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06495125 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06731270 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07155317 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07166406 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322 | NCT02693535 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT06581406 | Map |
| GA | Grady Health System | Atlanta30303 | NCT05675410 | Map |
| GA | Grady Health System | Atlanta30303 | NCT05987241 | Map |
| GA | Grady Health System | Atlanta30303 | NCT07166406 | Map |
| GA | Northside Hospital | Atlanta30342 | NCT05987241 | Map |
| GA | Piedmont Cancer Institute | Atlanta30318 | NCT07195695 | Map |
| GA | Winship Cancer Institute, Emory University | Atlanta30322 | NCT06264180 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT05675410 | Map |
| GA | Emory Decatur Hospital | Decatur30033 | NCT06203600 | Map |
| GA | Northside Hospital - Duluth | Duluth30096 | NCT05987241 | Map |
| GA | Emory Johns Creek Hospital | Johns Creek30097 | NCT05987241 | Map |
| GA | Emory Johns Creek Hospital | Johns Creek30097 | NCT06203600 | Map |
| GA | Northside Hospital - Gwinnett | Lawrenceville30046 | NCT05987241 | Map |
| GA | Atrium Health Navicent | Macon31201 | NCT05675410 | Map |
| GA | Northwest Georgia Oncology Centers | Marietta30060 | NCT07195695 | Map |
| GA | Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta30060 | NCT06646276 | Map |
| GA | CTCA at Southeastern Regional Medical Center | Newnan30265 | NCT06632327 | Map |
| GA | Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute | Savannah31405 | NCT02693535 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT04546399 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT05675410 | Map |
| GA | Summit Cancer Care | Savannah31405 | NCT02693535 | Map |
| GA | Tift Regional Medical Center | Tifton31794 | NCT05677490 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05677490 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT06203600 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT05677490 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT06203600 | Map |
| HI | Queen's Cancer Center - Pearlridge | ‘Aiea96701 | NCT05677490 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT02693535 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT05677490 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT06203600 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05677490 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT06203600 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT05677490 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT05987241 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT06029270 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT06203600 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT04546399 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT05675410 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06203600 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT05677490 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT06203600 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT05677490 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT06203600 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT05677490 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT06203600 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05677490 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT06203600 | Map |
| HI | The Queen's Medical Center | Honolulu96813 | NCT07075120 | Map |
| HI | The Queen's Medical Center - Kuakini | Honolulu96817 | NCT02693535 | Map |
| HI | The Queen's Medical Center - POB I | Honolulu96813 | NCT02693535 | Map |
| HI | The Queen's Medical Center - Punchbowl | Honolulu96813 | NCT02693535 | Map |
| HI | Straub Medical Center - Kahului Clinic | Kahului96732 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05136196 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT03866382 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05987241 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT06203600 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05112601 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05136196 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04546399 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05675410 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05136196 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT03866382 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05987241 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT06203600 | Map |
| ID | Beacon Clinic | Coeur d'Alene83815 | NCT06246916 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05112601 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05136196 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT03866382 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT04511013 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05677490 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05987241 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06029270 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06203600 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06632327 | Map |
| ID | Walter Knox Memorial Hospital | Emmett83617 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05112601 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05136196 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05675410 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05677490 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT04511013 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05112601 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05136196 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05675410 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05136196 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT03866382 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05675410 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05677490 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05987241 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT06203600 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05112601 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05136196 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83686 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05675410 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05677490 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05112601 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05136196 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT03866382 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT04511013 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05677490 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05987241 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06029270 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06203600 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06632327 | Map |
| ID | Kootenai Cancer Clinic | Sandpoint83864 | NCT04511013 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05112601 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05136196 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT03866382 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05677490 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05987241 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06029270 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06203600 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06632327 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05136196 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05675410 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05677490 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT05677490 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT06632327 | Map |
| IL | Saint Anthony's Health | Alton62002 | NCT04511013 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT07392892 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT05677490 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT06203600 | Map |
| IL | Rush - Copley Medical Center | Aurora60504 | NCT04511013 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05136196 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05647265 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05675410 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05677490 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06203600 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06632327 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05675410 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05677490 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05987241 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT06203600 | Map |
| IL | Illinois CancerCare - Bloomington | Bloomington61704 | NCT07392892 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05136196 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT04511013 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05677490 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05987241 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT06632327 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT07383441 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05136196 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT04511013 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05677490 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05987241 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT06632327 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT07383441 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT04511013 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT05677490 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT06632327 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT04511013 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT05677490 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT06632327 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05136196 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT04511013 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05677490 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05987241 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT06632327 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT07383441 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05136196 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04511013 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05327686 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05677490 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT06632327 | Map |
| IL | Saint Mary's Hospital | Centralia62801 | NCT04511013 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05675410 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05677490 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05987241 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT06203600 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago60611 | NCT06712875 | Map |
| IL | Cancer Treatment Centers of America-Chicago | Chicago60099 | NCT02693535 | Map |
| IL | Exelixis Clinical Site #26 | Chicago60612 | NCT05176483 | Map |
| IL | Illinois Cancer Specialists | Chicago60631 | NCT07392892 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT05677490 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT06632327 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT04546399 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT05675410 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT06064097 | Map |
| IL | Mount Sinai Hospital Medical Center | Chicago60608 | NCT05675410 | Map |
| IL | Mount Sinai Hospital Medical Center | Chicago60608 | NCT05677490 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT06581406 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT06264180 | Map |
| IL | Northwestern University | Chicago60611 | NCT05136196 | Map |
| IL | Northwestern University | Chicago60611 | NCT05327686 | Map |
| IL | Northwestern University | Chicago60611 | NCT05647265 | Map |
| IL | Northwestern University | Chicago60611 | NCT05675410 | Map |
| IL | Northwestern University | Chicago60611 | NCT05896839 | Map |
| IL | Northwestern University | Chicago60611 | NCT05987241 | Map |
| IL | Northwestern University | Chicago60611 | NCT06029270 | Map |
| IL | Northwestern University | Chicago60611 | NCT06203600 | Map |
| IL | Northwestern University | Chicago60611 | NCT06632327 | Map |
| IL | Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI | Chicago60611 | NCT06112314 | Map |
| IL | Rush MD Anderson Cancer Center | Chicago60612 | NCT03866382 | Map |
| IL | Swedish Covenant Hospital | Chicago60625 | NCT05675410 | Map |
| IL | Swedish Covenant Hospital | Chicago60625 | NCT05987241 | Map |
| IL | Swedish Covenant Hospital | Chicago60625 | NCT06203600 | Map |
| IL | The University of Chicago Medicine | Chicago60637 | NCT05533697 | Map |
| IL | University of Chicago Cancer Research Center | Chicago60637 | NCT04561206 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT03866382 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT04546399 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05272384 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05327686 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05647265 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05675410 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05677490 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05987241 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06064097 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT07166406 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT03686124 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT04665206 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT04572451 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT06581406 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT05502315 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT06743126 | Map |
| IL | University Of Chicago Medicine Comprehensive Cancer Center | Chicago60637 | NCT04295863 | Map |
| IL | University of Illinois | Chicago60612 | NCT05136196 | Map |
| IL | University of Illinois | Chicago60612 | NCT04546399 | Map |
| IL | University of Illinois | Chicago60612 | NCT05675410 | Map |
| IL | University of Illinois | Chicago60612 | NCT05677490 | Map |
| IL | University of Illinois | Chicago60612 | NCT05987241 | Map |
| IL | University of Illinois | Chicago60612 | NCT06029270 | Map |
| IL | University of Illinois | Chicago60612 | NCT06203600 | Map |
| IL | University of Illinois | Chicago60612 | NCT06632327 | Map |
| IL | University of Illinois Hospital and Health Sciences System | Chicago60612 | NCT07195695 | Map |
| IL | Affiliated Oncologists, LLC | Chicago Ridge60415 | NCT06561386 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05675410 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05677490 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05987241 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT06203600 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05112601 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04511013 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05327686 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05647265 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05675410 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05677490 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05987241 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06029270 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06203600 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06632327 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05136196 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT03866382 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04511013 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05327686 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05677490 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05987241 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06203600 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06632327 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT07383441 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05136196 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04511013 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05327686 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05675410 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05677490 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05987241 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06203600 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06632327 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT07383441 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05136196 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05675410 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05987241 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06029270 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06203600 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06632327 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05136196 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT04511013 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05677490 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05987241 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT06632327 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05675410 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05677490 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05987241 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT06203600 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05112601 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04511013 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05327686 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05647265 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05675410 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05677490 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05987241 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06029270 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06203600 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06632327 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05136196 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT03866382 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04511013 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05327686 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05675410 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05677490 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05987241 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06203600 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06632327 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05675410 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05677490 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05987241 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT06203600 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT05675410 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05136196 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT04511013 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05677490 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05987241 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT06632327 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT07383441 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05675410 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05987241 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT06203600 | Map |
| IL | Illinois CancerCare - Galesburg | Galesburg61401 | NCT07392892 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05136196 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT04511013 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05677490 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05987241 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT06632327 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT07383441 | Map |
| IL | Western Illinois Cancer Treatment Center | Galesburg61401 | NCT04511013 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05136196 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05675410 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05987241 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06029270 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06203600 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06632327 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05675410 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05987241 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT06203600 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05327686 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05647265 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05987241 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06029270 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06203600 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06632327 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05327686 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05647265 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05987241 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06029270 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06203600 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06632327 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05327686 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05677490 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05987241 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05675410 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05677490 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05987241 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT06203600 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05675410 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05987241 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT06203600 | Map |
| IL | Edward Hines Jr VA Hospital | Hines60141 | NCT06632327 | Map |
| IL | Hope and Healing Cancer Services | Hinsdale60521 | NCT06246916 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05136196 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT04511013 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05677490 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05987241 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT06632327 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT07383441 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05136196 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05327686 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05647265 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05987241 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06029270 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06203600 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06632327 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05675410 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05677490 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05987241 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT06203600 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05675410 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05677490 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05987241 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT06203600 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05136196 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT04511013 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05677490 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05987241 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT06632327 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT07383441 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05112601 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05327686 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05647265 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05675410 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05677490 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05987241 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06029270 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06203600 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06632327 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05136196 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT03866382 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT04546399 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05675410 | Map |
| IL | Trinity Medical Center | Moline61265 | NCT05677490 | Map |
| IL | Good Samaritan Regional Health Center | Mount Vernon62864 | NCT04511013 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT05677490 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT06632327 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT05675410 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05272384 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05327686 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05677490 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05987241 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT07166406 | Map |
| IL | Illinois Cancer Specialists | Niles60714 | NCT07392892 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT05112601 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05112601 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05677490 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05136196 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04511013 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05327686 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05677490 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05987241 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06203600 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06632327 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05327686 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05675410 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05677490 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT06632327 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT05327686 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT05987241 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT06203600 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT06632327 | Map |
| IL | Advocate Children's Hospital-Oak Lawn | Oak Lawn60453 | NCT05675410 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05675410 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05677490 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05987241 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT06203600 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05136196 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05327686 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05647265 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05675410 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05987241 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06029270 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06203600 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06632327 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05272384 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05327686 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05677490 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05987241 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT07166406 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05136196 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT04511013 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05677490 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05987241 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT06632327 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT07383441 | Map |
| IL | Illinois CancerCare-Ottawa-Fox River Cancer Center | Ottawa61350 | NCT07392892 | Map |
| IL | Advocate Children's Hospital-Park Ridge | Park Ridge60068 | NCT05675410 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05675410 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05677490 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05987241 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT06203600 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT06246916 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05136196 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT04511013 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05677490 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05987241 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT06632327 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT07383441 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT07392892 | Map |
| IL | Illinois Cancer Care | Peoria61615 | NCT06646276 | Map |
| IL | Illinois CancerCare | Peoria61615 | NCT06246916 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05136196 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT04511013 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05677490 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05987241 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT06632327 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT07383441 | Map |
| IL | Illinois CancerCare, P.C. | Peoria61615 | NCT07392892 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT04511013 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT05677490 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT06632327 | Map |
| IL | OSF Children's Hospital of Illinois | Peoria61637 | NCT04546399 | Map |
| IL | OSF Children's Hospital of Illinois | Peoria61637 | NCT05675410 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05136196 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT04511013 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05677490 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05987241 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT06632327 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT07383441 | Map |
| IL | Illinois CancerCare-Peru - Valley Regional Cancer Center | Peru61354 | NCT07392892 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT04511013 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT05677490 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT06632327 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT05675410 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05136196 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT04511013 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05677490 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05987241 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT06632327 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT07383441 | Map |
| IL | Mercyhealth Cancer Institute - Rockford | Rockford61114 | NCT06203600 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05327686 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05675410 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05677490 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05987241 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT06203600 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT06632327 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05136196 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT03866382 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05675410 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05896839 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05987241 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06203600 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06632327 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT07166406 | Map |
| IL | Memorial Medical Center | Springfield62781 | NCT04511013 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05136196 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT03866382 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04511013 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05327686 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05675410 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05677490 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05987241 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06203600 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06632327 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT07383441 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05136196 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT03866382 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04511013 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05327686 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05677490 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05987241 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06203600 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06632327 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05136196 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT03866382 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05327686 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05677490 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05987241 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06203600 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06632327 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05112601 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04511013 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05327686 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05647265 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05675410 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05677490 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05987241 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06029270 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06203600 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06632327 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT04511013 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05136196 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05675410 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05987241 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06029270 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06203600 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06632327 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05136196 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT04511013 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05677490 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05987241 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT06632327 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT07383441 | Map |
| IL | Illinois CancerCare-Washington | Washington61571 | NCT07392892 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05136196 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT04511013 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05647265 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05675410 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05677490 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT06632327 | Map |
| IL | Midwestern Regional Medical Center | Zion60099 | NCT06632327 | Map |
| IN | IU Health North Hospital | Carmel46032 | NCT05112601 | Map |
| IN | Northwest Cancer Center - Crown Point | Crown Point46307 | NCT05112601 | Map |
| IN | Northwest Cancer Center - Crown Point | Crown Point46307 | NCT05677490 | Map |
| IN | Northwest Cancer Center - Crown Point | Crown Point46307 | NCT06203600 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05327686 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05677490 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05987241 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT07166406 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT05112601 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT05677490 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT06203600 | Map |
| IN | Fort Wayne Medical Oncology and Hematology | Fort Wayne46825 | NCT06246916 | Map |
| IN | Goshen Center for Cancer Care | Goshen46526 | NCT06632327 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05112601 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05677490 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT06203600 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT05112601 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT05677490 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT06203600 | Map |
| IN | Ascension Saint Vincent Indianapolis Hospital | Indianapolis46260 | NCT05675410 | Map |
| IN | Community Health Network (The University of Texas MD Anderson Cancer Center) | Indianapolis46250 | NCT02693535 | Map |
| IN | Exelixis Clinical Site #4 | Indianapolis46250 | NCT05176483 | Map |
| IN | Franciscan Health Indianapolis | Indianapolis46237 | NCT05327686 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT06863311 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05112601 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05987241 | Map |
| IN | Richard L. Roudebush VA Medical Center, Indianapolis, IN | Indianapolis46202-2884 | NCT06275360 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT04546399 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT05675410 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT06064097 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT05112601 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT05677490 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT06203600 | Map |
| IN | Franciscan Health Mooresville | Mooresville46158 | NCT05327686 | Map |
| IN | The Community Hospital | Munster46321 | NCT05112601 | Map |
| IN | The Community Hospital | Munster46321 | NCT05677490 | Map |
| IN | The Community Hospital | Munster46321 | NCT06203600 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT05112601 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT05677490 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT06203600 | Map |
| IN | Reid Health | Richmond47374 | NCT04511013 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT05112601 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT05677490 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT06203600 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05136196 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT03866382 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04511013 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05327686 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05677490 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05987241 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05136196 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT03866382 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04511013 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05327686 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05677490 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05136196 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05675410 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT06029270 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT06203600 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT07166406 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT03866382 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT05677490 | Map |
| IA | McFarland Clinic - Boone | Boone50036 | NCT04511013 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04609046 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04511013 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT06029270 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT06203600 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT05136196 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT05677490 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06203600 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06632327 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT07383441 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT05136196 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT05677490 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06203600 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06632327 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT07383441 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT05136196 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05136196 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05675410 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT06029270 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT06203600 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT07166406 | Map |
| IA | Heartland Oncology and Hematology LLP | Council Bluffs51503 | NCT05677490 | Map |
| IA | Methodist Jennie Edmundson Hospital | Council Bluffs51503 | NCT05677490 | Map |
| IA | Methodist Jennie Edmundson Hospital | Council Bluffs51503 | NCT06029270 | Map |
| IA | Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ | Council Bluffs51503 | NCT06029270 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT07166406 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT04546399 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT05675410 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04609046 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04511013 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT06029270 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT06203600 | Map |
| IA | Iowa Lutheran Hospital | Des Moines50316 | NCT04511013 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04609046 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT03866382 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04511013 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05327686 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05675410 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05677490 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05987241 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT06029270 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT06203600 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT07166406 | Map |
| IA | Medical Oncology and Hematology Associates-Des Moines | Des Moines50309 | NCT04511013 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04609046 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05136196 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT03866382 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05987241 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT06029270 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05136196 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05675410 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT06029270 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT06203600 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05136196 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05675410 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT06029270 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT06203600 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT07166406 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05136196 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT03866382 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04511013 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05677490 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05987241 | Map |
| IA | Trinity Regional Medical Center | Fort Dodge50501 | NCT04511013 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT06029270 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT06203600 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06581406 | Map |
| IA | University of Iowa | Iowa City52242 | NCT05655312 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06264180 | Map |
| IA | University of Iowa Health Care | Iowa City52242 | NCT07404332 | Map |
| IA | University of Iowa- Site Number : 8400014 | Iowa City52242-1009 | NCT05584670 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05112601 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT03866382 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT04546399 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05675410 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05677490 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05987241 | Map |
| IA | McFarland Clinic - Jefferson | Jefferson50129 | NCT04511013 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05136196 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT03866382 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04511013 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05677490 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05987241 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Pella | Pella50219 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05136196 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05675410 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05987241 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT06029270 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT06203600 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT07166406 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT07166406 | Map |
| IA | Methodist West Hospital | West Des Moines50266-7700 | NCT04511013 | Map |
| IA | The Iowa Clinic PC | West Des Moines50266 | NCT07166406 | Map |
| KS | University of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008 | Fairway66205-2528 | NCT05584670 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT03816345 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT04511013 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT05677490 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT06632327 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT04511013 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT05677490 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT06632327 | Map |
| KS | HaysMed | Hays67601 | NCT03816345 | Map |
| KS | HaysMed | Hays67601 | NCT03866382 | Map |
| KS | HaysMed | Hays67601 | NCT05677490 | Map |
| KS | HaysMed | Hays67601 | NCT05987241 | Map |
| KS | HaysMed | Hays67601 | NCT06203600 | Map |
| KS | HaysMed | Hays67601 | NCT06632327 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT03816345 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05987241 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT03816345 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT03866382 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT05677490 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT05987241 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT06632327 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT03816345 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT03866382 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT05677490 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT05987241 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT06203600 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT06632327 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT03816345 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT05987241 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT03816345 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT03866382 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT05677490 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT05677490 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT06632327 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT03816345 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT03866382 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT05677490 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT05987241 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT06203600 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT06632327 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT03816345 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT03866382 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT05677490 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT05987241 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT06203600 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT06632327 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205 | NCT06246916 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205 | NCT07174453 | Map |
| KS | The University of Kansas Cancer Center (KUCC) - Westwood | Westwood66205 | NCT06112314 | Map |
| KS | University of Kansas Cancer Center | Westwood66205 | NCT06264180 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT03816345 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT03866382 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05987241 | Map |
| KS | Cancer Center of Kansas | Wichita67214 | NCT06561386 | Map |
| KS | Wesley Medical Center | Wichita67214 | NCT05675410 | Map |
| KY | King's Daughter's Medical Center | Ashland41101 | NCT06632327 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT06632327 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT06632327 | Map |
| KY | Saint Elizabeth Medical Center Edgewood | Edgewood41017 | NCT06561386 | Map |
| KY | St. Elizabeth Healthcare - Edgewood | Edgewood41017 | NCT06112314 | Map |
| KY | Baptist Health Lexington | Lexington40503 | NCT06561386 | Map |
| KY | Markey Cancer Center Clinical Research Organization | Lexington40536 | NCT06246916 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT06632327 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT06203600 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT06632327 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT06632327 | Map |
| KY | University of Kentucky | Lexington40536 | NCT05655312 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT03816345 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT04546399 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05675410 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05896839 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05987241 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT07166406 | Map |
| KY | Saint Joseph London | London40741 | NCT06632327 | Map |
| KY | Exelixis Clinical Site #122 | Louisville40202 | NCT05176483 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT04546399 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT05675410 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05112601 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05675410 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05677490 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05987241 | Map |
| KY | University of Louisville | Louisville40202 | NCT03080974 | Map |
| KY | University of Louisville Brown Cancer Center | Louisville40202 | NCT06264180 | Map |
| KY | University of Louisville-James Graham Brown Cancer Center | Louisville40202 | NCT03899155 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05112601 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05675410 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05677490 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05987241 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT06632327 | Map |
| KY | Owensboro Health Mitchell Memorial Cancer Center | Owensboro42303 | NCT06632327 | Map |
| KY | Mercy Health - Paducah Medical Oncology and Hematology | Paducah42003 | NCT04511013 | Map |
| LA | Louisiana Hematology Oncology Associates LLC | Baton Rouge70809 | NCT05327686 | Map |
| LA | Louisiana Hematology Oncology Associates LLC | Baton Rouge70809 | NCT05987241 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT05327686 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT06246916 | Map |
| LA | Ochsner Hematology Oncology North Shore - Covington (West Region) | Covington70433 | NCT06203600 | Map |
| LA | Mary Bird Perkins Cancer Center - Metairie | Metairie70002 | NCT05327686 | Map |
| LA | Mary Bird Perkins Cancer Center - Metairie | Metairie70002 | NCT05987241 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT04546399 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT05675410 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT06064097 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT05675410 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT05987241 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT06203600 | Map |
| LA | Tulane University School of Medicine | New Orleans70112 | NCT06632327 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT05677490 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT06632327 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT02693535 | Map |
| ME | Jackson Laboratory - Maine Cancer Genomics Initiative | Augusta04330 | NCT02693535 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT04546399 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT05675410 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT06632327 | Map |
| ME | MaineHealth Coastal Cancer Treatment Center | Bath04530 | NCT05675410 | Map |
| ME | Waldo County General Hospital | Belfast04915 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Biddeford | Biddeford04005 | NCT02693535 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT05987241 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT06632327 | Map |
| ME | Northern Light Cancer Care | Brewer04412 | NCT02693535 | Map |
| ME | Raish Peavey Haskell Children's Cancer and Treatment Center | Brewer04412 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -Brunswick | Brunswick04011 | NCT02693535 | Map |
| ME | New England Cancer Specialist | Kennebunk04043 | NCT02693535 | Map |
| ME | York Hopsital Oncology & Infusion Care in Kittery | Kittery03904 | NCT02693535 | Map |
| ME | Stephens Memorial Hospital | Norway04268 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT04609046 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT05675410 | Map |
| ME | Penobscot Bay Medical Center | Rockport04856 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care Center of York County | Sanford04073 | NCT05675410 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Sandford | Sanford04073 | NCT02693535 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT04546399 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT02693535 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT05675410 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT06064097 | Map |
| ME | Maine Medical Partner's Women's Health | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT04609046 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05112601 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05675410 | Map |
| ME | New England Cancer Specialist | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -South Portland | South Portland04106 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT04609046 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT05675410 | Map |
| ME | New England Cancer Specialist | Topsham04086 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in Wells | Wells04090 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in York | York Village03909 | NCT02693535 | Map |
| MD | Maryland Oncology Hematology, P.A. | Annapolis21401 | NCT07392892 | Map |
| MD | Exelixis Clinical Site #14 | Baltimore21201 | NCT05176483 | Map |
| MD | Johns Hopkins Hospital | Baltimore21231 | NCT03521830 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT03465592 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT07293351 | Map |
| MD | Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center | Baltimore21287 | NCT05919264 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT03816345 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT04546399 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05675410 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05677490 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05896839 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05987241 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06064097 | Map |
| MD | Maryland Proton Treatment Center | Baltimore21201 | NCT06800339 | Map |
| MD | MedStar Franklin Square Medical Center/Weinberg Cancer Institute | Baltimore21237 | NCT06632327 | Map |
| MD | MedStar Good Samaritan Hospital | Baltimore21239 | NCT06632327 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT04248569 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT06941857 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT04546399 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT05675410 | Map |
| MD | University of Maryland | Baltimore21201 | NCT05317858 | Map |
| MD | University of Maryland Greenebaum Cancer Center | Baltimore21201 | NCT06800339 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05675410 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05987241 | Map |
| MD | University of MD Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06743126 | Map |
| MD | Upper Chesapeake- Kaufman Cancer Center | Bel Air21014 | NCT06800339 | Map |
| MD | Maryland Oncology Hematology, P.A. | Bethesda20817 | NCT07392892 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT03816345 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03258567 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03866382 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT04902443 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05675410 | Map |
| MD | Maryland Oncology Hematology, P.A. | Brandywine20613 | NCT07392892 | Map |
| MD | Maryland Oncology Hematology, P.A. | Columbia21044 | NCT06246916 | Map |
| MD | Maryland Oncology Hematology, P.A. | Columbia21044 | NCT07392892 | Map |
| MD | UPMC Western Maryland | Cumberland21502 | NCT05987241 | Map |
| MD | UPMC Western Maryland | Cumberland21502 | NCT06203600 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT05677490 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT06632327 | Map |
| MD | FMH James M Stockman Cancer Institute | Frederick21702 | NCT03866382 | Map |
| MD | FMH James M Stockman Cancer Institute | Frederick21702 | NCT05987241 | Map |
| MD | Maryland Oncology Hematology, P.A. | Germantown20876 | NCT07392892 | Map |
| MD | Baltimore Washington Medical Center- Tate Cancer Center | Glen Burnie21061 | NCT06800339 | Map |
| MD | Maryland Oncology Hematology, P.A. | Largo20774 | NCT07392892 | Map |
| MD | Maryland Oncology Hematology, P.A. | Rockville20850 | NCT07392892 | Map |
| MD | Maryland Oncology Hematology, P.A. | Silver Spring20904 | NCT07392892 | Map |
| MA | Beverly Hospital | Beverly01915 | NCT05327686 | Map |
| MA | Beverly Hospital | Beverly01915 | NCT05987241 | Map |
| MA | Beverly Hospital | Beverly01915 | NCT06632327 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05987241 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06053658 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06708949 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06743126 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT07527858 | Map |
| MA | Beth Israel Deaconess Medical Center ( Site 0107) | Boston02215 | NCT07405164 | Map |
| MA | Boston Medical Center | Boston02118 | NCT05677490 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT05327686 | Map |
| MA | Dana Farber | Boston02215 | NCT06624644 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05428007 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05533697 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05901285 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05919264 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06112314 | Map |
| MA | Dana_Farber Cancer Institute (DFCI) | Boston02215 | NCT03899155 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04665206 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT03816345 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04561206 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05327686 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05675410 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05677490 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05987241 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06053658 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06064097 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07195695 | Map |
| MA | Dana-Farber Cancer Institute ( Site 0105) | Boston02215 | NCT07405164 | Map |
| MA | Exelixis Clinical Site #7 | Boston02215 | NCT05176483 | Map |
| MA | I-Mab Site 1002 | Boston02114 | NCT07432295 | Map |
| MA | Mass General Hospital | Boston02114 | NCT04900818 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT03686124 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04665206 | Map |
| MA | Massachusetts General Hospital | Boston02115 | NCT03803553 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06581406 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05428007 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05533697 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05919264 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06112314 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06743126 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT03816345 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05327686 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05779423 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06632327 | Map |
| MA | Dana-Farber Cancer Institute at Boston Medical Center - Brighton | Brighton02135 | NCT05677490 | Map |
| MA | Dana-Farber Cancer Institute at Boston Medical Center - Brighton | Brighton02135 | NCT05987241 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT03866382 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05327686 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05987241 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT06632327 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT07383441 | Map |
| MA | Dana-Farber Cancer Institute at Foxborough | Foxborough02035 | NCT05677490 | Map |
| MA | Dana-Farber Cancer Institute at Foxborough | Foxborough02035 | NCT05987241 | Map |
| MA | Addison Gilbert Hospital | Gloucester01930 | NCT05327686 | Map |
| MA | Addison Gilbert Hospital | Gloucester01930 | NCT05987241 | Map |
| MA | Addison Gilbert Hospital | Gloucester01930 | NCT06632327 | Map |
| MA | Dana Farber-Merrimack Valley | Methuen01844 | NCT05677490 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at Milford Regional | Milford01757 | NCT05677490 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at Milford Regional | Milford01757 | NCT05987241 | Map |
| MA | Lahey Clinic Peabody | Peabody01960 | NCT03866382 | Map |
| MA | Lahey Clinic Peabody | Peabody01960 | NCT05987241 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT05327686 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT06632327 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT07383441 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at South Shore | South Weymouth02190 | NCT05677490 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at South Shore | South Weymouth02190 | NCT05987241 | Map |
| MA | Baystate Medical Center | Springfield01199 | NCT05136196 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT06632327 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT05675410 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Alpena | Alpena49707 | NCT05677490 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT04546399 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT05675410 | Map |
| MI | Trinity Health Ann Arbor Hospital | Ann Arbor48106 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05136196 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT03866382 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05327686 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05675410 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05677490 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05987241 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT06203600 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06053658 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06246916 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06743126 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT04511013 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT06866262 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05136196 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05327686 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05987241 | Map |
| MI | VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor48105-2303 | NCT06275360 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05112601 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05136196 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT04511013 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05675410 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05987241 | Map |
| MI | McLaren Cancer Institute-Bay City | Bay City48706 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Bay City | Bay City48706 | NCT05987241 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05136196 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05675410 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05987241 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06203600 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT07383441 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05136196 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT03866382 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05327686 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05677490 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT06203600 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT04511013 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT05987241 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT03866382 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT05675410 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT05987241 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT06203600 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT07166406 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05136196 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05675410 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05987241 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06203600 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT07383441 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05136196 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT03866382 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05327686 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05677490 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT06203600 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05136196 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT03866382 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05327686 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05677490 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT06203600 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05136196 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05675410 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05987241 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06203600 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT07383441 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT03866382 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT03866382 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05675410 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05987241 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06203600 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05327686 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05675410 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05677490 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT03866382 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT05675410 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT05987241 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT06203600 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT07166406 | Map |
| MI | Michigan Hematology and Oncology Consultants | Dearborn48126 | NCT06463665 | Map |
| MI | Barbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006 | Detroit48201 | NCT05584670 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT04546399 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT05675410 | Map |
| MI | Exelixis Clinical Site #13 | Detroit48202 | NCT05176483 | Map |
| MI | Exelixis Clinical Site #65 | Detroit48201 | NCT05176483 | Map |
| MI | Henry Ford Cancer Center - Michigan | Detroit04820 | NCT06112314 | Map |
| MI | Henry Ford Cancer Institute/Henry Ford Health System | Detroit48202 | NCT06246916 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT03866382 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT02693535 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT05677490 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT03866382 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05533697 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05675410 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05987241 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06203600 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT07166406 | Map |
| MI | Karmanos Cancer Center ( Site 0108) | Detroit48201 | NCT07405164 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05675410 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05677490 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05987241 | Map |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT03866382 | — |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT05677490 | — |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT05136196 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT05677490 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT05987241 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06203600 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06632327 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05327686 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05675410 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05677490 | Map |
| MI | Oakland Medical Group | Farmington Hills48336 | NCT06463665 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05675410 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05677490 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05987241 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05136196 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT03866382 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05677490 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05987241 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT06203600 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT05677490 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05136196 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT03866382 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT02693535 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05677490 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05987241 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT06203600 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05136196 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT03866382 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05677490 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05987241 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT06203600 | Map |
| MI | McLaren Cancer Institute-Flint | Flint48532 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Gladwin | Gladwin48624 | NCT05677490 | Map |
| MI | Cancer Research Consortium of West Michigan | Grand Rapids49503 | NCT02693535 | Map |
| MI | Corewell Health | Grand Rapids49503 | NCT06264180 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05112601 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05136196 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05675410 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05987241 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT04546399 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT05675410 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06064097 | Map |
| MI | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids49503 | NCT04511013 | Map |
| MI | Research Site | Grand Rapids49503 | NCT07431281 | Map |
| MI | Site 04 | Grand Rapids49546 | NCT07276373 | Map |
| MI | Spectrum Health at Butterworth Campus | Grand Rapids49503 | NCT04511013 | Map |
| MI | START Midwest | Grand Rapids49503-2563 | NCT05267626 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05112601 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05136196 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT04511013 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05675410 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05987241 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT03866382 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT03866382 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Allegiance Health | Jackson49201 | NCT03866382 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05675410 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05987241 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06203600 | Map |
| MI | Allegiance Health | Jackson49201 | NCT07166406 | Map |
| MI | Ascension Borgess Cancer Center | Kalamazoo49009 | NCT04511013 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05112601 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05136196 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05675410 | Map |
| MI | Borgess Medical Center | Kalamazoo49048 | NCT04511013 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05112601 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05136196 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04511013 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04546399 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05675410 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05987241 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05112601 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05136196 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT04511013 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05675410 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05987241 | Map |
| MI | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing48910 | NCT05677490 | Map |
| MI | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing48910 | NCT05987241 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05136196 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT03866382 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT02693535 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05327686 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05677490 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05987241 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT06203600 | Map |
| MI | McLaren Cancer Institute-Lapeer Region | Lapeer48446 | NCT05677490 | Map |
| MI | Trinity Health Livonia Hospital | Livonia48154 | NCT02693535 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05136196 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT03866382 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05327686 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05675410 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05677490 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05987241 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06203600 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT07383441 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT03866382 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05677490 | Map |
| MI | Henry Ford Warren Hospital - Breast Macomb | Macomb48044 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Macomb | Mount Clemens48043 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Mount Pleasant | Mount Pleasant48858 | NCT05677490 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05112601 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05136196 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT04511013 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05675410 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05987241 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05112601 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05136196 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05987241 | Map |
| MI | Lakeland Hospital Niles | Niles49120 | NCT04511013 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05112601 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05136196 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT04511013 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05675410 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05987241 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT05675410 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT06203600 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT03866382 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05675410 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05987241 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06203600 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT07166406 | Map |
| MI | McLaren Cancer Institute-Northern Michigan | Petoskey49770 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Northern Michigan | Petoskey49770 | NCT05987241 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT05677490 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT03866382 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT05677490 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT03866382 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT05677490 | Map |
| MI | Trinity Health Oakland Hospital | Pontiac48341 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05136196 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT03866382 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05675410 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05677490 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05987241 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06203600 | Map |
| MI | McLaren-Port Huron | Port Huron48060 | NCT05677490 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05112601 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05136196 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05675410 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05987241 | Map |
| MI | Spectrum Health Reed City Hospital | Reed City49677 | NCT04511013 | Map |
| MI | Cancer Care Associates PC | Royal Oak48073 | NCT05677490 | Map |
| MI | Comprehensive Medical Center PLLC | Royal Oak48073 | NCT05677490 | Map |
| MI | Corewell Health Children's | Royal Oak48073 | NCT04546399 | Map |
| MI | Corewell Health Children's | Royal Oak48073 | NCT05675410 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05327686 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05675410 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05677490 | Map |
| MI | Hematology Oncology Consultants PC-Royal Oak | Royal Oak48073 | NCT05677490 | Map |
| MI | Oakland Colon Rectal Associates | Royal Oak48067 | NCT05677490 | Map |
| MI | Oakland Medical Group | Royal Oak48073 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT03866382 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT02693535 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT05987241 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05112601 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05136196 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05675410 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05987241 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT05112601 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT05987241 | Map |
| MI | Lakeland Medical Center Saint Joseph | Saint Joseph49085 | NCT04511013 | Map |
| MI | Marie Yeager Cancer Center | Saint Joseph49085 | NCT04511013 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT05675410 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT06203600 | Map |
| MI | Premier Hematology Oncology Care | Sterling Heights48312 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT03866382 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT05987241 | Map |
| MI | Michigan Cancer Research Consortium | Traverse City48341 | NCT02693535 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05112601 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05136196 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT04511013 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05675410 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05987241 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05327686 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05675410 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05677490 | Map |
| MI | Hematology Oncology Consultants PC-Troy | Troy48098 | NCT05677490 | Map |
| MI | Michigan Institute of Urology-Town Center | Troy48084 | NCT05677490 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT03866382 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT02693535 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford Madison Heights Hospital - Breast | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT03866382 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT03866382 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05675410 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05987241 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06203600 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT07166406 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT03866382 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT05675410 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT05987241 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT06203600 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT07166406 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05112601 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05136196 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT04511013 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05675410 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05987241 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05136196 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT03866382 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05136196 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05675410 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05987241 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06203600 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT07383441 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT05677490 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT05677490 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05136196 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05327686 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05677490 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05987241 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT06203600 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT06632327 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05136196 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05327686 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05677490 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT06203600 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT07166406 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT04511013 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT05677490 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT06632327 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT04511013 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT05677490 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT06632327 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05112601 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05136196 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04511013 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05675410 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05677490 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05987241 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06203600 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06632327 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT05677490 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT06632327 | Map |
| MN | Essentia Health - Saint Joseph's Crosslake Clinic | Crosslake56442 | NCT05677490 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05112601 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05136196 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT03866382 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05327686 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05677490 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06203600 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT07166406 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT05136196 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT05677490 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05112601 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05136196 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT03866382 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05327686 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05677490 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06203600 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT07166406 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT05327686 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT05677490 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT07166406 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05112601 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05327686 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05677490 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT07166406 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05112601 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05136196 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT03866382 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT04511013 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05327686 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05675410 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05677490 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05987241 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06203600 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06632327 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT05677490 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT06632327 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT05677490 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT05136196 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology, P.A | Fridley55432 | NCT06246916 | Map |
| MN | Unity Hospital | Fridley55432 | NCT04511013 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05112601 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05136196 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT03866382 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05327686 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05677490 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06203600 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT07166406 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT05677490 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT04511013 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05327686 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05677490 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT06632327 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT05677490 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT04511013 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT06632327 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05136196 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04511013 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05677490 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT06203600 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT06632327 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05112601 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05136196 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04511013 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05327686 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05675410 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05677490 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05987241 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06203600 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06632327 | Map |
| MN | Allina Health Cancer Institute | Minneapolis55407 | NCT06246916 | Map |
| MN | Allina Health Cancer Institute - Minneapolis | Minneapolis55407 | NCT06112314 | Map |
| MN | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis55404 | NCT04546399 | Map |
| MN | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis55404 | NCT05675410 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT04511013 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT05677490 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT06632327 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT03866382 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04511013 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05327686 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05677490 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05987241 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT06632327 | Map |
| MN | M Health Fairview University of Minnesota Medical Center | Minneapolis55455 | NCT04665206 | Map |
| MN | M Health Fairview University of Minnesota Medical Center | Minneapolis55455 | NCT05919264 | Map |
| MN | Minnesota Oncology and Hematology PA | Minneapolis55404-4526 | NCT05267626 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT03681561 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06264180 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT04546399 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT05327686 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT05647265 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT05675410 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT04511013 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT05677490 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT06632327 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT05677490 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT04511013 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT05677490 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT06632327 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT05136196 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Pequot Lakes Clinic | Pequot Lakes56472 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Pine River Clinic | Pine River56474 | NCT05677490 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT04511013 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT05677490 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT06632327 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT04511013 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT05677490 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT06632327 | Map |
| MN | Exelixis Clinical Site #68 | Rochester55905 | NCT05176483 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05223816 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05919264 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05136196 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03866382 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03017820 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05327686 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05647265 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05675410 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05802056 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06064097 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06632327 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT07226856 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT07510334 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT06581406 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT05655312 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT05677490 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT05987241 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT06632327 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05112601 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05136196 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04511013 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05675410 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05677490 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05987241 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06203600 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06632327 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05112601 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05136196 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT03866382 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04511013 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05327686 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05675410 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05677490 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05987241 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06203600 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06632327 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05112601 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05136196 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04511013 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05675410 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05677490 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05987241 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06203600 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06632327 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05112601 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05136196 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT03866382 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05327686 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05677490 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06203600 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT07166406 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05112601 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT04511013 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05327686 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05677490 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT06632327 | Map |
| MN | Essentia Health - Saint Joseph's Staples Clinic | Staples56479 | NCT05677490 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT03866382 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT04511013 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT05327686 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT05677490 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT06632327 | Map |
| MN | Sanford Thief River Falls Medical Center | Thief River Falls56701 | NCT05677490 | Map |
| MN | Sanford Thief River Falls Medical Center | Thief River Falls56701 | NCT06632327 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05112601 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05136196 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT03866382 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05327686 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05677490 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06203600 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT07166406 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05136196 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT03866382 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT04511013 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05327686 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05677490 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT06632327 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT04511013 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT05677490 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05136196 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT04511013 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05675410 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT06203600 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT06632327 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT05677490 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT06632327 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT04511013 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT05677490 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT07383441 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06632327 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT07383441 | Map |
| MS | Hattiesburg Clinic Hematology/Oncology | Hattiesburg39401-7233 | NCT06561386 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT03866382 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT04546399 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT05675410 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT05987241 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT06064097 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT07383441 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT07383441 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT07383441 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT05677490 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT06632327 | Map |
| MO | Saint Louis Cancer and Breast Institute-Ballwin | Ballwin63011 | NCT04511013 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT04511013 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT05677490 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT06632327 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT04511013 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT05677490 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT06632327 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT05677490 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT06632327 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05136196 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT03866382 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04511013 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05327686 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05675410 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05677490 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05987241 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06203600 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06632327 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT07383441 | Map |
| MO | Southeast Cancer Center | Cape Girardeau63703 | NCT04511013 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT05675410 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT04609046 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05136196 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03816345 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03866382 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05675410 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05896839 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05987241 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06203600 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06632327 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT07166406 | Map |
| MO | Missouri Cancer Associates | Columbia65201 | NCT07221149 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT05112601 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT05327686 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT05987241 | Map |
| MO | University of Missouri Children's Hospital | Columbia65212 | NCT05675410 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT04609046 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05136196 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03816345 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03866382 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05675410 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05896839 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05987241 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06203600 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06632327 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT07166406 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT03866382 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04511013 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05677490 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05987241 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT06632327 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT07383441 | Map |
| MO | Capital Region Southwest Campus | Jefferson City65109 | NCT04511013 | Map |
| MO | Freeman Health System | Joplin64804 | NCT04511013 | Map |
| MO | Freeman Health System | Joplin64804 | NCT05677490 | Map |
| MO | Freeman Health System | Joplin64804 | NCT06632327 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT04511013 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT05677490 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT06632327 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT04546399 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT05675410 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT06064097 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT03816345 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT03866382 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT05677490 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT05987241 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT06203600 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT06632327 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT05987241 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT03816345 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT05987241 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT03816345 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT03866382 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT05987241 | Map |
| MO | University of Kansas Cancer Center at North Kansas City Hospital | North Kansas City64116 | NCT03816345 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT05677490 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT06632327 | Map |
| MO | Delbert Day Cancer Institute at PCRMC | Rolla65401 | NCT04511013 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT04511013 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT05677490 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT06632327 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT05677490 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT06632327 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04511013 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT05677490 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT06632327 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT03866382 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04511013 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05677490 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05987241 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT06632327 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT07383441 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT04511013 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT05677490 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT06632327 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT04511013 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05327686 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05677490 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05987241 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT06632327 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT04546399 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT05675410 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT03866382 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04511013 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04546399 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05327686 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05675410 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05677490 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05987241 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06029270 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06632327 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05136196 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT03866382 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04511013 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05327686 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05677490 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05987241 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT06029270 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT06632327 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT05677490 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT06632327 | Map |
| MO | Mercy South | St Louis63128 | NCT06246916 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT03866382 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04511013 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05677490 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05987241 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06632327 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT07383441 | Map |
| MO | Research Site | St Louis63110 | NCT07431281 | Map |
| MO | Saint Louis Cancer and Breast Institute-South City | St Louis63109 | NCT04511013 | Map |
| MO | Saint Louis University Hospital | St Louis63110 | NCT05655312 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT04609046 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05136196 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT03816345 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT03866382 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05675410 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05896839 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05987241 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06203600 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06632327 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT07166406 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT04609046 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05136196 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03816345 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03866382 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05675410 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05896839 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05987241 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06203600 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06632327 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT07166406 | Map |
| MO | VA St. Louis Healthcare System | St Louis63106 | NCT06246916 | Map |
| MO | Veteran's Affairs Medical Center - Saint Louis | St Louis63125 | NCT05987241 | Map |
| MO | Veteran's Affairs Medical Center - Saint Louis | St Louis63125 | NCT06632327 | Map |
| MO | Washington University | St Louis63110-1010 | NCT05267626 | Map |
| MO | Washington University | St Louis63110 | NCT05533697 | Map |
| MO | Washington University | St Louis63110 | NCT06246916 | Map |
| MO | Washington University in St. Louis | St Louis63110 | NCT06745076 | Map |
| MO | Washington University of St. Louis | St Louis63110 | NCT05655312 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT04609046 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05112601 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05136196 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05187182 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03816345 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03866382 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT04546399 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05629546 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05675410 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05896839 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05919264 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05987241 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06064097 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06203600 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06632327 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06639607 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06794229 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06863311 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06968988 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07166406 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07293351 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT03866382 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04511013 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05677490 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05987241 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT06632327 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT07383441 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT03866382 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05677490 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05987241 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT06632327 | Map |
| MO | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills63127 | NCT04511013 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT04511013 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT05677490 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT06632327 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05112601 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05136196 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT03866382 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT04511013 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05677490 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05987241 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06029270 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06203600 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06632327 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05112601 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05136196 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT03866382 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT04511013 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05677490 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05987241 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06029270 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06203600 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06632327 | Map |
| MT | Intermountain Health West End Clinic | Billings59106 | NCT05112601 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT05112601 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT05677490 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT06203600 | Map |
| MT | St. Vincent Healthcare | Billings59102 | NCT06246916 | Map |
| MT | Bozeman Deaconess Hospital | Bozeman59715 | NCT04511013 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05112601 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05136196 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT03866382 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05677490 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05987241 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06029270 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06203600 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06632327 | Map |
| MT | Saint James Community Hospital and Cancer Treatment Center | Butte59701 | NCT05677490 | Map |
| MT | Benefis Healthcare- Sletten Cancer Institute | Great Falls59405 | NCT04511013 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05112601 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05136196 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT03866382 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05677490 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05987241 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06029270 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06203600 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06632327 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT04511013 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT05677490 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT06632327 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT05677490 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT06632327 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT05677490 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT06632327 | Map |
| MT | Kalispell Regional Medical Center | Kalispell59901 | NCT04511013 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05112601 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05136196 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT03866382 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05677490 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05987241 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06029270 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06203600 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06632327 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05112601 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05136196 | Map |
| MT | Community Medical Center | Missoula59804 | NCT03866382 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05677490 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05987241 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06029270 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06203600 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06632327 | Map |
| MT | Community Medical Hospital | Missoula59804 | NCT04511013 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT04511013 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05647265 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05677490 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05136196 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT03866382 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05327686 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05675410 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05677490 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05987241 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT06203600 | Map |
| NE | CHI Health Saint Francis | Grand Island68803 | NCT06632327 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT06632327 | Map |
| NE | Cancer Partners of Nebraska - Pine Lake | Lincoln68516 | NCT04511013 | Map |
| NE | Southeast Nebraska Cancer Center - 68th Street Place | Lincoln68516 | NCT04511013 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT06632327 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT06632327 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT06632327 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT04546399 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT05675410 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT06064097 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT06632327 | Map |
| NE | Exelixis Clinical Site #2 | Omaha68130 | NCT05176483 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT05655312 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT05677490 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT06029270 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05136196 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT03866382 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05327686 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05675410 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05677490 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05987241 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT06203600 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT05112601 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT05677490 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT06029270 | Map |
| NE | Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE | Omaha68105-1850 | NCT06275360 | Map |
| NE | Oncology Hematology West P.C. dba Nebraska Cancer Specialists | Omaha68130 | NCT06246916 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05136196 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03866382 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT04546399 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT02693535 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05327686 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05675410 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05677490 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05987241 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06064097 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06203600 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06743126 | Map |
| NV | Carson Tahoe Regional Medical Center | Carson City89703 | NCT05647265 | Map |
| NV | Carson Tahoe Regional Medical Center | Carson City89703 | NCT05677490 | Map |
| NV | Cancer and Blood Specialists-Henderson | Henderson89052 | NCT05647265 | Map |
| NV | Cancer and Blood Specialists-Henderson | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Horizon Ridge | Henderson89052 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Horizon Ridge | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson89074 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Green Valley | Henderson89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Green Valley | Henderson89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Pebble | Henderson89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Pebble | Henderson89074 | NCT05677490 | Map |
| NV | Oncology Las Vegas - Henderson | Henderson89074 | NCT05647265 | Map |
| NV | Oncology Las Vegas - Henderson | Henderson89074 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Green Valley | Henderson89074 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Green Valley | Henderson89074 | NCT05677490 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT04546399 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05647265 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05675410 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT06246916 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT05677490 | Map |
| NV | Exelixis Clinical Site #55 | Las Vegas89052 | NCT05176483 | Map |
| NV | Hope Cancer Care of Nevada | Las Vegas89103 | NCT05647265 | Map |
| NV | Hope Cancer Care of Nevada | Las Vegas89103 | NCT05677490 | Map |
| NV | Las Vegas Prostate Cancer Center | Las Vegas89113 | NCT05647265 | Map |
| NV | Las Vegas Prostate Cancer Center | Las Vegas89113 | NCT05677490 | Map |
| NV | Las Vegas Urology - Cathedral Rock | Las Vegas89128 | NCT05647265 | Map |
| NV | Las Vegas Urology - Cathedral Rock | Las Vegas89128 | NCT05677490 | Map |
| NV | Las Vegas Urology - Pecos | Las Vegas89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Pecos | Las Vegas89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Smoke Ranch | Las Vegas89128 | NCT05647265 | Map |
| NV | Las Vegas Urology - Smoke Ranch | Las Vegas89128 | NCT05677490 | Map |
| NV | Las Vegas Urology - Sunset | Las Vegas89113 | NCT05647265 | Map |
| NV | Las Vegas Urology - Sunset | Las Vegas89113 | NCT05677490 | Map |
| NV | Oncology Las Vegas - Tenaya | Las Vegas89128 | NCT05647265 | Map |
| NV | Oncology Las Vegas - Tenaya | Las Vegas89128 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT03866382 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05987241 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT06203600 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT03866382 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05987241 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT06203600 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT05677490 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT05647265 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT05677490 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT05647265 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT05677490 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT04546399 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT05647265 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT05677490 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT05647265 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT05677490 | Map |
| NV | University Cancer Center | Las Vegas89169 | NCT05647265 | Map |
| NV | University Cancer Center | Las Vegas89169 | NCT05677490 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT05647265 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Central | Las Vegas89106 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Central | Las Vegas89106 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Northwest | Las Vegas89128 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Northwest | Las Vegas89128 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Southwest | Las Vegas89113 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Southwest | Las Vegas89113 | NCT05677490 | Map |
| NV | Women's Cancer Center of Nevada | Las Vegas89106 | NCT05112601 | Map |
| NV | Hope Cancer Care of Nevada-Pahrump | Pahrump89048 | NCT05647265 | Map |
| NV | Hope Cancer Care of Nevada-Pahrump | Pahrump89048 | NCT05677490 | Map |
| NV | Cancer Care Specialists | Reno89511 | NCT07195695 | Map |
| NV | Radiation Oncology Associates | Reno89509 | NCT05647265 | Map |
| NV | Radiation Oncology Associates | Reno89509 | NCT05677490 | Map |
| NV | Renown Health Medical Oncology | Reno89502 | NCT07392892 | Map |
| NV | Renown Office of Clinical Research | Reno89502 | NCT07392892 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT04546399 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06561386 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT05647265 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT05675410 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT05677490 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06203600 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT07392892 | Map |
| NV | Saint Mary's Regional Medical Center | Reno89503 | NCT05647265 | Map |
| NV | Saint Mary's Regional Medical Center | Reno89503 | NCT05677490 | Map |
| NH | NH Oncology - Hematology, PA | Concord03103 | NCT02693535 | Map |
| NH | Dartmouth Cancer Center | Lebanon03756 | NCT05901285 | Map |
| NH | Dartmouth Hitchcock | Lebanon03756 | NCT06362369 | Map |
| NH | Dartmouth Hitchcock Cancer Center | Lebanon03756 | NCT06264180 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT06246916 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05136196 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04546399 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05675410 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06632327 | Map |
| NH | The Dana-Farber Cancer Institute at Londonderry | Londonderry03053 | NCT05677490 | Map |
| NH | Dartmouth Cancer Center - Manchester/ DCC Manchester | Manchester03104 | NCT06632327 | Map |
| NH | Solinsky Center for Cancer Care | Manchester03103 | NCT02693535 | Map |
| NH | Dartmouth Cancer Center - Nashua | Nashua03063 | NCT06632327 | Map |
| NH | New England Cancer Specialist | Portsmouth03801 | NCT02693535 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities | Basking Ridge07920 | NCT04991025 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05987241 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT07532902 | Map |
| NJ | Memorial Sloan Kettering Cancer Center Basking Ridge | Basking Ridge07920 | NCT06534983 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT05327686 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT05675410 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT06632327 | Map |
| NJ | Jefferson Cherry Hill Hospital | Cherry Hill08002 | NCT05677490 | Map |
| NJ | Jefferson Cherry Hill Hospital | Cherry Hill08002 | NCT05987241 | Map |
| NJ | Jefferson Cherry Hill Hospital | Cherry Hill08002 | NCT06203600 | Map |
| NJ | Exelixis Clinical Site #88 | East Brunswick08816 | NCT05176483 | Map |
| NJ | Research Site | East Brunswick08816 | NCT07431281 | Map |
| NJ | Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus | Elizabeth07207 | NCT05675410 | Map |
| NJ | Hunterdon Medical Center | Flemington08822 | NCT05675410 | Map |
| NJ | Exelixis Clinical Site #105 | Hackensack07601 | NCT05176483 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT04546399 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT05675410 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT05987241 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06064097 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06264180 | Map |
| NJ | Hackensack University Medical Center/John Theurer Cancer Center | Hackensack07601 | NCT04561206 | Map |
| NJ | John Theurer Cancer Center | Hackensack07601 | NCT05533697 | Map |
| NJ | John Theurer Cancer Center | Hackensack07601 | NCT06246916 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06015724 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06112314 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06618287 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06697197 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06764771 | Map |
| NJ | John Theurer Cancer Center Site Number : 8400001 | Hackensack07601 | NCT05584670 | Map |
| NJ | John Theurer Cancer Center, Hackensack Meridian Health | Hackensack07410 | NCT05715229 | Map |
| NJ | Jersey City Medical Center | Jersey City07302 | NCT05675410 | Map |
| NJ | Jersey City Medical Center | Jersey City07302 | NCT05987241 | Map |
| NJ | Monmouth Medical Center Southern Campus | Lakewood08701 | NCT05987241 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05675410 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05987241 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05675410 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05987241 | Map |
| NJ | Southern Ocean County Medical Center | Manahawkin08050 | NCT05987241 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05987241 | Map |
| NJ | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown07748 | NCT07532902 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT04991025 | Map |
| NJ | MSK Monmouth | Middletown07748 | NCT06534983 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05987241 | Map |
| NJ | Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale07645 | NCT07532902 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT04991025 | Map |
| NJ | MSK Bergen | Montvale07645 | NCT06534983 | Map |
| NJ | Atlantic Health System | Morristown07960 | NCT05901285 | Map |
| NJ | Atlantic Health System/Morristown Medical Center | Morristown07960 | NCT06743126 | Map |
| NJ | Atlantic Healthcare System | Morristown07960 | NCT05267626 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT04546399 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT05675410 | Map |
| NJ | Morristown Medical Center - Atlantic Health System | Morristown07960 | NCT06264180 | Map |
| NJ | Cooper CyberKnife Center | Mount Laurel08054 | NCT05327686 | Map |
| NJ | Cooper CyberKnife Center | Mount Laurel08054 | NCT06632327 | Map |
| NJ | Inspira Medical Center Mullica Hill | Mullica Hill08062 | NCT06463665 | Map |
| NJ | Jersey Shore Medical Center | Neptune City07753 | NCT05675410 | Map |
| NJ | Jersey Shore Medical Center | Neptune City07753 | NCT06064097 | Map |
| NJ | Jersey Shore Medical Center | Neptune City07753 | NCT06632327 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT03816345 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT04546399 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05675410 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05987241 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06246916 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT04546399 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT05675410 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT06064097 | Map |
| NJ | Saint Peter's University Hospital | New Brunswick08901 | NCT05675410 | Map |
| NJ | Newark Beth Israel Medical Center | Newark07112 | NCT04546399 | Map |
| NJ | Newark Beth Israel Medical Center | Newark07112 | NCT05675410 | Map |
| NJ | Newark Beth Israel Medical Center | Newark07112 | NCT06064097 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT06632327 | Map |
| NJ | The Valley Hospital Inc. | Paramus07652 | NCT06246916 | Map |
| NJ | Saint Joseph's Regional Medical Center | Paterson07503 | NCT04546399 | Map |
| NJ | Saint Joseph's Regional Medical Center | Paterson07503 | NCT05675410 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT06632327 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT05677490 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT05987241 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT06203600 | Map |
| NJ | Robert Wood Johnson University Hospital Somerset | Somerville08876 | NCT05987241 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05675410 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05987241 | Map |
| NJ | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township08043 | NCT06632327 | Map |
| NM | Lovelace Medical Center - Saint Joseph Square | Albuquerque87102 | NCT02693535 | Map |
| NM | Lovelace Medical Center-Saint Joseph Square | Albuquerque87102 | NCT05327686 | Map |
| NM | Lovelace Medical Center-Saint Joseph Square | Albuquerque87102 | NCT06203600 | Map |
| NM | Lovelace Radiation Oncology | Albuquerque87109 | NCT05327686 | Map |
| NM | Presbyterian Hospital | Albuquerque87106 | NCT05675410 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT02693535 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT05987241 | Map |
| NM | The University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT02693535 | Map |
| NM | University of New Mexico | Albuquerque87106 | NCT06624644 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05112601 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05136196 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06203600 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06632327 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT07166406 | Map |
| NM | University of New Mexico Comprehensive Cancer Center | Albuquerque87106 | NCT06646276 | Map |
| NM | Memorial Medical Center | Las Cruces88011 | NCT02693535 | Map |
| NM | Memorial Medical Center-Las Cruces | Las Cruces88011 | NCT06632327 | Map |
| NM | Presbyterian Rust Medical Center | Rio Rancho87124 | NCT02693535 | Map |
| NM | Presbyterian Rust Medical Center/Jorgensen Cancer Center | Rio Rancho87124 | NCT05987241 | Map |
| NY | Albany Medical Center | Albany12208 | NCT04546399 | Map |
| NY | Albany Medical Center | Albany12208 | NCT05675410 | Map |
| NY | Albany Medical Center | Albany12208 | NCT06064097 | Map |
| NY | New York Oncology Hematology | Albany12206 | NCT06246916 | Map |
| NY | Northwell Health Imbert Cancer Center | Bay Shore11706 | NCT05327686 | Map |
| NY | Northwell Health Imbert Cancer Center | Bay Shore11706 | NCT06203600 | Map |
| NY | Maimonides Medical Center | Brooklyn11219 | NCT04546399 | Map |
| NY | Maimonides Medical Center | Brooklyn11219 | NCT05987241 | Map |
| NY | New York-Presbyterian/Brooklyn Methodist Hospital | Brooklyn11215 | NCT05677490 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT03899155 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05675410 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06203600 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06264180 | Map |
| NY | Hematology Oncology Associates of CNY at Camillus | Camillus13031 | NCT05675410 | Map |
| NY | Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity) | Commack11725 | NCT04991025 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05987241 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) | Commack11725 | NCT07532902 | Map |
| NY | MSK Commack | Commack11725 | NCT06534983 | Map |
| NY | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse13057 | NCT05675410 | Map |
| NY | Memorial Sloan Kettering Westchester | East White Plains10604 | NCT05327686 | Map |
| NY | The New York Hospital Medical Center of Queens | Flushing11355 | NCT05677490 | Map |
| NY | The New York Hospital Medical Center of Queens | Flushing11355 | NCT05987241 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05327686 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05675410 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05677490 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05987241 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT06203600 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT06632327 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT05327686 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT05677490 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT06203600 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05384496 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05987241 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT04991025 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT07532902 | Map |
| NY | MSK Westchester | Harrison10604 | NCT06534983 | Map |
| NY | Northwell Health Cancer Institute | Lake Success11042 | NCT06112314 | Map |
| NY | Northwell Health Monter Cancer Center | Lake Success11042 | NCT02693535 | Map |
| NY | Northwell Health, R.J. Zuckerberg Cancer Center | Lake Success11042 | NCT06264180 | Map |
| NY | Northwell Health/ RJ Zuckerberg Cancer Center | Lake Success11042 | NCT06697197 | Map |
| NY | Northwell Health/ RJ Zuckerberg Cancer Center | Lake Success11042 | NCT07221149 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT04609046 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT05327686 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT05677490 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT06203600 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT04609046 | Map |
| NY | NYU Langone Hematology Oncology Associates-Mineola | Mineola11501 | NCT03899155 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05136196 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT03816345 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT03866382 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT04546399 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05272384 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05675410 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05896839 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06203600 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT02693535 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT05327686 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT05677490 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT06203600 | Map |
| NY | Cohen Children's Medical Center | New Hyde Park11040 | NCT02693535 | Map |
| NY | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park11040 | NCT05675410 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT06863311 | Map |
| NY | Exelixis Clinical Site #6 | New York10065 | NCT05176483 | Map |
| NY | Exelixis Clinical Site #60 | New York10032 | NCT05176483 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT05188118 | Map |
| NY | Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT07195695 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05136196 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT03816345 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT04546399 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05272384 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05327686 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05675410 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05896839 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06203600 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT06743126 | Map |
| NY | Lenox Hill Hospital | New York10075 | NCT05327686 | Map |
| NY | Lenox Hill Hospital | New York10075 | NCT05677490 | Map |
| NY | Manhattan Eye Ear and Throat Hospital | New York10065 | NCT05327686 | Map |
| NY | Manhattan Eye Ear and Throat Hospital | New York10065 | NCT05677490 | Map |
| NY | Manhattan Eye, Ear, and Throat Hospital | New York10065 | NCT02693535 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03686124 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04665206 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03803553 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04900818 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04546399 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05384496 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06581406 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05675410 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05919264 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05987241 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06534983 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06743126 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06745076 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07221149 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics | New York10065 | NCT05533697 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT04991025 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07532902 | Map |
| NY | Memorial Sloan-Kettering Cancer Center | New York10065 | NCT07195695 | Map |
| NY | Mount Sinai Chelsea | New York10011 | NCT05987241 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05675410 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05987241 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT07166406 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT04609046 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT03816345 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT03866382 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT04546399 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT05675410 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT04609046 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT03816345 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT03866382 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT04546399 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT05675410 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT05677490 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT05987241 | Map |
| NY | NYU Langone | New York10016 | NCT04900818 | Map |
| NY | NYU Langone Health | New York10016 | NCT05428007 | Map |
| NY | NYU Langone Health | New York10016 | NCT07504796 | Map |
| NY | NYU Langone Health-Perlmutter Cancer Center | New York10016 | NCT05533697 | Map |
| NY | NYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013 | New York10016-6402 | NCT05584670 | Map |
| NY | NYU Longone Health | New York10016 | NCT07246863 | Map |
| NY | Staten Island University Hospital | New York10305 | NCT02693535 | Map |
| NY | Veterans Affairs New York Harbor Healthcare System | New York10016 | NCT06561386 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT03803553 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT02693535 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT05677490 | Map |
| NY | Rochester General Hospital | Rochester14621 | NCT05987241 | Map |
| NY | Unity Park Ridge Campus | Rochester14626 | NCT05987241 | Map |
| NY | University of Rochester | Rochester14642 | NCT05112601 | Map |
| NY | University of Rochester | Rochester14642 | NCT04477343 | Map |
| NY | University of Rochester | Rochester14642 | NCT05675410 | Map |
| NY | University of Rochester | Rochester14642 | NCT05677490 | Map |
| NY | University of Rochester | Rochester14642 | NCT05987241 | Map |
| NY | University of Rochester | Rochester14642 | NCT06203600 | Map |
| NY | University of Rochester | Rochester14642 | NCT06632327 | Map |
| NY | University of Rochester | Rochester14642 | NCT06743126 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT06561386 | Map |
| NY | Phelps Hospital | Sleepy Hollow10591 | NCT02693535 | Map |
| NY | Phelps Memorial Hospital Center | Sleepy Hollow10591 | NCT05327686 | Map |
| NY | Phelps Memorial Hospital Center | Sleepy Hollow10591 | NCT05677490 | Map |
| NY | Phelps Memorial Hospital Center | Sleepy Hollow10591 | NCT06203600 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT04546399 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05675410 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05677490 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05987241 | Map |
| NY | Exelixis Clinical Site #76 | Syracuse13210 | NCT05176483 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05112601 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT04546399 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05675410 | Map |
| NY | SUNY Upstate Medical University | Syracuse13210 | NCT06561386 | Map |
| NY | Albert Einstein College of Medicine, Children's Hospital at Montefiore | The Bronx10467 | NCT03465592 | Map |
| NY | James J Peters VA Medical Center | The Bronx10468 | NCT06632327 | Map |
| NY | Montefiore Medical Center | The Bronx10461 | NCT06264180 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT04546399 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT05675410 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT06064097 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT07166406 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT05677490 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT05987241 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT07166406 | Map |
| NY | Montefiore Medical Center-Weiler Hospital | The Bronx10461 | NCT05677490 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05987241 | Map |
| NY | Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale11553 | NCT07532902 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT04991025 | Map |
| NY | MSK Nassau | Uniondale11553 | NCT06534983 | Map |
| NY | New York Medical Center/ Maria Fareri Children's Hospital | Valhalla10595 | NCT03465592 | Map |
| NY | New York Medical College | Valhalla10595 | NCT07013565 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05112601 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05675410 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05677490 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05987241 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT06632327 | Map |
| NC | Atrium Health Stanly/LCI-Albemarle | Albemarle28002 | NCT05987241 | Map |
| NC | Cone Health MedCenter Asheboro | Asheboro27205 | NCT06203600 | Map |
| NC | Messino Cancer Center | Asheville28806 | NCT06246916 | Map |
| NC | Mission Hospital | Asheville28801 | NCT04546399 | Map |
| NC | Mission Hospital | Asheville28801 | NCT05675410 | Map |
| NC | Cone Health Cancer Center at Alamance Regional | Burlington27215 | NCT06203600 | Map |
| NC | Duke Cancer Center Cary | Cary27518 | NCT05327686 | Map |
| NC | Duke Cancer Center Cary | Cary27518 | NCT05987241 | Map |
| NC | Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT02693535 | Map |
| NC | UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06743126 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT04609046 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT03866382 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT04546399 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05327686 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05675410 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05677490 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05987241 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27514 | NCT06264180 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT05327686 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT05987241 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT05327686 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT05987241 | Map |
| NC | Atrium Health's Levine Cancer Institute | Charlotte28277 | NCT02693535 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04546399 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05327686 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05675410 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05987241 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06064097 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06246916 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06697197 | Map |
| NC | Levine Cancer Institute-Ballantyne | Charlotte28277 | NCT05327686 | Map |
| NC | Levine Cancer Institute-Ballantyne | Charlotte28277 | NCT05987241 | Map |
| NC | Levine Cancer Institute-SouthPark | Charlotte28211 | NCT05987241 | Map |
| NC | Novant Health Cancer Institute | Charlotte28204 | NCT06246916 | Map |
| NC | Novant Health Weisiger Cancer Institute - Charlotte | Charlotte28204 | NCT06246916 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT04511013 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT05327686 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT05987241 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT05136196 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04511013 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT06203600 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT05327686 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT05987241 | Map |
| NC | Duke Cancer Center | Durham27710 | NCT06264180 | Map |
| NC | Duke Cancer Center Southpoint | Durham27713 | NCT05647265 | Map |
| NC | Duke Cancer Center Southpoint | Durham27713 | NCT05987241 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT06646276 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT07325136 | Map |
| NC | Duke Health System | Durham27710 | NCT06246916 | Map |
| NC | Duke University | Durham27705 | NCT05919264 | Map |
| NC | Duke University | Durham27750 | NCT06816927 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05112601 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT04546399 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05327686 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06581406 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05647265 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05675410 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05987241 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06064097 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06708949 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT07246863 | Map |
| NC | Exelixis Clinical Site #12 | Durham27710 | NCT05176483 | Map |
| NC | Levine Cancer Institute - Rutherford | Forest City28043 | NCT05987241 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT05327686 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT05987241 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT05136196 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04511013 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT06203600 | Map |
| NC | Cone Health Cancer Center | Greensboro27403 | NCT06203600 | Map |
| NC | Cone Health Cancer Center at Drawbridge Parkway | Greensboro27410 | NCT06203600 | Map |
| NC | East Carolina University | Greenville27834 | NCT04546399 | Map |
| NC | East Carolina University | Greenville27858 | NCT06561386 | Map |
| NC | East Carolina University | Greenville27834 | NCT05675410 | Map |
| NC | East Carolina University | Greenville27834 | NCT05677490 | Map |
| NC | East Carolina University | Greenville27834 | NCT06064097 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT03866382 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT05677490 | Map |
| NC | Hayworth Cancer Center | High Point27262 | NCT05327686 | Map |
| NC | University of North Carolina-Hillsborough Campus | Hillsborough27278 | NCT05677490 | Map |
| NC | Carolina Biooncology Institute | Huntersville28078 | NCT05267626 | Map |
| NC | Levine Cancer Institute - Huntersville | Huntersville28078 | NCT05987241 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT05136196 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04511013 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT06203600 | Map |
| NC | Atrium Health Lincoln/LCI-Lincolnton | Lincolnton28092 | NCT05987241 | Map |
| NC | Levine Cancer Institute - Union West | Matthews28104 | NCT05987241 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT05327686 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT05987241 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT05677490 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT05987241 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT06203600 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05327686 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05647265 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05987241 | Map |
| NC | Duke Women's Cancer Care Raleigh | Raleigh27607 | NCT05112601 | Map |
| NC | Annie Penn Memorial Hospital | Reidsville27320 | NCT06203600 | Map |
| NC | Atrium Health Cleveland/LCI-Cleveland | Shelby28150 | NCT05987241 | Map |
| NC | Wake Forest Baptist Health - Hematology Oncology - Statesville | Statesville28677 | NCT04511013 | Map |
| NC | Wake Forest Baptist Health - Wilkes Medical Center | Wilkesboro28659 | NCT04511013 | Map |
| NC | Wake Forest Baptist Health - Wilkes Medical Center | Wilkesboro28659 | NCT05327686 | Map |
| NC | Novant Health Zimmer Cancer Institute - Wilmington | Wilmington28401 | NCT06246916 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27103 | NCT05317858 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT04511013 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT04546399 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05327686 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05675410 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05987241 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06064097 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05136196 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05327686 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05677490 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05987241 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT06203600 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT06632327 | Map |
| ND | Sanford Health- Bismarck | Bismarck58501 | NCT02693535 | Map |
| ND | Sanford Medical Center | Bismarck58501 | NCT06646276 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05112601 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05136196 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05677490 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT06203600 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05136196 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT04546399 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05327686 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05675410 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05677490 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05987241 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06064097 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06203600 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06632327 | Map |
| ND | Sanford Fargo Medical Center | Fargo58102 | NCT06646276 | Map |
| ND | Sanford Health- Fargo | Fargo58122 | NCT02693535 | Map |
| ND | Sanford Medical Center Fargo | Fargo58104 | NCT05677490 | Map |
| ND | Sanford Medical Center Fargo | Fargo58104 | NCT06632327 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05136196 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05327686 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05677490 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05987241 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT06203600 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT06632327 | Map |
| ND | Sanford South University Medical Center | Fargo58103 | NCT05677490 | Map |
| ND | Sanford South University Medical Center | Fargo58103 | NCT06632327 | Map |
| ND | Southpointe-Sanford Medical Center Fargo | Fargo58103 | NCT05677490 | Map |
| ND | Southpointe-Sanford Medical Center Fargo | Fargo58103 | NCT06632327 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT05136196 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT05677490 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT04546399 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT05675410 | Map |
| OH | UH Seidman Cancer Center at UH Avon Health Center | Avon44011 | NCT05327686 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05112601 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT04511013 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05327686 | Map |
| OH | Indu and Raj Soin Medical Center | Beavercreek45431 | NCT04511013 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT03866382 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT04511013 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT05677490 | Map |
| OH | Saint Elizabeth Boardman Hospital | Boardman44512 | NCT04511013 | Map |
| OH | Gabrail Cancer and Research Center | Canton44718 | NCT06463665 | Map |
| OH | Dayton Physicians LLC-Miami Valley South | Centerville45459 | NCT04511013 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05112601 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05136196 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05327686 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05677490 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT06203600 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT05112601 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT04511013 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT03866382 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT04511013 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT05677490 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT06632327 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT04546399 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT05675410 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06064097 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT05112601 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT06203600 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT06632327 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT03899155 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT06646276 | Map |
| OH | Oncology Hematology Care Clinical Trials | Cincinnati45242 | NCT06246916 | Map |
| OH | Oncology Hematology Care Clinical Trials, LLC | Cincinnati45211 | NCT07392892 | Map |
| OH | Oncology Hematology Care Clinical Trials, LLC | Cincinnati45242 | NCT07392892 | Map |
| OH | Oncology Hematology Care Clinical Trials, LLC | Cincinnati45245 | NCT07392892 | Map |
| OH | Oncology Hematology Care Inc-Kenwood | Cincinnati45236 | NCT04511013 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT06632327 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT06632327 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT05327686 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT05987241 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT02693535 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT06561386 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05112601 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT04511013 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05327686 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT05361720 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT05901285 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT05919264 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06618287 | Map |
| OH | Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland44111 | NCT05112601 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT05112601 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT05675410 | Map |
| OH | Cleveland Clinic, Taussig Cancer Institute | Cleveland44195 | NCT06743126 | Map |
| OH | Exelixis Clinical Site #10 | Cleveland44106 | NCT05176483 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT04546399 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT05675410 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT06064097 | Map |
| OH | Seidman Cancer Center | Cleveland44106 | NCT06246916 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT07325136 | Map |
| OH | University Hospitals Cleveland Medical Center, Seidman Cancer Center | Cleveland44106 | NCT05919264 | Map |
| OH | University Hospitals Seidman Cancer Center | Cleveland44106 | NCT05361720 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT03866382 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT04511013 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT03866382 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT04511013 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT03866382 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT04511013 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT03866382 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT04511013 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT05677490 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT03866382 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT04511013 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT05677490 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT04546399 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT05675410 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT06064097 | Map |
| OH | Ohio State University | Columbus43210 | NCT06743126 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03681561 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04609046 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04697576 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05112601 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05234307 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03816345 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03866382 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04511013 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05327686 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05677490 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05987241 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07166406 | Map |
| OH | Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run | Columbus43026 | NCT03686124 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT03866382 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT04511013 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT03866382 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT04511013 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT05677490 | Map |
| OH | The Ohio State University | Columbus43210 | NCT06581406 | Map |
| OH | The Ohio State University | Columbus43210 | NCT06112314 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT06246916 | Map |
| OH | The Ohio State University- Martha Morehouse Tower | Columbus43210 | NCT06264180 | Map |
| OH | The Ohio University | Columbus43210 | NCT03899155 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT04546399 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT05675410 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT06064097 | Map |
| OH | Dayton Physician LLC-Miami Valley Hospital North | Dayton45415 | NCT04511013 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05327686 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05677490 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT06203600 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05136196 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05327686 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05677490 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT06203600 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05136196 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05327686 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05677490 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT06203600 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT03866382 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT04511013 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT03866382 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT04511013 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT04511013 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT04511013 | Map |
| OH | Oncology Hematology Care Clinical Trials, LLC | Fairfield45014 | NCT07392892 | Map |
| OH | Armes Family Cancer Center | Findlay45840 | NCT04511013 | Map |
| OH | Blanchard Valley Hospital | Findlay45840 | NCT04511013 | Map |
| OH | Orion Cancer Care | Findlay45840 | NCT04511013 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05136196 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05327686 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05677490 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT06203600 | Map |
| OH | Dayton Physicians LLC-Atrium | Franklin45005 | NCT04511013 | Map |
| OH | Central Ohio Breast and Endocrine Surgery | Gahanna43230 | NCT04511013 | Map |
| OH | Central Ohio Breast and Endocrine Surgery | Gahanna43230 | NCT05677490 | Map |
| OH | Dayton Physicians LLC-Wayne | Greenville45331 | NCT04511013 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05136196 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05327686 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05677490 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT06203600 | Map |
| OH | Wayne Hospital | Greenville45331 | NCT04511013 | Map |
| OH | Mount Carmel Grove City Hospital | Grove City43123 | NCT04511013 | Map |
| OH | Mount Carmel Grove City Hospital | Grove City43123 | NCT05677490 | Map |
| OH | Zangmeister Center Grove City | Grove City43123 | NCT04511013 | Map |
| OH | Zangmeister Center Grove City | Grove City43123 | NCT05677490 | Map |
| OH | Greater Dayton Cancer Center | Kettering45409 | NCT04511013 | Map |
| OH | Kettering Health | Kettering45429 | NCT02693535 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT03866382 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT04511013 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT03866382 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT04511013 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT05677490 | Map |
| OH | Saint Rita's Medical Center | Lima45801 | NCT04511013 | Map |
| OH | Saint Rita's Medical Center | Lima45801 | NCT05677490 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT03866382 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT04511013 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT03866382 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT04511013 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT05677490 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT03866382 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT04511013 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT03866382 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT05677490 | Map |
| OH | Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT05112601 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05112601 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05327686 | Map |
| OH | UH Seidman Cancer Center at Southwest General Hospital | Middleburg Heights44130 | NCT04511013 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT03866382 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT04511013 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT05677490 | Map |
| OH | Mount Carmel New Albany Surgical Hospital | New Albany43054 | NCT04511013 | Map |
| OH | Mount Carmel New Albany Surgical Hospital | New Albany43054 | NCT05677490 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT03866382 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT04511013 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT05677490 | Map |
| OH | Newark Radiation Oncology | Newark43055 | NCT04511013 | Map |
| OH | Newark Radiation Oncology | Newark43055 | NCT05677490 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT05112601 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT04511013 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT05327686 | Map |
| OH | Mercy Health - Perrysburg Hospital | Perrysburg43551 | NCT05677490 | Map |
| OH | Mercy Health Perrysburg Cancer Center | Perrysburg43551 | NCT04511013 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT03866382 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT04511013 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT05677490 | Map |
| OH | University Hospitals Portage Medical Center | Ravenna44266 | NCT04511013 | Map |
| OH | University Hospitals Portage Medical Center | Ravenna44266 | NCT05327686 | Map |
| OH | UH Seidman Cancer Center at Firelands Regional Medical Center | Sandusky44870 | NCT04511013 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT03866382 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT04511013 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT05677490 | Map |
| OH | Springfield Regional Medical Center | Springfield45505 | NCT04511013 | Map |
| OH | Springfield Regional Medical Center | Springfield45504 | NCT05677490 | Map |
| OH | ProMedica Flower Hospital | Sylvania43560 | NCT05987241 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT04511013 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT05677490 | Map |
| OH | Mercy Health - Saint Vincent Hospital | Toledo43608 | NCT05677490 | Map |
| OH | Mercy Health Sylvania Radiation Oncology Center | Toledo43623 | NCT05677490 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT04546399 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT05675410 | Map |
| OH | Saint Vincent Mercy Medical Center | Toledo43608 | NCT04511013 | Map |
| OH | Dayton Physicians LLC - Troy | Troy45373 | NCT04511013 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05136196 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05327686 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05677490 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT06203600 | Map |
| OH | University Hospitals Sharon Health Center | Wadsworth44281 | NCT04511013 | Map |
| OH | Saint Joseph Warren Hospital | Warren44484 | NCT04511013 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT05327686 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT05987241 | Map |
| OH | West Chester Hospital | West Chester45069 | NCT02693535 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT03866382 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT04511013 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT05677490 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT05112601 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT04511013 | Map |
| OH | Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center | Wilmington45177 | NCT05677490 | Map |
| OH | Saint Elizabeth Youngstown Hospital | Youngstown44501 | NCT04511013 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT03866382 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT04511013 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT05677490 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT03866382 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT05987241 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT06203600 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT06632327 | Map |
| OK | Integris Cancer Institute of Oklahoma | Oklahoma City73142 | NCT06203600 | Map |
| OK | Integris Southwest Medical Center | Oklahoma City73109 | NCT06203600 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04511013 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT05677490 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT06632327 | Map |
| OK | University of Oklahoma Health Science Center | Oklahoma City73104 | NCT03259867 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04609046 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05112601 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05136196 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT03866382 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04511013 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04546399 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05327686 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05675410 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05677490 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05987241 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06029270 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06064097 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06203600 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06632327 | Map |
| OK | Natalie Warren Bryant Cancer Center at Saint Francis | Tulsa74136 | NCT04546399 | Map |
| OK | Natalie Warren Bryant Cancer Center at Saint Francis | Tulsa74136 | NCT05675410 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT05112601 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT05327686 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT06203600 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa74146 | NCT06246916 | Map |
| OR | Saint Alphonsus Cancer Care Center-Baker City | Baker City97814 | NCT05677490 | Map |
| OR | Saint Alphonsus Medical Center-Baker City | Baker City97814 | NCT04511013 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05136196 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT04511013 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05647265 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05677490 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05136196 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT04511013 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05647265 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05677490 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT07166406 | Map |
| OR | Providence Cancer Institute Clackamas Clinic | Clackamas97015 | NCT04511013 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT04511013 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT05647265 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT05677490 | Map |
| OR | Oncology Associates of Oregon PC | Eugene97401 | NCT06246916 | Map |
| OR | Oncology Associates Of Oregon, Pc | Eugene97401 | NCT07221149 | Map |
| OR | Legacy Mount Hood Medical Center | Gresham97030 | NCT06632327 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT05647265 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT05677490 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05136196 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT03866382 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04511013 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05647265 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05675410 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05677490 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06203600 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT07166406 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05136196 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT03866382 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05677490 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05987241 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT06203600 | Map |
| OR | Saint Alphonsus Medical Center-Ontario | Ontario97914 | NCT04511013 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05136196 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT03866382 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04511013 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05647265 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05675410 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05677490 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05987241 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06203600 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT07166406 | Map |
| OR | Exelixis Clinical Site #51 | Portland97239 | NCT05176483 | Map |
| OR | Kaiser Foundation Hospitals | Portland97227 | NCT06246916 | Map |
| OR | Legacy Emanuel Children's Hospital | Portland97227 | NCT04546399 | Map |
| OR | Legacy Emanuel Children's Hospital | Portland97227 | NCT05675410 | Map |
| OR | Legacy Good Samaritan Hospital and Medical Center | Portland97210 | NCT06632327 | Map |
| OR | Northwest Cancer Specialists, P.C. | Portland97213-2982 | NCT07221149 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT05317858 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT03866382 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04546399 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05675410 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05919264 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05987241 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06203600 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06246916 | Map |
| OR | Providence Cancer Institute | Portland97213 | NCT07195695 | Map |
| OR | Providence Cancer Institute Franz Clinic | Portland97213 | NCT06743126 | Map |
| OR | Providence Health & Services | Portland97213 | NCT02693535 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05112601 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05136196 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT03866382 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04511013 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05647265 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05675410 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05677490 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05987241 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06029270 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06203600 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT07166406 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05112601 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05136196 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT03866382 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04511013 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05647265 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05675410 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05677490 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05987241 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06029270 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06203600 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT07166406 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT04511013 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT05647265 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT05677490 | Map |
| OR | Salem Hospital | Salem97301 | NCT06632327 | Map |
| OR | Legacy Meridian Park Hospital | Tualatin97062 | NCT06632327 | Map |
| PA | Lehigh Valley Hospital - Cedar Crest | Allentown18103 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT03866382 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04546399 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05327686 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05675410 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05677490 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05987241 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06064097 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06203600 | Map |
| PA | UPMC Altoona | Altoona16601 | NCT05987241 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT05112601 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT05327686 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT05987241 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT06203600 | Map |
| PA | Alliance Cancer Specialists, PC | Bensalem19020 | NCT07392892 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT03866382 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05327686 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05677490 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05987241 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT06203600 | Map |
| PA | Lehigh Valley Hospital- Muhlenberg | Bethlehem18017 | NCT02693535 | Map |
| PA | UPMC Hillman Cancer Center at Butler Health System | Butler16001 | NCT05112601 | Map |
| PA | Carlisle Regional Cancer Center | Carlisle17015 | NCT05327686 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT05327686 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT05677490 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT06632327 | Map |
| PA | UPMC Hillman Cancer Center - Passavant - Cranberry | Cranberry Township16066 | NCT05112601 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT04546399 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05327686 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05675410 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05677490 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06203600 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06632327 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT07166406 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT05677490 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT06203600 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT06632327 | Map |
| PA | Alliance Cancer Specialists, PC | Doylestown18901 | NCT07392892 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT03866382 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT02693535 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05677490 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05987241 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT06203600 | Map |
| PA | St. Luke's University Health Network | Easton18045 | NCT06246916 | Map |
| PA | Saint Vincent Hospital | Erie16544 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT03866382 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05987241 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT06203600 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT05112601 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT05327686 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05112601 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT03866382 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05327686 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05987241 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT06203600 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT05327686 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT05987241 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT06203600 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT05327686 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT05677490 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT06632327 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT03866382 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT05677490 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT06203600 | Map |
| PA | Exelixis Clinical Site #104 | Hershey17033 | NCT05176483 | Map |
| PA | Penn State Children's Hospital | Hershey17033 | NCT04546399 | Map |
| PA | Penn State Children's Hospital | Hershey17033 | NCT05675410 | Map |
| PA | Penn State Children's Hospital | Hershey17033 | NCT06064097 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05327686 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT05112601 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT05327686 | Map |
| PA | Jefferson Hospital | Jefferson Hills15025 | NCT05327686 | Map |
| PA | UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown15901 | NCT05112601 | Map |
| PA | UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown15901 | NCT06203600 | Map |
| PA | Lancaster General Ann B Barshinger Cancer Institute | Lancaster17601 | NCT06203600 | Map |
| PA | Lancaster General Health | Lancaster17601 | NCT03899155 | Map |
| PA | Lancaster General Hospital | Lancaster17601 | NCT03646617 | Map |
| PA | Lancaster General Hospital - Ann B Barshinger Cancer Institute | Lancaster17601 | NCT06561386 | Map |
| PA | Alliance Cancer Specialists, PC | Langhorne19047 | NCT07392892 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT05327686 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT05677490 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT06203600 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT06632327 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT07166406 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT05677490 | Map |
| PA | UPMC Cancer Center at UPMC McKeesport | McKeesport15132 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05987241 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT06203600 | Map |
| PA | Alliance Cancer Specialists, PC | Media19063 | NCT07392892 | Map |
| PA | Forbes Hospital | Monroeville15146 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT03866382 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT05987241 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT06203600 | Map |
| PA | UPMC Hillman Cancer Center in Coraopolis | Moon Township15108 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - Part of Frick Hospital | Mount Pleasant15666 | NCT05112601 | Map |
| PA | Arnold Palmer Cancer Center Medical Oncology Norwin | N. Huntingdon15642 | NCT05112601 | — |
| PA | Arnold Palmer Cancer Center Medical Oncology Norwin | N. Huntingdon15642 | NCT03866382 | — |
| PA | Arnold Palmer Cancer Center Medical Oncology Norwin | N. Huntingdon15642 | NCT06203600 | — |
| PA | UPMC Cancer Center-Natrona Heights | Natrona Heights15065 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT06203600 | Map |
| PA | Abramson Cancer Center | Philadelphia19104 | NCT03646617 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT04546399 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05675410 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06064097 | Map |
| PA | Einstein Medical Center Philadelphia | Philadelphia19141 | NCT05677490 | Map |
| PA | Exelixis Clinical Site #98 | Philadelphia19104 | NCT05176483 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT03686124 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05263050 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT02693535 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05498792 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05655312 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06246916 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06264180 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06743126 | Map |
| PA | Hospital of the University of Pennsylvania | Philadelphia19104 | NCT07319195 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT05987241 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT06203600 | Map |
| PA | Penn Medicine Abramson Cancer Center | Philadelphia19104 | NCT06708949 | Map |
| PA | Saint Christopher's Hospital for Children | Philadelphia19134 | NCT04546399 | Map |
| PA | Saint Christopher's Hospital for Children | Philadelphia19134 | NCT05675410 | Map |
| PA | Thomas Jeffersion University, Sidney Kimmel Cancer Center | Philadelphia19107 | NCT06743126 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06581406 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06112314 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06264180 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05136196 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05675410 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05987241 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06203600 | Map |
| PA | Thomas Jefferson University, Honickman Center | Philadelphia19107 | NCT03686124 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT06743126 | Map |
| PA | University of Pennsylvania, Perelamn Center for Advanced Medicine | Philadelphia19104 | NCT03686124 | Map |
| PA | University of Pennsylvania, Perelman School of Medicine | Philadelphia19104 | NCT05919264 | Map |
| PA | UPenn | Philadelphia19107 | NCT06624644 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT05327686 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT04546399 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT05675410 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT06064097 | Map |
| PA | Exelixis Clinical Site #24 | Pittsburgh15232 | NCT05176483 | Map |
| PA | Exelixis Clinical Site #32 | Pittsburgh15212 | NCT05176483 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05112601 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT03816345 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT03866382 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04511013 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05327686 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05896839 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05987241 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT06203600 | Map |
| PA | University of Pittsburgh Medical Center | Pittsburgh15232 | NCT03686124 | Map |
| PA | University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center | Pittsburgh15232 | NCT06246916 | Map |
| PA | University of Pittsburgh Medical Center, Hillman Cancer Center | Pittsburgh15232 | NCT05919264 | Map |
| PA | UPMC | Pittsburgh15232 | NCT06264180 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT04114136 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT04572451 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06581406 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT05655312 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06112314 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06743126 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07223411 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07223424 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05112601 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05327686 | Map |
| PA | UPMC-Mercy Hospital | Pittsburgh15219 | NCT05112601 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05112601 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT03866382 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05327686 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05987241 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT06203600 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT05112601 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT03866382 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT05327686 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT05987241 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT06203600 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT05112601 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT05327686 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT05987241 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT06203600 | Map |
| PA | UPMC-Shadyside Hospital | Pittsburgh15232 | NCT05327686 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT05327686 | Map |
| PA | Geisinger Cancer Services-Pottsville | Pottsville17901 | NCT05327686 | Map |
| PA | Geisinger Cancer Services-Pottsville | Pottsville17901 | NCT05677490 | Map |
| PA | Community Medical Center | Scranton18510 | NCT05327686 | Map |
| PA | Community Medical Center | Scranton18510 | NCT05677490 | Map |
| PA | Community Medical Center | Scranton18510 | NCT06203600 | Map |
| PA | Alliance Cancer Specialists, PC | Sellersville18960 | NCT07392892 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT05112601 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT05327686 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT06203600 | Map |
| PA | UPMC Cancer Center-Uniontown | Uniontown15401 | NCT06203600 | Map |
| PA | UPMC Cancer Center-Washington | Washington15301 | NCT05112601 | Map |
| PA | UPMC West Mifflin-Cancer Center Jefferson | West Mifflin15122 | NCT05112601 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05327686 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05677490 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05987241 | Map |
| PA | Wexford Health and Wellness Pavilion | Wexford15090 | NCT05327686 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05327686 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05677490 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06203600 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06632327 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT07166406 | Map |
| PA | Divine Providence Hospital | Williamsport17754 | NCT05327686 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT05677490 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT05987241 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT06203600 | Map |
| PA | Alliance Cancer Specialists, PC | Wynnewood19096 | NCT07392892 | Map |
| PA | UPMC Memorial | York17408 | NCT05327686 | Map |
| RI | Brown University Health Cancer Institute | Providence02906 | NCT06362369 | Map |
| RI | Lifespan Cancer Institute | Providence02903 | NCT06246916 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04609046 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04933903 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04546399 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05317858 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05675410 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06264180 | Map |
| RI | Rhode Island Hospital Site Number : 8400004 | Providence02903 | NCT05584670 | Map |
| RI | Women and Infants Hospital | Providence02905 | NCT05112601 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT05675410 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT05987241 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT06203600 | Map |
| SC | AnMed Health Cancer Center | Anderson29621 | NCT05987241 | Map |
| SC | SC Cancer Specialists at St. Joseph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | St. Joseph's/Candler Smith | Bluffton29910 | NCT02693535 | Map |
| SC | Summit Cancer Care at St. Josph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05675410 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05987241 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04609046 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT03866382 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05327686 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05675410 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05677490 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05987241 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06029270 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06203600 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06632327 | Map |
| SC | MUSC Hollings Cancer Center | Charleston29425 | NCT07293351 | Map |
| SC | Ralph H Johnson VA Medical Center | Charleston29401 | NCT06203600 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT04546399 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT05675410 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT06064097 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05987241 | Map |
| SC | McLeod Regional Medical Center | Florence29506 | NCT06632327 | Map |
| SC | Gibbs Cancer Center-Gaffney | Gaffney29341 | NCT05987241 | Map |
| SC | Gibbs Cancer Center-Gaffney | Gaffney29341 | NCT06632327 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT04546399 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT05675410 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT06064097 | Map |
| SC | Prisma Health Cancer Institute | Greenville29605 | NCT06112314 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05987241 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT04546399 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05675410 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05987241 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05987241 | Map |
| SC | Prisma Health Greenville Memorial Hospital | Greenville29605 | NCT05987241 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT05675410 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT06632327 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT05675410 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT06632327 | Map |
| SC | Self Regional Healthcare | Greenwood29646 | NCT05327686 | Map |
| SC | Self Regional Healthcare | Greenwood29646 | NCT06632327 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT05987241 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT06632327 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05987241 | Map |
| SC | South Carolina Cancer Specialists | Hilton Head Island29926 | NCT02693535 | Map |
| SC | Carolina Urologic Research Center, LLC | Myrtle Beach29572 | NCT07293351 | Map |
| SC | Exelixis Clinical Site #9 | Myrtle Beach29572 | NCT05176483 | Map |
| SC | Levine Cancer Institute-Rock Hill | Rock Hill29732 | NCT05987241 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05987241 | Map |
| SC | North Grove Medical Park | Spartanburg29303 | NCT06632327 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT05987241 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT06632327 | Map |
| SC | Spartanburg Medical Center - Mary Black Campus | Spartanburg29307 | NCT06632327 | Map |
| SC | Spartanburg Regional Healthcare System - Spartanburg Medical Center (SMC) | Spartanburg29303 | NCT06112314 | Map |
| SC | SMC Center for Hematology Oncology Union | Union29379 | NCT05987241 | Map |
| SC | SMC Center for Hematology Oncology Union | Union29379 | NCT06632327 | Map |
| SD | Avera Cancer Institute-Aberdeen | Aberdeen57401 | NCT05677490 | Map |
| SD | Avera Cancer Institute - Mitchell | Mitchell57301 | NCT05677490 | Map |
| SD | Avera Cancer Institute at Pierre | Pierre57501 | NCT05677490 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05136196 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05677490 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT06203600 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT05677490 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06743126 | Map |
| SD | Sanford Cancer Center | Sioux Falls57104 | NCT06646276 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05136196 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05327686 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05677490 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05987241 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT06203600 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT06632327 | Map |
| SD | Sanford Cancer Center Oncology Clinic and Pharmacy | Sioux Falls57104 | NCT02693535 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05136196 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT04546399 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05327686 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05675410 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05677490 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05987241 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06064097 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06203600 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06632327 | Map |
| SD | Avera Cancer Institute at Yankton | Yankton57078 | NCT05677490 | Map |
| TN | T C Thompson Children's Hospital | Chattanooga37403 | NCT05675410 | Map |
| TN | Tennessee Oncology - Chattanooga | Chattanooga37404 | NCT06246916 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06632327 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT07383441 | Map |
| TN | The West Clinic, PLLC dba West Cancer Center | Germantown38138 | NCT06581406 | Map |
| TN | The West Clinic, PLLC dba West Cancer Center | Germantown38138 | NCT06764771 | Map |
| TN | West Cancer Center and Research Institute | Germantown38138 | NCT06264180 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT04546399 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT05675410 | Map |
| TN | The University of Tennessee - Knoxville (UTK) | Knoxville37920 | NCT06112314 | Map |
| TN | University of Tennessee | Knoxville37920 | NCT06264180 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT06581406 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT06246916 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06632327 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT07383441 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT06064097 | Map |
| TN | Exelixis Clinical Site #3 | Nashville37203 | NCT05176483 | Map |
| TN | Research Site | Nashville37203 | NCT07431281 | Map |
| TN | Sara Cannon Research Institute Tennessee | Nashville37203 | NCT05533697 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT04561206 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203-1619 | NCT05267626 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT06581406 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT05919264 | Map |
| TN | Sarah Cannon Research Institute (SCRI) Oncology Partners | Nashville37203 | NCT06246916 | Map |
| TN | Sarah Cannon Research Institute: USA/TN | Nashville37203 | NCT06112314 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06646276 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06743126 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07221149 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07325136 | Map |
| TN | Tennesse Oncology | Nashville37203 | NCT03899155 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT06246916 | Map |
| TN | Tennessee Oncology - Nashville / Sarah Cannon Research Institute | Nashville37203 | NCT02693535 | Map |
| TN | Tennessee Oncology, PLLC | Nashville37203 | NCT06112314 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT04546399 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT05675410 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT06064097 | Map |
| TN | Vanderbilt Ingram Cancer Center | Nashville37232 | NCT05919264 | Map |
| TN | Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic) | Nashville37232 | NCT06581406 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06047379 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06708949 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT07210632 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT03866382 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT04546399 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05361720 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05501665 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05675410 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05987241 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06064097 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06203600 | Map |
| TN | Vanderbilt-Ingram Cancer Center | Nashville37232 | NCT07188896 | Map |
| TX | Hendrick Health | Abilene79601 | NCT07195695 | Map |
| TX | Texas Oncology - West Texas | Abilene79606 | NCT06561386 | Map |
| TX | Texas Oncology - Amarillo Cancer Center | Amarillo79124 | NCT07221149 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT04546399 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT05675410 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT06064097 | Map |
| TX | Exelixis Clinical Site #46 | Austin78705 | NCT05176483 | Map |
| TX | Texas Oncology - Austin Central | Austin78745 | NCT06463665 | Map |
| TX | Texas Oncology - Austin Central, Central Austin Cancer Center | Austin78731 | NCT06246916 | Map |
| TX | Texas Oncology - Austin Midtown, Midtown Medical Center I | Austin78705 | NCT06246916 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT06646276 | Map |
| TX | Texas Oncology (Balcones) - SCRI | Austin78731-4214 | NCT05267626 | Map |
| TX | Texas Oncology-Austin Central | Austin78731 | NCT07221149 | Map |
| TX | World Research Link | Baytown77521 | NCT06463665 | Map |
| TX | Texas Oncology | Beaumont77702 | NCT07221149 | Map |
| TX | Texas Oncology - Bedford | Bedford76022 | NCT06246916 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT04546399 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT05675410 | Map |
| TX | Baylor University | Dallas75246 | NCT06743126 | Map |
| TX | Baylor, Scott and White Research Institute | Dallas75246 | NCT06047379 | Map |
| TX | Exelixis Clinical Site #111 | Dallas75246 | NCT05176483 | Map |
| TX | Exelixis Clinical Site #89 | Dallas75246 | NCT05176483 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT04546399 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT05675410 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05112601 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05327686 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05677490 | Map |
| TX | Texas Oncology | Dallas75246 | NCT06246916 | Map |
| TX | Texas Oncology | Dallas75246 | NCT06264180 | Map |
| TX | Texas Oncology - Medical City | Dallas75230 | NCT06246916 | Map |
| TX | University of Texas Southwestern | Dallas75235-9179 | NCT06112314 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT05502315 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06264180 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06708949 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06743126 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06794229 | Map |
| TX | University of Texas, Southwestern Medical Center | Dallas75390 | NCT05361720 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT06581406 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT06053658 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT03816345 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT03866382 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05327686 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05647265 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05677490 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05987241 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT04609046 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05112601 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT03816345 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT03866382 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT04546399 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05327686 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05647265 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05675410 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05987241 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT06064097 | Map |
| TX | Texas Oncology - Northeast Texas | Denison75020 | NCT07221149 | Map |
| TX | El Paso Children's Hospital | El Paso79905 | NCT04546399 | Map |
| TX | El Paso Children's Hospital | El Paso79905 | NCT05675410 | Map |
| TX | Center For Disease And Blood Disorder | Fort Worth76104 | NCT06246916 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT04546399 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT05675410 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06064097 | Map |
| TX | Tarrant County Hospital District/JPS Health Network | Fort Worth76104 | NCT05677490 | Map |
| TX | Texas Oncology - Fort Worth | Fort Worth76104 | NCT06246916 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05112601 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT03816345 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT03866382 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05327686 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05647265 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05677490 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05987241 | Map |
| TX | Texas Oncology - DFW | Grapevine76051 | NCT07221149 | Map |
| TX | Texas Oncology - Grapevine | Grapevine76051 | NCT06246916 | Map |
| TX | Texas Oncology - Harlingen, Medical Arts Pavillion | Harlingen78550 | NCT06246916 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05675410 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05987241 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06064097 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06203600 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT05987241 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT06203600 | Map |
| TX | Lyndon Baines Johnson General Hospital | Houston77026-1967 | NCT05987241 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04745949 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05048212 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04380545 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04546399 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03025256 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05704647 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06053658 | Map |
| TX | MD Anderson | Houston77030 | NCT05266612 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT04665206 | Map |
| TX | MD Anderson Cancer Center | Houston77030-4000 | NCT05267626 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05663710 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06362369 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06534983 | Map |
| TX | MD Anderson Cancer Center | Houston77090 | NCT06561087 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07401875 | Map |
| TX | Michael E DeBakey VA Medical Center | Houston77030 | NCT05987241 | Map |
| TX | Michael E. DeBakey VA Medical Center, Houston, TX | Houston77030-4211 | NCT06275360 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT04995003 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT06708949 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT02693535 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT05919264 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06246916 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06264180 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06743126 | Map |
| TX | The University Of Texas Md Anderson Cancer Center | Houston77030 | NCT06581406 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT03686124 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06561386 | Map |
| TX | University of Texas MD Anderson Cancer Center Site Number : 8400005 | Houston77030-4000 | NCT05584670 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT03816345 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT05675410 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT06064097 | Map |
| TX | Exelixis Clinical Site #73 | Irving75063 | NCT05176483 | Map |
| TX | NEXT Oncology | Irving75039 | NCT07563738 | Map |
| TX | NEXT Oncology - Irving | Irving75039 | NCT06618287 | Map |
| TX | US Oncology Investigational Products Center (IPC) | Irving75063 | NCT07392892 | Map |
| TX | Texas Oncology - Longview | Longview75601 | NCT06246916 | Map |
| TX | Covenant Children's Hospital | Lubbock79410 | NCT04546399 | Map |
| TX | Covenant Children's Hospital | Lubbock79410 | NCT05675410 | Map |
| TX | Joe Arrington Cancer Research & Treatment Center | Lubbock79410 | NCT06246916 | Map |
| TX | UMC Cancer Center / UMC Health System | Lubbock79415 | NCT04546399 | Map |
| TX | UMC Cancer Center / UMC Health System | Lubbock79415 | NCT05675410 | Map |
| TX | Texas Oncology - McAllen | McAllen78503 | NCT06246916 | Map |
| TX | Texas Oncology-Palestine Cancer Center | Palestine75801 | NCT06246916 | Map |
| TX | Exelixis Clinical Site #50 | Plano75075 | NCT05176483 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05112601 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT03816345 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT03866382 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05327686 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05647265 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05677490 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05987241 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT04546399 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT05675410 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT06064097 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT04546399 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT05675410 | Map |
| TX | NEXT Oncology | San Antonio78229 | NCT04665206 | Map |
| TX | Site 01 | San Antonio78229 | NCT07276373 | Map |
| TX | South Texas Accelerated Research Therapeutics, LLC | San Antonio78229 | NCT05919264 | Map |
| TX | START San Antonio ( Site 0104) | San Antonio78229 | NCT07405164 | Map |
| TX | START South Texas Accelerated Research Therapeutics | San Antonio78229 | NCT05267626 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT07221149 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT04546399 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT05675410 | Map |
| TX | Scott and White Memorial Hospital | Temple76508 | NCT05327686 | Map |
| TX | Scott and White Memorial Hospital | Temple76508 | NCT05675410 | Map |
| TX | Exelixis Clinical Site #70 | Tyler75601 | NCT05176483 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT06646276 | Map |
| TX | Texas Oncology-Tyler, Northeast Texas Cancer Institute | Tyler75702 | NCT06246916 | Map |
| TX | The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center | Tyler75701 | NCT06561386 | Map |
| TX | Texas Oncology - Weslaco, Knapp Medical Plaza | Weslaco78596 | NCT06246916 | Map |
| UT | Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center | Cedar City84720 | NCT02693535 | Map |
| UT | Farmington Health Center | Farmington84025 | NCT05677490 | Map |
| UT | Farmington Health Center | Farmington84025 | NCT06203600 | Map |
| UT | Intermountain Health | Murray84107 | NCT06264180 | Map |
| UT | Community Cancer Trials of Utah | Ogden84405 | NCT07195695 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06264180 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06365619 | Map |
| UT | Huntsman Cancer Institute at the University of Utah | Salt Lake City84112 | NCT03646617 | Map |
| UT | Huntsman Cancer Institute, University of Utah | Salt Lake City84112 | NCT06743126 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05136196 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04511013 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05675410 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05677490 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05896839 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05987241 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06203600 | Map |
| UT | Intermountain Healthcare | Salt Lake City84107 | NCT02693535 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT04546399 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT05675410 | Map |
| UT | University of Utah - Huntsman Cancer Institute | Salt Lake City84112 | NCT05267626 | Map |
| UT | University of Utah Huntsman Cancer Institute | Salt Lake City84112 | NCT06112314 | Map |
| UT | University of Utah Huntsman Cancer Institute | Salt Lake City84112 | NCT06246916 | Map |
| UT | University of Utah Sugarhouse Health Center | Salt Lake City84106 | NCT05677490 | Map |
| UT | University of Utah Sugarhouse Health Center | Salt Lake City84106 | NCT06203600 | Map |
| UT | Dixie Regional Medical Center-River Road Campus | St. George84770 | NCT02693535 | Map |
| UT | Site 02 | West Valley City84119 | NCT07276373 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT05327686 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT05677490 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT05987241 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT04546399 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05327686 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05675410 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05677490 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05987241 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05327686 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05677490 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05987241 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT06264180 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT05136196 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT06632327 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT05136196 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT05327686 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT07166406 | Map |
| VA | Virginia Cancer Specialists, PC | Arlington22201 | NCT04665206 | Map |
| VA | Virginia Cancer Specialists, PC | Arlington22201 | NCT07392892 | Map |
| VA | Exelixis Clinical Site #66 | Charlottesville22903 | NCT05176483 | Map |
| VA | University of Virginia | Charlottesville22908 | NCT05919264 | Map |
| VA | University of Virginia | Charlottesville22908 | NCT06246916 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05112601 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05675410 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05677490 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05987241 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06064097 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06632327 | Map |
| VA | UVA Health-UVA Emily Couric Clinical Cancer Center | Charlottesville22903 | NCT06112314 | Map |
| VA | Virginia Oncology Associates | Chesapeake23320 | NCT07392892 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT05136196 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT05327686 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT05677490 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT07166406 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05136196 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22042 | NCT02693535 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05327686 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05677490 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT06246916 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT07166406 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT07563738 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT06246916 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT07392892 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05136196 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT04546399 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05675410 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05677490 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT07166406 | Map |
| VA | Virginia Oncology Associates | Hampton23666 | NCT07392892 | Map |
| VA | Inova Loudoun Hospital | Leesburg20176 | NCT07166406 | Map |
| VA | Centra Alan B Pearson Regional Cancer Center | Lynchburg24501 | NCT05136196 | Map |
| VA | Centra Alan B Pearson Regional Cancer Center | Lynchburg24501 | NCT05677490 | Map |
| VA | Virginia Cancer Specialists, PC | Manassas20110 | NCT07392892 | Map |
| VA | Bon Secours Memorial Regional Medical Center | Mechanicsville23116 | NCT05987241 | Map |
| VA | Bon Secours Saint Francis Medical Center | Midlothian23114 | NCT05327686 | Map |
| VA | Bon Secours Saint Francis Medical Center | Midlothian23114 | NCT05987241 | Map |
| VA | Virginia Oncology Associates | Newport News23606 | NCT07392892 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT04546399 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT05675410 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT06064097 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06246916 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT07392892 | Map |
| VA | Naval Medical Center - Portsmouth | Portsmouth23708-2197 | NCT05675410 | Map |
| VA | Virginia Cancer Specialists, PC | Reston20190 | NCT07392892 | Map |
| VA | Bon Secours Cancer Institute at Reynolds Crossing | Richmond23230 | NCT05327686 | Map |
| VA | Bon Secours Richmond Community Hospital | Richmond23223 | NCT05987241 | Map |
| VA | Bon Secours Saint Mary's Hospital | Richmond23226 | NCT05987241 | Map |
| VA | Henrico Doctor's Hospital | Richmond23229 | NCT05112601 | Map |
| VA | Johnston Willis Hospital | Richmond23235 | NCT05317858 | Map |
| VA | Richmond VA Medical Center, Richmond, VA | Richmond23249-0001 | NCT06275360 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05136196 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05677490 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05987241 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT06203600 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05136196 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT03816345 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04546399 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05675410 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05677490 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05987241 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06064097 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06203600 | Map |
| VA | Virginia Cancer Institute | Richmond23229 | NCT05136196 | Map |
| VA | Virginia Cancer Institute | Richmond23229 | NCT05677490 | Map |
| VA | Virginia Commonwealth University | Richmond23219 | NCT06743126 | Map |
| VA | Virginia Commonwealth University | Richmond23298 | NCT06794229 | Map |
| VA | Virginia Commonwealth University (VCU) - Massey Cancer Center | Richmond23298-0070 | NCT06112314 | Map |
| VA | Virginia Commonwealth University Massey Cancer Center | Richmond23298 | NCT06246916 | Map |
| VA | Carilion Children's | Roanoke24014 | NCT05675410 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc. | Roanoke24014 | NCT06246916 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc. | Roanoke24014 | NCT06646276 | Map |
| VA | Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem | Salem24153 | NCT07221149 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05677490 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05987241 | Map |
| VA | VCU Health Tappahannock Hospital | Tappahannock22560 | NCT05136196 | Map |
| VA | Virginia Oncology Associates | Virginia Beach23456 | NCT07392892 | Map |
| VA | Virginia Cancer Specialists, PC | Woodbridge22191 | NCT07392892 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT05647265 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT05677490 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT04511013 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT05647265 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT05677490 | Map |
| WA | Northwest Medical Specialties | Bonney Lake98391 | NCT02693535 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT05647265 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT05677490 | Map |
| WA | Swedish Cancer Institute - Edmonds | Edmonds98026 | NCT06646276 | Map |
| WA | Swedish Cancer Institute - Edmonds Campus | Edmonds98026 | NCT06246916 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05112601 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04511013 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05647265 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05677490 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT04511013 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT05647265 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT05677490 | Map |
| WA | Northwest Medical Specialties | Federal Way98003 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Gig Harbor98332 | NCT02693535 | Map |
| WA | Swedish Cancer Institute - Issaquah Campus | Issaquah98029 | NCT06246916 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05112601 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04511013 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05647265 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05677490 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT03866382 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT04511013 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT05647265 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT05677490 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT06246916 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05647265 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05677490 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT04511013 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT05647265 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT05677490 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT05647265 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT05677490 | Map |
| WA | Northwest Medical Specialties | Olympia98502 | NCT02693535 | Map |
| WA | Jefferson Healthcare | Port Townsend98368 | NCT04511013 | Map |
| WA | Northwest Medical Specialties | Puyallup98373 | NCT02693535 | Map |
| WA | Valley Medical Center | Renton98055 | NCT03866382 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05647265 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05675410 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05677490 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT05098210 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06745076 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT03686124 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06581406 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06697197 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06743126 | Map |
| WA | Fred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010 | Seattle98109-4405 | NCT05584670 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109 | NCT06534983 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT04546399 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT05675410 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06064097 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT02693535 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT06246916 | Map |
| WA | Swedish Medical Center | Seattle98104 | NCT06618287 | Map |
| WA | Swedish Medical Center | Seattle98104 | NCT06646276 | Map |
| WA | Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill Campus | Seattle98104 | NCT06112314 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT04511013 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT05647265 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT05677490 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT04511013 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT05647265 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT05677490 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05112601 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04511013 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05647265 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05677490 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06029270 | Map |
| WA | University of Washington Medical Center | Seattle98195 | NCT06534983 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT05327686 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT05987241 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT04511013 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT05647265 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Shelton | Shelton98584 | NCT04511013 | Map |
| WA | Saint Joseph Medical Center Hematology and Oncology - Silverdale | Silverdale98383 | NCT06632327 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT05647265 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT05677490 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT05647265 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT05677490 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT05647265 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT05677490 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT04546399 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT05675410 | Map |
| WA | Madigan Army Medical Center | Tacoma98431 | NCT04546399 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT04546399 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT05675410 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT06064097 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT06047379 | Map |
| WA | Legacy Cancer Institute Medical Oncology and Day Treatment | Vancouver98684 | NCT06632327 | Map |
| WA | Legacy Salmon Creek Hospital | Vancouver98686 | NCT06632327 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT04511013 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT05647265 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT05677490 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT04511013 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05647265 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05677490 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT05647265 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Yelm | Yelm98597 | NCT04511013 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT04546399 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05675410 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05677490 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05987241 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT05327686 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT05675410 | Map |
| WV | West Virginia University | Morgantown26506 | NCT06246916 | Map |
| WV | West Virginia University | Morgantown26506 | NCT06264180 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT04609046 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT04546399 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT05987241 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT04511013 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT05327686 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT05677490 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT06203600 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05987241 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT06632327 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05112601 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05136196 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT03866382 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05327686 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05677490 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06203600 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT07166406 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05112601 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05327686 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05677490 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Berlin | Berlin54923 | NCT06632327 | Map |
| WI | Aurora Cancer Care - Burlington | Burlington53105 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT06203600 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT05677490 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT06632327 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05675410 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05677490 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05987241 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT06203600 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04609046 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05136196 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT03866382 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04511013 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05327686 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05677490 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05987241 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT06203600 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT06632327 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT07166406 | Map |
| WI | Mayo Clinic Health System-Eau Claire Clinic | Eau Claire54701 | NCT03866382 | Map |
| WI | Aurora Health Care - Germantown Health Center | Germantown53022 | NCT02693535 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT03866382 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05675410 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05677490 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT06203600 | Map |
| WI | Aurora Cancer Care - Grafton | Grafton53024 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05987241 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT06203600 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT03866382 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT02693535 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05675410 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05677490 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05987241 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05136196 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05327686 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05987241 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06632327 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05136196 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT04546399 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05327686 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05675410 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05987241 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06632327 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT05327686 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT05677490 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT07166406 | Map |
| WI | Tamarack Health Hayward Medical Center | Hayward54843 | NCT05677490 | Map |
| WI | Aurora Cancer Care - Kenosha South | Kenosha53142 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT06203600 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04609046 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05136196 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04511013 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05675410 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05677490 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Ladysmith | Ladysmith54848 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Ladysmith | Ladysmith54848 | NCT06632327 | Map |
| WI | SSM Health Cancer Care | Madison53717 | NCT04295863 | Map |
| WI | University of Wisconsin | Madison53705 | NCT03681561 | Map |
| WI | University of Wisconsin | Madison53705 | NCT05502315 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT04989946 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT04511013 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT04150640 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT06246916 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05327686 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05675410 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05987241 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT06203600 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04546399 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05327686 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05675410 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05987241 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06203600 | Map |
| WI | University Of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06581406 | Map |
| WI | University of Wisconsin, Carbone Cancer Center | Madison53705 | NCT05919264 | Map |
| WI | UW Carbone Cancer Center | Madison53705 | NCT04900818 | Map |
| WI | UW Hospital and Clinics | Madison53792 | NCT07281924 | Map |
| WI | William S Middleton VA Medical Center | Madison53705 | NCT06203600 | Map |
| WI | Aurora Bay Area Medical Center | Marinette54143 | NCT02693535 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT03866382 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05675410 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05677490 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05987241 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT06203600 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04609046 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05136196 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT03866382 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04511013 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05327686 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05675410 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05677490 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05987241 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06203600 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06632327 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT07166406 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT04511013 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT05677490 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT06203600 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT05327686 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT06632327 | Map |
| WI | Aurora Cancer Care Milwaukee | Milwaukee53209 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT06203600 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT03866382 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05675410 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05677490 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05987241 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT06203600 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT03866382 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53223 | NCT02693535 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05675410 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05677490 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05987241 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT06203600 | Map |
| WI | Aurora St. Luke's Medical Center | Milwaukee53215 | NCT02693535 | Map |
| WI | Aurora West Allis Medical Center | Milwaukee53227 | NCT02693535 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT04546399 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT05675410 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT06064097 | Map |
| WI | Exelixis Clinical Site #33 | Milwaukee53226 | NCT05176483 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT03259867 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05136196 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05327686 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05987241 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06632327 | Map |
| WI | Zablocki Veterans Administration Medical Center | Milwaukee53295 | NCT06632327 | Map |
| WI | Marshfield Clinic-Minocqua Center | Minocqua54548 | NCT04511013 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04609046 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05136196 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT03866382 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05327686 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT06203600 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT06632327 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05136196 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT03866382 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05327686 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05675410 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05677490 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05987241 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06029270 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06203600 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06632327 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT07166406 | Map |
| WI | ThedaCare Regional Medical Center - Neenah | Neenah54956 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Neillsville | Neillsville54456 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Neillsville | Neillsville54456 | NCT06632327 | Map |
| WI | ThedaCare Cancer Care - New London | New London54961 | NCT06632327 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05136196 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT04511013 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05327686 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05677490 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT06632327 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT05327686 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT06632327 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05136196 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT03866382 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05327686 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05675410 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05677490 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05987241 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06029270 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06203600 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06632327 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05136196 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05987241 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06632327 | Map |
| WI | ThedaCare Cancer Care - Oshkosh | Oshkosh54904 | NCT06632327 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT03866382 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05675410 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05677490 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05987241 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT06203600 | Map |
| WI | Aurora Cancer Care - Racine | Racine53406 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT06203600 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT05327686 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT06203600 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT03866382 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT04511013 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05327686 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05677490 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT06632327 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Shawano | Shawano54166 | NCT06632327 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05136196 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05327686 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05675410 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05987241 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06632327 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT05677490 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06203600 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06632327 | Map |
| WI | Vince Lombardi Cancer Center | Sheboygan53081 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT03866382 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05675410 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05677490 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05987241 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT06203600 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT05327686 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT05677490 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT07166406 | Map |
| WI | Ascension Saint Michael's Hospital | Stevens Point54481 | NCT04511013 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT05327686 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT06203600 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04609046 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05136196 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT03866382 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04511013 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05327686 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05677490 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05987241 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06203600 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06632327 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05136196 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05327686 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05675410 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05987241 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06203600 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06632327 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT03866382 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT02693535 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05675410 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05677490 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05987241 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT06203600 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05136196 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05327686 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05677490 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT07166406 | Map |
| WI | Vince Lombardi Cancer Clinic - Two Rivers | Two Rivers54241 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT03866382 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05675410 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05677490 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05987241 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT06203600 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT05136196 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT03866382 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT05677490 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT05987241 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06029270 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06203600 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06632327 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05136196 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT03866382 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05327686 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05675410 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05677490 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05987241 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06029270 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06203600 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06632327 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Waupaca | Waupaca54981 | NCT06632327 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT04511013 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT05327686 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT05677490 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT06203600 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT05677490 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT06632327 | Map |
| WI | Aurora Cancer Care - Milwaukee West | Wauwatosa53226 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT03866382 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05675410 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05987241 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT06203600 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT03866382 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05675410 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05677490 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05987241 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT06203600 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT05327686 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04609046 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05136196 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT03866382 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04511013 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05327686 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05987241 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06203600 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT07166406 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT04511013 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT05327686 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT06203600 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT05677490 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT06632327 | Map |
| WY | Cheyenne Regional Medical Center-West | Cheyenne82001 | NCT04511013 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT05677490 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT06632327 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT04511013 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT05677490 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT06632327 | Map |
| WY | Welch Cancer Center | Sheridan82801 | NCT04511013 | Map |
Nivolumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | no longer available | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 7 | 6 | 1 | 10 | 4 | 2 | 2 | 32 | ||||
| P1 | 41 | 54 | 1 | 132 | 59 | 19 | 2 | 8 | 9 | 325 | ||
| P1/P2 | 42 | 38 | 1 | 114 | 50 | 17 | 2 | 1 | 24 | 289 | ||
| P2 | 122 | 160 | 2 | 244 | 92 | 38 | 5 | 11 | 58 | 732 | ||
| P2/P3 | 6 | 4 | 5 | 2 | 1 | 3 | 1 | 2 | 24 | |||
| P3 | 26 | 37 | 54 | 10 | 4 | 2 | 4 | 137 | ||||
| P4 | 4 | 7 | 1 | 1 | 2 | 15 | ||||||
| N/A | 12 | 7 | 1 | 30 | 3 | 1 | 1 | 9 | 5 | 1 | 70 |
Recruiting Nivolumab clinical trials (291)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05732389 | RESET-RImmunotherapy in Patients With Early dMMR Rectal Cancer | P2 | Cancer of Rectum | 39 | Feb 2023 |
| NCT06639607 | PRiME IIPEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma | P1/P2 | Diffuse Midline Glioma | 68 | Jun 2026 |
| NCT04995003 | CARHER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | P1 | Sarcoma | 25 | Dec 2021 |
| NCT07369791 | NOBLENivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. | P2 | Advanced Biliary Tract Cancer(BTC) | 76 | May 2026 |
| NCT06999980 | Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | P2 | Cutaneous Melanoma | 494 | Feb 2026 |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | P3 | Non-small Cell Lung Cancer | 400 | Jan 2026 |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | P2 | Cutaneous Squamous Cell Carcinoma | 20 | Jun 2024 |
| NCT07541170 | KRASCENDO 3A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) | P3 | Non-small Cell Lung Cancer | 400 | Sep 2026 |
| NCT07403877 | TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer | P2 | Colorectal Cancer (MSI-H) | 114 | Feb 2026 |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | P3 | Advanced Melanoma | 400 | Jul 2024 |
| NCT06151236 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | P2 | Merkel Cell Carcinoma | 20 | Mar 2024 |
| NCT06240143 | MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | P1/P2 | Melanoma | 96 | Mar 2024 |
| NCT04248569 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | P1 | Fibrolamellar Hepatocellular Carcinoma (FLC) | 56 | Apr 2020 |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | P3 | Advanced Clear Cell Renal Cell Carcinoma | 718 | Jun 2026 |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | P3 | Von Hippel-Lindau Disease | 450 | Mar 2026 |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | P1 | Soft Tissue Sarcomas | 18 | Aug 2026 |
| NCT07230613 | NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | P2 | Cutaneous Melanoma, Stage III | 50 | Jan 2026 |
| NCT07514767 | NOCANOEvaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma | P2 | Oral Squamous Cell Carcinoma (OSCC) | 60 | May 2026 |
| NCT06488482 | Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma | P3 | High-risk Melanoma | 1,792 | Dec 2024 |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | P2 | Advanced Clear Cell Renal Cell Carcinoma | 18 | Apr 2026 |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | P3 | Melanoma | 560 | Sep 2024 |
| NCT07319195 | WINIT-BCWindow Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC) | Early P1 | Breast Cancer | 32 | Apr 2026 |
| NCT06745076 | Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma | P2 | Advanced Hodgkin Lymphoma | 125 | Mar 2025 |
| NCT03815890 | BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | P2 | Breast Cancer | 80 | Oct 2019 |
| NCT07551583 | Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | P2 | Hodgkin Lymphoma | 15 | Oct 2026 |
| NCT07338981 | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | P3 | Advanced Kidney Cancer | 142 | Apr 2026 |
| NCT07221149 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | P2/P3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | 690 | Mar 2026 |
| NCT07092670 | MELAFERTMELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. | — | Melanoma | 270 | Aug 2025 |
| NCT06683755 | TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | P1/P2 | Melanoma | 30 | May 2025 |
| NCT06561386 | RELATIVITY1093A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | P3 | Non-small Cell Lung Cancer | 1,000 | Oct 2024 |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | P2 | Basal Cell Carcinoma | 57 | Nov 2018 |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | P2 | Endometrial Adenocarcinoma | 81 | Jun 2022 |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | P2/P3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma | 840 | May 2026 |
| NCT07355205 | FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | P2 | Non-small Cell Lung Cancer Stage IV | 26 | Jun 2026 |
| NCT03686124 | ACTengineACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | P1/P2 | Refractory Cancer | 375 | May 2019 |
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | P2 | Solid Tumors | 260 | Jul 2026 |
| NCT06364631 | CARE1CARE1 Pragmatic Clinical Trial | P3 | Metastatic Kidney Cancer | 1,250 | Apr 2024 |
| NCT06794775 | SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | P3 | Malignant Melanoma Stage III | 128 | Jul 2025 |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | P1 | B-Cell Non-Hodgkin Lymphoma | 99 | Apr 2017 |
| NCT03026140 | NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | P2 | Colon Carcinoma | 353 | Mar 2017 |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumors | 361 | Sep 2022 |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | P1 | Solid Tumor | 40 | Apr 2022 |
| NCT07328087 | COLONYVAQ™-CRCCOLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer | Early P1 | Colorectal Cancer Metastatic | 12 | Feb 2026 |
| NCT07293351 | RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | P1/P2 | Advanced Renal Cell Carcinoma (RCC) | 254 | Mar 2026 |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | — | Locally Advanced Melanoma | 20 | Nov 2025 |
| NCT06743126 | SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | Melanoma, Cutaneous Malignant | 360 | Jan 2025 |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | P2/P3 | Metastatic Uveal Melanoma | 280 | Dec 2024 |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | P3 | Gastric Cancer | 2,130 | Feb 2026 |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | P2 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | 131 | Oct 2025 |
| NCT07219459 | GDFATHERHCC01Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure | P2 | Unresectable or Metastatic Hepatocellular Carcinoma | 104 | Mar 2026 |
| NCT06646276 | TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | P3 | Extensive-Stage Small Cell Lung Cancer | 530 | Feb 2025 |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | P1/P2 | Primary Mediastinal (Thymic) Large B-cell Lymphoma | 22 | Sep 2024 |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | P1/P2 | Locally Advanced Clear Cell Renal Cell Carcinoma | 55 | Aug 2025 |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | P1 | Metastatic Soft-tissue Sarcoma | 18 | Jan 2026 |
| NCT03886311 | TNTTalimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | P2 | Sarcoma | 200 | May 2019 |
| NCT03138161 | SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | P1/P2 | Advanced Soft Tissue Sarcoma | 250 | Apr 2017 |
| NCT07061379 | PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen | — | PROMs | 144 | Jul 2025 |
| NCT06816927 | GIANTTrial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab | P2 | Newly Diagnosed Glioblastoma | 92 | Nov 2025 |
| NCT03258567 | EBVNivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | P2 | Epstein-Barr Virus Infections | 40 | Apr 2018 |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | P4 | Metastatic Melanoma | 90 | Apr 2026 |
| NCT07460765 | HNSCCSafety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | P1 | Hnscc | 40 | Apr 2026 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | P3 | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | 1,875 | May 2023 |
| NCT07210632 | HGGWindow Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | Early P1 | Brain Cancer | 38 | Mar 2026 |
| NCT07404332 | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | P1 | Solid Tumor | 35 | Feb 2026 |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | P2/P3 | Melanoma (Skin Cancer) | 135 | Aug 2025 |
| NCT02813135 | ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | Pediatric Cancer | 472 | Aug 2016 |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | P1/P2 | Lung Cancer | 416 | Feb 2025 |
| NCT07281924 | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis | P1/P2 | Metastatic Melanoma | 15 | Jun 2026 |
| NCT07529873 | N'FORCEPhase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma | P2 | Squamous Cell Carcinoma of Head and Neck (SCCHN) | 131 | May 2026 |
| NCT06963905 | SIMONESaci Nivo Rela for TNBC | P1/P2 | Metastatic Triple-negative Breast Cancer | 60 | Dec 2025 |
| NCT07050043 | LEDANGLow Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC | P3 | NSCLC (Non-small Cell Lung Carcinoma) | 123 | May 2025 |
| NCT07188896 | RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | Advanced Renal Cell Carcinoma (aRCC) | 120 | Apr 2026 |
| NCT07223424 | PSI-ImmunePatient Preference for Subcutaneous vs. Intravenous Immune Therapy | P2 | Renal Cell Carcinoma | 880 | Nov 2025 |
| NCT05629546 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | P1 | Advanced Melanoma | 33 | Nov 2024 |
| NCT06926790 | GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) | P2 | Lung Cancer - Non Small Cell | 69 | Feb 2025 |
| NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | P2 | Hodgkin Lymphoma | 83 | Jan 2024 |
| NCT06169956 | NENIAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany | — | Resectable Non-small Cell Lung Cancer | 400 | Nov 2023 |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | P2/P3 | Muscle Invasive Bladder Urothelial Carcinoma | 992 | Feb 2024 |
| NCT07430202 | FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | P1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | 27 | Aug 2026 |
| NCT06365619 | NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | P2 | Melanoma | 25 | Jun 2026 |
| NCT07432295 | GIVA-2Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | P2 | Solid Tumor | 180 | Feb 2026 |
| NCT05909618 | 14Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases | P2 | Advanced Glioblastoma | 33 | Jul 2023 |
| NCT07013565 | ACCELERATEChemoimmunotherapy for ALK+ Relapsed/Refractory ALCL | P2 | Anaplastic Large Cell Lymphoma, ALK-Positive | 20 | Aug 2025 |
| NCT05176483 | STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | P1 | Renal Cell Carcinoma (RCC) | 1,314 | Dec 2021 |
| NCT06889493 | NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | P1 | Neuroendocrine Carcinoma | 36 | May 2025 |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | P3 | Resectable Lung Non-Small Cell Carcinoma | 1,100 | Dec 2024 |
| NCT05802056 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | P1 | Clinical Stage IV Gastric Cancer AJCC v8 | 15 | Nov 2023 |
| NCT06800339 | NEORADJUVANTA Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer | P1 | Non-Small Cell Lung Cancer | 18 | Apr 2025 |
| NCT06275360 | RIVALRepositioning Immunotherapy in VetArans With Lung Cancer | P2 | Non-Small Cell Lung Cancer | 25 | Mar 2024 |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | P1/P2 | Solid Tumor, Adult | 434 | Mar 2021 |
| NCT06712927 | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | P2 | Melanoma | 60 | Aug 2025 |
| NCT06319196 | ClearMeClear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | P2 | Cutaneous Melanoma | 54 | Aug 2026 |
| NCT07546812 | GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas | P2 | HER2-negative | 120 | May 2026 |
| NCT07398937 | ECTOP-1036Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC | P2 | Resectable Stage II-IIIa Squamous NSCLC | 116 | Feb 2026 |
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT05795244 | NIVECStudy of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | P2 | Endometrial Neoplasms | 30 | Oct 2023 |
| NCT05655312 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | P1/P2 | Recurrent Melanoma (Skin) | 300 | Jun 2023 |
| NCT03685890 | NivoILPEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | P1/P2 | Melanoma | 74 | Apr 2019 |
| NCT05652673 | IPI-NIVOSafe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | N/A | Melanoma Stage IV | 80 | Feb 2023 |
| NCT07401875 | SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | P1 | Phase 1b | 35 | Mar 2026 |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | P2 | Melanoma Stage III | 29 | Sep 2020 |
| NCT07174453 | Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies | P3 | Solid Tumor Malignancies | 192 | Oct 2025 |
| NCT07563738 | TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212 | P1/P2 | Mesothelioma | 229 | Mar 2026 |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | Advanced Lung Adenocarcinoma | 50 | Jul 2024 |
| NCT06519682 | CAYAA Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) | N/A | High Grade Glioma | 20 | Dec 2024 |
| NCT03340129 | ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | P2 | Melanoma Stage Iv | 218 | Aug 2019 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | Cancer | 1,500 | Aug 2019 |
| NCT06463665 | VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | P2 | Advanced Non-squamous Non-small-cell Lung Cancer | 142 | Sep 2024 |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | P1/P2 | Low Grade Glioma | 27 | Apr 2025 |
| NCT06794229 | EXPLORE-RCCNeoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | P2 | Locally Advanced Renal Cell Carcinoma | 69 | Oct 2025 |
| NCT06561087 | Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions | P2 | Premalignant Lesion | 45 | Feb 2025 |
| NCT07459543 | FDCA Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India | P4 | Untreated Melanoma | 30 | Nov 2026 |
| NCT07176975 | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers | P1 | Solid Tumors | 46 | Aug 2027 |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | P1 | Diffuse Pleural Mesothelioma | 60 | Apr 2026 |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | P2 | Metastatic Nasopharyngeal Carcinoma | 156 | Jul 2024 |
| NCT06253611 | BIGFirst-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | P2 | Gastric Cancer | 120 | Apr 2024 |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | P1 | Gastric Cancer | 42 | Jun 2023 |
| NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer | P1/P2 | Relapsed/Refractory Small Cell Lung Cancer | 240 | Feb 2026 |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | P1 | Clear Cell Renal Cell Carcinoma | 16 | Mar 2026 |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | P1 | Uveal Melanoma | 15 | May 2026 |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | P3 | Primary Mediastinal Lymphoma | 100 | Apr 2022 |
| NCT03080974 | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | P2 | Pancreatic Adenocarcinoma | 10 | Aug 2017 |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | P2/P3 | Recurrent Classic Hodgkin Lymphoma | 374 | Dec 2026 |
| NCT03465592 | HLATrial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | P1/P2 | Sarcoma | 39 | May 2018 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | Advanced Hepatocellular Carcinoma | 226 | Feb 2026 |
| NCT06983210 | GRAPEClinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | P2 | Urothelial Carcinoma Bladder | 43 | May 2025 |
| NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | P3 | Advanced (Unresectable or Metastatic) Melanoma | 632 | Dec 2025 |
| NCT06823479 | MATISSE 2Towards Cure Via Only Ultra-short ICB in CSCC | P2 | Cutaneous Squamous Cell Carcinoma (CSCC) | 41 | May 2025 |
| NCT07233668 | IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC | N/A | Metastatic Renal Cell Carcinoma ( mRCC) | 172 | Dec 2025 |
| NCT07028125 | CANIQOLDigital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma | P4 | Renal Cell Carcinoma (Kidney Cancer) | 83 | Oct 2025 |
| NCT06984146 | Nivo40-AVD for Advanced Classic Hodgkin Lymphoma | P2 | Hodgkin Lymphoma, Adult | 54 | Apr 2025 |
| NCT07084610 | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | P2 | Non-Small Cell Lung Cancer | 30 | Feb 2025 |
| NCT05187429 | NIVO-LDLow Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy | P1/P2 | HIV I Infection | 42 | Jan 2023 |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumors | 413 | Feb 2025 |
| NCT07527858 | GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | P2 | Advanced Microsatellite Stable Colorectal Cancer | 170 | May 2026 |
| NCT06863311 | EXACTTrial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | P2 | Advanced Renal Cell Carcinoma | 70 | Mar 2026 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | Pancreatic Cancer | 20 | Sep 2025 |
| NCT07209059 | FINISH-HLPET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | P2 | Hodgkin Lymphoma | 30 | Jul 2025 |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | P1/P2 | Advanced Cancer | 126 | Aug 2024 |
| NCT06031233 | MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | Oncology | 776 | Sep 2023 |
| NCT04989946 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | P1/P2 | Prostate Cancer | 60 | Dec 2021 |
| NCT02693535 | TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | Lymphoma, Non-Hodgkin | 4,200 | Mar 2016 |
| NCT06708949 | RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | Renal Cell Carcinoma, Clear Cell | 15 | Mar 2025 |
| NCT07226856 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | P2 | Metastatic Pancreatic Adenocarcinoma | 43 | Dec 2025 |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | P2 | Locally Advanced Solid Tumor | 30 | Mar 2025 |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | P2 | Melanoma Stage III | 90 | May 2024 |
| NCT05317000 | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | P2 | Squamous Cell Carcinoma of Head and Neck | 50 | Mar 2023 |
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | P2 | Non Small Cell Lung Cancer Metastatic | 108 | May 2026 |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | P3 | Advanced Esophageal Adenocarcinoma | 382 | Jan 2023 |
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | P2 | Renal Cell Carcinoma | 48 | Jan 2024 |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | P1 | Anatomic Stage IV Breast Cancer AJCC v8 | 25 | Jun 2022 |
| NCT06245356 | TRIFLUOX-DPSafety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | P2 | Metastatic Colorectal Cancer | 73 | Mar 2025 |
| NCT07100704 | OrionRecurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab | P2 | Recurrent/ Metastatic Olfactory Neuroblastoma | 14 | Apr 2025 |
| NCT07152678 | BRIGHT-ESCCBrachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma | P2 | Esophageal Cancer | 60 | Sep 2025 |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | P2 | Hepato Cellular Carcinoma (HCC) | 230 | Jun 2026 |
| NCT07147101 | HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Advanced Hepatocellular Carcinoma (HCC) | 150 | Sep 2025 |
| NCT06490536 | The Sagittarius Trial | P3 | Colon Cancer Stage II | 700 | Oct 2024 |
| NCT07128680 | EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | P1 | Advanced Clear Cell Renal Cell Carcinoma | 33 | Mar 2026 |
| NCT06237920 | TURANDORELAStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | P2 | Urologic Neoplasms | 90 | Feb 2024 |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | Early P1 | Muscle Invasive Bladder Urothelial Carcinoma | 18 | Jun 2024 |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | P2 | Melanoma (Skin) | 30 | Feb 2023 |
| NCT06908993 | COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | P3 | Advanced Non Small Cell Lung Cancer | 133 | Dec 2025 |
| NCT05934331 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study | P2 | Malignant Neoplasms of Digestive Organs | 276 | Jul 2023 |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | P1/P2 | Unresectable Hepatocellular Carcinoma | 33 | Feb 2026 |
| NCT04546399 | B-ALLA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | P2 | Down Syndrome | 461 | Dec 2020 |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | P1/P2 | Solid Tumor | 542 | Nov 2022 |
| NCT05327686 | SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | P2 | Metastatic Renal Cell Carcinoma | 240 | Feb 2023 |
| NCT03563729 | MEMBRAINSMelanoma Metastasized to the Brain and Steroids | P2 | Malignant Melanoma | 80 | Jun 2018 |
| NCT07213557 | Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy | P2 | Advanced or Metastatic Gastrooesophageal Carcinoma | 84 | Mar 2026 |
| NCT06624475 | NEONNeoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | P2 | Basal Cell Carcinoma | 30 | Aug 2025 |
| NCT06638931 | ANTARESAgnostic Therapy in Rare Solid Tumors | P2 | Urachal Cancer | 28 | Jul 2024 |
| NCT05845450 | UNICORNPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | P2 | Colorectal Cancer | 197 | May 2023 |
| NCT06346197 | CIMECombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | P3 | Gastric Cancer | 132 | Dec 2025 |
| NCT07017816 | JACOBA Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. | Early P1 | CNS Malignancies | 18 | Dec 2025 |
| NCT06934057 | CABOLDCabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | P4 | Kidney Cancer | 50 | May 2025 |
| NCT07542262 | NIVO402025Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers | P2 | Colorectal Cancer | 128 | Jun 2025 |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | P2 | Uterine Cervical Neoplasms | 112 | Aug 2022 |
| NCT07422779 | MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | N/A | Metastatic Melanoma | 100 | Mar 2022 |
| NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | P1 | HER2-Expressing Solid Tumors | 60 | Nov 2025 |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | P1 | Autoimmune Disease | 300 | Jul 2019 |
| NCT07394062 | ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | Nonsmall Cell Lung Cancer, Stage IV | 400 | Feb 2026 |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | Melanoma | 105 | Feb 2023 |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | P1/P2 | Stage III Hepatocellular Carcinoma AJCC v8 | 15 | Jan 2021 |
| NCT06019130 | NPC-NivoNivolumab in Children and Adults With Nasopharyngeal Carcinoma | P2 | Nasopharyngeal Carcinoma | 57 | Jan 2023 |
| NCT06731270 | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | P2 | Advanced Lung Non-Small Cell Carcinoma | 20 | Apr 2025 |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | P2 | Metastatic Melanoma | 37 | Sep 2023 |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | P1 | Hepatocellular Carcinoma (HCC) | 15 | Apr 2026 |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | P1 | Head and Neck Cancer | 15 | Jan 2026 |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | P2 | Advanced Acral Melanoma | 99 | Oct 2025 |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | P2 | Leptomeningeal Metastasis | 97 | Mar 2025 |
| NCT06724159 | SOGUG-PRINCISObservational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. | — | Genitourinary Cancers | 500 | Dec 2024 |
| NCT05681780 | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | P1 | Non Small Cell Lung Cancer | 20 | Mar 2023 |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | P2 | Brain Metastases | 20 | Sep 2022 |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | P1/P2 | Solid Tumor | 49 | Jul 2022 |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | P1 | Clinical Stage I Cutaneous Melanoma AJCC v8 | 36 | Oct 2021 |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | P1 | Solid Tumor | 330 | Jun 2021 |
| NCT04150640 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | P2 | Esophageal Adenocarcinoma | 52 | Jul 2020 |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | P3 | Metastatic Colon Cancer | 400 | Apr 2020 |
| NCT03646617 | RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | P2 | Metastatic Melanoma | 54 | Nov 2018 |
| NCT04204837 | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | P2 | Squamous Cell Carcinoma of the Skin | 61 | Mar 2017 |
| NCT02925234 | DRUPThe Drug Rediscovery Protocol (DRUP Trial) | P2 | Cancer | 1,550 | Aug 2016 |
| NCT05317858 | LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | P3 | Brain Tumor | 30 | Aug 2022 |
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | P1 | Viral Associated Malignancies | 58 | Dec 2021 |
| NCT06274437 | A Study of BND-35 in Participants With Advanced Solid Tumors | P1 | Cancer | 280 | Jun 2024 |
| NCT05901285 | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | P1 | Advanced Solid Tumor | 48 | Nov 2023 |
| NCT05039073 | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | P2 | Recurrent Classic Hodgkin Lymphoma | 46 | May 2022 |
| NCT03690986 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | P1 | Squamous Cell Carcinoma of the Head and Neck | 50 | Nov 2018 |
| NCT03406247 | ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | P2 | Head and Neck Squamous Cell Carcinoma | 140 | Feb 2018 |
| NCT06534983 | IMCODE004A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) | P2 | Muscle-invasive Urothelial Carcinoma | 62 | Dec 2024 |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | P2/P3 | Advanced Esophageal Adenocarcinoma | 224 | Jun 2024 |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | P2 | Lung Cancer, Nonsmall Cell | 33 | Oct 2023 |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | P1/P2 | Advanced Cancer | 100 | Jun 2023 |
| NCT06112314 | PRISM-MEL-301IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | P3 | Advanced Melanoma | 680 | Jun 2024 |
| NCT06764771 | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | P1 | Advanced Malignant Tumors | 437 | Mar 2025 |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | P2 | Melanoma | 72 | Sep 2020 |
| NCT06364917 | DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | P2 | Non Small Cell Lung Cancer | 24 | May 2025 |
| NCT05310643 | NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | P2 | Metastatic Colorectal Cancer | 30 | May 2022 |
| NCT05112549 | IT-PD1Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) | P1 | Leptomeningeal Disease | 46 | Oct 2021 |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Early P1 | Locally Advanced or Metastatic Melanoma | 12 | Nov 2022 |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 35 | Aug 2020 |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | P1/P2 | Diffuse Astrocytoma, IDH-Mutant | 134 | Nov 2023 |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | P1/P2 | Cancer | 595 | May 2023 |
| NCT04745949 | PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | P2 | Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | 31 | May 2021 |
| NCT04741997 | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Early P1 | Melanoma Stage III | 50 | May 2021 |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | P1/P2 | Hodgkin Lymphoma | 54 | Sep 2018 |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | P2 | Advanced Clear Cell Renal Cell Carcinoma | 54 | Dec 2022 |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | P1 | Gastroesophageal Adenocarcinoma | 20 | Jun 2025 |
| NCT06015724 | DARANIVOVAXAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | P2 | Pancreatic Ductal Adenocarcinoma | 54 | Jan 2024 |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | P2 | Hepatocellular Carcinoma | 60 | Apr 2021 |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | P2 | Acral Lentiginous Melanoma | 112 | Jan 2021 |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | P1/P2 | CNS Tumor | 91 | May 2020 |
| NCT03259867 | TATE-PD1Combination of TATE and PD-1 Inhibitor in Liver Cancer | P2 | Hepatocellular Carcinoma | 54 | Jul 2017 |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | P1 | Recurrent B-Cell Non-Hodgkin Lymphoma | 32 | Nov 2022 |
| NCT06931613 | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment | P2 | Relapsed or Refractory Hodgkin Lymphoma | 20 | Jun 2022 |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | P1 | Acral Lentiginous Melanoma | 75 | May 2018 |
| NCT06554613 | Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC | P2 | Non-Small Cell Lung Cancer | 156 | Jul 2024 |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | P2 | Mucosal Melanoma | 20 | May 2022 |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | P1 | Melanoma | 50 | Nov 2021 |
| NCT05715229 | G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | P2 | Carcinoma, Non-Small-Cell Lung | 108 | Sep 2023 |
| NCT05502315 | CANOPYStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | P2 | Castration-resistant Prostate Cancer | 47 | Feb 2023 |
| NCT05817903 | AxInAxitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | P2 | Metastatic Renal Cell Carcinoma | 118 | Apr 2023 |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | P1 | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 47 | May 2021 |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | P1 | Glioblastoma (GBM) | 34 | Jun 2025 |
| NCT05310591 | CAPTiRALLCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | P1/P2 | B Acute Lymphoblastic Leukemia | 26 | Mar 2023 |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | P1 | Advanced Solid Tumor | 50 | Jul 2024 |
| NCT05597800 | LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | P2 | NSCLC Stage IV | 105 | Feb 2023 |
| NCT05749900 | HERBOTFirst-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) | P1/P2 | HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer | 44 | May 2023 |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | P2 | Metastatic Renal Cell Carcinoma | 111 | Jan 2022 |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | P2 | Bladder Adenocarcinoma | 314 | May 2019 |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | Lung Non-Small Cell Carcinoma | 25 | May 2023 |
| NCT07276373 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | P1/P2 | Neoplasms | 50 | Jan 2026 |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | P1/P2 | Clinical Stage III Cutaneous Melanoma AJCC v8 | 16 | Jul 2024 |
| NCT05476796 | LOGICANOxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | P2 | Gastric Adenocarcinoma | 118 | Jun 2023 |
| NCT03297606 | CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | Lymphoma, Non-Hodgkin | 720 | Mar 2018 |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | P2 | Clinical Stage III Cutaneous Melanoma AJCC v8 | 150 | Dec 2022 |
| NCT06064097 | NPCA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | P2 | Stage II Nasopharyngeal Carcinoma AJCC v8 | 50 | Jun 2024 |
| NCT06265285 | CCBWComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | P2 | Advanced Esophageal Squamous Cell Carcinoma | 50 | Apr 2024 |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Early P1 | Renal Cell Carcinoma | 20 | Feb 2023 |
| NCT05234307 | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | P1 | Metastatic Lung Non-Small Cell Carcinoma | 30 | Nov 2022 |
| NCT05257590 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 95 | May 2022 |
| NCT05745233 | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites | N/A | Malignant Ascites | 30 | Jan 2021 |
| NCT04477343 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | P1 | Pancreatic Ductal Adenocarcinoma | 20 | Nov 2020 |
| NCT07196384 | GLOWOptical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW | P1 | Esophageal Cancer | 15 | Dec 2025 |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | P2 | Pleural Biphasic Mesothelioma | 26 | Nov 2024 |
| NCT04159818 | TONIC-2Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | P2 | Metastatic Breast Cancer | 52 | Feb 2020 |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | P2 | Urothelial Carcinoma | 23 | Nov 2024 |
| NCT04966663 | ctDNA Lung RCTUsing ctDNA to Determine Therapies for Lung Cancer | P2 | Non Small Cell Lung Cancer | 66 | Mar 2022 |
| NCT04495296 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | P1/P2 | Advanced Cancer | 320 | Aug 2020 |
| NCT06158919 | G/GEJ cancerA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer | N/A | Gastric Cancer/Adenocarcinoma of Esophagogastric Junction | 58 | Nov 2023 |
| NCT04991025 | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | P2 | Lung Cancer | 60 | Oct 2022 |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | P1 | Advanced Clear Cell Renal Cell Carcinoma | 28 | Jun 2024 |
| NCT04561206 | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | P2 | Relapsed Classic Hodgkin Lymphoma | 31 | Nov 2021 |
| NCT06532149 | EROSERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | NSCLC Stage IV | 80 | Aug 2024 |
| NCT04933903 | LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | P2 | Non Small Cell Lung Cancer | 25 | Oct 2021 |
| NCT05727410 | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma | P2 | High-grade Salivary Gland Carcinoma | 50 | Nov 2022 |
| NCT03844256 | CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study | P1/P2 | Urinary Bladder Cancer | 50 | Jan 2019 |
| NCT04866654 | RAFTINGRadiation Free Chemotherapy for Early Hodgkin Lymphoma | P2 | Hodgkin Lymphoma | 160 | Mar 2021 |
| NCT06008925 | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | P1/P2 | Metastatic Gastric Cancer | 43 | Nov 2022 |
| NCT05203913 | CNN-BCCisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer | P2 | Muscle-Invasive Bladder Carcinoma | 32 | May 2023 |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | P1/P2 | Advanced Solid Tumor | 159 | Apr 2022 |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | P2 | Locally Advanced Nasopharyngeal Carcinoma | 57 | Feb 2022 |
| NCT04400539 | IMPALAThe IMmunotherapy Pleural 5-ALA PDT | P2 | Mesotheliomas Pleural | 20 | May 2022 |
| NCT04295863 | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | P1 | Metastatic Cancer | 264 | Jun 2020 |
| NCT06163820 | BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | P1/P2 | Melanoma Brain Metastases | 46 | May 2025 |
| NCT05223816 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | P2 | Hepatocellular Carcinoma | 97 | Jan 2024 |
| NCT05266612 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | P1 | Solid Tumor | 12 | Nov 2022 |
| NCT04535713 | GALLANTGALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | P2 | Sarcoma | 260 | Sep 2020 |
| NCT03707808 | myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | P1/P2 | Solid Tumor | 18 | Jan 2018 |
| NCT06097975 | NEO-GLITIPNIA Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma | P1 | Recurrent Glioblastoma | 18 | Mar 2024 |
| NCT05739045 | Nivolumab Combined With SOX Used in the Perioperative Treatment | P2 | Immune Suppression | 46 | Nov 2022 |
| NCT04823403 | HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | P1 | Hepatocellular Carcinoma | 27 | Nov 2020 |
Nivolumab clinical trials by indication
Melanoma (93)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06240143 | MARIANE | P1/P2 | recruiting | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma |
| NCT06246916 | — | P3 | recruiting | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) |
| NCT07092670 | MELAFERT | N/A | recruiting | MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. |
| NCT06683755 | TRINITY | P1/P2 | not yet recruiting | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) |
| NCT03470922 | RELATIVITY-047 | P2/P3 | active not recruiting | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma |
| NCT04930783 | — | P1 | active not recruiting | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma |
| NCT06365619 | NeoRelapse | P2 | recruiting | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma |
| NCT03999749 | — | P2 | active not recruiting | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma |
| + 85 more, see All trials below. | ||||
Hepatocellular Carcinoma (35)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03383458 | CheckMate 9DX | P3 | active not recruiting | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation |
| NCT04658147 | HCC | P1 | active not recruiting | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) |
| NCT04472767 | — | P2 | recruiting | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma |
| NCT04912765 | — | P2 | recruiting | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC |
| NCT03259867 | TATE-PD1 | P2 | recruiting | Combination of TATE and PD-1 Inhibitor in Liver Cancer |
| NCT05257590 | — | P2 | recruiting | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma |
| NCT03695952 | — | N/A | active not recruiting | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors |
| NCT04039607 | CheckMate 9DW | P3 | active not recruiting | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma |
| + 27 more, see All trials below. | ||||
Metastatic Melanoma (28)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07504796 | — | P4 | recruiting | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab |
| NCT07281924 | — | P1/P2 | recruiting | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis |
| NCT07422779 | MAK | N/A | recruiting | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia |
| NCT05779423 | — | P2 | recruiting | Cryoablation+Ipilimumab+Nivolumab in Melanoma |
| NCT05034536 | — | P2 | active not recruiting | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma |
| NCT03646617 | RadVax | P2 | recruiting | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma |
| NCT03122522 | — | P2 | active not recruiting | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy |
| NCT03645928 | — | P2 | terminated | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
| + 20 more, see All trials below. | ||||
Non-Small Cell Lung Cancer (27)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04564157 | NADIM-ADJUVANT | P3 | active not recruiting | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy |
| NCT03228667 | — | P2 | active not recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors |
| NCT06800339 | NEORADJUVANT | P1 | recruiting | A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer |
| NCT06275360 | RIVAL | P2 | recruiting | Repositioning Immunotherapy in VetArans With Lung Cancer |
| NCT07084610 | — | P2 | recruiting | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer |
| NCT06946797 | CheckMate-1533 | P2 | active not recruiting | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| NCT02259621 | NA_00092076 | P2 | active not recruiting | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC |
| NCT06554613 | — | P2 | recruiting | Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC |
| + 19 more, see All trials below. | ||||
Advanced Cancer (27)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06362369 | — | P1/P2 | recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy |
| NCT05663710 | — | P1/P2 | recruiting | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC |
| NCT04495296 | — | P1/P2 | recruiting | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
| NCT04396821 | — | P1/P2 | active not recruiting | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors |
| NCT03459222 | — | P1/P2 | completed | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread |
| NCT03369223 | — | P1/P2 | completed | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors |
| NCT02743494 | CheckMate 577 | P3 | completed | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer |
| NCT03994601 | — | P1/P2 | completed | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers |
| + 19 more, see All trials below. | ||||
Renal Cell Carcinoma (26)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07223424 | PSI-Immune | P2 | recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy |
| NCT05148546 | NESCIO | P2 | active not recruiting | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer |
| NCT06053658 | — | P2 | recruiting | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma |
| NCT03172754 | — | P1/P2 | active not recruiting | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma |
| NCT03873402 | — | P3 | active not recruiting | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer |
| NCT03937219 | COSMIC-313 | P3 | active not recruiting | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| NCT05188118 | — | Early P1 | recruiting | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma |
| NCT05501054 | — | P1/P2 | active not recruiting | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. |
| + 18 more, see All trials below. | ||||
Non Small Cell Lung Cancer (25)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03838159 | NADIMII | P2 | active not recruiting | NADIM II: Neo-Adjuvant Immunotherapy |
| NCT05681780 | — | P1 | recruiting | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC |
| NCT05012254 | NIVIPI-Brain | P2 | active not recruiting | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases |
| NCT06364917 | DISCERN | P2 | recruiting | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC |
| NCT03527108 | — | P2 | active not recruiting | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC |
| NCT04966663 | ctDNA Lung RCT | P2 | recruiting | Using ctDNA to Determine Therapies for Lung Cancer |
| NCT04933903 | LOW | P2 | recruiting | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab |
| NCT03377023 | — | P1/P2 | active not recruiting | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer |
| + 17 more, see All trials below. | ||||
Solid Tumor (23)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05076760 | — | P1 | recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors |
| NCT07404332 | — | P1 | recruiting | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors |
| NCT07432295 | GIVA-2 | P2 | recruiting | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) |
| NCT05584670 | — | P1/P2 | recruiting | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors |
| NCT05423262 | — | P1/P2 | recruiting | A Study of TRK-950 in Patients With Advanced Solid Tumors |
| NCT04900818 | — | P1 | recruiting | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors |
| NCT03872947 | — | P1 | active not recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
| NCT05266612 | — | P1 | recruiting | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors |
| + 15 more, see All trials below. | ||||
Cancer (23)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03899155 | — | P2 | recruiting | Pan Tumor Rollover Study |
| NCT02925234 | DRUP | P2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT06274437 | — | P1 | recruiting | A Study of BND-35 in Participants With Advanced Solid Tumors |
| NCT05919264 | — | P1/P2 | recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors |
| NCT04300244 | NIPU | P2 | active not recruiting | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma |
| NCT04336241 | — | P1 | active not recruiting | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
| NCT03400332 | — | P1/P2 | completed | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers |
| NCT02966548 | — | P1 | completed | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors |
| + 15 more, see All trials below. | ||||
Gastric Cancer (20)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07431281 | — | P3 | recruiting | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 |
| NCT06253611 | BIG | P2 | recruiting | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer |
| NCT05187182 | — | P1 | recruiting | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer |
| NCT06346197 | CIME | P3 | recruiting | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas |
| NCT03044613 | — | P1 | active not recruiting | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer |
| NCT06256328 | — | P2 | active not recruiting | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
| NCT05111626 | FORTITUDE-102 | P3 | active not recruiting | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. |
| NCT05322577 | FORTITUDE-103 | P1/P2 | active not recruiting | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. |
| + 12 more, see All trials below. | ||||
Hodgkin Lymphoma (19)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07551583 | — | P2 | not yet recruiting | Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL |
| NCT06812858 | — | P2 | recruiting | PD-1 Inhibitors Maintenance for cHL Post-autoHCT |
| NCT07209059 | FINISH-HL | P2 | recruiting | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma |
| NCT05723055 | NAHL | P2 | active not recruiting | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
| NCT03681561 | — | P1/P2 | recruiting | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma |
| NCT03033914 | B | P1/P2 | active not recruiting | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) |
| NCT03843294 | TAA-T | P1 | active not recruiting | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma |
| NCT04938232 | — | P2 | active not recruiting | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL |
| + 11 more, see All trials below. | ||||
Non-small Cell Lung Cancer (19)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07195695 | — | P3 | recruiting | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations |
| NCT07541170 | KRASCENDO 3 | P3 | not yet recruiting | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) |
| NCT06561386 | RELATIVITY1093 | P3 | recruiting | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% |
| NCT05867121 | — | P1 | active not recruiting | A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 |
| NCT04623775 | NSCLC | P2 | active not recruiting | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) |
| NCT05354102 | FIH | P1 | unknown | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 |
| NCT04123379 | NSCLC | P2 | completed | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) |
| NCT03285321 | NSCLC | P2 | completed | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) |
| + 11 more, see All trials below. | ||||
Breast Cancer (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07319195 | WINIT-BC | Early P1 | recruiting | Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC) |
| NCT03815890 | BELLINI | P2 | recruiting | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO |
| NCT03546686 | — | P2 | active not recruiting | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer |
| NCT03789110 | NIMBUS | P2 | active not recruiting | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer |
| NCT03414684 | — | P2 | active not recruiting | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer |
| NCT02499367 | TONIC | P2 | unknown | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients |
| NCT04591431 | ROME | P2 | unknown | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy |
| NCT02833233 | — | N/A | completed | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer |
| + 10 more, see All trials below. | ||||
Advanced Solid Tumors (16)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533697 | — | P1/P2 | recruiting | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors |
| NCT06697197 | — | P1/P2 | recruiting | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors |
| NCT06544655 | — | P1 | active not recruiting | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors |
| NCT06880549 | — | P1 | active not recruiting | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors |
| NCT05888831 | — | P1/P2 | active not recruiting | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors |
| NCT05407675 | — | P1/P2 | completed | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors |
| NCT05625412 | — | P1 | completed | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors |
| NCT04943900 | — | P1 | completed | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors |
| + 8 more, see All trials below. | ||||
Colorectal Cancer (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05845450 | UNICORN | P2 | recruiting | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) |
| NCT07542262 | NIVO402025 | P2 | enrolling by invitation | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers |
| NCT04117087 | — | P1 | active not recruiting | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
| NCT06410534 | — | P2 | withdrawn | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer |
| NCT03981146 | ANICCA | P2 | completed | A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer |
| NCT03377361 | CheckMate 9N9 | P1/P2 | completed | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread |
| NCT04072198 | NIVACOR | P2 | completed | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients |
| NCT04907539 | RNF43 | P2 | completed | A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) |
| + 7 more, see All trials below. | ||||
Lung Cancer (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06618287 | — | P1/P2 | recruiting | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors |
| NCT05633667 | VELOCITY-Lung | P2 | active not recruiting | Study of Novel Treatment Combinations in Patients With Lung Cancer |
| NCT06572722 | ECTOP-1030 | P2 | withdrawn | Perioperative Immunotherapy for NSCLC (ECTOP-1030) |
| NCT04991025 | — | P2 | recruiting | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery |
| NCT03417037 | — | P3 | withdrawn | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer |
| NCT03575793 | — | P1/P2 | completed | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer |
| NCT02664181 | PRECISE | P2 | completed | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial |
| NCT02481830 | CheckMate331 | P3 | completed | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer |
| + 7 more, see All trials below. | ||||
Prostate Cancer (14)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04989946 | — | P1/P2 | recruiting | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer |
| NCT03600350 | — | P2 | active not recruiting | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer |
| NCT03061539 | — | P2 | active not recruiting | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature |
| NCT03637543 | — | P2 | active not recruiting | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer |
| NCT03543189 | — | P1/P2 | active not recruiting | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy |
| NCT03689699 | MAGIC-8 | P1/P2 | active not recruiting | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) |
| NCT04019964 | — | P2 | completed | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer |
| NCT03338790 | CheckMate 9KD | P2 | completed | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer |
| + 6 more, see All trials below. | ||||
Clear Cell Renal Cell Carcinoma (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07187869 | — | P1 | not yet recruiting | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study |
| NCT03793166 | — | P3 | active not recruiting | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study |
| NCT04810078 | CheckMate-67T | P3 | active not recruiting | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread |
| NCT05239533 | — | P2 | active not recruiting | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer |
| NCT02210117 | — | Early P1 | active not recruiting | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery |
| NCT06049576 | — | P1 | active not recruiting | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| NCT04300140 | — | P1/P2 | terminated | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
| NCT03680521 | — | P2 | completed | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma |
| + 5 more, see All trials below. | ||||
Head and Neck Cancer (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07216833 | — | P1 | not yet recruiting | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT05327270 | — | P1 | active not recruiting | Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions |
| NCT03247712 | — | P1/P2 | active not recruiting | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer |
| NCT02919683 | — | P2 | active not recruiting | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity |
| NCT03355560 | — | P2 | completed | Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy |
| NCT03700905 | IMSTAR-HN | P3 | unknown | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy |
| NCT03894891 | — | P2 | completed | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer |
| NCT02741570 | CheckMate 651 | P3 | completed | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| + 5 more, see All trials below. | ||||
Metastatic Renal Cell Carcinoma (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03055013 | — | P3 | active not recruiting | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy |
| NCT05327686 | SAMURAI | P2 | recruiting | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial |
| NCT05817903 | AxIn | P2 | recruiting | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients |
| NCT05263050 | — | P2 | recruiting | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors |
| NCT03595124 | — | P2 | active not recruiting | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) |
| NCT06284564 | BOOST-RCC | P2 | active not recruiting | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) |
| NCT04090710 | CYTOSHRINK | P2 | active not recruiting | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer |
| NCT03075423 | — | P2 | completed | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC |
| + 5 more, see All trials below. | ||||
Pancreatic Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06941857 | — | P2 | recruiting | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer |
| NCT03563248 | — | P2 | active not recruiting | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer |
| NCT05721846 | CheckVAC | P1 | active not recruiting | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer |
| NCT04361162 | — | P2 | active not recruiting | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer |
| NCT02451982 | — | P2 | active not recruiting | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas |
| NCT03161379 | — | P2 | completed | GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer |
| NCT05116917 | INFLUENCE | P2 | terminated | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. |
| NCT03190265 | — | P2 | completed | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer |
| + 4 more, see All trials below. | ||||
Glioblastoma (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04323046 | — | P1 | active not recruiting | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults |
| NCT04047706 | — | P1 | active not recruiting | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma |
| NCT04606316 | — | P1 | active not recruiting | Surgical Nivolumab And Ipilimumab For Recurrent GBM |
| NCT03743662 | — | P2 | active not recruiting | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma |
| NCT03233152 | GlitIpNi | P1/P2 | active not recruiting | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. |
| NCT04817254 | ICI | P2 | completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
| NCT03452579 | — | P2 | active not recruiting | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM |
| NCT03493932 | — | P1 | completed | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade |
| + 4 more, see All trials below. | ||||
Solid Tumors (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07492680 | — | P2 | not yet recruiting | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) |
| NCT07176975 | — | P1 | not yet recruiting | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers |
| NCT04423029 | — | P1 | completed | A Study of DF6002 Alone and in Combination With Nivolumab |
| NCT04704154 | — | P2 | completed | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors |
| NCT02426892 | — | P2 | completed | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors |
| NCT02593786 | CheckMate 077 | P1/P2 | completed | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors |
| NCT03347123 | ECHO-208 | P1/P2 | terminated | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) |
| NCT02702492 | PANAMA | P1 | terminated | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) |
| + 2 more, see All trials below. | ||||
Metastatic Colorectal Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06245356 | TRIFLUOX-DP | P2 | recruiting | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
| NCT05310643 | NIPIRESCUE | P2 | recruiting | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC |
| NCT04008030 | CheckMate 8HW | P3 | active not recruiting | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) |
| NCT03867799 | — | P2 | active not recruiting | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer |
| NCT03547999 | — | P2 | terminated | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC |
| NCT04166383 | — | P2 | terminated | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) |
| NCT03832621 | MAYA | P2 | completed | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer |
| NCT04430985 | IMMUNOX | P2 | withdrawn | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer |
| + 2 more, see All trials below. | ||||
Multiple Myeloma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06523621 | — | P2 | active not recruiting | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel |
| NCT02719613 | — | P2 | completed | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab |
| NCT03227432 | — | P2 | withdrawn | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma |
| NCT03292263 | — | P1/P2 | unknown | ASCT With Nivolumab in Patients With Multiple Myeloma |
| NCT02681302 | CPIT001 | P1/P2 | terminated | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence |
| NCT02726581 | CheckMate 602 | P3 | completed | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma |
| NCT03782064 | DC | P2 | terminated | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma |
| NCT02612779 | — | P2 | completed | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. |
| + 2 more, see All trials below. | ||||
Advanced Melanoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06264180 | — | P3 | recruiting | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] |
| NCT05629546 | — | P1 | recruiting | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors |
| NCT04462406 | — | P2 | active not recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial |
| NCT06112314 | PRISM-MEL-301 | P3 | recruiting | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
| NCT04495257 | RCC | P1 | completed | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) |
| NCT04493203 | — | P2 | completed | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma |
| NCT07079644 | — | N/A | completed | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database |
| NCT06590480 | RPL-EAP-001 | N/A | no longer available | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma |
| + 2 more, see All trials below. | ||||
Urothelial Carcinoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02845323 | — | P2 | active not recruiting | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder |
| NCT05200988 | Indi-Blade | P2 | active not recruiting | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC |
| NCT06682728 | — | P2 | recruiting | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence |
| NCT06421311 | URADJ | N/A | terminated | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France |
| NCT03387761 | NABUCCO | P1 | completed | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy |
| NCT04871594 | TURANDOT | P1 | completed | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer |
| NCT03511391 | CHEERS | P2 | completed | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors |
| NCT04200963 | — | P1 | completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma |
| + 2 more, see All trials below. | ||||
Advanced Solid Tumor (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05901285 | — | P1 | recruiting | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors |
| NCT06302426 | — | P1 | recruiting | Trial of INI-4001 in Patients With Advanced Solid Tumours |
| NCT05163041 | — | P1/P2 | active not recruiting | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression |
| NCT04735978 | — | P1 | active not recruiting | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours |
| NCT05933265 | — | P1/P2 | active not recruiting | Study of LP-184 in Patients With Advanced Solid Tumors |
| NCT05267626 | — | P1/P2 | recruiting | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer |
| NCT04349267 | — | P1/P2 | completed | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors |
| NCT04042116 | — | P1/P2 | suspended | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor |
| + 2 more, see All trials below. | ||||
Bladder Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03171025 | NEXT | P2 | active not recruiting | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer |
| NCT03520491 | — | P2 | active not recruiting | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy |
| NCT06059547 | — | P2 | active not recruiting | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer |
| NCT02553642 | CA209-260 | P2 | completed | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) |
| NCT03558087 | — | P2 | completed | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing |
| NCT03993249 | MIBC | P2 | unknown | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy |
| NCT04209114 | — | P3 | completed | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer |
| NCT03980041 | MARIO-275 | P2 | completed | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) |
| + 2 more, see All trials below. | ||||
Mesothelioma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07563738 | TEADCO | P1/P2 | recruiting | A 2-part Phase 1/2 Open-label Trial on ODM-212 |
| NCT03907852 | TC-210 | P1/P2 | active not recruiting | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer |
| NCT03918252 | — | P2 | active not recruiting | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma |
| NCT04334759 | DREAM3R | P3 | completed | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma |
| NCT04040231 | — | P1 | completed | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma |
| NCT02899299 | CheckMate743 | P3 | completed | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients |
| NCT05041062 | — | P2 | completed | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma |
| NCT03063450 | CONFIRM | P3 | completed | CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma |
| + 1 more, see All trials below. | ||||
Head and Neck Squamous Cell Carcinoma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04848116 | Spark2 | P2 | active not recruiting | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca |
| NCT03406247 | ADJORL1 | P2 | recruiting | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma |
| NCT05280457 | TRINITY | P2 | active not recruiting | HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy |
| NCT05821751 | PRINCESS | N/A | unknown | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors |
| NCT03878979 | — | P2 | completed | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN |
| NCT05472506 | — | P1 | withdrawn | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer |
| NCT03317327 | REPORT | P1/P2 | completed | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors |
| NCT03169764 | HNSCC | P1/P2 | withdrawn | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
| + 1 more, see All trials below. | ||||
Advanced Clear Cell Renal Cell Carcinoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07383441 | — | P3 | recruiting | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
| NCT07510334 | — | P2 | recruiting | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
| NCT07000149 | eVOLVE-RCC02 | P3 | active not recruiting | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC |
| NCT07128680 | EXL01 | P1 | recruiting | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer |
| NCT05361720 | — | P2 | recruiting | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study |
| NCT05122546 | — | P1 | active not recruiting | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer |
| NCT06399419 | — | P1 | recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer |
| NCT04904302 | — | P2 | terminated | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer |
Gastric Adenocarcinoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06504615 | METAGIO | N/A | active not recruiting | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France |
| NCT05476796 | LOGICAN | P2 | recruiting | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
| NCT07529613 | T-DXd_HER2Low | P1/P2 | completed | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma |
| NCT05394740 | — | P1/P2 | completed | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy |
| NCT05001360 | — | N/A | withdrawn | Study of FMT Combined With Nivolumab in Gastric Cancer |
| NCT04503967 | OASIS | P2 | unknown | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer |
| NCT02862535 | — | P1 | terminated | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT02864381 | — | P2 | completed | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma |
Melanoma (Skin) (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05704647 | — | P2 | recruiting | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases |
| NCT06377111 | — | P1 | active not recruiting | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma |
| NCT03543969 | — | Early P1 | active not recruiting | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma |
| NCT03405155 | — | P2 | completed | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery |
| NCT04901988 | DETECTION | P2/P3 | terminated | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION |
| NCT01176474 | — | P1 | completed | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma |
| NCT03949153 | CRIRIN | P1/P2 | completed | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis |
| NCT02652455 | — | Early P1 | completed | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma |
Carcinoma, Non-Small-Cell Lung (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04025879 | — | P3 | active not recruiting | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer |
| NCT05715229 | G360-IIT | P2 | recruiting | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy |
| NCT03083691 | BIOLUMA | P2 | completed | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer |
| NCT03669523 | DENIVOS | P2 | completed | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) |
| NCT03262779 | — | P2 | completed | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. |
| NCT02954991 | — | P2 | terminated | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer |
| NCT03663166 | NSCLC | P1/P2 | terminated | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) |
| NCT04023617 | — | P2 | unknown | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC |
Squamous Cell Carcinoma of the Head and Neck (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03690986 | — | P1 | recruiting | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer |
| NCT03341936 | — | P2 | active not recruiting | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN |
| NCT04326257 | — | P2 | completed | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy |
| NCT04659369 | — | P1 | terminated | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC |
| NCT05068609 | VOLUME-PRO | N/A | completed | A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) |
| NCT02105636 | — | P3 | completed | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) |
| NCT03349710 | — | P3 | completed | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer |
| NCT02124850 | — | P1 | terminated | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab |
Esophageal Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03544736 | INEC | P1/P2 | active not recruiting | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) |
| NCT07152678 | BRIGHT-ESCC | P2 | recruiting | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma |
| NCT07196384 | GLOW | P1 | not yet recruiting | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW |
| NCT05491616 | SANO-3 | P2 | active not recruiting | Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study |
| NCT06499298 | — | N/A | completed | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer |
| NCT03416244 | RAMONA | P2 | completed | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer |
| NCT02569242 | — | P3 | completed | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer |
Non-small Cell Lung Cancer (NSCLC) (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06487156 | FINN | N/A | active not recruiting | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT07215962 | — | N/A | active not recruiting | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% |
| NCT07141563 | — | N/A | completed | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC |
| NCT06735781 | — | N/A | completed | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France |
| NCT03735628 | — | P1 | completed | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors |
| NCT05468294 | Nivokin | P1/P2 | unknown | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer |
| NCT02840994 | — | P1 | completed | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer |
Clinical Stage III Cutaneous Melanoma AJCC v8 (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04940299 | — | P2 | active not recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT05896839 | — | P1/P2 | recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer |
| NCT05136196 | — | P2 | recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study |
| NCT02224781 | — | P3 | active not recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma |
| NCT03816332 | — | P1 | active not recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers |
| NCT04967196 | — | P1 | terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma |
| NCT03033576 | — | P2 | completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma |
Malignant Melanoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03563729 | MEMBRAINS | P2 | recruiting | Melanoma Metastasized to the Brain and Steroids |
| NCT05089370 | DEC-C | P1/P2 | active not recruiting | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma |
| NCT04223648 | MEDI4736 | Early P1 | withdrawn | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma |
| NCT04382664 | — | P2 | completed | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma |
| NCT02523313 | — | P2 | completed | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED |
| NCT02935790 | — | P1 | completed | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab |
| NCT02186249 | CheckMate218 | N/A | no longer available | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
Acute Myeloid Leukemia (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02275533 | — | P2 | active not recruiting | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial |
| NCT04913922 | AARON | P2 | unknown | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML |
| NCT03092674 | — | P2/P3 | completed | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
| NCT04277442 | — | P1 | completed | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia |
| NCT03417154 | — | P2 | completed | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS |
| NCT03358719 | — | P1 | completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
| NCT03381118 | — | P2 | terminated | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients |
Small Cell Lung Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03670056 | — | P2 | active not recruiting | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy |
| NCT03043599 | — | P1/P2 | completed | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer |
| NCT02247349 | — | P1/P2 | completed | BMS-986012 in Relapsed/Refractory SCLC |
| NCT03958045 | — | P2 | completed | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma |
| NCT03406715 | SCLC | P2 | terminated | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) |
| NCT03325816 | — | P1/P2 | completed | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer |
| NCT03026166 | — | P1/P2 | terminated | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer |
Advanced Renal Cell Carcinoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06863311 | EXACT | P2 | recruiting | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC |
| NCT05928806 | ARCITECT | P2 | suspended | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial |
| NCT02231749 | — | P3 | completed | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) |
| NCT03117309 | — | P2 | completed | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma |
| NCT03829111 | CBM588 | P1 | completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer |
| NCT04203901 | — | P2 | terminated | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma |
Colorectal Cancer Metastatic (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07328087 | COLONYVAQ™-CRC | Early P1 | recruiting | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer |
| NCT04730544 | NIPISAFE | P2 | active not recruiting | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. |
| NCT03388190 | METIMMOX | P2 | completed | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin |
| NCT04721301 | — | P1 | completed | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial |
| NCT03647839 | MODULATE | P2 | completed | Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer |
| NCT03982121 | ISILI | P1 | withdrawn | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy |
Neoplasms (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02817633 | AMBER | P1 | active not recruiting | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
| NCT07276373 | — | P1/P2 | recruiting | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies |
| NCT05964101 | GALAXY-1 | P2 | unknown | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma |
| NCT05898828 | R | P1/P2 | withdrawn | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer |
| NCT04350463 | — | P2 | completed | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers |
| NCT03792724 | INTRUST | P1/P2 | unknown | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors |
Ovarian Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04024878 | — | P1 | active not recruiting | NeoVax With Nivolumab in Patients With Ovarian Cancer |
| NCT03355976 | — | P2 | active not recruiting | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
| NCT05601752 | SURPASS-3 | P2 | active not recruiting | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) |
| NCT05715216 | OMP-313M32 | P2 | active not recruiting | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer |
| NCT02737787 | — | P1 | completed | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer |
| NCT03959761 | ICONIC | P1/P2 | completed | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma |
Carcinoma, Hepatocellular (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05337137 | RELATIVITY-106 | P1/P2 | completed | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer |
| NCT03418922 | — | P1 | completed | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma |
| NCT04310709 | RENOBATE | P2 | completed | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma |
| NCT03572582 | IMMUTACE | P2 | completed | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma |
| NCT02859324 | HCC | P1/P2 | completed | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) |
| NCT03939975 | — | P2 | completed | Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC |
Sarcoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04995003 | CAR | P1 | recruiting | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma |
| NCT03886311 | TNT | P2 | recruiting | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma |
| NCT03465592 | HLA | P1/P2 | recruiting | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma |
| NCT03463408 | — | Early P1 | active not recruiting | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma |
| NCT04535713 | GALLANT | P2 | recruiting | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma |
| NCT04741438 | RAR-Immune | P3 | unknown | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype |
Metastatic Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03693014 | — | P2 | active not recruiting | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors |
| NCT04295863 | — | P1 | recruiting | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers |
| NCT05043714 | NEBULA | P1 | completed | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours |
| NCT04208958 | ConsortiumIO | P1/P2 | completed | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer |
| NCT03453892 | ST-ICI | N/A | completed | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition |
| NCT03758781 | — | P1 | completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors |
Uveal Melanoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07501117 | — | P1 | not yet recruiting | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma |
| NCT04463368 | SCANDIUM II | P1 | completed | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases |
| NCT02913417 | — | P1/P2 | unknown | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases |
| NCT03922880 | — | P1 | completed | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma |
| NCT02626962 | GEM1402 | P2 | completed | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma |
Cutaneous Melanoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06999980 | Neo IRENIE | P2 | recruiting | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) |
| NCT06319196 | ClearMe | P2 | recruiting | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma |
| NCT03929029 | — | P1 | active not recruiting | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma |
| NCT02519322 | — | P2 | completed | Neoadjuvant and Adjuvant Checkpoint Blockade |
| NCT03633110 | — | P1/P2 | completed | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine |
Melanoma Stage III (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04562129 | — | P2 | recruiting | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients |
| NCT06295159 | — | P2 | recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma |
| NCT04741997 | — | Early P1 | recruiting | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma |
| NCT04013854 | — | P2 | active not recruiting | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab |
| NCT04007588 | BMS-986205 | P2 | withdrawn | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma |
Squamous Cell Carcinoma of Head and Neck (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317000 | — | P2 | recruiting | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC |
| NCT03576417 | NIVOPOSTOP | P3 | active not recruiting | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck |
| NCT05743270 | — | P2 | withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
| NCT05027204 | SCCHN | P1/P2 | unknown | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) |
| NCT05802290 | NIVACTOR | P3 | completed | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN |
NSCLC (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05684276 | DUMAS | P2 | active not recruiting | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors |
| NCT05180799 | — | P1/P2 | active not recruiting | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors |
| NCT06094296 | NSCLC | P2 | terminated | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) |
| NCT05583188 | VIGOR | P4 | terminated | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC |
| NCT05061017 | PG545 | P2 | completed | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) |
Colorectal Adenocarcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05504252 | METIMMOX-2 | P2 | active not recruiting | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin |
| NCT04963283 | MSS | P2 | active not recruiting | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer |
| NCT04457284 | — | P2 | active not recruiting | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer |
| NCT03576963 | — | P1/P2 | withdrawn | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer |
| NCT03800602 | — | P2 | completed | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer |
Lymphoma, Non-Hodgkin (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02693535 | TAPUR | P2 | recruiting | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
| NCT03297606 | CAPTUR | P2 | recruiting | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) |
| NCT05255601 | RELATIVITY-069 | P1/P2 | completed | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma |
| NCT03366272 | NIVEAU | P2/P3 | completed | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients |
| NCT03310619 | PLATFORM | P1/P2 | completed | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies |
Solid Tumor, Adult (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665206 | — | P1/P2 | recruiting | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors |
| NCT04165330 | — | P1/P2 | active not recruiting | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors |
| NCT04143711 | — | P1/P2 | completed | Study of DF1001 in Patients With Advanced Solid Tumors |
| NCT04761198 | — | P1/P2 | completed | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors |
| NCT03728179 | RACIN | P1 | completed | RACIN in Patients With Advanced TIL-negative Solid Tumors |
Advanced Malignant Solid Neoplasm (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04317105 | — | P1/P2 | active not recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN |
| NCT04021043 | BMS-986156 | P1/P2 | completed | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers |
| NCT02419495 | KPT-330 | P1 | terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies |
| NCT02408861 | — | P1 | terminated | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| NCT03326258 | — | P1/P2 | withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery |
Carcinoma, Renal Cell (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138512 | CheckMate 914 | P3 | completed | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney |
| NCT03012581 | AcSé | P2 | completed | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types |
| NCT02917772 | TITAN-RCC | P2 | completed | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma |
| NCT03136627 | — | P1/P2 | completed | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC |
| NCT02962804 | RCC | P2 | withdrawn | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) |
Various Advanced Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02632409 | CheckMate 274 | P3 | active not recruiting | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer |
| NCT03143153 | CheckMate 648 | P3 | completed | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin |
| NCT02488759 | CheckMate358 | P1/P2 | completed | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
| NCT03130959 | CheckMate 908 | P2 | completed | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies |
| NCT02387996 | — | P2 | completed | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer |
Recurrent Classic Hodgkin Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07572123 | — | P2/P3 | not yet recruiting | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma |
| NCT05039073 | — | P2 | recruiting | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors |
| NCT05162976 | — | P1 | active not recruiting | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed |
| NCT01896999 | — | P1/P2 | active not recruiting | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
Non Small Cell Lung Cancer Metastatic (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07420439 | — | P2 | not yet recruiting | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease |
| NCT03168464 | — | P1/P2 | terminated | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) |
| NCT03304093 | CHIVA2 | P2 | completed | Immunotherapy by Nivolumab for HIV+ Patients |
| NCT03353675 | NSCLC | P2 | completed | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) |
Hepatocellular Carcinoma (HCC) (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07075120 | — | P1 | recruiting | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer |
| NCT03510871 | HCC | P2 | completed | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) |
| NCT07053202 | — | N/A | completed | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma |
| NCT03071094 | HCC | P1/P2 | terminated | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) |
Advanced Hepatocellular Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07166406 | — | P3 | recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
| NCT04611165 | Nextrah | P2 | completed | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC |
| NCT03841201 | — | P2 | completed | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma |
| NCT03059147 | — | P1 | terminated | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma |
Metastatic Pancreatic Adenocarcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07226856 | — | P2 | recruiting | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma |
| NCT04787991 | REVOLUTION | P1 | completed | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
| NCT04050085 | SD-101 | P1 | completed | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer |
| NCT03214250 | — | P1/P2 | completed | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
Malignant Melanoma Stage III (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06794775 | SWE-NEO | P3 | recruiting | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma |
| NCT04949113 | NADINA | P3 | active not recruiting | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma |
| NCT02977052 | OpACIN-neo | P2 | unknown | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab |
| NCT04133948 | DONIMI | P1/P2 | completed | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma |
Metastatic Uveal Melanoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06581406 | — | P2/P3 | recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| NCT05987332 | — | P2/P3 | active not recruiting | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| NCT04552223 | — | P2 | completed | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma |
| NCT01585194 | — | P2 | completed | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma |
Recurrent Glioblastoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04003649 | — | P1 | active not recruiting | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM |
| NCT06097975 | NEO-GLITIPNI | P1 | recruiting | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma |
| NCT02017717 | CheckMate 143 | P3 | completed | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients |
| NCT03430791 | — | P2 | terminated | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma |
Merkel Cell Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06151236 | — | P2 | recruiting | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma |
| NCT03071406 | — | P2 | active not recruiting | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma |
| NCT02196961 | ADMEC-O | P2 | completed | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation |
| NCT03798639 | — | P1 | completed | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer |
Muscle-Invasive Bladder Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04506554 | — | P2 | active not recruiting | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer |
| NCT05203913 | CNN-BC | P2 | recruiting | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer |
| NCT04876313 | NURE-Combo | P2 | unknown | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) |
| NCT04610671 | — | P1 | completed | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC |
Nasopharyngeal Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06019130 | NPC-Nivo | P2 | recruiting | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma |
| NCT03097939 | — | P2 | unknown | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma |
| NCT03267498 | NPC | P2 | completed | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) |
| NCT03390738 | — | P2 | withdrawn | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy |
Esophageal Squamous Cell Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04229459 | — | P2 | active not recruiting | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. |
| NCT05213312 | — | P2/P3 | unknown | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC |
| NCT03987815 | — | P2 | unknown | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma |
| NCT04936399 | EAMS | N/A | completed | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom |
Epithelial Ovarian Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03522246 | ATHENA | P3 | active not recruiting | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
| NCT04620954 | ORION-02 | P1/P2 | unknown | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin |
| NCT03824704 | ARIES | P2 | terminated | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) |
| NCT03100006 | ORION-01 | P1/P2 | terminated | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin |
Head and Neck Squamous Cell Carcinoma (HNSCC) (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04080804 | — | P2 | active not recruiting | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer |
| NCT04603248 | — | N/A | completed | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT02764593 | — | P1 | completed | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer |
| NCT02684253 | SBRT | P2 | completed | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
Malignant Pleural Mesothelioma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04162015 | — | P1 | active not recruiting | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma |
| NCT04013334 | — | P2 | unknown | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma |
| NCT03048474 | INITIATE | P2 | completed | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma |
| NCT02497508 | NivoMes | P2 | completed | Nivolumab in Patients With Recurrent Malignant Mesothelioma |
Biliary Tract Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03785873 | — | P1/P2 | completed | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer |
| NCT03639935 | — | P2 | completed | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy |
| NCT02829918 | — | P2 | completed | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers |
| NCT04057365 | BTC | P2 | terminated | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) |
Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03502733 | — | P1 | active not recruiting | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma |
| NCT03229278 | — | P1 | completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma |
| NCT02038946 | FL | P2 | completed | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) |
| NCT02857426 | CheckMate 647 | P2 | completed | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) |
Recurrent Non-Small Cell Lung Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03048500 | — | P2 | unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
| NCT02823990 | — | P2 | completed | TG4010 and Nivolumab in Patients With Lung Cancer |
| NCT03023904 | — | P2 | withdrawn | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads |
| NCT03121417 | — | P2 | withdrawn | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer |
High Grade Glioma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06519682 | CAYA | N/A | recruiting | A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) |
| NCT04267146 | NIVOGLIO | P1/P2 | completed | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma |
| NCT03925246 | REVOLUMAB | P2 | completed | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas |
NSCLC Stage IV (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05597800 | LUNGVIR | P2 | not yet recruiting | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome |
| NCT06532149 | EROS | N/A | recruiting | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
| NCT04507906 | — | P1/P2 | completed | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC |
Metastatic Nasopharyngeal Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06029270 | — | P2 | recruiting | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer |
| NCT05904080 | — | P2 | suspended | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer |
| NCT04458909 | — | P3 | terminated | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer |
Pancreatic Ductal Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06015724 | DARANIVOVAX | P2 | recruiting | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer |
| NCT04477343 | — | P1 | recruiting | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT03496662 | PDAC | P1/P2 | completed | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) |
Brain Metastases (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05048212 | — | P2 | recruiting | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases |
| NCT03458455 | TREATMENT | N/A | unknown | Improved Therapy Response Assessment in Metastatic Brain Tumors |
| NCT02460068 | NIBIT-M2 | P3 | unknown | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis |
Classical Hodgkin Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05352828 | ACTION | P1 | active not recruiting | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy |
| NCT02940301 | — | P2 | active not recruiting | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
| NCT03004833 | NIVAHL | P2 | completed | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma |
Metastatic Colon Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05308446 | — | P2 | active not recruiting | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation |
| NCT04599140 | — | P1/P2 | active not recruiting | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial |
| NCT04044430 | — | P1 | terminated | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer |
Locally Advanced Bladder Urothelial Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04637594 | IMAGINE | P3 | active not recruiting | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy |
| NCT04953104 | — | P2 | active not recruiting | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT04848519 | — | P2 | active not recruiting | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
Advanced Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02465060 | — | P2 | active not recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
| NCT06400264 | — | P2 | withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) |
| NCT04439214 | — | P2 | completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) |
Osteosarcoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04803877 | SARC038 | P2 | active not recruiting | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma |
| NCT03628209 | — | P1 | active not recruiting | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma |
| NCT05302921 | — | P2 | completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors |
Metastatic Malignant Solid Neoplasm (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04840589 | — | P1 | suspended | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors |
| NCT04957615 | — | P2 | active not recruiting | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression |
| NCT03525925 | — | P1 | completed | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors |
HNSCC (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03917537 | — | N/A | unknown | WGA in Platinum-refractory HNSCC Underwent Nivolumab |
| NCT04272333 | — | Early P1 | terminated | Intratumoral Microdosing of Motolimod in HNSCC |
| NCT03652142 | — | N/A | unknown | Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma |
Acral Lentiginous Melanoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04511013 | — | P2 | recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases |
| NCT03025256 | — | P1 | recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease |
| NCT02978443 | — | P2 | terminated | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab |
Metastatic Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04159818 | TONIC-2 | P2 | recruiting | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients |
| NCT03807765 | — | P1 | completed | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases |
| NCT04061863 | KORNELIA | P1/P2 | unknown | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer |
Urinary Bladder Neoplasms (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03661320 | — | P3 | active not recruiting | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer |
| NCT04149574 | CheckMate 7G8 | P3 | terminated | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) |
| NCT03519256 | CheckMate 9UT | P2 | terminated | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder |
Pancreatic Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03080974 | — | P2 | recruiting | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma |
| NCT03816358 | — | P1 | active not recruiting | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer |
| NCT03404960 | Parpvax | P1/P2 | completed | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy |
Non-Small Cell Lung Cancer (NSCLC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03767348 | IGNYTE | P2 | active not recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) |
| NCT04026412 | CheckMate73L | P3 | completed | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery |
| NCT03444766 | — | P4 | completed | Study of Nivolumab for Advanced Cancers in India |
Soft Tissue Sarcoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03277924 | ImmunoSarc | P1/P2 | completed | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas |
| NCT04118166 | — | P2 | completed | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma |
| NCT02982486 | — | P2 | unknown | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma |
Melanoma Stage Iv (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03340129 | ABC-X | P2 | recruiting | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
| NCT03991130 | — | P2 | terminated | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma |
| NCT03161756 | CHARLI | P1/P2 | unknown | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma |
Urinary Bladder Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03844256 | CRIMI | P1/P2 | recruiting | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study |
| NCT03529890 | RACE IT | P2 | unknown | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder |
| NCT02897765 | NEO-PV-01 | P1 | completed | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer |
Recurrent Hodgkin Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01703949 | — | P2 | active not recruiting | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma |
| NCT03016871 | — | P2 | active not recruiting | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL |
| NCT03739619 | — | P1/P2 | completed | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
Neoplasms by Site (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01968109 | — | P1/P2 | completed | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors |
| NCT03656718 | — | P1/P2 | completed | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) |
| NCT01629758 | — | P1 | completed | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors |
Advanced Malignancies (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03126110 | — | P1/P2 | completed | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies |
| NCT03158272 | — | P1 | completed | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread |
| NCT03241173 | — | P1/P2 | completed | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies |
Hodgkin Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02927769 | CheckMate 744 | P2 | completed | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment |
| NCT01716806 | HL | P2 | completed | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) |
| NCT02181738 | CheckMate 205 | P2 | completed | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) |
Metastatic Malignant Neoplasm in the Brain (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02696993 | — | P1/P2 | active not recruiting | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer |
| NCT02910700 | — | P2 | active not recruiting | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma |
| NCT02716948 | — | P1 | completed | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine |
Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02530463 | — | P2 | active not recruiting | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome |
| NCT02464657 | MDS | P1/P2 | completed | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) |
| NCT02599649 | MDS | P2 | terminated | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) |
Soft Tissue Sarcomas (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07444619 | — | P1 | not yet recruiting | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas |
| NCT03149120 | — | P2 | withdrawn | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas |
Advanced Renal Cell Carcinoma (aRCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07188896 | RCC | P2 | recruiting | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) |
| NCT06345183 | — | N/A | completed | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients |
Brain Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07210632 | HGG | Early P1 | recruiting | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) |
| NCT02617589 | CheckMate 498 | P3 | completed | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) |
Advanced Non-squamous Non-small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06463665 | VIRO-25 | P2 | recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| NCT07485166 | — | N/A | active not recruiting | Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases |
Colorectal Cancer (MSI-H) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07403877 | TORCH-OPTIMA | P2 | not yet recruiting | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer |
| NCT07523763 | NIVO1002024 | P2 | active not recruiting | Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer |
Cutaneous Melanoma, Stage III (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07230613 | NEOREM-NEO-1 | P2 | recruiting | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma |
| NCT03719131 | — | P2 | active not recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy |
Metastatic Soft-tissue Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06968988 | — | P1 | recruiting | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma |
| NCT04551430 | — | P2 | active not recruiting | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma |
Advanced Non Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06908993 | COMET | P3 | recruiting | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated |
| NCT03351361 | eNERGY | P3 | completed | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients |
Clinical Stage IV Cutaneous Melanoma AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05717140 | — | P1 | withdrawn | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung |
| NCT05341349 | — | P1 | terminated | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases |
Metastatic Non-Squamous Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07246863 | — | P2 | recruiting | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC |
| NCT03906071 | SAPPHIRE | P3 | completed | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer |
Basal Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03521830 | — | P2 | recruiting | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma |
| NCT06624475 | NEON | P2 | recruiting | Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma |
Non Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06767956 | — | P1/P2 | withdrawn | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy |
| NCT03620578 | HO152 | P2 | active not recruiting | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL |
Gastroesophageal Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05733689 | — | P1 | recruiting | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) |
| NCT04021108 | — | P2 | active not recruiting | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) |
Neuroendocrine Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06889493 | NEC | P1 | recruiting | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) |
| NCT03591731 | NIPINEC | P2 | completed | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) |
Kidney Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06934057 | CABOLD | P4 | recruiting | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma |
| NCT04322955 | Cyto-KIK | P2 | active not recruiting | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition |
Leptomeningeal Metastasis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06901817 | — | P2 | recruiting | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases |
| NCT05598853 | IT-IO | P1 | active not recruiting | Intrathecal Double Checkpoint Inhibition |
Advanced Esophageal Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05677490 | — | P3 | recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma |
| NCT06203600 | — | P2/P3 | recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial |
Cutaneous Squamous Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06288191 | — | P2 | recruiting | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma |
| NCT04620200 | MATISSE | P2 | completed | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery |
Recurrent Transformed Chronic Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06247540 | — | P2 | withdrawn | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| NCT05672173 | — | P2 | active not recruiting | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation |
Muscle Invasive Bladder Urothelial Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05987241 | — | P2/P3 | recruiting | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study |
| NCT06204614 | — | Early P1 | enrolling by invitation | Drug Screening Using IMD in Bladder Cancer |
Lung Cancer, Nonsmall Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06667154 | — | P2 | recruiting | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy |
| NCT06003075 | — | P2 | terminated | Induction Chemo-Nivo in Unresectable Stage III NSCLC |
Endometrial Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05795244 | NIVEC | P2 | recruiting | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) |
| NCT04570839 | — | P1/P2 | completed | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. |
Upper Gastrointestinal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06361563 | — | N/A | completed | Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada |
| NCT06361576 | — | N/A | completed | Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada |
Oncology (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06031233 | MINUTE | P4 | recruiting | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie |
| NCT04299880 | — | P1 | completed | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols |
Esophageal Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04150640 | — | P2 | recruiting | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma |
| NCT05480384 | — | P2 | active not recruiting | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction |
Lung Non-Small Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05501665 | — | P1/P2 | recruiting | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer |
| NCT05022394 | — | P1/P2 | withdrawn | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study |
Castration-resistant Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05502315 | CANOPY | P2 | recruiting | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer |
| NCT03554317 | COMBAT-CRPC | P2 | completed | COMbination of Bipolar Androgen Therapy and Nivolumab |
Cancer of Rectum (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05732389 | RESET-R | P2 | recruiting | Immunotherapy in Patients With Early dMMR Rectal Cancer |
| NCT02948348 | — | P1/P2 | unknown | Study to Nivolumab Following Preoperative Chemoradiotherapy |
Metastatic Gastric Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06008925 | — | P1/P2 | recruiting | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer |
| NCT05859477 | NIVOFGFR2 | P2 | unknown | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer |
Lung Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929041 | — | P2/P3 | suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative |
| NCT03391869 | — | P3 | active not recruiting | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer |
Chronic Hepatitis B (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05343481 | — | P2 | completed | Efficacy of VTP-300 in Chronic Hepatitis B Infection |
| NCT04891770 | SLGN | P2 | completed | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Urothelial Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03036098 | CheckMate901 | P3 | active not recruiting | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer |
| NCT05219435 | VEXILLUM | P2 | completed | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer |
Non-Small Cell Lung Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03469960 | DICIPLE | P3 | completed | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr |
| NCT05265650 | Noelia | P1/P2 | unknown | Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC |
Endometrial Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05112601 | — | P2 | recruiting | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
| NCT04106414 | — | P2 | active not recruiting | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment |
Mucosal Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05384496 | — | P2 | recruiting | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma |
| NCT03241186 | — | P2 | active not recruiting | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma |
Advanced Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05162118 | — | P1/P2 | unknown | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer |
| NCT03336216 | — | P2 | completed | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
Prostatic Neoplasms, Castration-Resistant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04717154 | INSPIRE | P2 | completed | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer |
| NCT05169684 | — | P2 | terminated | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer |
Mesothelioma, Malignant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05136677 | CheckMate 6DW | P2 | completed | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants |
| NCT03502746 | — | P2 | terminated | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma |
Stage IV Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05088889 | — | P1 | unknown | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer |
| NCT04377048 | — | P2 | unknown | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer |
Renal Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05215470 | CLARA | P2 | active not recruiting | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy |
| NCT03469713 | NIVES | P2 | completed | Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma |
Pancreatic Cancer Stage IV (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03697564 | — | P2 | completed | Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer |
| NCT04953962 | — | P2 | completed | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer |
Renal Cell Carcinoma (RCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05176483 | STELLAR-002 | P1 | recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors |
| NCT03311334 | — | P1/P2 | terminated | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors |
Metastatic Non Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04884282 | COMBI-TED | P2 | active not recruiting | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) |
| NCT05236608 | ADIVO Lung | P1/P2 | unknown | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC |
Unresectable Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04688658 | — | P1/P2 | terminated | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma |
| NCT01927419 | CheckMate 069 | P2 | completed | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma |
Adult Solid Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04892043 | — | P1 | terminated | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors |
| NCT04084951 | — | P1 | completed | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors |
Unresectable or Metastatic Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04674683 | — | P3 | active not recruiting | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma |
| NCT01844505 | — | P3 | completed | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) |
Advanced Biliary Tract Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04969887 | MOST-CIRCUIT | P2 | active not recruiting | Combination Immunotherapy in Rare Cancers Under InvesTigation |
| NCT04172402 | — | P2 | completed | NGS as the First-line Treatment in Advanced Biliary Tract Cancer |
Metastatic Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04611126 | — | P1/P2 | terminated | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer |
| NCT03287674 | — | P1/P2 | completed | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer |
Locally Advanced Esophageal Squamous Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03914443 | — | P1 | completed | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma |
| NCT05130684 | Neo-NTP-CRT | P2 | unknown | Neo-NTP-CRT for Locally Advanced ESCC |
Stage III Hepatocellular Carcinoma AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04380545 | — | P1/P2 | recruiting | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer |
| NCT03439891 | — | P2 | completed | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer |
Small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04610658 | — | P1 | terminated | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC |
| NCT04173325 | — | P1 | terminated | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer |
Triple Negative Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04331067 | — | P1/P2 | active not recruiting | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer |
| NCT03487666 | OXEL | P2 | completed | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease |
Anal Basaloid Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03233711 | — | P3 | active not recruiting | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer |
| NCT04444921 | EA2176 | P3 | active not recruiting | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients |
Leiomyosarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04420975 | — | P1 | active not recruiting | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma |
| NCT04624178 | — | P2 | active not recruiting | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma |
Metastatic Castration-resistant Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04109729 | Rad2Nivo | P1 | active not recruiting | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer |
| NCT03835533 | PORTER | P1 | completed | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations |
Advanced Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04263051 | Optim-UCPVax | P2 | completed | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer |
| NCT02639234 | — | P2 | withdrawn | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer |
Gliosarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04396860 | — | P2/P3 | completed | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma |
| NCT02311920 | — | P1 | completed | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04310007 | — | P2 | active not recruiting | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer |
| NCT03468985 | — | P2 | completed | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer Stage II (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04699721 | — | P2 | active not recruiting | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC |
| NCT03383302 | STILE | P1/P2 | completed | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects |
Metastatic Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04212026 | IRE | P2 | terminated | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. |
| NCT02866383 | CheckPAC | P2 | completed | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients |
Rectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03921684 | — | P2 | active not recruiting | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients |
| NCT04124601 | CHINOREC | P2 | completed | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer |
Lung Squamous Cell Carcinoma Stage IV (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04306042 | — | N/A | unknown | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy |
| NCT02831933 | ENSIGN | P2 | terminated | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma |
Myelodysplastic Syndromes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04044209 | — | P2 | withdrawn | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS |
| NCT03259516 | — | P1/P2 | terminated | Nivolumab With Chemotherapy in Refractory MDS |
Neuroblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02914405 | MiniVan | P1 | active not recruiting | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma |
| NCT04239040 | — | P1 | terminated | GVAX Plus Checkpoint Blockade in Neuroblastoma |
Chronic Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03884998 | — | P1 | active not recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma |
| NCT03892044 | — | P1 | completed | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma |
Liver Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03143270 | — | Early P1 | active not recruiting | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer |
| NCT04707547 | RFA | P4 | completed | Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy |
Neuroendocrine Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03980925 | GEP | P2 | completed | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. |
| NCT03420521 | — | P2 | terminated | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors |
Metastatic Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03893695 | HCC | P1/P2 | completed | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) |
| NCT03695250 | — | P1/P2 | terminated | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer |
Peripheral T Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03927105 | BMS-986227 | P2 | completed | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma |
| NCT03586999 | — | P1/P2 | completed | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas |
Chordoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02989636 | — | P1 | active not recruiting | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma |
| NCT03623854 | — | P2 | completed | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma |
Small Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03850067 | — | P1 | completed | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer |
| NCT03662074 | — | P2 | terminated | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer |
Aggressive Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03749018 | — | P2 | active not recruiting | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma |
| NCT03704714 | — | P1/P2 | suspended | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma |
Colorectal Neoplasms Malignant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03507699 | — | P1 | completed | Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer |
| NCT03993626 | CAROSELL | P1/P2 | unknown | A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer |
Ann Arbor Stage I Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03233347 | — | P2 | active not recruiting | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma |
| NCT03712202 | — | P2 | active not recruiting | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
Cervical Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03298893 | NiCOL | P1/P2 | completed | Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL) |
| NCT03527264 | — | P2 | terminated | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer |
Recurrent Plasma Cell Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03605719 | — | P1 | completed | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma |
| NCT03333746 | — | P2 | terminated | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Diffuse Large B Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03311958 | — | Early P1 | completed | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance |
| NCT03259529 | BeGeRN | P1/P2 | completed | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL |
Glioblastoma Multiforme (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04195139 | NUTMEG | P2 | active not recruiting | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM |
| NCT02550249 | Neo-nivo | P2 | completed | Neoadjuvant Nivolumab in Glioblastoma |
Hematologic Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02663518 | TTI-621 | P1 | terminated | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors |
| NCT02985554 | — | P1 | terminated | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies |
Squamous Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02924233 | — | P1/P2 | withdrawn | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer |
| NCT02475382 | CheckMate 169 | N/A | no longer available | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen |
Advanced Solid Tumors Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02099058 | PK | P1 | active not recruiting | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors |
| NCT02955251 | — | P1 | completed | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors |
Malignant Glioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02829931 | — | P1 | completed | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas |
| NCT02529072 | AVERT | P1 | completed | Nivolumab With DC Vaccines for Recurrent Brain Tumors |
Pediatric Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02813135 | ESMART | P1/P2 | recruiting | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors |
| NCT03126643 | — | N/A | approved for marketing | Expanded Access to Nivolumab (Opdivo) |
Stage IB Lung Non-Small Cell Carcinoma AJCC v7 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02595944 | ANVIL | P3 | active not recruiting | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) |
| NCT02194738 | — | N/A | active not recruiting | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
Malignant Solid Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02754141 | — | P1/P2 | completed | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab |
| NCT02518958 | PRIMETIME | P1 | completed | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab |
Recurrent Squamous Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02785952 | — | P3 | active not recruiting | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
| NCT02154490 | — | N/A | completed | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
Squamous Cell Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01642004 | NSCLC | P3 | completed | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) |
| NCT01721759 | BMS-936558 | P2 | completed | Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens |
Untreated Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07459543 | FDC | P4 | not yet recruiting | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India |
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07430202 | FLC | P1 | not yet recruiting | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
Hepato Cellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07494435 | — | P2 | not yet recruiting | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC |
Advanced Biliary Tract Cancer(BTC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07369791 | NOBLE | P2 | not yet recruiting | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. |
Squamous Cell Carcinoma of Head and Neck (SCCHN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07529873 | N'FORCE | P2 | not yet recruiting | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma |
Oral Squamous Cell Carcinoma (OSCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07514767 | NOCANO | P2 | not yet recruiting | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma |
Diffuse Midline Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06639607 | PRiME II | P1/P2 | recruiting | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma |
Advanced Microsatellite Stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07527858 | GS-1811 | P2 | recruiting | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer |
Advanced Kidney Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07338981 | — | P3 | not yet recruiting | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. |
HER2-negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07546812 | GS-1811 | P2 | recruiting | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas |
Hnscc (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07460765 | HNSCC | P1 | not yet recruiting | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) |
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07392892 | — | P2/P3 | recruiting | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer |
Diffuse Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07532902 | — | P1 | recruiting | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer |
Non-small Cell Lung Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07355205 | FLINN | P2 | not yet recruiting | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
Advanced Renal Cell Carcinoma (RCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07293351 | RCC | P1/P2 | recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) |
Phase 1b (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07401875 | SHARK | P1 | recruiting | A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) |
Von Hippel-Lindau Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07405164 | — | P3 | recruiting | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) |
Unresectable or Metastatic Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07219459 | GDFATHERHCC01 | P2 | recruiting | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure |
Advanced or Metastatic Gastrooesophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07213557 | — | P2 | recruiting | Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy |
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07221149 | — | P2/P3 | recruiting | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) |
Nonsmall Cell Lung Cancer, Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07394062 | ALCG-01 | N/A | recruiting | Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) |
Unresectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07482059 | — | P1/P2 | recruiting | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma |
Resectable Stage II-IIIa Squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07398937 | ECTOP-1036 | P2 | recruiting | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC |
Relapsed/Refractory Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07325136 | — | P1/P2 | recruiting | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer |
Advanced (Unresectable or Metastatic) Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07221734 | — | P3 | recruiting | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma |
Metastatic Triple-negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06963905 | SIMONE | P1/P2 | recruiting | Saci Nivo Rela for TNBC |
CNS Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07017816 | JACOB | Early P1 | recruiting | A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. |
Metastatic Renal Cell Carcinoma ( mRCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07233668 | IVE in mRCC | N/A | not yet recruiting | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC |
Newly Diagnosed Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06816927 | GIANT | P2 | recruiting | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab |
HER2-Expressing Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07334119 | — | P1 | recruiting | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors |
Locally Advanced Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07223411 | — | N/A | recruiting | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma |
Locally Advanced Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06794229 | EXPLORE-RCC | P2 | recruiting | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis |
Advanced Acral Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155317 | — | P2 | recruiting | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial |
Solid Tumor Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07174453 | — | P3 | recruiting | Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies |
Renal Cell Carcinoma (Kidney Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07028125 | CANIQOL | P4 | recruiting | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma |
Advanced Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07147101 | HCC-IM-1 | N/A | recruiting | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment |
Microsatellite-stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07011550 | — | P2 | suspended | Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer |
Locally Advanced Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06866262 | — | P1/P2 | recruiting | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial |
Anaplastic Large Cell Lymphoma, ALK-Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07013565 | ACCELERATE | P2 | recruiting | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL |
Melanoma (Skin Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06624644 | — | P2/P3 | recruiting | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma |
Recurrent High-grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07031765 | Peds CHAMP1ON | P1 | active not recruiting | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma |
PROMs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07061379 | PROMOTING | N/A | recruiting | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen |
Glioblastoma (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06896110 | — | P1 | enrolling by invitation | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma |
Melanoma Brain Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06163820 | BETTER | P1/P2 | recruiting | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases |
NSCLC (Non-small Cell Lung Carcinoma) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07050043 | LEDANG | P3 | recruiting | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC |
Cutaneous Squamous Cell Carcinoma (CSCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06823479 | MATISSE 2 | P2 | recruiting | Towards Cure Via Only Ultra-short ICB in CSCC |
Urothelial Carcinoma Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06983210 | GRAPE | P2 | recruiting | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma |
Recurrent/ Metastatic Olfactory Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07100704 | Orion | P2 | recruiting | Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab |
Hodgkin Lymphoma, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06984146 | — | P2 | recruiting | Nivo40-AVD for Advanced Classic Hodgkin Lymphoma |
Advanced Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06731270 | — | P2 | recruiting | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy |
Low Grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06712875 | — | P1/P2 | recruiting | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas |
Advanced Malignant Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06764771 | — | P1 | recruiting | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors |
Renal Cell Carcinoma, Clear Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06708949 | RCC | P2 | recruiting | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) |
Locally Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06534190 | — | P2 | recruiting | CD8 PET Imaging in Metastatic Solid Tumours |
Advanced Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06745076 | — | P2 | recruiting | Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma |
Premalignant Lesion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06561087 | — | P2 | recruiting | Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions |
Extensive-Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06646276 | TIGOS | P3 | recruiting | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). |
Lung Cancer - Non Small Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06926790 | GALAXY 3 | P2 | recruiting | Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) |
Melanoma, Cutaneous Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06743126 | SUPRAME | P3 | recruiting | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
High-risk Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06488482 | — | P3 | recruiting | Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma |
Genitourinary Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06724159 | SOGUG-PRINCIS | N/A | recruiting | Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. |
Resectable Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06632327 | — | P3 | recruiting | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer |
LOCALLY ADVANCED CERVICAL CANCERS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06715241 | COLIBRI-2 | P2 | active not recruiting | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS |
Muscle-invasive Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06534983 | IMCODE004 | P2 | recruiting | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) |
Diffuse Hemispheric Glioma, H3 G34-Mutant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05457959 | — | P1 | withdrawn | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant |
Pleural Biphasic Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05647265 | — | P2 | recruiting | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma |
Progressive Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06325683 | — | P2 | suspended | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma |
Metastatic Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07024862 | — | N/A | active not recruiting | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy |
Colon Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06490536 | — | P3 | recruiting | The Sagittarius Trial |
Primary Mediastinal (Thymic) Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06871007 | — | P1/P2 | enrolling by invitation | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma |
Advanced Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06495125 | — | P2 | recruiting | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer |
Urachal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06638931 | ANTARES | P2 | recruiting | Agnostic Therapy in Rare Solid Tumors |
Recurrent Ependymoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06466798 | — | P1 | withdrawn | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies |
Cancer of Gastrointestinal Tract (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05153304 | — | P1/P2 | withdrawn | Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers |
Stage II Nasopharyngeal Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06064097 | NPC | P2 | recruiting | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) |
Oropharyngeal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06771674 | — | N/A | completed | Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma |
Recurrent Squamous Cell Carcinoma of the Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06357858 | — | P1 | withdrawn | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck |
Adenocarcinoma of the Esophagogastric Junction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06681298 | — | P2 | active not recruiting | A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab |
Advanced Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06265285 | CCBW | P2 | recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program |
Metastatic Kidney Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06364631 | CARE1 | P3 | recruiting | CARE1 Pragmatic Clinical Trial |
ICB-refractory Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06250335 | ICB | P2 | active not recruiting | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients |
Urologic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06237920 | TURANDORELA | P2 | recruiting | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab |
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06191796 | XL092 | P1 | terminated | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) |
Resectable Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06169956 | NENI | N/A | recruiting | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany |
Clinical Stage IV Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05802056 | — | P1 | recruiting | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis |
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06158919 | G/GEJ cancer | N/A | recruiting | A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer |
Unresectable Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06097728 | eVOLVE-Meso | P3 | active not recruiting | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma |
Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05504642 | CERAD-IMMUNE | P2 | withdrawn | Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients |
Diffuse Astrocytoma, IDH-Mutant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047379 | — | P1/P2 | recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis |
Locally Advanced Extraskeletal Myxoid Chondrosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05836571 | — | P2 | active not recruiting | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma |
IDH1-mutant Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05921760 | — | P1/P2 | terminated | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma |
Follicular Lymphoma Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05788081 | TOP-FLOR | P2 | active not recruiting | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. |
Stage II Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05418972 | Neo ReNi II | P2 | active not recruiting | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma |
Atypical Teratoid Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05407441 | — | P1/P2 | active not recruiting | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors |
Malignant Neoplasms of Digestive Organs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05934331 | — | P2 | recruiting | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study |
Advanced Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05909618 | 14 | P2 | recruiting | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases |
Acute Anterior ST Segment Elevation Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05887830 | — | P1/P2 | unknown | Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial |
Metastatic Prostate Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05445609 | CMP-001 | P2 | suspended | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer |
Recurrent Melanoma (Skin) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05655312 | — | P1/P2 | recruiting | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma |
Refractory Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05767684 | — | P1 | unknown | Neoantigen Derived DCs as Cancer Treatment |
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05749900 | HERBOT | P1/P2 | recruiting | First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) |
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05675410 | — | P3 | recruiting | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab |
Resectable Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05472623 | Neo-Kan | P2 | withdrawn | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab |
B Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05310591 | CAPTiRALL | P1/P2 | recruiting | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence |
Safety Issues (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05772624 | — | P2 | unknown | Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma |
Melanoma Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05652673 | IPI-NIVO | N/A | recruiting | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial |
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05500092 | — | P2 | active not recruiting | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer |
HIV I Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05187429 | NIVO-LD | P1/P2 | recruiting | Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy |
BCLC Stage B Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05199285 | — | P2 | terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab |
Non-Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05678673 | STELLAR-304 | P3 | active not recruiting | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma |
Gastroenteropancreatic Neuroendocrine Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05262556 | — | P1 | active not recruiting | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas |
Locally Advanced or Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05498792 | — | Early P1 | recruiting | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma |
Advanced Upper Gastrointestinal Tract Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05568095 | STAR-221 | P3 | active not recruiting | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
Metastatic Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05234307 | — | P1 | recruiting | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer |
High-grade Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05727410 | — | P2 | recruiting | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma |
Immune Suppression (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05739045 | — | P2 | recruiting | Nivolumab Combined With SOX Used in the Perioperative Treatment |
Recurrent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05272384 | — | P1 | recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma |
Colorectal Cancer Liver Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05588297 | — | P2 | unknown | Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases |
Carcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05347212 | — | P2 | active not recruiting | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla |
Pancreas Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05435053 | CHECKPOINT | P2 | terminated | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer |
Uterine Cervical Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05492123 | — | P2 | recruiting | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer |
Chronic Hepatitis B Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04638439 | P1101 | P1 | completed | The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection |
Brain Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317858 | LIMITLESS | P3 | recruiting | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
Anal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05111574 | — | P2 | active not recruiting | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery |
Melanoma, Ocular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05169957 | HAMMER I | P1 | completed | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) |
AIDS-Related Anal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929028 | — | P2 | active not recruiting | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer |
PD-1 Antibody (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05461235 | — | P2 | unknown | Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma |
Hematopoietic and Lymphoid Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04781855 | — | P1 | withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation |
Refractory Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04845139 | — | N/A | unknown | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma |
Primary Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05393674 | — | P2 | completed | Fedratinib in Combination With Nivolumab |
Anatomic Stage IV Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05098210 | — | P1 | recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer |
Refractory Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05200143 | — | P2 | terminated | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma |
Relapsed or Refractory Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06931613 | — | P2 | enrolling by invitation | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment |
B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05385263 | — | P2 | unknown | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion |
Mesotheliomas Pleural (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04400539 | IMPALA | P2 | recruiting | The IMmunotherapy Pleural 5-ALA PDT |
Prostatic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05150236 | ANZUP2001 | P2 | unknown | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC |
Colorectal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05328908 | RELATIVITY-123 | P3 | terminated | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer |
Resectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04965714 | — | P2 | withdrawn | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer |
Primary Mediastinal Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06188676 | — | P3 | recruiting | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL |
Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05144529 | TOP2101 | P2 | terminated | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC |
Locally Advanced Rectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04751370 | — | P2 | active not recruiting | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer |
Locally Advanced Nasopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04910347 | — | P2 | recruiting | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma |
Viral Associated Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04902443 | — | P1 | recruiting | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV |
Advanced Differentiated Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04514484 | — | P1 | active not recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV |
Relapsed Classic Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04561206 | — | P2 | recruiting | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04652960 | — | P1 | active not recruiting | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome |
Clinical Stage I Cutaneous Melanoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04697576 | — | P1 | recruiting | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma |
Leptomeningeal Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05112549 | IT-PD1 | P1 | recruiting | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) |
Primary Mediastinal Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04759586 | — | P3 | active not recruiting | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
Metastatic Head-and-neck Squamous-cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04831320 | — | P2 | active not recruiting | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor |
Solid Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04891718 | — | Early P1 | withdrawn | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia |
Metastatic Uveal Melanoma in the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04935229 | PERIO | P1 | terminated | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma |
Advanced or Metastatic Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04887870 | — | P2/P3 | completed | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study |
Advanced or Metastatic Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04785820 | RO7121661 | P2 | completed | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus |
Nerve Sheath Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04465643 | — | P1 | completed | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor |
Metastatic Prostate Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04709276 | CHAMP | P2 | active not recruiting | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer |
Ependymoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04730349 | PIVOT IO 020 | P1/P2 | terminated | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer |
Gastro-Oesophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04879368 | INTEGRATEIIb | P3 | completed | RegoNivo vs Standard of Care Chemotherapy in AGOC |
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04609046 | — | P1 | recruiting | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma |
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04745949 | PACIFIC | P2 | recruiting | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy |
Metastatic Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04863885 | — | P1/P2 | active not recruiting | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients |
Carcinoma, Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04151563 | CheckMate 79X | P1/P2 | withdrawn | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy |
Advanced Bladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04902040 | — | P1/P2 | terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies |
Non Small Cell Lung Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04577638 | AIRING | P2 | completed | Accelerated Radio-Immunotherapy for Lung Cancer |
Advanced Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04785287 | BMS986218 | P1/P2 | terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies |
Rectal Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04503694 | REGINA | P2 | active not recruiting | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer |
Extensive-stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04702880 | — | P2 | completed | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer |
Advance Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04850755 | — | P1 | completed | A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies |
Effect of Drug (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05482451 | — | Early P1 | active not recruiting | Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer |
Carcinosarcoma of Ovary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04149275 | — | P2 | withdrawn | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma |
Metastatic Colorectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04729322 | — | P2 | active not recruiting | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders |
Metastatic Hormone Refractory Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04477512 | — | P1 | completed | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) |
Esophagogastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04757363 | — | P2 | active not recruiting | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer |
Constitutional Mismatch Repair Deficiency Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04500548 | — | P1 | withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study |
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04594811 | — | P1 | terminated | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma |
Malignant Ascites (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05745233 | — | N/A | enrolling by invitation | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites |
Upper Urinary Tract Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05160285 | — | P2 | unknown | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma |
Astrocytoma, IDH-Mutant, Grade 4 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04145115 | — | P2 | active not recruiting | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden |
Hepatitis B (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04778904 | VTP-300 | P1/P2 | completed | First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV |
Down Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04546399 | B-ALL | P2 | recruiting | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
Kidney Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04513522 | CheckMate 7C9 | P4 | completed | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India |
Clinical Stage III Cutaneous Melanoma AJCC V8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04375527 | — | P2 | terminated | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma |
Papillary Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04413123 | — | P2 | active not recruiting | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC |
Brain Metastases, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04434560 | — | P2 | terminated | Neoadjuvant Immunotherapy in Brain Metastases |
Skin Angiosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04339738 | — | P2 | active not recruiting | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma |
Metastatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04315155 | BENEFIT | P1 | withdrawn | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation |
BRAF NP_004324.2:p.V600M (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04061980 | — | P2 | active not recruiting | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer |
Metastatic Microsatellite Stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04575922 | — | P2 | unknown | Nivolumab+Ipilimumab+RT in MSS mCRC |
Cancer, Hepatocellular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04340193 | CheckMate 74W | P3 | completed | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer |
Malignant Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04416568 | — | P2 | active not recruiting | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers |
Advanced Malignant Skin Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04387084 | — | P1 | active not recruiting | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy |
Clear-Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04518046 | — | P1 | completed | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies |
Renal Cell Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04749602 | — | P2 | completed | Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. |
Metastatic Large Cell Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04079712 | — | P2 | active not recruiting | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
Adrenocortical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04187404 | Spencer | P1/P2 | terminated | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma |
B Cell Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03920631 | MicroBLITZ | P1 | withdrawn | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas |
Cervix Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04256213 | COLIBRI | N/A | completed | COL Immunotherapy Before Radiochimio + Ipilimumab |
Malignant Melanoma Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04309409 | NivoMela | P3 | active not recruiting | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma |
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03575234 | — | P1 | withdrawn | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer |
Neuroendocrine Tumours (NET) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04525638 | — | P2 | unknown | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours |
Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04311710 | CheckMate 76U | P1 | terminated | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types |
Obesity, COVID-19 Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04413838 | NIVISCO | P2 | unknown | Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection |
Indolent Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04431635 | — | P1 | terminated | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma |
Recurrent Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04205409 | — | P2 | completed | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies |
Metastatic or Unresectable Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04187833 | — | P2 | completed | Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes |
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04282109 | NIVOTAX | P2 | completed | Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) |
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04247165 | LAPTOP | P1/P2 | completed | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. |
Advanced Colon Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04362839 | — | P1 | completed | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer |
CNS Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03838042 | — | P1/P2 | recruiting | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies |
Primary Central Nervous System Lymphoma (PCNSL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04401774 | — | P2 | completed | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy |
Progress Free Survival (PFS) and Overall Survival (OS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04393220 | — | P2 | completed | Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma |
Hormone Sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04126070 | — | P2 | active not recruiting | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors |
Fibrolamellar Hepatocellular Carcinoma (FLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04248569 | — | P1 | recruiting | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma |
Metastatic Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03803553 | — | P3 | recruiting | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer |
COVID19- Infection With SARS-CoV-2 Virus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04343144 | CORIMUNO-NIVO | P2 | unknown | Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort. |
COVID-19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04356508 | COVID-19 | P2 | unknown | COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 |
Leukemia, Myeloid, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04361058 | — | P1 | withdrawn | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03878524 | SMMART | P1 | terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
Brain and Nervous System (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04022980 | — | P1 | completed | Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma |
SCCHN (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04107103 | NivoPlus | P2 | completed | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma |
NSCLC Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04205552 | NEOpredict | P2 | completed | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients |
Soft Tissue Sarcoma Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04095208 | CONGRATS | P2 | completed | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study |
HER2-positive Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04278144 | — | P1/P2 | terminated | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
Relapsed Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04119336 | — | P2 | terminated | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma |
Non-small Cell Lung Cancer Stage I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04271384 | — | P2 | completed | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer |
Differentiated Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03914300 | — | P2 | active not recruiting | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer |
BCC - Basal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04570683 | — | Early P1 | unknown | Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas |
Esophagus Cancer, Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03995017 | RiME | P1/P2 | unknown | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma |
Lung Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05081674 | BLISS | P2 | completed | Brazilian Lung Immunotherapy Study |
Carcinoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04197310 | — | P2 | completed | Cabozantinib and Nivolumab for Carcinoid Tumors |
Recurrent Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03484819 | — | P2 | completed | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma |
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03767582 | — | P1/P2 | completed | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
NK/T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04230330 | — | P1 | withdrawn | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma |
Cancer of Unknown Primary Site (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04131621 | CheCUP | P2 | unknown | Nivolumab/Ipilimumab in Second Line CUP-syndrome |
Uveal Melanoma, Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04283890 | CHOPIN | P1/P2 | active not recruiting | PHP and Immunotherapy in Metastasized UM |
Giant Cell Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03014804 | — | P2 | withdrawn | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma |
AML, Childhood (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03825367 | — | P1/P2 | unknown | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML |
Stage III Non-small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04085250 | — | P2 | unknown | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy |
Prostate Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05655715 | CheckPRO | P2 | completed | Checkpoint Inhibitors and SBRT for MCRPC |
Recurrent/Metastatic Carcinosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05224999 | — | P2 | unknown | Nivolumab for Recurrent/Metastatic Carcinosarcoma |
Castration Levels of Testosterone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04159896 | — | P2 | terminated | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer |
Advanced Solid Tumor Historically Known for High EphA2 Expression (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04180371 | — | P1/P2 | active not recruiting | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
Localized Oesogastric Adenocarcimona (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04006262 | NEONIPIGA | P2 | active not recruiting | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. |
Melanoma With Brain Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03903640 | — | P2 | terminated | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis |
Aml (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04128020 | — | P1 | withdrawn | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia |
Basaloid Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03952585 | — | P2/P3 | active not recruiting | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer |
ALK Gene Rearrangement (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04013542 | — | P1 | active not recruiting | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer |
Advanced Cutaneous Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03834233 | CA209-9JC | P2 | unknown | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma |
Oropharynx Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03829722 | — | P2 | completed | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer |
Solid Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04078295 | E7389-LF | P1/P2 | active not recruiting | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor |
Relapsed Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04134325 | — | Early P1 | active not recruiting | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma |
Ann Arbor Stage III Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03907488 | — | P3 | active not recruiting | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
Human Papilloma Virus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03944915 | DEPEND | P2 | completed | De-Escalation Therapy for Human Papillomavirus Negative Disease |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04044859 | SURPASS | P1 | active not recruiting | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) |
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03811015 | — | P3 | active not recruiting | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer |
Advanced NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04043195 | NSCLC | P1/P2 | active not recruiting | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC |
Pituitary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04042753 | — | P2 | completed | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors |
Basal Cell Nevus Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03767439 | — | P2 | withdrawn | Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome |
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03799445 | — | P2 | terminated | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma |
Oropharynx Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03838263 | IMMUNEBOOST | P2 | completed | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer |
Borderline Resectable Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03970252 | — | Early P1 | completed | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer |
Gastric and Esophagogastric Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03443856 | VESTIGE | P2 | active not recruiting | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence |
Autoimmune Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03816345 | — | P1 | recruiting | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO |
Recurrent Head and Neck Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03727061 | — | P1 | terminated | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer |
Anatomic Stage 0 Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04185311 | — | P1 | terminated | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted |
Carcinoma, Squamous Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03906526 | — | P1 | terminated | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer |
Anaplastic Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05696548 | NAVIGATION | P2 | active not recruiting | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) |
Autoimmune Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03656627 | — | P1 | terminated | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease |
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04050761 | ProNiHN | N/A | completed | A Study of Nivolumab in Patients With Head and Neck Cancer. |
Grade 2 Meningioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03604978 | — | P1/P2 | active not recruiting | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma |
BRAF NP_004324.2:p.V600E (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04017650 | — | P1/P2 | active not recruiting | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer |
Resectable Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03768531 | — | P2 | withdrawn | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer |
DDR Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04761744 | — | P2 | unknown | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers |
Refractory Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03686124 | ACTengine | P1/P2 | recruiting | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors |
Bladder Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03866382 | — | P2 | recruiting | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
Squamous Cell Carcinoma of the Oral Cavity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03721757 | NICO | P2 | completed | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer |
Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03604991 | — | P2/P3 | suspended | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery |
Advanced Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04771715 | PD-1 | N/A | unknown | Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer |
Urinary Bladder Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03785925 | PIVOT-10 | P2 | completed | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer |
Renal Cell Carcinoma, Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03562507 | ERICA | P2 | terminated | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma |
Oral Cavity Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03843515 | NeoNivo | P1 | unknown | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction |
Lip (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03854032 | — | P2 | active not recruiting | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck |
Breast Neoplasm Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03650894 | HER | P2 | active not recruiting | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03718767 | — | P2 | active not recruiting | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype |
Advanced Solid Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03956680 | — | P1 | completed | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers |
Childhood Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03585465 | Metro-PD1 | P1/P2 | terminated | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors |
Acute Myeloid Leukemia and Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02846376 | CPIT-002 | P1 | terminated | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant |
Gastroesophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03610711 | REACTION | P1/P2 | active not recruiting | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer |
Malignant Pleural Effusion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03597009 | — | P1/P2 | terminated | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion |
Recurrent Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03655002 | IRX-2 | P1 | active not recruiting | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer |
Central Nervous System B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03770416 | — | P2 | completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma |
Mucinous Adenocarcinoma of the Colon (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03693846 | — | P2 | terminated | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors |
Microsatellite Stable (MSS) Colorectal Adenocarcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03642067 | MSS | P2 | completed | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer |
Metastatic Hormone-sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03879122 | — | P2/P3 | unknown | A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer |
Pleural Mesothelioma Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04177953 | — | P2 | completed | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery |
Bronchial Dysplasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03347838 | — | P2 | active not recruiting | Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers |
Recurrent Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03798314 | — | P1 | completed | Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma |
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03711058 | MSS | P1/P2 | completed | Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer |
Inoperable œsophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03437200 | CRUCIAL | P2 | terminated | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer |
Radiotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03589339 | — | P1 | active not recruiting | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
Cervix Uteri--Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03808168 | — | P2 | withdrawn | Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia |
Metastatic Malignant Neoplasm in the Bone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03749460 | — | P1/P2 | completed | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers |
Clinical Stage 0 Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03776487 | — | P2 | active not recruiting | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer |
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03703050 | NIVO-ALCL | P2 | active not recruiting | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) |
Bladder Cancer TNM Staging Primary Tumor (T) T2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03518320 | — | P1 | terminated | Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer |
Locally Advanced Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06235164 | — | N/A | unknown | The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer |
Grade I Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03728361 | — | P2 | active not recruiting | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer |
ALK-Positive Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03038672 | — | P2 | active not recruiting | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas |
Metastatic Castration Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03570619 | IMPACT | P2 | completed | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations |
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03769155 | — | P1 | active not recruiting | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma |
Intermediate Risk Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03815942 | ADVANCE | P1/P2 | terminated | VAccination in Early and ADvanced Prostate caNCEr |
Leukoplakia, Oral (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03692325 | — | P2 | completed | Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia |
Locally Advanced Unresectable Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04098432 | CA209-9KH | P1/P2 | completed | STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma |
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03607890 | L | P2 | active not recruiting | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
Carcinoma, Squamous Cell of Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03715946 | — | P2 | completed | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer |
Adenocarcinoma of the Stomach (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03647969 | — | P2 | completed | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer |
Recurrent Squamous Cell Carcinoma of the Head or Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03652233 | — | P1 | withdrawn | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03684811 | — | P1/P2 | completed | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation |
Pan Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03668119 | CheckMate 848 | P2 | completed | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) |
Unresectable Stage III Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03235245 | EBIN | P2 | active not recruiting | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib |
Advanced Metastatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03651271 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03121677 | — | P1 | terminated | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma |
Allogeneic Hematopoietic Stem Cell Transplantation Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03600155 | — | P1 | completed | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome |
Lymphoma, B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03569696 | NivoM | P2 | unknown | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy |
Colon Adenoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03631641 | — | P2 | terminated | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy |
Germ Cell Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03726281 | — | P2 | withdrawn | Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors |
High-Risk Resectable NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03732664 | — | P1 | completed | ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer |
Recurrent Adult Brain Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03890952 | — | P2 | completed | Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma |
Solid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03721679 | — | P1/P2 | terminated | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 |
Malignant Peritoneal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03508570 | — | P1 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis |
Metastatic Hormone-Sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03532217 | — | P1 | completed | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer |
Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03588936 | — | P1 | terminated | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant |
Melanoma Stage Iii (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03620019 | — | P2 | completed | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma |
Squamous Cell Carcinoma, Head And Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03575598 | SNOW | Early P1 | completed | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study |
Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03635892 | — | P2 | active not recruiting | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma |
Toxicity, Drug (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03638375 | ACTME | P1/P2 | unknown | TIL and Anti-PD1 in Metastatic Melanoma |
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03620123 | OPTIM | P2 | completed | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck |
Thymic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03583086 | — | P1/P2 | completed | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors |
Pharmacokinetics of Zolbetuximab (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03505320 | ILUSTRO | P2 | active not recruiting | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer |
Recurrent Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03521570 | — | P2 | completed | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer |
Melanoma Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03514901 | — | P2 | unknown | To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
Recurrent Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03558750 | — | P1 | terminated | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma |
Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03557359 | — | P2 | completed | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas |
Colon Cancer Stage II/III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04123925 | NICOLE | P2 | completed | Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study |
Recurrent or Metastatic Nasopharyngeal Carcinom (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06440187 | HN17-11 | P2 | completed | Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 |
Metastatic Adult Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03590210 | NiTraSarc | P2 | completed | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas |
Adenocarcinoma of the Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04046614 | NintNivo | P1/P2 | completed | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology |
Extensive Stage Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03382561 | — | P2 | completed | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer |
Locally Advanced Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03299946 | HCC | P1 | completed | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) |
Relapsed Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03305445 | — | P1 | completed | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL |
Metastatic Urothelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03451331 | — | P2 | completed | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer |
Kaposi Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03316274 | — | Early P1 | completed | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma |
Metastatic Malignant Neoplasm in the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03472586 | — | P2 | completed | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver |
Bone Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03449108 | TNBC | P2 | active not recruiting | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas |
Epstein-Barr Virus Infections (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03258567 | EBV | P2 | recruiting | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas |
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03421652 | — | P2 | completed | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo |
Advanced Endometrial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03367741 | — | P2 | active not recruiting | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer |
Thymoma Type B3 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03134118 | NIVOTHYM | P2 | active not recruiting | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) |
Classic Kaposi Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03219671 | CKS | P2 | unknown | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) |
Breast Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03432741 | — | P1 | terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03442569 | — | P2 | completed | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC |
Newly Diagnosed High Grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03425292 | — | P1 | completed | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer |
Glioma, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03576612 | GMCI | P1 | completed | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas |
Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03184194 | — | P2 | completed | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide |
Leptomeningeal Carcinomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02939300 | — | P2 | completed | Ipilimumab and Nivolumab in Leptomeningeal Metastases |
Breast Cancer Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03342417 | — | P2 | terminated | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients |
MGMT-unmethylated Glioblastoma (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03367715 | — | P2 | completed | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma |
Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03388632 | — | P1 | completed | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers |
Muscle Invasive Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03294304 | MIBC | P2 | completed | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy |
Non Small Cell Lung Cancer Stage IIIB (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03302247 | — | P2 | terminated | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy |
Advanced and Metastatic Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03406871 | REGONIVO | P1 | completed | Regorafenib and Nivolumab Simultaneous Combination Therapy |
Adenocarcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03371381 | — | P1/P2 | terminated | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung |
Genitourinary Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03333616 | — | P2 | active not recruiting | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Non-Squamous Non-Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03366766 | — | P2 | terminated | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer |
Squamous Cell Carcinoma of the Oropharynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03370276 | — | P1/P2 | completed | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
Colon Carcinoma Metastatic in the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03373188 | — | P1 | completed | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer |
Kidney Medullary Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03274258 | — | P2 | terminated | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma |
Metastatic Cancer Colorectal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03350126 | NIPICOL | P2 | active not recruiting | iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab |
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03342911 | — | P2 | completed | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
Metastatic Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03250273 | — | P2 | completed | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma |
Cervical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03220009 | — | P2 | withdrawn | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03283046 | — | P1 | withdrawn | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma |
Renal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03203473 | — | P2 | active not recruiting | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) |
Recurrent B Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02879695 | — | P1 | active not recruiting | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia |
MSS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03271047 | MSS | P2 | completed | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation |
Dedifferentiated Liposarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03307616 | — | P2 | active not recruiting | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery |
Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03246958 | — | P2 | completed | Nivolumab Plus Ipilimumab in Thyroid Cancer |
Anaplastic Large Cell Lymphoma, ALK-Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02978625 | — | P2 | active not recruiting | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
Squamous Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03542461 | EDEN | P3 | unknown | Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) |
HER2/Neu Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02892734 | — | P2 | terminated | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer |
Squamous-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03823625 | SQUINT | P2 | unknown | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) |
SARCOMA (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03282344 | — | P2 | active not recruiting | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
Biliary Tract Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03101566 | — | P2 | completed | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer |
Stage IV Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03223155 | COSINR | P1 | active not recruiting | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer |
Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03190174 | — | P1/P2 | completed | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers |
Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02923934 | — | P2 | completed | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers |
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02819804 | — | P1 | terminated | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
METASTATIC NON-SMALL CELL LUNG CANCER (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03224871 | — | Early P1 | completed | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. |
Lip, Oral Cavity and Pharynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03238365 | — | Early P1 | completed | Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck |
High Grade Serous Ovarian (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03245892 | — | P1 | completed | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer |
Uterine Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03241745 | — | P2 | completed | A Study of Nivolumab in Selected Uterine Cancer Patients |
Recurrent/Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05535569 | EBV | P1/P2 | completed | Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer |
Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03173950 | — | P2 | completed | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers |
Recurrent and/or Metastatic Platinum-refractory SCCHN (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03226756 | TopNIVO | P2 | completed | Nivolumab in Recurrent and/or Metastatic SCCHN |
Transitional Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03219775 | TITAN-TCC | P2 | unknown | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma |
EGFR Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02947386 | — | P1 | completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer |
HPV-Related Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03107182 | OPTIMA-II | P2 | completed | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer |
Lung Atypical Carcinoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03110978 | — | P2 | active not recruiting | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer |
Hodgkin's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138499 | CheckMate 812 | P3 | terminated | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, |
Hematopoietic/Lymphoid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03121534 | — | P2 | terminated | Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation |
Stage I Lung Non-Small Cell Cancer AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03158129 | — | P2 | completed | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer |
ALK Gene Translocation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02846792 | — | P1/P2 | terminated | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer |
Metastatic Kidney Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03050060 | — | P2 | terminated | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer |
Malignant Melanoma Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03166397 | — | P2 | unknown | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients |
Clear-Cell Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02978404 | — | P2 | completed | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases |
Clear Cell Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02960906 | BIONIKK | P2 | completed | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer |
Oral Cavity SCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03021993 | — | P2 | completed | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer |
Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03343652 | NB001 | P1/P2 | completed | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma |
Salivary Gland Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03172624 | — | P2 | completed | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer |
Advanced Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03061188 | — | P1 | completed | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma |
Major Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03146650 | — | P2 | unknown | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer |
Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03075553 | — | P2 | terminated | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
Refractory or Recurrent Hypermutated Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02992964 | — | P1/P2 | terminated | Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers |
Larynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03162731 | — | Early P1 | completed | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer |
Microsatellite Stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03104439 | — | P2 | active not recruiting | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer |
Haematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03146468 | NIVALLO | P2 | unknown | Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation |
Locally Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03119428 | — | P1 | terminated | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors |
Advanced Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138161 | SAINT | P1/P2 | recruiting | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma |
Peritoneal Carcinomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03172416 | PIPAC | P1 | unknown | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis |
B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03017820 | — | P1 | recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma |
Classic Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03057795 | — | P2 | active not recruiting | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma |
Colon Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03026140 | NICHE | P2 | recruiting | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer |
Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03132038 | NISCAHN | P2 | completed | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck |
Non-Small-Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02864251 | CheckMate722 | P3 | completed | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy |
EGFR Activating Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02949843 | — | P2 | terminated | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations |
Squamous Cell Carcinoma of the Skin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04204837 | — | P2 | recruiting | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin |
Kidney Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03065179 | RADVAX | P2 | completed | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients |
Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03003637 | IMCISION | P1/P2 | completed | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma |
Acute Adult T-Cell Leukemia/Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02631746 | — | P2 | completed | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma |
Grade 3a Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03015896 | — | P1/P2 | active not recruiting | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
Carcinoma,Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03044626 | FORCE | P2 | completed | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC |
Cancer Treated With Immune-checkpoint Inhibitors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03963518 | SURROGATE-ICI | N/A | completed | Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI) |
Acinar Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02834013 | — | P2 | active not recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03041181 | — | P2 | terminated | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor |
Adult Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02775292 | NYM | P1 | completed | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 |
Solid Tumors Induced by Prior Radiation Exposure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02864316 | — | P2 | terminated | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure |
Non-Small-Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02967133 | — | P2 | terminated | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer |
Lung Cancer, Nonsmall Cell, Stage I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02950038 | NSCLC | P2 | withdrawn | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) |
Advanced Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02955290 | — | P1/P2 | active not recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer |
HepatoCellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03033446 | — | P2 | completed | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma |
Gastrointestinal Stromal Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02880020 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery |
Severe Sepsis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02960854 | — | P1 | completed | A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock. |
Stage III/IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02857569 | NIVIPIT | P1/P2 | completed | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma |
Colorectal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02991196 | — | P1 | terminated | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer |
Broad Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02913313 | — | P1/P2 | completed | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors |
Antibodies, Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02901145 | — | P1/P2 | unknown | Nivolumab in Relapsed Pediatric Solid Tumors |
Advanced Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02935634 | FRACTION-GC | P2 | completed | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer |
Stage III Skin Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02437279 | OpACIN | P1 | unknown | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients |
Diffuse Intrinsic Pontine Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02960230 | — | P1/P2 | completed | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas |
Metastatic Renal Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02899078 | — | P1/P2 | completed | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer |
Peritoneal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02873962 | — | P2 | active not recruiting | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib |
Smoldering Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02903381 | — | P2 | completed | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma |
Refractory Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02860546 | — | P2 | completed | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC |
Non-small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02812667 | NSCLC | P1 | completed | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Triple-Negative Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02834247 | — | P1 | terminated | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors |
Clear Cell Renal Cell Carcinoma (ccRCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02771626 | NSCLC | P1/P2 | terminated | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) |
Stage IIIA Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02837029 | — | P1 | completed | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer |
Metastatic Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02781506 | — | P2 | terminated | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma |
Ann Arbor Stage IB Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02758717 | — | P2 | active not recruiting | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma |
Brain Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02667587 | CheckMate548 | P3 | completed | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) |
Solid Tumors and Hematologic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02712905 | — | P1/P2 | terminated | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies |
Untreated Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02754726 | — | P2 | completed | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
Stage IIIC Skin Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02941744 | ipniv | P1/P2 | completed | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases |
Meningiomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02648997 | — | P2 | active not recruiting | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma |
Metastatic Carcinoma in the Adrenal Cortex (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02720484 | — | P2 | terminated | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer |
NonHodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02973113 | PREVALE | P1 | completed | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) |
Non-Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02659059 | CheckMate 568 | P2 | completed | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer |
Anatomic Stage III Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02453620 | — | P1 | active not recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer |
Non-Hodgkin's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02581631 | CheckMate 436 | P1/P2 | completed | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas |
Squamous Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02852083 | ModuLung | P2 | unknown | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC |
Advanced Solid Tumors (Part A/B/C/D) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02637531 | — | P1 | unknown | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 |
Limited Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02046733 | STIMULI | P2 | completed | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease |
Encephalitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02856451 | — | N/A | completed | Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab |
Non-small Cell Lung Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02434081 | NICOLAS | P2 | completed | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma |
Stage III Cutaneous Melanoma AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02339571 | — | P2/P3 | active not recruiting | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma |
Malignant Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02534506 | — | P1 | completed | Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02532231 | — | P2 | completed | Nivolumab in AML in Remission at High Risk for Relapse |
Human Papillomavirus-Related Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02379520 | HESTIA | P1 | completed | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA |
Locally Advanced Bone Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02500797 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
Recurrent Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02498600 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Bladder Small Cell Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02496208 | — | P1 | active not recruiting | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
Nasopharyngeal Nonkeratinizing Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02339558 | — | P2 | completed | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer |
Triple-Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02393794 | TNBC | P1/P2 | active not recruiting | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) |
Loss of Chromosome 17p (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02420912 | — | P2 | completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation |
Advanced Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02419417 | BET | P1/P2 | completed | Study of BMS-986158 in Subjects With Select Advanced Cancers |
ALK-positive NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02393625 | — | P1 | active not recruiting | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer |
Metastatic Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02428192 | — | P2 | completed | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma |
Cervical Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02257528 | — | P2 | active not recruiting | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer |
Hepatomegaly (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02421354 | — | P2 | terminated | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis |
Anal Canal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02314169 | — | P2 | active not recruiting | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer |
Acute Bilineal Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02397720 | — | P2 | completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia |
Hematologic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02329847 | — | P1/P2 | completed | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies |
Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02335918 | — | P1/P2 | completed | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors |
Advanced Stage Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02350764 | — | P2 | completed | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs |
Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02213289 | PANGEA-IMBBP | P2 | completed | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression |
Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02309177 | — | P1 | completed | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer |
Previously Treated Metastatic Adenocarcinoma of the Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02243371 | — | P2 | completed | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab |
B-cell Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02327078 | ECHO-204 | P1/P2 | completed | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) |
ccRCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02293980 | MK-3795-001 | P1 | active not recruiting | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) |
Stage III (Unresectable) or Stage IV Advanced Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02142218 | Checkmate 168 | N/A | no longer available | Expanded Access Program With Nivolumab to Treat Melanoma |
Stage IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02054520 | — | P2 | terminated | Immunotherapy Study for Patients With Stage IV Melanoma |
Select Advanced Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02118337 | AMP-514 | P1/P2 | completed | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies |
Non Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02066636 | CheckMate153 | P3 | completed | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen |
Stage IV or Recurrent Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02041533 | — | P3 | completed | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) |
Microsatellite Unstable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02060188 | CheckMate142 | P2 | completed | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread |
Lymphoma. Non-Hodgkin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02038933 | DLBCL | P2 | completed | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) |
Chronic Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02011945 | — | P1 | completed | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia |
Advanced or Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01928394 | — | P1/P2 | completed | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors |
BRAF V600E Mutation Present (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01940809 | — | P1 | terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery |
Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01822509 | — | P1 | completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant |
Advanced or Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01783938 | — | P2 | completed | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) |
Non-Squamous Cell Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01673867 | CheckMate057 | P3 | completed | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC |
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01668784 | BMS-936558 | P3 | completed | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) |
CANCER,NOS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01714739 | — | P1/P2 | completed | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01592370 | — | P1/P2 | completed | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma |
Other (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05170685 | — | N/A | no longer available | Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab |
Nivolumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FDC | NCT07459543 | P4 | not yet recruiting | Untreated Melanoma | 30 | — |
| CANIQOL | NCT07028125 | P4 | recruiting | Renal Cell Carcinoma (Kidney Cancer) | 83 | — |
| MINUTE | NCT06031233 | P4 | recruiting | Oncology | 776 | — |
| CABOLD | NCT06934057 | P4 | recruiting | Kidney Cancer | 50 | — |
| NIVOPTIMIZE | NCT06116461 | P4 | unknown | Melanoma | 34 | — |
| VIGOR | NCT05583188 | P4 | terminated | NSCLC | 5 | PMID 24384493 |
| CheckMate 7C9 | NCT04513522 | P4 | completed | Kidney Neoplasms | 101 | — |
| CHECKMATE 920 | NCT02982954 | P4 | completed | Renal Cell Carcinoma | 211 | PMID 35210307 |
| CheckMate 374 | NCT02596035 | P4 | completed | Renal Cell Carcinoma | 197 | — |
| RFA | NCT04707547 | P4 | completed | Liver Cancer | 5 | PMID 18202772 |
| PAIR | NCT02626065 | P4 | completed | Metastatic Melanoma | 32 | PMID 38939518 |
| KRASCENDO 3 | NCT07541170 | P3 | not yet recruiting | Non-small Cell Lung Cancer | 400 | — |
| RELATIVITY1093 | NCT06561386 | P3 | recruiting | Non-small Cell Lung Cancer | 1,000 | — |
| eVOLVE-RCC02 | NCT07000149 | P3 | active not recruiting | Advanced Clear Cell Renal Cell Carcinoma | 1,116 | — |
| CARE1 | NCT06364631 | P3 | recruiting | Metastatic Kidney Cancer | 1,250 | — |
| SWE-NEO | NCT06794775 | P3 | recruiting | Malignant Melanoma Stage III | 128 | — |
| SUPRAME | NCT06743126 | P3 | recruiting | Melanoma, Cutaneous Malignant | 360 | — |
| TIGOS | NCT06646276 | P3 | recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | — |
| NADIM-ADJUVANT | NCT04564157 | P3 | active not recruiting | Non-Small Cell Lung Cancer | 210 | — |
| CheckMate 9DX | NCT03383458 | P3 | active not recruiting | Hepatocellular Carcinoma | 545 | — |
| LEDANG | NCT07050043 | P3 | recruiting | NSCLC (Non-small Cell Lung Carcinoma) | 123 | — |
| ATHENA | NCT03522246 | P3 | active not recruiting | Epithelial Ovarian Cancer | 1,097 | PMID 35658487 |
| IMAGINE | NCT04637594 | P3 | active not recruiting | Locally Advanced Bladder Urothelial Carcinoma | 3 | — |
| NADINA | NCT04949113 | P3 | active not recruiting | Malignant Melanoma Stage III | 423 | PMID 37104746 |
| eVOLVE-Meso | NCT06097728 | P3 | active not recruiting | Unresectable Pleural Mesothelioma | 861 | — |
| COMET | NCT06908993 | P3 | recruiting | Advanced Non Small Cell Lung Cancer | 133 | — |
| STELLAR-304 | NCT05678673 | P3 | active not recruiting | Non-Clear Cell Renal Cell Carcinoma | 317 | PMID 40008409 |
| CIME | NCT06346197 | P3 | recruiting | Gastric Cancer | 132 | — |
| NivoMela | NCT04309409 | P3 | active not recruiting | Malignant Melanoma Stage II | 374 | — |
| LIMITLESS | NCT05317858 | P3 | recruiting | Brain Tumor | 30 | — |
| RELATIVITY-127 | NCT05625399 | P3 | active not recruiting | Melanoma | 579 | — |
| PRISM-MEL-301 | NCT06112314 | P3 | recruiting | Advanced Melanoma | 680 | — |
| NIVOPOSTOP | NCT03576417 | P3 | active not recruiting | Squamous Cell Carcinoma of Head and Neck | 680 | PMID 41448222 |
| CheckMate76K | NCT04099251 | P3 | active not recruiting | Melanoma | 790 | PMID 40139004 |
| CheckMate 274 | NCT02632409 | P3 | active not recruiting | Various Advanced Cancer | 709 | PMID 35288066 |
| CheckMate-67T | NCT04810078 | P3 | active not recruiting | Clear Cell Renal Cell Carcinoma | 681 | — |
| EA2176 | NCT04444921 | P3 | active not recruiting | Anal Basaloid Carcinoma | 205 | — |
| COSMIC-313 | NCT03937219 | P3 | active not recruiting | Renal Cell Carcinoma | 855 | PMID 34550754 |
| FORTITUDE-102 | NCT05111626 | P3 | active not recruiting | Gastric Cancer | 515 | PMID 38308771 |
| ANVIL | NCT02595944 | P3 | active not recruiting | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | 903 | PMID 41911908 |
| CheckMate 9DW | NCT04039607 | P3 | active not recruiting | Hepatocellular Carcinoma | 732 | PMID 40349714 |
| STAR-221 | NCT05568095 | P3 | active not recruiting | Advanced Upper Gastrointestinal Tract Adenocarcinoma | 1,040 | — |
| CheckMate 8HW | NCT04008030 | P3 | active not recruiting | Metastatic Colorectal Cancer | 839 | PMID 39602630 |
| CheckMate901 | NCT03036098 | P3 | active not recruiting | Urothelial Cancer | 1,314 | PMID 37870949 |
| CheckMate 9ER | NCT03141177 | P3 | active not recruiting | Renal Cell Carcinoma | 701 | PMID 41617395 |
| DICIPLE | NCT03469960 | P3 | completed | Non-Small Cell Lung Cancer Metastatic | 265 | — |
| SAPPHIRE | NCT03906071 | P3 | completed | Metastatic Non-Squamous Non-Small Cell Lung Cancer | 577 | — |
| RAR-Immune | NCT04741438 | P3 | unknown | Sarcoma | 96 | — |
| RELATIVITY-123 | NCT05328908 | P3 | terminated | Colorectal Neoplasms | 770 | — |
| DREAM3R | NCT04334759 | P3 | completed | Mesothelioma | 214 | PMID 33358660 |
| INTEGRATEIIb | NCT04879368 | P3 | completed | Gastro-Oesophageal Cancer | 462 | PMID 36814222 |
| RELATIVITY-098 | NCT05002569 | P3 | terminated | Melanoma | 1,093 | PMID 41109920 |
| CheckMate 648 | NCT03143153 | P3 | completed | Various Advanced Cancer | 970 | PMID 37139963 |
| CheckMate 816 | NCT02998528 | P3 | completed | Non Small Cell Lung Cancer | 505 | PMID 40454642 |
| CheckMate73L | NCT04026412 | P3 | completed | Non-Small Cell Lung Cancer (NSCLC) | 925 | PMID 34489161 |
| CheckMate 577 | NCT02743494 | P3 | completed | Advanced Cancer | 794 | PMID 33789008 |
| CheckMate 227 | NCT02477826 | P3 | completed | Non-Small Cell Lung Cancer | 2,747 | PMID 31195357 |
| CheckMate 9LA | NCT03215706 | P3 | completed | Non-Small Cell Lung Cancer | 719 | PMID 39270380 |
| CheckMate 238 | NCT02388906 | P3 | completed | Melanoma | 906 | PMID 39378385 |
| CheckMate 7DX | NCT04100018 | P3 | completed | Prostate Cancer | 1,030 | PMID 41449150 |
| CheckMate 143 | NCT02017717 | P3 | completed | Recurrent Glioblastoma | 529 | PMID 30522968 |
| CheckMate649 | NCT02872116 | P3 | completed | Gastric Cancer | 2,031 | PMID 37713657 |
| IMSTAR-HN | NCT03700905 | P3 | unknown | Head and Neck Cancer | 276 | PMID 27247226 |
| CheckMate548 | NCT02667587 | P3 | completed | Brain Neoplasms | 716 | PMID 35511454 |
| CheckMate-6GE | NCT05297565 | P3 | completed | Melanoma | 14 | — |
| CheckMate 914 | NCT03138512 | P3 | completed | Carcinoma, Renal Cell | 1,641 | PMID 36774933 |
| CheckMate 7FL | NCT04109066 | P3 | completed | Breast Cancer | 521 | PMID 38913933 |
| CheckMate 74W | NCT04340193 | P3 | completed | Cancer, Hepatocellular | 26 | — |
| CheckMate 078 | NCT02613507 | P3 | completed | Non-Small Cell Lung Cancer | 504 | PMID 30659987 |
| CheckMate 7G8 | NCT04149574 | P3 | terminated | Urinary Bladder Neoplasms | 13 | — |
| CheckMate743 | NCT02899299 | P3 | completed | Mesothelioma | 605 | PMID 33206991 |
| CONFIRM | NCT03063450 | P3 | completed | Mesothelioma | 332 | PMID 29669604 |
| EDEN | NCT03542461 | P3 | unknown | Squamous Non-small Cell Lung Cancer | 125 | PMID 39700681 |
| TKI | NCT03729245 | P3 | terminated | Renal Cell Carcinoma | 623 | PMID 38838287 |
| CheckMate722 | NCT02864251 | P3 | completed | Non-Small-Cell Lung Carcinoma | 367 | PMID 38252907 |
| PIVOT-12 | NCT04410445 | P3 | terminated | Melanoma | 765 | PMID 35073733 |
| CheckMate 651 | NCT02741570 | P3 | completed | Head and Neck Cancer | 947 | PMID 33684371 |
| CheckMate331 | NCT02481830 | P3 | completed | Lung Cancer | 569 | — |
| eNERGY | NCT03351361 | P3 | completed | Advanced Non Small Cell Lung Cancer | 217 | PMID 39486424 |
| CheckMate 602 | NCT02726581 | P3 | completed | Multiple Myeloma | 170 | — |
| CheckMate 498 | NCT02617589 | P3 | completed | Brain Cancer | 560 | PMID 35419607 |
| CheckMate 384 | NCT02713867 | P3 | completed | Lung Cancer | 363 | — |
| CheckMate057 | NCT01673867 | P3 | completed | Non-Squamous Cell Non-small Cell Lung Cancer | 582 | PMID 29408986 |
| CheckMate 451 | NCT02538666 | P3 | completed | Lung Cancer | 907 | PMID 33683919 |
| CheckMate153 | NCT02066636 | P3 | completed | Non Small Cell Lung Cancer (NSCLC) | 1,428 | PMID 31121324 |
| NSCLC | NCT01642004 | P3 | completed | Squamous Cell Non-small Cell Lung Cancer | 272 | PMID 29023213 |
| BMS-936558 | NCT01668784 | P3 | completed | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | 821 | PMID 31272883 |
| CheckMate870 | NCT03195491 | P3 | completed | Lung Cancer | 400 | — |
| CheckMate 066 | NCT01721772 | P3 | completed | Melanoma | 418 | PMID 32997575 |
| CheckMate 812 | NCT03138499 | P3 | terminated | Hodgkin's Disease | 23 | — |
| CheckMate 915 | NCT03068455 | P3 | completed | Melanoma | 1,844 | PMID 35512259 |
| NIVACTOR | NCT05802290 | P3 | completed | Squamous Cell Carcinoma of Head and Neck | 124 | — |
| CheckMate 401 | NCT02599402 | P3 | completed | Melanoma | 533 | PMID 37307514 |
| NIBIT-M2 | NCT02460068 | P3 | unknown | Brain Metastases | 168 | PMID 25538176 |
| CheckMate 955 | NCT03048136 | P3 | withdrawn | Non-Small Cell Lung Cancer | 0 | — |
| RESET-R | NCT05732389 | P2 | recruiting | Cancer of Rectum | 39 | — |
| NOBLE | NCT07369791 | P2 | not yet recruiting | Advanced Biliary Tract Cancer(BTC) | 76 | — |
| Neo IRENIE | NCT06999980 | P2 | recruiting | Cutaneous Melanoma | 494 | — |
| Neo ReNi II | NCT05418972 | P2 | active not recruiting | Stage II Melanoma | 20 | — |
| TORCH-OPTIMA | NCT07403877 | P2 | not yet recruiting | Colorectal Cancer (MSI-H) | 114 | — |
| NEOREM-NEO-1 | NCT07230613 | P2 | recruiting | Cutaneous Melanoma, Stage III | 50 | — |
| NOCANO | NCT07514767 | P2 | not yet recruiting | Oral Squamous Cell Carcinoma (OSCC) | 60 | — |
| BELLINI | NCT03815890 | P2 | recruiting | Breast Cancer | 80 | PMID 39284953 |
| REGINA | NCT04503694 | P2 | active not recruiting | Rectal Cancer Stage II | 72 | — |
| FLINN | NCT07355205 | P2 | not yet recruiting | Non-small Cell Lung Cancer Stage IV | 26 | — |
| NICHE | NCT03026140 | P2 | recruiting | Colon Carcinoma | 353 | PMID 34606846 |
| GDFATHERHCC01 | NCT07219459 | P2 | recruiting | Unresectable or Metastatic Hepatocellular Carcinoma | 104 | — |
| TNT | NCT03886311 | P2 | recruiting | Sarcoma | 200 | — |
| GIANT | NCT06816927 | P2 | recruiting | Newly Diagnosed Glioblastoma | 92 | PMID 40016450 |
| EBV | NCT03258567 | P2 | recruiting | Epstein-Barr Virus Infections | 40 | — |
| N'FORCE | NCT07529873 | P2 | not yet recruiting | Squamous Cell Carcinoma of Head and Neck (SCCHN) | 131 | — |
| COLIBRI-2 | NCT06715241 | P2 | active not recruiting | LOCALLY ADVANCED CERVICAL CANCERS | 77 | — |
| RCC | NCT07188896 | P2 | recruiting | Advanced Renal Cell Carcinoma (aRCC) | 120 | — |
| PSI-Immune | NCT07223424 | P2 | recruiting | Renal Cell Carcinoma | 880 | — |
| Spark2 | NCT04848116 | P2 | active not recruiting | Head and Neck Squamous Cell Carcinoma | 24 | — |
| GALAXY 3 | NCT06926790 | P2 | recruiting | Lung Cancer - Non Small Cell | 69 | — |
| NeoRelapse | NCT06365619 | P2 | recruiting | Melanoma | 25 | — |
| GIVA-2 | NCT07432295 | P2 | recruiting | Solid Tumor | 180 | — |
| 14 | NCT05909618 | P2 | recruiting | Advanced Glioblastoma | 33 | — |
| ACCELERATE | NCT07013565 | P2 | recruiting | Anaplastic Large Cell Lymphoma, ALK-Positive | 20 | — |
| RIVAL | NCT06275360 | P2 | recruiting | Non-Small Cell Lung Cancer | 25 | — |
| ClearMe | NCT06319196 | P2 | recruiting | Cutaneous Melanoma | 54 | — |
| GS-1811 | NCT07546812 | P2 | recruiting | HER2-negative | 120 | — |
| ECTOP-1036 | NCT07398937 | P2 | recruiting | Resectable Stage II-IIIa Squamous NSCLC | 116 | — |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| NIVEC | NCT05795244 | P2 | recruiting | Endometrial Neoplasms | 30 | PMID 39530558 |
| VELOCITY-Lung | NCT05633667 | P2 | active not recruiting | Lung Cancer | 192 | — |
| ECTOP-1030 | NCT06572722 | P2 | withdrawn | Lung Cancer | 0 | — |
| ABC-X | NCT03340129 | P2 | recruiting | Melanoma Stage Iv | 218 | PMID 33450821 |
| VIRO-25 | NCT06463665 | P2 | recruiting | Advanced Non-squamous Non-small-cell Lung Cancer | 142 | — |
| EXPLORE-RCC | NCT06794229 | P2 | recruiting | Locally Advanced Renal Cell Carcinoma | 69 | — |
| BIG | NCT06253611 | P2 | recruiting | Gastric Cancer | 120 | — |
| NESCIO | NCT05148546 | P2 | active not recruiting | Renal Cell Carcinoma | 69 | — |
| GRAPE | NCT06983210 | P2 | recruiting | Urothelial Carcinoma Bladder | 43 | PMID 38849479 |
| MATISSE 2 | NCT06823479 | P2 | recruiting | Cutaneous Squamous Cell Carcinoma (CSCC) | 41 | — |
| ICB | NCT06250335 | P2 | active not recruiting | ICB-refractory Melanoma | 4 | — |
| GS-1811 | NCT07527858 | P2 | recruiting | Advanced Microsatellite Stable Colorectal Cancer | 170 | — |
| EXACT | NCT06863311 | P2 | recruiting | Advanced Renal Cell Carcinoma | 70 | — |
| FINISH-HL | NCT07209059 | P2 | recruiting | Hodgkin Lymphoma | 30 | — |
| IGNYTE | NCT03767348 | P2 | active not recruiting | Non-Small Cell Lung Cancer (NSCLC) | 340 | PMID 40627813 |
| TAPUR | NCT02693535 | P2 | recruiting | Lymphoma, Non-Hodgkin | 4,200 | PMID 36753688 |
| ABC | NCT02374242 | P2 | active not recruiting | Melanoma | 76 | PMID 37132182 |
| RCC | NCT06708949 | P2 | recruiting | Renal Cell Carcinoma, Clear Cell | 15 | — |
| NAHL | NCT05723055 | P2 | active not recruiting | Hodgkin Lymphoma | 9 | — |
| NADIMII | NCT03838159 | P2 | active not recruiting | Non Small Cell Lung Cancer | 90 | PMID 41805895 |
| CheckMate-1533 | NCT06946797 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 76 | — |
| TRIFLUOX-DP | NCT06245356 | P2 | recruiting | Metastatic Colorectal Cancer | 73 | — |
| Orion | NCT07100704 | P2 | recruiting | Recurrent/ Metastatic Olfactory Neuroblastoma | 14 | — |
| BRIGHT-ESCC | NCT07152678 | P2 | recruiting | Esophageal Cancer | 60 | — |
| COMBI-TED | NCT04884282 | P2 | active not recruiting | Metastatic Non Small Cell Lung Cancer | 105 | PMID 36946237 |
| CHAMP | NCT04709276 | P2 | active not recruiting | Metastatic Prostate Neuroendocrine Carcinoma | 41 | — |
| TURANDORELA | NCT06237920 | P2 | recruiting | Urologic Neoplasms | 90 | — |
| B-ALL | NCT04546399 | P2 | recruiting | Down Syndrome | 461 | — |
| CMP-001 | NCT05445609 | P2 | suspended | Metastatic Prostate Adenocarcinoma | 10 | — |
| SAMURAI | NCT05327686 | P2 | recruiting | Metastatic Renal Cell Carcinoma | 240 | — |
| MEMBRAINS | NCT03563729 | P2 | recruiting | Malignant Melanoma | 80 | — |
| DUMAS | NCT05684276 | P2 | active not recruiting | NSCLC | 22 | — |
| NEON | NCT06624475 | P2 | recruiting | Basal Cell Carcinoma | 30 | — |
| ANTARES | NCT06638931 | P2 | recruiting | Urachal Cancer | 28 | PMID 32101663 |
| UNICORN | NCT05845450 | P2 | recruiting | Colorectal Cancer | 197 | — |
| NIPISAFE | NCT04730544 | P2 | active not recruiting | Colorectal Cancer Metastatic | 96 | — |
| NIVO402025 | NCT07542262 | P2 | enrolling by invitation | Colorectal Cancer | 128 | — |
| METIMMOX-2 | NCT05504252 | P2 | active not recruiting | Colorectal Adenocarcinoma | 80 | PMID 20421432 |
| Cyto-KIK | NCT04322955 | P2 | active not recruiting | Kidney Cancer | 38 | — |
| NPC-Nivo | NCT06019130 | P2 | recruiting | Nasopharyngeal Carcinoma | 57 | — |
| RadVax | NCT03646617 | P2 | recruiting | Metastatic Melanoma | 54 | — |
| NIVOTHYM | NCT03134118 | P2 | active not recruiting | Thymoma Type B3 | 55 | PMID 34393061 |
| DRUP | NCT02925234 | P2 | recruiting | Cancer | 1,550 | PMID 37424386 |
| NIVIPI-Brain | NCT05012254 | P2 | active not recruiting | Non Small Cell Lung Cancer | 71 | — |
| ADJORL1 | NCT03406247 | P2 | recruiting | Head and Neck Squamous Cell Carcinoma | 140 | — |
| IMCODE004 | NCT06534983 | P2 | recruiting | Muscle-invasive Urothelial Carcinoma | 62 | — |
| ARCITECT | NCT05928806 | P2 | suspended | Advanced Renal Cell Carcinoma | 120 | — |
| NEXT | NCT03171025 | P2 | active not recruiting | Bladder Cancer | 200 | PMID 40102029 |
| NA_00092076 | NCT02259621 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 39 | PMID 31754049 |
| CheckMate 7UA | NCT04495010 | P2 | withdrawn | Melanoma | 0 | — |
| DISCERN | NCT06364917 | P2 | recruiting | Non Small Cell Lung Cancer | 24 | — |
| NIPIRESCUE | NCT05310643 | P2 | recruiting | Metastatic Colorectal Cancer | 30 | — |
| Indi-Blade | NCT05200988 | P2 | active not recruiting | Urothelial Carcinoma | 50 | PMID 37711193 |
| PACIFIC | NCT04745949 | P2 | recruiting | Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | 31 | — |
| DARANIVOVAX | NCT06015724 | P2 | recruiting | Pancreatic Ductal Adenocarcinoma | 54 | — |
| TATE-PD1 | NCT03259867 | P2 | recruiting | Hepatocellular Carcinoma | 54 | PMID 35504436 |
| TOP-FLOR | NCT05788081 | P2 | active not recruiting | Follicular Lymphoma Stage II | 40 | — |
| ILUSTRO | NCT03505320 | P2 | active not recruiting | Pharmacokinetics of Zolbetuximab | 143 | PMID 40341124 |
| NIVO-ALCL | NCT03703050 | P2 | active not recruiting | Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma | 45 | — |
| TNBC | NCT03449108 | P2 | active not recruiting | Bone Sarcoma | 30 | — |
| G360-IIT | NCT05715229 | P2 | recruiting | Carcinoma, Non-Small-Cell Lung | 108 | PMID 32816849 |
| CANOPY | NCT05502315 | P2 | recruiting | Castration-resistant Prostate Cancer | 47 | — |
| AxIn | NCT05817903 | P2 | recruiting | Metastatic Renal Cell Carcinoma | 118 | — |
| NIVO1002024 | NCT07523763 | P2 | active not recruiting | Colorectal Cancer (MSI-H) | 30 | — |
| LUNGVIR | NCT05597800 | P2 | not yet recruiting | NSCLC Stage IV | 105 | — |
| NIPU | NCT04300244 | P2 | active not recruiting | Cancer | 118 | PMID 39133306 |
| MOST-CIRCUIT | NCT04969887 | P2 | active not recruiting | Advanced Biliary Tract Cancer | 240 | PMID 40608313 |
| NIMBUS | NCT03789110 | P2 | active not recruiting | Breast Cancer | 30 | PMID 40360544 |
| MSS | NCT04963283 | P2 | active not recruiting | Colorectal Adenocarcinoma | 48 | — |
| LOGICAN | NCT05476796 | P2 | recruiting | Gastric Adenocarcinoma | 118 | PMID 38762353 |
| TRINITY | NCT05280457 | P2 | active not recruiting | Head and Neck Squamous Cell Carcinoma | 21 | — |
| EBIN | NCT03235245 | P2 | active not recruiting | Unresectable Stage III Melanoma | 271 | PMID 40449497 |
| CAPTUR | NCT03297606 | P2 | recruiting | Lymphoma, Non-Hodgkin | 720 | — |
| NPC | NCT06064097 | P2 | recruiting | Stage II Nasopharyngeal Carcinoma AJCC v8 | 50 | — |
| CCBW | NCT06265285 | P2 | recruiting | Advanced Esophageal Squamous Cell Carcinoma | 50 | — |
| NAVIGATION | NCT05696548 | P2 | active not recruiting | Anaplastic Thyroid Cancer | 51 | — |
| HER | NCT03650894 | P2 | active not recruiting | Breast Neoplasm Female | 30 | — |
| TONIC-2 | NCT04159818 | P2 | recruiting | Metastatic Breast Cancer | 52 | — |
| ctDNA Lung RCT | NCT04966663 | P2 | recruiting | Non Small Cell Lung Cancer | 66 | — |
| CLARA | NCT05215470 | P2 | active not recruiting | Renal Cancer Metastatic | 100 | — |
| SANO-3 | NCT05491616 | P2 | active not recruiting | Esophageal Cancer | 77 | — |
| L | NCT03607890 | P2 | active not recruiting | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | 38 | — |
| HO152 | NCT03620578 | P2 | active not recruiting | Non Hodgkin Lymphoma | 97 | — |
| BOOST-RCC | NCT06284564 | P2 | active not recruiting | Metastatic Renal Cell Carcinoma | 10 | — |
| LOW | NCT04933903 | P2 | recruiting | Non Small Cell Lung Cancer | 25 | — |
| SURPASS-3 | NCT05601752 | P2 | active not recruiting | Ovarian Cancer | 66 | — |
| CERAD-IMMUNE | NCT05504642 | P2 | withdrawn | Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases | 0 | — |
| CYTOSHRINK | NCT04090710 | P2 | active not recruiting | Metastatic Renal Cell Carcinoma | 66 | — |
| RAFTING | NCT04866654 | P2 | recruiting | Hodgkin Lymphoma | 160 | PMID 40135712 |
| SARC038 | NCT04803877 | P2 | active not recruiting | Osteosarcoma | 48 | — |
| VESTIGE | NCT03443856 | P2 | active not recruiting | Gastric and Esophagogastric Junction Adenocarcinoma | 197 | PMID 32083013 |
| IV | NCT05496192 | P2 | withdrawn | Melanoma | 0 | — |
| CNN-BC | NCT05203913 | P2 | recruiting | Muscle-Invasive Bladder Carcinoma | 32 | — |
| GALAXY-1 | NCT05964101 | P2 | unknown | Neoplasms | 25 | — |
| IMPALA | NCT04400539 | P2 | recruiting | Mesotheliomas Pleural | 20 | — |
| AARON | NCT04913922 | P2 | unknown | Acute Myeloid Leukemia | 30 | — |
| CONGRATS | NCT04095208 | P2 | completed | Soft Tissue Sarcoma Adult | 68 | — |
| ICI | NCT04817254 | P2 | completed | Glioblastoma | 47 | — |
| ANIMATE | NCT03337919 | P2 | unknown | Hodgkin Lymphoma | 78 | — |
| NSCLC | NCT04623775 | P2 | active not recruiting | Non-small Cell Lung Cancer | 468 | — |
| OMP-313M32 | NCT05715216 | P2 | active not recruiting | Ovarian Cancer | 20 | — |
| PORTSIDE | NCT05926960 | P2 | terminated | Melanoma | 38 | — |
| GALLANT | NCT04535713 | P2 | recruiting | Sarcoma | 260 | PMID 27234989 |
| NUTMEG | NCT04195139 | P2 | active not recruiting | Glioblastoma Multiforme | 103 | PMID 39777725 |
| NIPICOL | NCT03350126 | P2 | active not recruiting | Metastatic Cancer Colorectal | 57 | PMID 37269904 |
| INSPIRE | NCT04717154 | P2 | completed | Prostatic Neoplasms, Castration-Resistant | 69 | — |
| NEOpredict | NCT04205552 | P2 | completed | NSCLC Stage II | 90 | PMID 38689060 |
| CheckMate 6DW | NCT05136677 | P2 | completed | Mesothelioma, Malignant | 102 | — |
| NEONIPIGA | NCT04006262 | P2 | active not recruiting | Localized Oesogastric Adenocarcimona | 32 | PMID 35969830 |
| Neo-Kan | NCT05472623 | P2 | withdrawn | Resectable Non-Small Cell Lung Cancer | 0 | — |
| TONIC | NCT02499367 | P2 | unknown | Breast Cancer | 84 | PMID 41406937 |
| NSCLC | NCT04123379 | P2 | completed | Non-small Cell Lung Cancer | 48 | — |
| VEXILLUM | NCT05219435 | P2 | completed | Urothelial Cancer | 25 | — |
| NURE-Combo | NCT04876313 | P2 | unknown | Muscle-Invasive Bladder Carcinoma | 29 | PMID 39241203 |
| ROME | NCT04591431 | P2 | unknown | Breast Cancer | 400 | PMID 41963505 |
| OpACIN-neo | NCT02977052 | P2 | unknown | Malignant Melanoma Stage III | 186 | PMID 36989829 |
| IMAGINE | NCT04062656 | P2 | unknown | Gastric Cancer | 21 | — |
| REFINE | NCT04913025 | P2 | unknown | Renal Cell Carcinoma | 160 | PMID 36519749 |
| PICASSO | NCT04988841 | P2 | completed | Melanoma | 70 | — |
| NIBIT-ML1 | NCT04250246 | P2 | unknown | Melanoma | 184 | PMID 24384533 |
| NICO | NCT03721757 | P2 | completed | Squamous Cell Carcinoma of the Oral Cavity | 21 | — |
| ATLAS | NCT04966676 | P2 | terminated | Non Small Cell Lung Cancer | 5 | — |
| RO7121661 | NCT04785820 | P2 | completed | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | 190 | — |
| CheckMate 9KD | NCT03338790 | P2 | completed | Prostate Cancer | 292 | PMID 35977756 |
| MATISSE | NCT04620200 | P2 | completed | Cutaneous Squamous Cell Carcinoma | 50 | PMID 41062829 |
| CheckMate 650 | NCT02985957 | P2 | completed | Prostate Cancer | 351 | PMID 32916128 |
| ANZUP2001 | NCT05150236 | P2 | unknown | Prostatic Neoplasms | 93 | — |
| NIPINEC | NCT03591731 | P2 | completed | Neuroendocrine Carcinoma | 185 | PMID 41774886 |
| NIVOFGFR2 | NCT05859477 | P2 | unknown | Metastatic Gastric Cancer | 23 | — |
| Optim-UCPVax | NCT04263051 | P2 | completed | Advanced Non-small Cell Lung Cancer | 60 | PMID 23264913 |
| ANICCA | NCT03981146 | P2 | completed | Colorectal Cancer | 35 | PMID 41407398 |
| IMMUNEBOOST | NCT03838263 | P2 | completed | Oropharynx Cancer | 62 | PMID 41570275 |
| NPC | NCT03267498 | P2 | completed | Nasopharyngeal Carcinoma | 40 | — |
| NIVACOR | NCT04072198 | P2 | completed | Colorectal Cancer | 73 | PMID 32867715 |
| CheckMate142 | NCT02060188 | P2 | completed | Microsatellite Unstable Colorectal Cancer | 385 | PMID 28734759 |
| TOP2101 | NCT05144529 | P2 | terminated | Lung Cancer Metastatic | 19 | — |
| MSS | NCT03642067 | P2 | completed | Microsatellite Stable (MSS) Colorectal Adenocarcinomas | 59 | — |
| OPTIMA-II | NCT03107182 | P2 | completed | HPV-Related Squamous Cell Carcinoma | 72 | PMID 38842838 |
| ADMEC-O | NCT02196961 | P2 | completed | Merkel Cell Carcinoma | 180 | PMID 37451295 |
| CheckPRO | NCT05655715 | P2 | completed | Prostate Cancer Metastatic | 90 | PMID 36717150 |
| CMP-001 | NCT04401995 | P2 | completed | Melanoma | 9 | — |
| NSCLC | NCT06094296 | P2 | terminated | NSCLC | 1 | — |
| SLGN | NCT04891770 | P2 | completed | Chronic Hepatitis B | 103 | — |
| HCC | NCT03510871 | P2 | completed | Hepatocellular Carcinoma (HCC) | 43 | PMID 40972843 |
| SECOMBIT | NCT02631447 | P2 | completed | Metastatic Melanoma | 251 | PMID 39315864 |
| CheckMate 744 | NCT02927769 | P2 | completed | Hodgkin Disease | 72 | PMID 36564047 |
| PRECISE | NCT02664181 | P2 | completed | Lung Cancer | 13 | — |
| OXEL | NCT03487666 | P2 | completed | Triple Negative Breast Cancer | 45 | PMID 40274284 |
| BreastImmune03 | NCT03818685 | P2 | unknown | Breast Cancer | 95 | PMID 41314029 |
| CA209-260 | NCT02553642 | P2 | completed | Bladder Cancer | 81 | PMID 29489427 |
| RNF43 | NCT04907539 | P2 | completed | Colorectal Cancer | 25 | — |
| IMPACT | NCT03570619 | P2 | completed | Metastatic Castration Resistant Prostate Cancer | 56 | — |
| NIVOTAX | NCT04282109 | P2 | completed | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 141 | — |
| PG545 | NCT05061017 | P2 | completed | NSCLC | 13 | PMID 36634920 |
| METIMMOX | NCT03388190 | P2 | completed | Colorectal Cancer Metastatic | 80 | PMID 38664577 |
| CHINOREC | NCT04124601 | P2 | completed | Rectal Cancer | 80 | PMID 40844778 |
| CheckMate 9TN | NCT03770299 | P2 | withdrawn | Non-Small Cell Lung Cancer | 0 | — |
| Neo-NTP-CRT | NCT05130684 | P2 | unknown | Locally Advanced Esophageal Squamous Cell Carcinoma | 43 | PMID 41862680 |
| NSCLC | NCT03285321 | P2 | completed | Non-small Cell Lung Cancer | 105 | — |
| CHEERS | NCT03511391 | P2 | completed | Urothelial Carcinoma | 99 | PMID 37410476 |
| GEJ | NCT03662659 | P2 | completed | Gastric Cancer | 274 | PMID 38723227 |
| MIBC | NCT03993249 | P2 | unknown | Bladder Cancer | 78 | — |
| Nextrah | NCT04611165 | P2 | completed | Advanced Hepatocellular Carcinoma | 50 | PMID 38463541 |
| BIOLUMA | NCT03083691 | P2 | completed | Carcinoma, Non-Small-Cell Lung | 90 | — |
| AG-120 | NCT04056910 | P2 | completed | Advanced Solid Tumor | 15 | PMID 41138165 |
| AcSé | NCT03012581 | P2 | completed | Carcinoma, Renal Cell | 269 | — |
| DEPEND | NCT03944915 | P2 | completed | Human Papilloma Virus | 35 | PMID 40048190 |
| INFLUENCE | NCT05116917 | P2 | terminated | Pancreatic Cancer | 19 | — |
| DENIVOS | NCT03669523 | P2 | completed | Carcinoma, Non-Small-Cell Lung | 82 | — |
| NivoM | NCT03569696 | P2 | unknown | Lymphoma, B-Cell | 50 | — |
| HL | NCT01716806 | P2 | completed | Hodgkin Disease | 131 | PMID 24359243 |
| RACE IT | NCT03529890 | P2 | unknown | Urinary Bladder Cancer | 33 | PMID 31900121 |
| CHECKPOINT | NCT05435053 | P2 | terminated | Pancreas Cancer | 9 | — |
| NIVOLEP | NCT03630640 | P2 | completed | Hepatocellular Carcinoma | 43 | PMID 28453431 |
| CheckMate 848 | NCT03668119 | P2 | completed | Pan Tumor | 212 | PMID 39107131 |
| BLISS | NCT05081674 | P2 | completed | Lung Neoplasm | 154 | — |
| IRE | NCT04212026 | P2 | terminated | Metastatic Pancreatic Cancer | 8 | — |
| BMS-986227 | NCT03927105 | P2 | completed | Peripheral T Cell Lymphoma | 4 | — |
| TOP1705 | NCT03573947 | P2 | completed | Non-small Cell Lung Cancer | 46 | — |
| IBC | NCT03742986 | P2 | completed | Breast Cancer | 8 | — |
| GEP | NCT03980925 | P2 | completed | Neuroendocrine Tumors | 37 | — |
| TKI | NCT05039736 | P2 | withdrawn | Hepatocellular Carcinoma | 0 | — |
| NivoPlus | NCT04107103 | P2 | completed | SCCHN | 6 | PMID 19934295 |
| CheckMate 592 | NCT03001882 | P2 | completed | Non-Small Cell Lung Cancer | 230 | — |
| AIRING | NCT04577638 | P2 | completed | Non Small Cell Lung Cancer Stage III | 8 | — |
| NA_00084192 | NCT01928576 | P2 | completed | Non-Small Cell Lung Cancer | 143 | — |
| TITAN-TCC | NCT03219775 | P2 | unknown | Transitional Cell Carcinoma | 169 | PMID 38722641 |
| COMBAT-CRPC | NCT03554317 | P2 | completed | Castration-resistant Prostate Cancer | 45 | PMID 38167882 |
| Nivo-DHAP | NCT04091490 | P2 | completed | Hodgkin Lymphoma | 40 | PMID 12377653 |
| CheCUP | NCT04131621 | P2 | unknown | Cancer of Unknown Primary Site | 194 | PMID 37875494 |
| UNISoN | NCT03177239 | P2 | unknown | Renal Cell Carcinoma | 85 | — |
| CheckMate 205 | NCT02181738 | P2 | completed | Hodgkin Disease | 294 | PMID 27451390 |
| CA209-9JC | NCT03834233 | P2 | unknown | Advanced Cutaneous Squamous Cell Carcinoma | 24 | PMID 36274573 |
| RENOBATE | NCT04310709 | P2 | completed | Carcinoma, Hepatocellular | 42 | PMID 38374347 |
| CheckPAC | NCT02866383 | P2 | completed | Metastatic Pancreatic Cancer | 160 | PMID 37744345 |
| MARIO-275 | NCT03980041 | P2 | completed | Bladder Cancer | 49 | — |
| TITAN-RCC | NCT02917772 | P2 | completed | Carcinoma, Renal Cell | 200 | PMID 37844597 |
| ERICA | NCT03562507 | P2 | terminated | Renal Cell Carcinoma, Metastatic | 8 | — |
| CRUCIAL | NCT03437200 | P2 | terminated | Inoperable œsophageal Cancer | 8 | — |
| BTC | NCT04057365 | P2 | terminated | Biliary Tract Cancer | 15 | — |
| CKS | NCT03219671 | P2 | unknown | Classic Kaposi Sarcoma | 20 | — |
| CheckMate 9UT | NCT03519256 | P2 | terminated | Urinary Bladder Neoplasms | 142 | — |
| L | NCT03606174 | P2 | terminated | Urothelial Carcinoma | 260 | — |
| NIVAHL | NCT03004833 | P2 | completed | Classical Hodgkin Lymphoma | 110 | PMID 41926569 |
| PIVOT-10 | NCT03785925 | P2 | completed | Urinary Bladder Neoplasm | 192 | — |
| OPTIM | NCT03620123 | P2 | completed | Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 54 | — |
| TopNIVO | NCT03226756 | P2 | completed | Recurrent and/or Metastatic Platinum-refractory SCCHN | 351 | — |
| SCLC | NCT03406715 | P2 | terminated | Small Cell Lung Cancer | 14 | — |
| ICON | NCT03409198 | P2 | completed | Breast Cancer | 82 | PMID 38242720 |
| FRACTION-GC | NCT02935634 | P2 | completed | Advanced Gastric Cancer | 190 | — |
| ILLUMINATE-206 | NCT03865082 | P2 | active not recruiting | Solid Tumor | 30 | — |
| CheckMate 714 | NCT02823574 | P2 | completed | Head and Neck Cancer | 425 | PMID 37022706 |
| CheckMate 907 | NCT03090737 | P2 | completed | Non-Small Cell Lung Cancer | 129 | — |
| CheckMate 568 | NCT02659059 | P2 | completed | Non-Small-Cell Lung Cancer | 324 | PMID 30785829 |
| INTEGA | NCT03409848 | P2 | completed | Gastric Cancer | 97 | PMID 32487035 |
| ImmunoProst | NCT03040791 | P2 | unknown | Prostate Cancer | 38 | — |
| NIVALLO | NCT03146468 | P2 | unknown | Haematological Malignancy | 14 | — |
| CHIVA2 | NCT03304093 | P2 | completed | Non Small Cell Lung Cancer Metastatic | 30 | — |
| NiTraSarc | NCT03590210 | P2 | completed | Metastatic Adult Soft Tissue Sarcoma | 92 | — |
| NIMBLe | NCT03461952 | P2 | terminated | Advanced Solid Tumors | 4 | — |
| STIMULI | NCT02046733 | P2 | completed | Limited Stage Small Cell Lung Cancer | 222 | PMID 22858559 |
| CheckMate 908 | NCT03130959 | P2 | completed | Various Advanced Cancer | 166 | PMID 36808285 |
| IMMUTACE | NCT03572582 | P2 | completed | Carcinoma, Hepatocellular | 49 | — |
| TRIPPLE-R | NCT04258150 | P2 | terminated | Pancreatic Cancer | 26 | PMID 36592507 |
| FRACTION-RCC | NCT02996110 | P2 | completed | Advanced Cancer | 182 | PMID 36328377 |
| RAMONA | NCT03416244 | P2 | completed | Esophageal Cancer | 66 | PMID 30871493 |
| NISCAHN | NCT03132038 | P2 | completed | Salivary Gland Carcinoma | 98 | PMID 39886516 |
| STARVE-PC | NCT02601014 | P2 | completed | Prostate Cancer | 32 | PMID 33636027 |
| MAYA | NCT03832621 | P2 | completed | Metastatic Colorectal Cancer | 135 | PMID 35258987 |
| NIVISCO | NCT04413838 | P2 | unknown | Obesity, COVID-19 Infection | 120 | — |
| IMMUNOX | NCT04430985 | P2 | withdrawn | Metastatic Colorectal Cancer | 0 | — |
| COVID-19 | NCT04356508 | P2 | unknown | COVID-19 | 15 | — |
| Checkmate 171 | NCT02409368 | P2 | completed | Non-Small Cell Lung Cancer | 812 | PMID 32028209 |
| REVOLUMAB | NCT03925246 | P2 | completed | High Grade Glioma | 43 | PMID 38537315 |
| CC-122 | NCT03834623 | P2 | completed | Melanoma | 23 | — |
| OASIS | NCT04503967 | P2 | unknown | Gastric Adenocarcinoma | 48 | PMID 39406730 |
| NIRVANA | NCT02799901 | P2 | completed | Melanoma | 72 | PMID 34088741 |
| CheckMate 7A8 | NCT04075604 | P2 | completed | Breast Cancer | 23 | — |
| GEM1402 | NCT02626962 | P2 | completed | Uveal Melanoma | 52 | PMID 33417511 |
| NIVES | NCT03469713 | P2 | completed | Renal Cancer Metastatic | 69 | PMID 32203306 |
| MIBC | NCT03294304 | P2 | completed | Muscle Invasive Bladder Cancer | 43 | — |
| NIVOREN | NCT03013335 | P2 | completed | Metastatic Renal Cell Carcinoma | 730 | PMID 35977881 |
| CheckMate 627 | NCT02832167 | P2 | completed | Cancer | 239 | — |
| CONTESSA TRIO | NCT03952325 | P2 | terminated | Breast Cancer | 294 | — |
| HN17-11 | NCT06440187 | P2 | completed | Recurrent or Metastatic Nasopharyngeal Carcinom | 38 | — |
| BMS-936558 | NCT01721759 | P2 | completed | Squamous Cell Non-small Cell Lung Cancer | 117 | PMID 25704439 |
| MDX-1106 | NCT01354431 | P2 | completed | Renal Cell Carcinoma | 168 | PMID 25452452 |
| MODULATE | NCT03647839 | P2 | completed | Colorectal Cancer Metastatic | 90 | — |
| SQUINT | NCT03823625 | P2 | unknown | Squamous-Cell Lung Cancer | 112 | PMID 39836372 |
| CheckMate 069 | NCT01927419 | P2 | completed | Unresectable Melanoma | 142 | PMID 25891304 |
| MSS | NCT03271047 | P2 | completed | MSS | 75 | PMID 38600471 |
| NSCLC | NCT03353675 | P2 | completed | Non Small Cell Lung Cancer Metastatic | 44 | — |
| BIONIKK | NCT02960906 | P2 | completed | Clear Cell Metastatic Renal Cell Carcinoma | 200 | PMID 35390339 |
| DC | NCT03782064 | P2 | terminated | Multiple Myeloma | 5 | — |
| NIVOSWITCH | NCT02959554 | P2 | terminated | Metastatic Renal Cell Carcinoma | 49 | PMID 33058158 |
| SBRT | NCT02684253 | P2 | completed | Head and Neck Squamous Cell Carcinoma (HNSCC) | 65 | PMID 32822275 |
| FORCE | NCT03044626 | P2 | completed | Carcinoma,Non-Small-Cell Lung | 101 | PMID 31703637 |
| FL | NCT02038946 | P2 | completed | Lymphoma | 116 | PMID 32870269 |
| CheckMate 647 | NCT02857426 | P2 | completed | Lymphoma | 66 | — |
| RADVAX | NCT03065179 | P2 | completed | Kidney Cancer Metastatic | 29 | — |
| ENSIGN | NCT02831933 | P2 | terminated | Lung Squamous Cell Carcinoma Stage IV | 11 | — |
| NASIR-HCC | NCT03380130 | P2 | completed | Hepatocellular Carcinoma | 41 | PMID 31848672 |
| DLBCL | NCT02038933 | P2 | completed | Lymphoma. Non-Hodgkin | 121 | PMID 30620669 |
| CORIMUNO-NIVO | NCT04343144 | P2 | unknown | COVID19- Infection With SARS-CoV-2 Virus | 92 | — |
| CheckMate204 | NCT02320058 | P2 | completed | Melanoma | 119 | PMID 33880555 |
| ARIES | NCT03824704 | P2 | terminated | Epithelial Ovarian Cancer | 1 | — |
| PANGEA-IMBBP | NCT02213289 | P2 | completed | Adenocarcinoma | 80 | — |
| ModuLung | NCT02852083 | P2 | unknown | Squamous Cell Lung Cancer | 86 | — |
| SBRT | NCT03599362 | P2 | terminated | Pancreatic Cancer | 7 | — |
| GIADA | NCT04659551 | P2 | completed | Breast Cancer | 43 | PMID 34667023 |
| NICOLAS | NCT02434081 | P2 | completed | Non-small Cell Lung Cancer Stage III | 94 | PMID 28551359 |
| Cypress 2 | NCT03382912 | P2 | terminated | Non Small Cell Lung Cancer | 52 | PMID 33166722 |
| FRACTION-Lung | NCT02750514 | P2 | terminated | Advanced Cancer | 295 | — |
| RISE-M | NCT03634800 | P2 | terminated | Multiple Myeloma | 6 | — |
| INITIATE | NCT03048474 | P2 | completed | Malignant Pleural Mesothelioma | 36 | PMID 33166791 |
| BMS-986205 | NCT04007588 | P2 | withdrawn | Melanoma Stage III | 0 | — |
| NLG2107 | NCT03301636 | P2 | terminated | Melanoma | 21 | — |
| NICOLE | NCT04123925 | P2 | completed | Colon Cancer Stage II/III | 22 | — |
| MAPS2 | NCT02716272 | P2 | completed | Mesothelioma | 125 | PMID 30660609 |
| MDS | NCT02599649 | P2 | terminated | Leukemia | 10 | PMID 30001986 |
| BMS-936558 | NCT02156804 | P2 | completed | Melanoma | 1,009 | PMID 31581055 |
| ADAPTeR | NCT02446860 | P2 | terminated | Renal Cell Carcinoma | 15 | PMID 34715028 |
| CA209-322 | NCT02621515 | P2 | terminated | Melanoma | 7 | — |
| NivoMes | NCT02497508 | P2 | completed | Malignant Pleural Mesothelioma | 33 | — |
| Neo-nivo | NCT02550249 | P2 | completed | Glioblastoma Multiforme | 29 | — |
| NSCLC | NCT02950038 | P2 | withdrawn | Lung Cancer, Nonsmall Cell, Stage I | 0 | — |
| RCC | NCT02962804 | P2 | withdrawn | Carcinoma, Renal Cell | 0 | — |
Terminated and withdrawn Nivolumab trials (315)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06247540withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- NCT04929041suspendedTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
- NCT05457959withdrawnPeptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
- NCT07011550suspendedPhase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
- NCT06572722withdrawnPerioperative Immunotherapy for NSCLC (ECTOP-1030)
- NCT04840589suspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
- NCT06325683suspendedAnti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- NCT05445609suspendedVidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
- NCT05904080suspendedTesting Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
- NCT06767956withdrawnGolcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
- NCT05928806suspendedAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
- NCT04495010withdrawnNeoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- NCT06466798withdrawnFourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
- NCT05153304withdrawnPersonalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
- NCT03604991suspendedNivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
- NCT05504642withdrawnChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
- NCT04268888suspendedNivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
- NCT05496192withdrawnA Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
- NCT05743270withdrawnStudy of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
- NCT04151563withdrawnA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- NCT03799445terminatedIpilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
- NCT04904302terminatedSitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
- NCT06357858withdrawnASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
- NCT04785287terminatedAnti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
- NCT03645928terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT05926960terminatedA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- NCT03575234withdrawnNivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
- NCT05717140withdrawnAerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
- NCT03585465terminatedNivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
- NCT03958383terminatedIT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- NCT03274258terminatedPhase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
- NCT03520686terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- NCT04315155withdrawnEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
- NCT06410534withdrawnA Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
- NCT05199285terminatedA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- NCT05472623withdrawnNeoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
- NCT03417037withdrawnAn Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
- NCT05328908terminatedA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- NCT03704714suspendedNivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
- NCT06191796terminatedStudy of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- NCT06421311terminatedObservational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
- NCT05002569terminatedA Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- NCT04223648withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
- NCT04902040terminatedPlinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- NCT04781855withdrawnIpilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
- NCT04966676terminatedStudy of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
- NCT04278144terminatedA First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
- NCT04688658terminatedDuvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
- NCT04050462terminatedNivolumab Combined With BMS-986253 in HCC Patients
- NCT03991130terminatedHigh Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
- NCT03227432withdrawnAn Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
- NCT04375527terminatedBinimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
- NCT05921760terminatedIvosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
- NCT06034860terminatedStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
- NCT03727061terminatedPorfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
- NCT04187404terminatedA Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- NCT04125719withdrawnPVSRIPO in Combination With Nivolumab in Melanoma
- NCT03704077withdrawnAn Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- NCT05144529terminatedA Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- NCT02419495terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- NCT05543629terminatedA Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
- NCT02408861terminatedNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- NCT03446040terminatedAn Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
- NCT03646123terminatedClinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- NCT06094296terminatedA Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- NCT05898828withdrawnPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
- NCT05220722terminatedPressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- NCT05200143terminatedStudy of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- NCT04695977terminatedCMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
- NCT04935229terminatedIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
- NCT05375084terminatedSHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
- NCT06003075terminatedInduction Chemo-Nivo in Unresectable Stage III NSCLC
- NCT05341349terminatedStereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
- NCT04305249terminatedSafety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
- NCT02681302terminatedCheck Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
- NCT04967196terminatedIpilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
- NCT05581719terminatedA Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
- NCT03110107terminatedFirst-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- NCT05583188terminatedNeoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
- NCT03770299withdrawnAn Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- NCT03547999terminatedA Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
- NCT04611126terminatedT-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
- NCT04239040terminatedGVAX Plus Checkpoint Blockade in Neuroblastoma
- NCT03552380terminatedStudy of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
- NCT04698187terminatedCMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
- NCT04429321terminatedNivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- NCT04042116suspendedA Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- NCT02635061terminatedSelective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
- NCT04060407withdrawnCD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
- NCT02846376terminatedSingle Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
- NCT05169684terminatedA Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- NCT05001360withdrawnStudy of FMT Combined With Nivolumab in Gastric Cancer
- NCT02992964terminatedPilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
- NCT04431635terminatedDose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- NCT03502746terminatedPhase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
- NCT04892043terminatedStudy of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
- NCT04149574terminatedA Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
- NCT05116917terminatedImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
- NCT03812562terminatedNivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
- NCT04659369terminatedStudy of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
- NCT04044209withdrawnA Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
- NCT04203901terminatedDendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
- NCT04270864terminatedIntratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- NCT05435053terminatedIrreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
- NCT04458909terminatedTesting the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
- NCT04300140terminatedSafety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- NCT05395052terminatedFT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- NCT03121677terminatedPersonalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
- NCT04212026terminatedIrreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
- NCT04899921terminatedTroriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
- NCT04594811terminatedNT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- NCT04185311terminatedIpilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
- NCT03920631withdrawnMicrotransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
- NCT05039736withdrawnA Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
- NCT05472506withdrawnOral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
- NCT04322643terminatedIntermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- NCT04610658terminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- NCT04965714withdrawnNivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
- NCT03366766terminatedNivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
- NCT03768531withdrawnSafety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
- NCT04901988terminatedCirculating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
- NCT03576963withdrawnGuadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
- NCT04311710terminatedA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- NCT06400264withdrawnTesting Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
- NCT04319224terminatedVopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- NCT04166383terminatedVB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
- NCT03785210terminatedNivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
- NCT03126461withdrawnSAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
- NCT04801966terminatedSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- NCT03014804withdrawnAutologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
- NCT03652233withdrawnAfatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- NCT03311334terminatedA Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
- NCT02663518terminatedA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
- NCT03729245terminatedA Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- NCT03562507terminatedMulti-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
- NCT03437200terminatedCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- NCT03432741terminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- NCT04044651withdrawnLenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- NCT04057365terminatedStudy of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
- NCT04410445terminatedStudy to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- NCT04655157terminatedSafety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- NCT03519256terminatedA Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- NCT03606174terminatedA Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- NCT03970382suspendedA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
- NCT02978443terminatedA Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
- NCT04044430terminatedEncorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
- NCT03149120withdrawnStudy of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
- NCT04730349terminatedA Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
- NCT04500548withdrawnTesting the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- NCT04891718withdrawnCIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
- NCT04173325terminatedFeasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
- NCT03406715terminatedCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
- NCT03435640terminatedREVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
- NCT03781960terminatedAbemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
- NCT03495713terminatedLymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
- NCT03519308terminatedA Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
- NCT02712905terminatedAn Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- NCT04119336terminatedNivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
- NCT04272333terminatedIntratumoral Microdosing of Motolimod in HNSCC
- NCT03168464terminatedRadiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- NCT01940809terminatedIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
- NCT04159896terminatedESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
- NCT03444753terminatedAn Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
- NCT03121534terminatedIbrutinib, Nivolumab and Blinatumomab in Richter Transformation
- NCT03461952terminatedNivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
- NCT03662074terminatedSubsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
- NCT04955262withdrawnA CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- NCT03906526terminatedA Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- NCT03927248withdrawnPAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
- NCT03169777withdrawnQUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- NCT03169738withdrawnQUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- NCT03167177withdrawnQUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
- NCT03169764withdrawnQUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- NCT04758949withdrawnFL-101 in Surgically Resectable Non-Small Cell Lung Cancer
- NCT03251924terminatedA Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- NCT03655613terminatedAPL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
- NCT04069936terminatedMarrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
- NCT03425331terminatedBiomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
- NCT03420521terminatedNivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- NCT04258150terminatedIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- NCT04088500terminatedA Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
- NCT02954991terminatedPhase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
- NCT03903640terminatedOptune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
- NCT03663166terminatedRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
- NCT04430985withdrawnFOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
- NCT03220009withdrawnNivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
- NCT03952325terminatedTesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- NCT04434560terminatedNeoadjuvant Immunotherapy in Brain Metastases
- NCT02781506terminatedNivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
- NCT03646461terminatedTrial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
- NCT04361058withdrawnNivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
- NCT03879811withdrawnDetermining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
- NCT03307603withdrawnYttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
- NCT03656627terminatedNivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
- NCT03695250terminatedBMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
- NCT03693846terminatedNivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
- NCT03425461terminatedAnti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
- NCT04149275withdrawnCabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- NCT03138499terminatedA Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
- NCT05022394withdrawnSapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
- NCT02323126terminatedStudy of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
- NCT03071094terminatedA Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
- NCT03782064terminatedDendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
- NCT02959554terminatedStudy in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- NCT03347123terminatedA Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- NCT03430791terminatedTrial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
- NCT04042506withdrawnSBRT as a Vaccination for Metastatic Melanoma
- NCT03721679terminatedPoly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
- NCT02702492terminatedPAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
- NCT03631641terminatedNivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
- NCT02949843terminatedTargeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
- NCT02054520terminatedImmunotherapy Study for Patients With Stage IV Melanoma
- NCT03728465terminatedEvaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
- NCT03422094terminatedNeoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
- NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- NCT03526185terminatedA Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
- NCT03527264terminatedBrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
- NCT02831933terminatedTrial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
- NCT03283046withdrawnStudy of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- NCT03354962terminatedInduction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
- NCT03115801terminatedA Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
- NCT03572478terminatedRucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
- NCT04128020withdrawnAzacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
- NCT03259425terminatedNeoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
- NCT03824704terminatedA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
- NCT03655444terminatedAbemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
- NCT03597282terminatedA Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- NCT02595918terminatedNivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
- NCT02466568withdrawnStudy of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
- NCT03023904withdrawnNivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
- NCT03588936terminatedNivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
- NCT03050060terminatedImage Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- NCT03059147terminatedPhase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- NCT03815942terminatedVAccination in Early and ADvanced Prostate caNCEr
- NCT02985554terminatedPhase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
- NCT03707457terminatedBiomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
- NCT03599362terminatedStudy of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
- NCT04230330withdrawnNivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
- NCT03808168withdrawnNivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia
- NCT03724968terminatedNivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- NCT03511222terminatedVorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
- NCT03758729withdrawnPhase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
- NCT02341625terminatedA Study of BMS-986148 in Patients With Select Advanced Solid Tumors
- NCT02771626terminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
- NCT03100006terminatedPhase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- NCT03382912terminatedStudy of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
- NCT03767439withdrawnNivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- NCT03982121withdrawnStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- NCT03597009terminatedA Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
- NCT02750514terminatedAn Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
- NCT03634800terminatedRadiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
- NCT03565406terminatedA Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- NCT03539198terminatedStudy of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
- NCT04007588withdrawnA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- NCT03518320terminatedSafety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
- NCT03363776terminatedAn Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
- NCT03091491terminatedStudy of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
- NCT03301636terminatedA Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
- NCT02862535terminatedStudy to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT03048136withdrawnA Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
- NCT03302247terminatedDepletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
- NCT03026166terminatedA Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- NCT03509584terminatedPhase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
- NCT03382886terminatedNivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
- NCT03726281withdrawnNivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
- NCT03390738withdrawnNivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
- NCT03342417terminatedCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
- NCT03075553terminatedNivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- NCT02253992terminatedAn Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
- NCT03041181terminatedSingle Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
- NCT03119428terminatedA Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
- NCT03558750terminatedRituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
- NCT03203304terminatedStereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- NCT03121417withdrawnNivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
- NCT02892734terminatedIpilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- NCT02599649terminatedLirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
- NCT02768558terminatedCisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
- NCT03259516terminatedNivolumab With Chemotherapy in Refractory MDS
- NCT02834247terminatedA Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
- NCT03333746terminatedLenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- NCT02720484terminatedNivolumab in Treating Patients With Metastatic Adrenocortical Cancer
- NCT03371381terminatedAn Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
- NCT02302339terminatedA Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
- NCT03381118terminatedHaploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
- NCT02864316terminatedPhase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
- NCT02446860terminatedA Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
- NCT02819804terminatedNivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- NCT03351231terminatedAn Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
- NCT02846792terminatedNivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
- NCT02923531terminatedAddition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
- NCT02621515terminatedNivo/Ipi Combination Therapy in Symptomatic Brain Metastases
- NCT03348904terminatedNivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- NCT03106610terminatedTrial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
- NCT02723006terminatedStudy to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- NCT03326258withdrawnGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- NCT03342352withdrawnNivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- NCT03386838withdrawnAn Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
- NCT02421354terminatedNivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
- NCT03149159withdrawnInvestigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
- NCT02469701terminatedAdvanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
- NCT03023527terminatedNivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- NCT02967133terminatedA Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
- NCT02828124terminatedA Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
- NCT02423954terminatedStudy of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- NCT02991196terminatedAntibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
- NCT02639234withdrawnVigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
- NCT02924233withdrawnSym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
- NCT02648633terminatedStereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
- NCT02736123withdrawnNeoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
- NCT02472977terminatedSafety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
- NCT02950038withdrawnStudy of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
- NCT02962804withdrawnCombination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
- NCT02124850terminatedA Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
- NCT02400385withdrawnA Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
- NCT02357732withdrawnStudy of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
All Nivolumab trials (1624)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05732389 | RESET-R | Immunotherapy in Patients With Early dMMR Rectal Cancer | P2 | recruiting | 39 | Odense University Hospital | Feb 2023 |
| NCT06639607 | PRiME II | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma | P1/P2 | recruiting | 68 | Washington University School of Medicine | Jun 2026 |
| NCT04995003 | CAR | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | P1 | recruiting | 25 | Baylor College of Medicine | Dec 2021 |
| NCT07369791 | NOBLE | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. | P2 | not yet recruiting | 76 | National Health Research Institutes, Taiwan | May 2026 |
| NCT03544736 | INEC | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | P1/P2 | active not recruiting | 30 | Oslo University Hospital | Apr 2018 |
| NCT06999980 | Neo IRENIE | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | P2 | recruiting | 494 | Melanoma Institute Australia | Feb 2026 |
| NCT05352828 | ACTION | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | P1 | active not recruiting | 15 | Tessa Therapeutics | Jul 2022 |
| NCT04134325 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | Early P1 | active not recruiting | 10 | UNC Lineberger Comprehensive Cancer Center | Sep 2019 | |
| NCT04044859 | SURPASS | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | P1 | active not recruiting | 120 | USWM CT, LLC | Aug 2019 |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | P3 | recruiting | 400 | Boehringer Ingelheim | Jan 2026 | |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | P2 | recruiting | 20 | Melanoma Institute Australia | Jun 2024 | |
| NCT05418972 | Neo ReNi II | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma | P2 | active not recruiting | 20 | Melanoma Institute Australia | Aug 2023 |
| NCT07541170 | KRASCENDO 3 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) | P3 | not yet recruiting | 400 | Hoffmann-La Roche | Sep 2026 |
| NCT07403877 | TORCH-OPTIMA | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer | P2 | not yet recruiting | 114 | Fudan University | Feb 2026 |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | P3 | recruiting | 400 | Replimune, Inc. | Jul 2024 | |
| NCT06151236 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | P2 | recruiting | 20 | Melanoma Institute Australia | Mar 2024 | |
| NCT06240143 | MARIANE | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | P1/P2 | recruiting | 96 | The Netherlands Cancer Institute | Mar 2024 |
| NCT04248569 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | P1 | recruiting | 56 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Apr 2020 | |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | P3 | recruiting | 718 | SWOG Cancer Research Network | Jun 2026 | |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | P3 | recruiting | 450 | Merck Sharp & Dohme LLC | Mar 2026 | |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | P1 | not yet recruiting | 18 | M.D. Anderson Cancer Center | Aug 2026 | |
| NCT07230613 | NEOREM-NEO-1 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | P2 | recruiting | 50 | UNICANCER | Jan 2026 |
| NCT07514767 | NOCANO | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma | P2 | not yet recruiting | 60 | Prof. Lars Olaf Cardell | May 2026 |
| NCT06488482 | Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma | P3 | recruiting | 1,792 | Uppsala University | Dec 2024 | |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | P2 | recruiting | 18 | Mayo Clinic | Apr 2026 | |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | P3 | recruiting | 560 | Regeneron Pharmaceuticals | Sep 2024 | |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | P2/P3 | active not recruiting | 600 | National Cancer Institute (NCI) | Nov 2015 | |
| NCT07319195 | WINIT-BC | Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC) | Early P1 | recruiting | 32 | Jennifer Zhang | Apr 2026 |
| NCT06745076 | Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma | P2 | recruiting | 125 | University of Washington | Mar 2025 | |
| NCT03815890 | BELLINI | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | P2 | recruiting | 80 | The Netherlands Cancer Institute | Oct 2019 |
| NCT07551583 | Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | P2 | not yet recruiting | 15 | M.D. Anderson Cancer Center | Oct 2026 | |
| NCT07338981 | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | P3 | not yet recruiting | 142 | Guliz Ozgun | Apr 2026 | |
| NCT07031765 | Peds CHAMP1ON | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma | P1 | active not recruiting | 12 | University of Florida | Jul 2025 |
| NCT04503694 | REGINA | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer | P2 | active not recruiting | 72 | Jules Bordet Institute | Mar 2021 |
| NCT03769155 | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | P1 | active not recruiting | 41 | Emory University | Dec 2018 | |
| NCT07221149 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | P2/P3 | recruiting | 690 | Bristol-Myers Squibb | Mar 2026 | |
| NCT07092670 | MELAFERT | MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. | — | recruiting | 270 | Intergruppo Melanoma Italiano | Aug 2025 |
| NCT06683755 | TRINITY | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | P1/P2 | not yet recruiting | 30 | M.D. Anderson Cancer Center | May 2025 |
| NCT06561386 | RELATIVITY1093 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | P3 | recruiting | 1,000 | Bristol-Myers Squibb | Oct 2024 |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | P2 | recruiting | 57 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2018 | |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | P2 | recruiting | 81 | National Cancer Institute (NCI) | Jun 2022 | |
| NCT07000149 | eVOLVE-RCC02 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | P3 | active not recruiting | 1,116 | AstraZeneca | Jul 2025 |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | P2/P3 | recruiting | 840 | Pfizer | May 2026 | |
| NCT07355205 | FLINN | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | P2 | not yet recruiting | 26 | Washington University School of Medicine | Jun 2026 |
| NCT03686124 | ACTengine | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | P1/P2 | recruiting | 375 | Immatics US, Inc. | May 2019 |
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | P2 | not yet recruiting | 260 | Bristol-Myers Squibb | Jul 2026 | |
| NCT06364631 | CARE1 | CARE1 Pragmatic Clinical Trial | P3 | recruiting | 1,250 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2024 |
| NCT06794775 | SWE-NEO | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | P3 | recruiting | 128 | Hildur Helgadottir | Jul 2025 |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | P1 | recruiting | 99 | Mayo Clinic | Apr 2017 | |
| NCT03026140 | NICHE | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | P2 | recruiting | 353 | The Netherlands Cancer Institute | Mar 2017 |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | P1/P2 | recruiting | 361 | ModernaTX, Inc. | Sep 2022 | |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | P1 | recruiting | 40 | Memgen, Inc. | Apr 2022 | |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | withdrawn | 0 | Northwestern University | Mar 2024 | |
| NCT07328087 | COLONYVAQ™-CRC | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer | Early P1 | recruiting | 12 | Biogenea Pharmaceuticals Ltd. | Feb 2026 |
| NCT07293351 | RCC | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | P1/P2 | recruiting | 254 | Bristol-Myers Squibb | Mar 2026 |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | — | recruiting | 20 | John Kirkwood | Nov 2025 | |
| NCT06743126 | SUPRAME | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | recruiting | 360 | Immatics US, Inc. | Jan 2025 |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | P2/P3 | recruiting | 280 | Replimune, Inc. | Dec 2024 | |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | P3 | recruiting | 2,130 | AstraZeneca | Feb 2026 | |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | P2 | recruiting | 131 | CatalYm GmbH | Oct 2025 | |
| NCT07219459 | GDFATHERHCC01 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure | P2 | recruiting | 104 | CatalYm GmbH | Mar 2026 |
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | P2 | active not recruiting | 40 | National Cancer Institute (NCI) | Aug 2022 | |
| NCT06646276 | TIGOS | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | P3 | recruiting | 530 | Bristol-Myers Squibb | Feb 2025 |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | P1/P2 | enrolling by invitation | 22 | St. Petersburg State Pavlov Medical University | Sep 2024 | |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | P1/P2 | recruiting | 55 | University of Michigan Rogel Cancer Center | Aug 2025 | |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | P1 | recruiting | 18 | Washington University School of Medicine | Jan 2026 | |
| NCT03886311 | TNT | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | P2 | recruiting | 200 | Sarcoma Oncology Research Center, LLC | May 2019 |
| NCT03138161 | SAINT | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | P1/P2 | recruiting | 250 | Sarcoma Oncology Research Center, LLC | Apr 2017 |
| NCT07061379 | PROMOTING | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen | — | recruiting | 144 | IRCCS San Raffaele | Jul 2025 |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | P3 | active not recruiting | 819 | National Cancer Institute (NCI) | Apr 2017 | |
| NCT06816927 | GIANT | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab | P2 | recruiting | 92 | Duke University | Nov 2025 |
| NCT03258567 | EBV | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | P2 | recruiting | 40 | National Cancer Institute (NCI) | Apr 2018 |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | P4 | recruiting | 90 | NYU Langone Health | Apr 2026 | |
| NCT07460765 | HNSCC | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | P1 | not yet recruiting | 40 | Vanderbilt-Ingram Cancer Center | Apr 2026 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | P3 | recruiting | 1,875 | National Cancer Institute (NCI) | May 2023 | |
| NCT04564157 | NADIM-ADJUVANT | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | P3 | active not recruiting | 210 | Fundación GECP | Jan 2021 |
| NCT07210632 | HGG | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | Early P1 | recruiting | 38 | Eben Rosenthal | Mar 2026 |
| NCT07404332 | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | P1 | recruiting | 35 | Mohammed Milhem | Feb 2026 | |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | P2/P3 | recruiting | 135 | Linnaeus Therapeutics, Inc. | Aug 2025 | |
| NCT02813135 | ESMART | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | recruiting | 472 | Gustave Roussy, Cancer Campus, Grand Paris | Aug 2016 |
| NCT03383458 | CheckMate 9DX | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | P3 | active not recruiting | 545 | Bristol-Myers Squibb | Apr 2018 |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | P1/P2 | recruiting | 416 | Bristol-Myers Squibb | Feb 2025 | |
| NCT07281924 | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis | P1/P2 | recruiting | 15 | University of Wisconsin, Madison | Jun 2026 | |
| NCT07529873 | N'FORCE | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma | P2 | not yet recruiting | 131 | Groupe Oncologie Radiotherapie Tete et Cou | May 2026 |
| NCT06963905 | SIMONE | Saci Nivo Rela for TNBC | P1/P2 | recruiting | 60 | Yale University | Dec 2025 |
| NCT07050043 | LEDANG | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC | P3 | recruiting | 123 | Dr Arvindran A/L Alaga | May 2025 |
| NCT06715241 | COLIBRI-2 | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS | P2 | active not recruiting | 77 | ARCAGY/ GINECO GROUP | Dec 2024 |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | P2 | active not recruiting | 40 | ImmunityBio, Inc. | Dec 2018 | |
| NCT03522246 | ATHENA | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | P3 | active not recruiting | 1,097 | pharmaand GmbH | May 2018 |
| NCT03470922 | RELATIVITY-047 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | P2/P3 | active not recruiting | 714 | Bristol-Myers Squibb | Apr 2018 |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | P2/P3 | suspended | 427 | National Cancer Institute (NCI) | Oct 2022 | |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | P1 | withdrawn | 0 | Jonsson Comprehensive Cancer Center | Dec 2024 | |
| NCT07188896 | RCC | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | recruiting | 120 | Brian Rini | Apr 2026 |
| NCT07223424 | PSI-Immune | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | P2 | recruiting | 880 | Diwakar Davar | Nov 2025 |
| NCT05629546 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | P1 | recruiting | 33 | Washington University School of Medicine | Nov 2024 | |
| NCT04848116 | Spark2 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca | P2 | active not recruiting | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Apr 2021 |
| NCT06926790 | GALAXY 3 | Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) | P2 | recruiting | 69 | The First Affiliated Hospital of Guangzhou Medical University | Feb 2025 |
| NCT06487156 | FINN | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | active not recruiting | 404 | Bristol-Myers Squibb | Oct 2023 |
| NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | P2 | recruiting | 83 | St. Petersburg State Pavlov Medical University | Jan 2024 | |
| NCT06169956 | NENI | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany | — | recruiting | 400 | Bristol-Myers Squibb | Nov 2023 |
| NCT04637594 | IMAGINE | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | P3 | active not recruiting | 3 | Alliance for Clinical Trials in Oncology | May 2022 |
| NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | P1 | active not recruiting | 10 | Dana-Farber Cancer Institute | Jan 2022 | |
| NCT04462406 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | P2 | active not recruiting | 150 | ECOG-ACRIN Cancer Research Group | Feb 2021 | |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | P2/P3 | recruiting | 992 | National Cancer Institute (NCI) | Feb 2024 | |
| NCT07430202 | FLC | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | P1 | not yet recruiting | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 2026 |
| NCT06365619 | NeoRelapse | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | P2 | recruiting | 25 | University of Utah | Jun 2026 |
| NCT07432295 | GIVA-2 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | P2 | recruiting | 180 | I-Mab Biopharma US Limited | Feb 2026 |
| NCT05909618 | 14 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases | P2 | recruiting | 33 | Sheba Medical Center | Jul 2023 |
| NCT07011550 | Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer | P2 | suspended | 7 | M.D. Anderson Cancer Center | Aug 2025 | |
| NCT07013565 | ACCELERATE | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL | P2 | recruiting | 20 | New York Medical College | Aug 2025 |
| NCT05176483 | STELLAR-002 | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | P1 | recruiting | 1,314 | Exelixis | Dec 2021 |
| NCT01703949 | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | P2 | active not recruiting | 28 | University of Washington | Mar 2013 | |
| NCT06889493 | NEC | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | P1 | recruiting | 36 | Peter Hosein, MD | May 2025 |
| NCT04658147 | HCC | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | P1 | active not recruiting | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2021 |
| NCT05500092 | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer | P2 | active not recruiting | 17 | Montefiore Medical Center | Jan 2023 | |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | P3 | recruiting | 1,100 | Alliance for Clinical Trials in Oncology | Dec 2024 | |
| NCT05802056 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | P1 | recruiting | 15 | Mayo Clinic | Nov 2023 | |
| NCT03999749 | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | active not recruiting | 71 | NYU Langone Health | Jun 2019 | |
| NCT06800339 | NEORADJUVANT | A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer | P1 | recruiting | 18 | University of Maryland, Baltimore | Apr 2025 |
| NCT06275360 | RIVAL | Repositioning Immunotherapy in VetArans With Lung Cancer | P2 | recruiting | 25 | VA Office of Research and Development | Mar 2024 |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | P1/P2 | recruiting | 434 | Vivace Therapeutics, Inc | Mar 2021 | |
| NCT06712927 | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | P2 | recruiting | 60 | Stanford University | Aug 2025 | |
| NCT06319196 | ClearMe | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | P2 | recruiting | 54 | University Health Network, Toronto | Aug 2026 |
| NCT07546812 | GS-1811 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas | P2 | recruiting | 120 | Gilead Sciences | May 2026 |
| NCT07398937 | ECTOP-1036 | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC | P2 | recruiting | 116 | Fudan University | Feb 2026 |
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT05795244 | NIVEC | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | P2 | recruiting | 30 | Yonsei University | Oct 2023 |
| NCT05655312 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | P1/P2 | recruiting | 300 | Perspective Therapeutics | Jun 2023 | |
| NCT04283890 | CHOPIN | PHP and Immunotherapy in Metastasized UM | P1/P2 | active not recruiting | 83 | Leiden University Medical Center | Dec 2019 |
| NCT03685890 | NivoILP | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | P1/P2 | recruiting | 74 | Vastra Gotaland Region | Apr 2019 |
| NCT05652673 | IPI-NIVO | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | N/A | recruiting | 80 | Erasmus Medical Center | Feb 2023 |
| NCT07401875 | SHARK | A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | P1 | recruiting | 35 | M.D. Anderson Cancer Center | Mar 2026 |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | P2 | recruiting | 29 | H. Lee Moffitt Cancer Center and Research Institute | Sep 2020 | |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | P2 | active not recruiting | 29 | Baruch Brenner | Apr 2019 | |
| NCT07174453 | Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies | P3 | recruiting | 192 | University of Kansas Medical Center | Oct 2025 | |
| NCT07563738 | TEADCO | A 2-part Phase 1/2 Open-label Trial on ODM-212 | P1/P2 | recruiting | 229 | Orion Corporation, Orion Pharma | Mar 2026 |
| NCT05633667 | VELOCITY-Lung | Study of Novel Treatment Combinations in Patients With Lung Cancer | P2 | active not recruiting | 192 | Gilead Sciences | Mar 2023 |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | recruiting | 50 | Emory University | Jul 2024 | |
| NCT06572722 | ECTOP-1030 | Perioperative Immunotherapy for NSCLC (ECTOP-1030) | P2 | withdrawn | 0 | Fudan University | Sep 2024 |
| NCT06519682 | CAYA | A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) | N/A | recruiting | 20 | Daniel Morgenstern | Dec 2024 |
| NCT03340129 | ABC-X | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | P2 | recruiting | 218 | Melanoma Institute Australia | Aug 2019 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | recruiting | 1,500 | Bristol-Myers Squibb | Aug 2019 | |
| NCT06463665 | VIRO-25 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | P2 | recruiting | 142 | Genelux Corporation | Sep 2024 |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | P1/P2 | recruiting | 27 | Ann & Robert H Lurie Children's Hospital of Chicago | Apr 2025 | |
| NCT06794229 | EXPLORE-RCC | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | P2 | recruiting | 69 | Qian Qin | Oct 2025 |
| NCT06561087 | Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions | P2 | recruiting | 45 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT07459543 | FDC | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India | P4 | not yet recruiting | 30 | Bristol-Myers Squibb | Nov 2026 |
| NCT07176975 | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers | P1 | not yet recruiting | 46 | Boehringer Ingelheim | Aug 2027 | |
| NCT06681298 | A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab | P2 | active not recruiting | 36 | xiaohua li | May 2024 | |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | P1 | recruiting | 60 | Memorial Sloan Kettering Cancer Center | Apr 2026 | |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | P2 | recruiting | 156 | National Cancer Institute (NCI) | Jul 2024 | |
| NCT06253611 | BIG | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | P2 | recruiting | 120 | GERCOR - Multidisciplinary Oncology Cooperative Group | Apr 2024 |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | P1 | recruiting | 42 | Washington University School of Medicine | Jun 2023 | |
| NCT05148546 | NESCIO | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | P2 | active not recruiting | 69 | The Netherlands Cancer Institute | Apr 2022 |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | P1 | active not recruiting | 22 | Dana-Farber Cancer Institute | Nov 2020 | |
| NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer | P1/P2 | recruiting | 240 | Bristol-Myers Squibb | Feb 2026 | |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | P1 | not yet recruiting | 16 | M.D. Anderson Cancer Center | Mar 2026 | |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | P1 | not yet recruiting | 15 | Inge Marie Svane | May 2026 | |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | P3 | recruiting | 100 | National Research Center for Hematology, Russia | Apr 2022 | |
| NCT03080974 | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | P2 | recruiting | 10 | University of Louisville | Aug 2017 | |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | P2/P3 | not yet recruiting | 374 | National Cancer Institute (NCI) | Dec 2026 | |
| NCT03465592 | HLA | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | P1/P2 | recruiting | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2018 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | recruiting | 226 | NRG Oncology | Feb 2026 | |
| NCT06983210 | GRAPE | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | P2 | recruiting | 43 | Nagoya University | May 2025 |
| NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | P3 | recruiting | 632 | mAbxience Research S.L. | Dec 2025 | |
| NCT06823479 | MATISSE 2 | Towards Cure Via Only Ultra-short ICB in CSCC | P2 | recruiting | 41 | The Netherlands Cancer Institute | May 2025 |
| NCT07233668 | IVE in mRCC | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC | N/A | not yet recruiting | 172 | Seoul National University Hospital | Dec 2025 |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | P1/P2 | active not recruiting | 49 | Susan Chi, MD | Aug 2023 | |
| NCT04551430 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | P2 | active not recruiting | 105 | Washington University School of Medicine | Jan 2021 | |
| NCT07028125 | CANIQOL | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma | P4 | recruiting | 83 | Centre Francois Baclesse | Oct 2025 |
| NCT06984146 | Nivo40-AVD for Advanced Classic Hodgkin Lymphoma | P2 | recruiting | 54 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Apr 2025 | |
| NCT07084610 | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | P2 | recruiting | 30 | Hospital das Clínicas de Ribeirão Preto | Feb 2025 | |
| NCT05187429 | NIVO-LD | Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy | P1/P2 | recruiting | 42 | University of Melbourne | Jan 2023 |
| NCT06250335 | ICB | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | P2 | active not recruiting | 4 | M.D. Anderson Cancer Center | Mar 2024 |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | P1/P2 | recruiting | 413 | Bristol-Myers Squibb | Feb 2025 | |
| NCT07527858 | GS-1811 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | P2 | recruiting | 170 | Gilead Sciences | May 2026 |
| NCT06863311 | EXACT | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | P2 | recruiting | 70 | Karie Runcie | Mar 2026 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | recruiting | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2025 | |
| NCT07209059 | FINISH-HL | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | P2 | recruiting | 30 | National Research Center for Hematology, Russia | Jul 2025 |
| NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | P2 | active not recruiting | 1 | Wake Forest University Health Sciences | Feb 2025 | |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | P1/P2 | recruiting | 126 | 7 Hills Pharma, LLC | Aug 2024 | |
| NCT06031233 | MINUTE | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | recruiting | 776 | Isala | Sep 2023 |
| NCT04989946 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | P1/P2 | recruiting | 60 | University of Wisconsin, Madison | Dec 2021 | |
| NCT03767348 | IGNYTE | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | P2 | active not recruiting | 340 | Replimune, Inc. | Sep 2017 |
| NCT02693535 | TAPUR | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | recruiting | 4,200 | American Society of Clinical Oncology | Mar 2016 |
| NCT02374242 | ABC | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | P2 | active not recruiting | 76 | Melanoma Institute Australia | Nov 2014 |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | P2 | active not recruiting | 24 | Providence Health & Services | Oct 2020 | |
| NCT04949113 | NADINA | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | P3 | active not recruiting | 423 | The Netherlands Cancer Institute | Jul 2021 |
| NCT06708949 | RCC | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | recruiting | 15 | M.D. Anderson Cancer Center | Mar 2025 |
| NCT07226856 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | P2 | recruiting | 43 | Mayo Clinic | Dec 2025 | |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | P2 | recruiting | 30 | University Medical Center Groningen | Mar 2025 | |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | P2 | recruiting | 90 | H. Lee Moffitt Cancer Center and Research Institute | May 2024 | |
| NCT05723055 | NAHL | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | P2 | active not recruiting | 9 | University of Utah | May 2023 |
| NCT05317000 | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | P2 | recruiting | 50 | Barbara Burtness | Mar 2023 | |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | P2 | active not recruiting | 81 | Fox Chase Cancer Center | Dec 2020 | |
| NCT03838159 | NADIMII | NADIM II: Neo-Adjuvant Immunotherapy | P2 | active not recruiting | 90 | Fundación GECP | May 2019 |
| NCT06097728 | eVOLVE-Meso | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | P3 | active not recruiting | 861 | AstraZeneca | Nov 2023 |
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | P2 | not yet recruiting | 108 | Intergroupe Francophone de Cancerologie Thoracique | May 2026 | |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | P3 | recruiting | 382 | Alliance for Clinical Trials in Oncology | Jan 2023 | |
| NCT03907852 | TC-210 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | P1/P2 | active not recruiting | 57 | TCR2 Therapeutics | Apr 2019 |
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | P2 | recruiting | 48 | M.D. Anderson Cancer Center | Jan 2024 | |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | P1 | recruiting | 25 | Fred Hutchinson Cancer Center | Jun 2022 | |
| NCT06946797 | CheckMate-1533 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | P2 | active not recruiting | 76 | Bristol-Myers Squibb | Sep 2025 |
| NCT06245356 | TRIFLUOX-DP | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | P2 | recruiting | 73 | UNICANCER | Mar 2025 |
| NCT07100704 | Orion | Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab | P2 | recruiting | 14 | National Cancer Center Hospital East | Apr 2025 |
| NCT07152678 | BRIGHT-ESCC | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma | P2 | recruiting | 60 | National Taiwan University Hospital | Sep 2025 |
| NCT04884282 | COMBI-TED | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) | P2 | active not recruiting | 105 | Fondazione Ricerca Traslazionale | Oct 2021 |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | P1 | active not recruiting | 11 | Dana-Farber Cancer Institute | Nov 2020 | |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | P2 | not yet recruiting | 230 | Zhejiang Haichang Biotech Co., Ltd. | Jun 2026 | |
| NCT07147101 | HCC-IM-1 | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | recruiting | 150 | Fudan University | Sep 2025 |
| NCT06490536 | The Sagittarius Trial | P3 | recruiting | 700 | IFOM ETS - The AIRC Institute of Molecular Oncology | Oct 2024 | |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | P1 | suspended | 66 | National Cancer Institute (NCI) | Feb 2022 | |
| NCT06504615 | METAGIO | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France | — | active not recruiting | 208 | Bristol-Myers Squibb | Dec 2024 |
| NCT04709276 | CHAMP | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | P2 | active not recruiting | 41 | Andrew J. Armstrong, MD | Jun 2021 |
| NCT07128680 | EXL01 | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | P1 | recruiting | 33 | City of Hope Medical Center | Mar 2026 |
| NCT06237920 | TURANDORELA | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | P2 | recruiting | 90 | The Netherlands Cancer Institute | Feb 2024 |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | Early P1 | enrolling by invitation | 18 | Brigham and Women's Hospital | Jun 2024 | |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | P2 | recruiting | 30 | M.D. Anderson Cancer Center | Feb 2023 | |
| NCT06908993 | COMET | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | P3 | recruiting | 133 | Intergroupe Francophone de Cancerologie Thoracique | Dec 2025 |
| NCT06325683 | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | P2 | suspended | 184 | National Cancer Institute (NCI) | Nov 2024 | |
| NCT05934331 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study | P2 | recruiting | 276 | LaNova Medicines Zhejiang Co., Ltd. | Jul 2023 | |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | P1/P2 | recruiting | 33 | West China Hospital | Feb 2026 | |
| NCT05678673 | STELLAR-304 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | P3 | active not recruiting | 317 | Exelixis | Jan 2023 |
| NCT04546399 | B-ALL | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | P2 | recruiting | 461 | National Cancer Institute (NCI) | Dec 2020 |
| NCT04323046 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | P1 | active not recruiting | 9 | Sabine Mueller, MD, PhD | Oct 2020 | |
| NCT03546686 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | P2 | active not recruiting | 51 | University of Texas Southwestern Medical Center | Nov 2019 | |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | P2 | active not recruiting | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 2019 | |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | P1/P2 | recruiting | 542 | Sanofi | Nov 2022 | |
| NCT05445609 | CMP-001 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | P2 | suspended | 10 | Emory University | Jun 2023 |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | P2 | suspended | 50 | National Cancer Institute (NCI) | Feb 2024 | |
| NCT05327686 | SAMURAI | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | P2 | recruiting | 240 | NRG Oncology | Feb 2023 |
| NCT03563729 | MEMBRAINS | Melanoma Metastasized to the Brain and Steroids | P2 | recruiting | 80 | Inge Marie Svane | Jun 2018 |
| NCT05684276 | DUMAS | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors | P2 | active not recruiting | 22 | Fundación GECP | May 2023 |
| NCT07213557 | Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy | P2 | recruiting | 84 | National Cancer Institute, Naples | Mar 2026 | |
| NCT06624475 | NEON | Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | P2 | recruiting | 30 | University of California, San Diego | Aug 2025 |
| NCT06638931 | ANTARES | Agnostic Therapy in Rare Solid Tumors | P2 | recruiting | 28 | Instituto do Cancer do Estado de São Paulo | Jul 2024 |
| NCT05845450 | UNICORN | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | P2 | recruiting | 197 | Gruppo Oncologico del Nord-Ovest | May 2023 |
| NCT06346197 | CIME | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | P3 | recruiting | 132 | Centre Leon Berard | Dec 2025 |
| NCT07017816 | JACOB | A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. | Early P1 | recruiting | 18 | Children's National Research Institute | Dec 2025 |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy | P1/P2 | withdrawn | 0 | University of Pittsburgh | Jun 2025 | |
| NCT06934057 | CABOLD | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | P4 | recruiting | 50 | Gustave Roussy, Cancer Campus, Grand Paris | May 2025 |
| NCT04730544 | NIPISAFE | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | P2 | active not recruiting | 96 | GERCOR - Multidisciplinary Oncology Cooperative Group | May 2021 |
| NCT07542262 | NIVO402025 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers | P2 | enrolling by invitation | 128 | Blokhin's Russian Cancer Research Center | Jun 2025 |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | P2 | recruiting | 112 | Hospital Israelita Albert Einstein | Aug 2022 | |
| NCT07422779 | MAK | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | N/A | recruiting | 100 | Institute of Oncology Ljubljana | Mar 2022 |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | P1/P2 | active not recruiting | 56 | Sarcoma Oncology Research Center, LLC | Oct 2019 | |
| NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | P1 | recruiting | 60 | Myeloid Therapeutics | Nov 2025 | |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | P1 | recruiting | 300 | National Cancer Institute (NCI) | Jul 2019 | |
| NCT05504252 | METIMMOX-2 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin | P2 | active not recruiting | 80 | University Hospital, Akershus | Oct 2022 |
| NCT07394062 | ALCG-01 | Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | recruiting | 400 | Gazi University | Feb 2026 |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | recruiting | 105 | NYU Langone Health | Feb 2023 | |
| NCT04322955 | Cyto-KIK | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | P2 | active not recruiting | 38 | Mark Stein | Jun 2020 |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | P1/P2 | recruiting | 15 | M.D. Anderson Cancer Center | Jan 2021 | |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | P1 | active not recruiting | 14 | Jonsson Comprehensive Cancer Center | Oct 2020 | |
| NCT04309409 | NivoMela | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | P3 | active not recruiting | 374 | University Hospital, Essen | Jul 2020 |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | P3 | active not recruiting | 633 | Amgen | Nov 2023 | |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | P3 | active not recruiting | 1,175 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | P2/P3 | active not recruiting | 420 | IDEAYA Biosciences | Oct 2023 | |
| NCT06019130 | NPC-Nivo | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | P2 | recruiting | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Jan 2023 |
| NCT06731270 | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | P2 | recruiting | 20 | Emory University | Apr 2025 | |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | P2 | recruiting | 37 | Massachusetts General Hospital | Sep 2023 | |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | P1 | recruiting | 15 | University of Hawaii | Apr 2026 | |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | P1 | not yet recruiting | 15 | Kyunghee Burkitt, DO, PhD | Jan 2026 | |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | P2 | recruiting | 99 | Emory University | Oct 2025 | |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | P2 | recruiting | 97 | Shanghai Cancer Hospital, China | Mar 2025 | |
| NCT06724159 | SOGUG-PRINCIS | Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. | — | recruiting | 500 | Spanish Oncology Genito-Urinary Group | Dec 2024 |
| NCT05681780 | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | P1 | recruiting | 20 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2023 | |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | P2 | recruiting | 20 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 49 | Toray Industries, Inc | Jul 2022 | |
| NCT05034536 | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | P2 | active not recruiting | 36 | Massachusetts General Hospital | Feb 2022 | |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | P1 | recruiting | 36 | Carlo Contreras | Oct 2021 | |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | P2 | active not recruiting | 35 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | P1 | recruiting | 330 | I-Mab Biopharma US Limited | Jun 2021 | |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | P2 | active not recruiting | 15 | M.D. Anderson Cancer Center | Feb 2021 | |
| NCT04150640 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | P2 | recruiting | 52 | University of Wisconsin, Madison | Jul 2020 | |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | P2 | active not recruiting | 60 | Xiangya Hospital of Central South University | Jul 2020 | |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | P3 | recruiting | 400 | Massachusetts General Hospital | Apr 2020 | |
| NCT04013542 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | P1 | active not recruiting | 21 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT03610711 | REACTION | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | P1/P2 | active not recruiting | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2019 |
| NCT03646617 | RadVax | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | P2 | recruiting | 54 | Abramson Cancer Center at Penn Medicine | Nov 2018 |
| NCT03600350 | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | P2 | active not recruiting | 19 | University of Wisconsin, Madison | Sep 2018 | |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | P3 | active not recruiting | 344 | National Cancer Institute (NCI) | Jul 2018 | |
| NCT03134118 | NIVOTHYM | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | P2 | active not recruiting | 55 | European Organisation for Research and Treatment of Cancer - EORTC | Apr 2018 |
| NCT03223155 | COSINR | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer | P1 | active not recruiting | 78 | University of Chicago | Sep 2017 |
| NCT02845323 | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder | P2 | active not recruiting | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2017 | |
| NCT04204837 | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | P2 | recruiting | 61 | Salzburger Landeskliniken | Mar 2017 | |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | P1/P2 | active not recruiting | 80 | M.D. Anderson Cancer Center | Dec 2016 | |
| NCT02925234 | DRUP | The Drug Rediscovery Protocol (DRUP Trial) | P2 | recruiting | 1,550 | The Netherlands Cancer Institute | Aug 2016 |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | P1/P2 | active not recruiting | 38 | M.D. Anderson Cancer Center | Jun 2019 | |
| NCT03661320 | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer | P3 | active not recruiting | 855 | Bristol-Myers Squibb | Nov 2018 | |
| NCT05012254 | NIVIPI-Brain | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | P2 | active not recruiting | 71 | Fundación GECP | Nov 2021 |
| NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | P1/P2 | active not recruiting | 51 | Roswell Park Cancer Institute | Dec 2016 | |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | P2 | active not recruiting | 52 | M.D. Anderson Cancer Center | Dec 2016 | |
| NCT05317858 | LIMITLESS | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | P3 | recruiting | 30 | InSightec | Aug 2022 |
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | P1 | recruiting | 58 | National Cancer Institute (NCI) | Dec 2021 | |
| NCT06274437 | A Study of BND-35 in Participants With Advanced Solid Tumors | P1 | recruiting | 280 | Biond Biologics | Jun 2024 | |
| NCT05901285 | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | P1 | recruiting | 48 | Vaxiion Therapeutics | Nov 2023 | |
| NCT05039073 | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | P2 | recruiting | 46 | Emory University | May 2022 | |
| NCT03690986 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | P1 | recruiting | 50 | Emory University | Nov 2018 | |
| NCT03406247 | ADJORL1 | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | P2 | recruiting | 140 | Gustave Roussy, Cancer Campus, Grand Paris | Feb 2018 |
| NCT05625399 | RELATIVITY-127 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | P3 | active not recruiting | 579 | Bristol-Myers Squibb | Mar 2023 |
| NCT06534983 | IMCODE004 | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) | P2 | recruiting | 62 | Hoffmann-La Roche | Dec 2024 |
| NCT05928806 | ARCITECT | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | P2 | suspended | 120 | Michael B. Atkins, MD | Sep 2023 |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | P2/P3 | recruiting | 224 | National Cancer Institute (NCI) | Jun 2024 | |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | P2 | recruiting | 33 | Aline Fusco Fares, MD | Oct 2023 | |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | P1/P2 | active not recruiting | 46 | H. Lee Moffitt Cancer Center and Research Institute | Apr 2021 | |
| NCT03307616 | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | P2 | active not recruiting | 32 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT03171025 | NEXT | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer | P2 | active not recruiting | 200 | University of Utah | Jul 2017 |
| NCT02259621 | NA_00092076 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | P2 | active not recruiting | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2014 |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | P1/P2 | recruiting | 100 | M.D. Anderson Cancer Center | Jun 2023 | |
| NCT04495010 | CheckMate 7UA | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | P2 | withdrawn | 0 | Bristol-Myers Squibb | Mar 2021 |
| NCT06112314 | PRISM-MEL-301 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | P3 | recruiting | 680 | Immunocore Ltd | Jun 2024 |
| NCT06764771 | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | P1 | recruiting | 437 | Bristol-Myers Squibb | Mar 2025 | |
| NCT06544655 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | P1 | active not recruiting | 213 | Bristol-Myers Squibb | Oct 2024 | |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | P2 | recruiting | 72 | Dan Zandberg | Sep 2020 | |
| NCT06364917 | DISCERN | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | P2 | recruiting | 24 | University of Alabama at Birmingham | May 2025 |
| NCT05310643 | NIPIRESCUE | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | P2 | recruiting | 30 | GERCOR - Multidisciplinary Oncology Cooperative Group | May 2022 |
| NCT05112549 | IT-PD1 | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) | P1 | recruiting | 46 | University Hospital Tuebingen | Oct 2021 |
| NCT03576417 | NIVOPOSTOP | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | P3 | active not recruiting | 680 | Groupe Oncologie Radiotherapie Tete et Cou | Oct 2018 |
| NCT02530463 | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome | P2 | active not recruiting | 99 | M.D. Anderson Cancer Center | Sep 2015 | |
| NCT05200988 | Indi-Blade | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC | P2 | active not recruiting | 50 | The Netherlands Cancer Institute | Mar 2022 |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Early P1 | recruiting | 12 | Fox Chase Cancer Center | Nov 2022 | |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | P2 | recruiting | 35 | University of California, Irvine | Aug 2020 | |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | P2 | active not recruiting | 68 | National Cancer Institute (NCI) | Sep 2017 | |
| NCT06377111 | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma | P1 | active not recruiting | 12 | University Health Network, Toronto | Jun 2024 | |
| NCT06101134 | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | P2 | active not recruiting | 100 | Bristol-Myers Squibb | Nov 2023 | |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | P1/P2 | recruiting | 134 | Neonc Technologies, Inc. | Nov 2023 | |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | P1/P2 | recruiting | 595 | Parabilis Medicines, Inc. | May 2023 | |
| NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | P1 | active not recruiting | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2017 | |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | P1 | active not recruiting | 145 | Nanobiotix | Jan 2019 | |
| NCT04387084 | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | P1 | active not recruiting | 10 | University of Southern California | Aug 2020 | |
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | P1 | active not recruiting | 42 | ModernaTX, Inc. | Mar 2025 | |
| NCT04745949 | PACIFIC | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | P2 | recruiting | 31 | M.D. Anderson Cancer Center | May 2021 |
| NCT06256328 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | P2 | active not recruiting | 226 | Ono Pharmaceutical Co., Ltd. | Jan 2024 | |
| NCT04741997 | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Early P1 | recruiting | 50 | H. Lee Moffitt Cancer Center and Research Institute | May 2021 | |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | P1/P2 | active not recruiting | 288 | BicycleTx Limited | Nov 2019 | |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | P1/P2 | recruiting | 54 | Veronika Bachanova | Sep 2018 | |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | P3 | active not recruiting | 461 | Bristol-Myers Squibb | Nov 2019 | |
| NCT05347212 | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | P2 | active not recruiting | 30 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies | P1 | withdrawn | 0 | Jeffrey Treiber | Jul 2024 | |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | P2 | recruiting | 54 | Vanderbilt-Ingram Cancer Center | Dec 2022 | |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | P1 | recruiting | 20 | University of California, Irvine | Jun 2025 | |
| NCT05153304 | Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | P1/P2 | withdrawn | 0 | University of California, San Diego | Jun 2024 | |
| NCT06015724 | DARANIVOVAX | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | P2 | recruiting | 54 | Georgetown University | Jan 2024 |
| NCT04835805 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | P1 | active not recruiting | 65 | Genentech, Inc. | May 2021 | |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | P2 | recruiting | 60 | National Cancer Centre, Singapore | Apr 2021 | |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | P2 | recruiting | 112 | SWOG Cancer Research Network | Jan 2021 | |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | P1/P2 | recruiting | 91 | University Hospital Heidelberg | May 2020 | |
| NCT03061539 | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | P2 | active not recruiting | 380 | University College, London | Feb 2018 | |
| NCT03259867 | TATE-PD1 | Combination of TATE and PD-1 Inhibitor in Liver Cancer | P2 | recruiting | 54 | Teclison Ltd. | Jul 2017 |
| NCT04099251 | CheckMate76K | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma | P3 | active not recruiting | 790 | Bristol-Myers Squibb | Oct 2019 |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | P1 | recruiting | 32 | National Cancer Institute (NCI) | Nov 2022 | |
| NCT05912244 | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | P2 | active not recruiting | 43 | Memorial Sloan Kettering Cancer Center | Jun 2023 | |
| NCT05788081 | TOP-FLOR | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. | P2 | active not recruiting | 40 | Olivia Newton-John Cancer Research Institute | Aug 2023 |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | P2 | active not recruiting | 86 | National Cancer Institute (NCI) | Jul 2022 | |
| NCT06931613 | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment | P2 | enrolling by invitation | 20 | St. Petersburg State Pavlov Medical University | Jun 2022 | |
| NCT04117087 | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | P1 | active not recruiting | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2020 | |
| NCT04047706 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | P1 | active not recruiting | 18 | Northwestern University | Aug 2019 | |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | P1 | recruiting | 75 | M.D. Anderson Cancer Center | May 2018 | |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | P2 | active not recruiting | 798 | National Cancer Institute (NCI) | Jan 2017 | |
| NCT06554613 | Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC | P2 | recruiting | 156 | Second Affiliated Hospital of Nanchang University | Jul 2024 | |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | P2 | recruiting | 20 | Memorial Sloan Kettering Cancer Center | May 2022 | |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | P1 | recruiting | 50 | Yana Najjar | Nov 2021 | |
| NCT04957615 | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | P2 | active not recruiting | 16 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT03505320 | ILUSTRO | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | P2 | active not recruiting | 143 | Astellas Pharma Global Development, Inc. | Jun 2018 |
| NCT02632409 | CheckMate 274 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer | P3 | active not recruiting | 709 | Bristol-Myers Squibb | Mar 2016 |
| NCT04464759 | LIMIT | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | P1/P2 | active not recruiting | 41 | Ravi Amaravadi, MD | Oct 2020 |
| NCT04810078 | CheckMate-67T | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | P3 | active not recruiting | 681 | Bristol-Myers Squibb | May 2021 |
| NCT04317105 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | P1/P2 | active not recruiting | 54 | National Cancer Institute (NCI) | Jul 2020 | |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | P2 | active not recruiting | 36 | Fox Chase Cancer Center | Oct 2020 | |
| NCT03703050 | NIVO-ALCL | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) | P2 | active not recruiting | 45 | Gustave Roussy, Cancer Campus, Grand Paris | Jan 2019 |
| NCT03563248 | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | P2 | active not recruiting | 168 | Massachusetts General Hospital | Aug 2018 | |
| NCT03449108 | TNBC | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | P2 | active not recruiting | 30 | M.D. Anderson Cancer Center | Apr 2018 |
| NCT03104439 | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | P2 | active not recruiting | 84 | Massachusetts General Hospital | May 2017 | |
| NCT03143270 | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | Early P1 | active not recruiting | 20 | Memorial Sloan Kettering Cancer Center | Apr 2017 | |
| NCT03122522 | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | P2 | active not recruiting | 70 | Memorial Sloan Kettering Cancer Center | Apr 2017 | |
| NCT05715229 | G360-IIT | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | P2 | recruiting | 108 | Hackensack Meridian Health | Sep 2023 |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | P1 | active not recruiting | 33 | City of Hope Medical Center | Jan 2022 | |
| NCT05502315 | CANOPY | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | P2 | recruiting | 47 | Rana McKay, MD | Feb 2023 |
| NCT02393625 | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | P1 | active not recruiting | 57 | Novartis Pharmaceuticals | May 2015 | |
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | P1/P2 | active not recruiting | 98 | Fox Chase Cancer Center | Jun 2017 | |
| NCT04229459 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | P2 | active not recruiting | 12 | Baruch Brenner | Feb 2020 | |
| NCT05817903 | AxIn | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | P2 | recruiting | 118 | Consorzio Oncotech | Apr 2023 |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | P1 | recruiting | 47 | National Cancer Institute (NCI) | May 2021 | |
| NCT02785952 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | P3 | active not recruiting | 275 | SWOG Cancer Research Network | Dec 2015 | |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | P1 | enrolling by invitation | 34 | Andrew P. Groves | Jun 2025 | |
| NCT07523763 | NIVO1002024 | Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer | P2 | active not recruiting | 30 | Blokhin's Russian Cancer Research Center | Mar 2024 |
| NCT05310591 | CAPTiRALL | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | P1/P2 | recruiting | 26 | Assistance Publique - Hôpitaux de Paris | Mar 2023 |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | P2 | active not recruiting | 9 | Memorial Sloan Kettering Cancer Center | Feb 2022 | |
| NCT04444921 | EA2176 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | P3 | active not recruiting | 205 | National Cancer Institute (NCI) | Nov 2020 |
| NCT04078295 | E7389-LF | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | P1/P2 | active not recruiting | 125 | Eisai Co., Ltd. | Sep 2019 |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | P3 | active not recruiting | 339 | M.D. Anderson Cancer Center | Dec 2017 | |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | P1 | recruiting | 50 | Inimmune Corporation | Jul 2024 | |
| NCT05597800 | LUNGVIR | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | P2 | not yet recruiting | 105 | Universita di Verona | Feb 2023 |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | P2 | active not recruiting | 26 | National Cancer Institute (NCI) | May 2015 | |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | P3 | active not recruiting | 994 | National Cancer Institute (NCI) | Aug 2019 | |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | P2 | active not recruiting | 143 | National Cancer Institute (NCI) | May 2015 | |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | P1/P2 | active not recruiting | 38 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT04300244 | NIPU | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | P2 | active not recruiting | 118 | Åslaug Helland | May 2020 |
| NCT07485166 | Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases | — | active not recruiting | 810 | Brigham and Women's Hospital | Mar 2026 | |
| NCT05289193 | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | P2 | active not recruiting | 28 | Memorial Sloan Kettering Cancer Center | Mar 2022 | |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | P3 | active not recruiting | 437 | Bristol-Myers Squibb | Jun 2019 | |
| NCT03655002 | IRX-2 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | P1 | active not recruiting | 8 | City of Hope Medical Center | Feb 2019 |
| NCT04969887 | MOST-CIRCUIT | Combination Immunotherapy in Rare Cancers Under InvesTigation | P2 | active not recruiting | 240 | Olivia Newton-John Cancer Research Institute | Aug 2021 |
| NCT02817633 | AMBER | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | P1 | active not recruiting | 463 | Tesaro, Inc. | Jul 2016 |
| NCT05749900 | HERBOT | First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) | P1/P2 | recruiting | 44 | Yonsei University | May 2023 |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | P2 | recruiting | 111 | Fox Chase Cancer Center | Jan 2022 | |
| NCT04757363 | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | P2 | active not recruiting | 39 | Memorial Sloan Kettering Cancer Center | Feb 2021 | |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | P2 | recruiting | 314 | National Cancer Institute (NCI) | May 2019 | |
| NCT03789110 | NIMBUS | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | P2 | active not recruiting | 30 | Dana-Farber Cancer Institute | Mar 2019 |
| NCT03057795 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | P2 | active not recruiting | 62 | City of Hope Medical Center | Apr 2017 | |
| NCT04963283 | MSS | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | P2 | active not recruiting | 48 | University of Colorado, Denver | Jun 2021 |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | P1 | active not recruiting | 8 | National Cancer Institute (NCI) | Nov 2021 | |
| NCT05327270 | Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | P1 | active not recruiting | 18 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | recruiting | 25 | Vanderbilt-Ingram Cancer Center | May 2023 | |
| NCT07276373 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | P1/P2 | recruiting | 50 | Corcept Therapeutics | Jan 2026 | |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | P1/P2 | recruiting | 16 | National Cancer Institute (NCI) | Jul 2024 | |
| NCT05476796 | LOGICAN | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | P2 | recruiting | 118 | UNICANCER | Jun 2023 |
| NCT05280457 | TRINITY | HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy | P2 | active not recruiting | 21 | Yonsei University | Apr 2022 |
| NCT04831320 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | P2 | active not recruiting | 46 | Washington University School of Medicine | Sep 2021 | |
| NCT03816358 | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | P1 | active not recruiting | 74 | National Cancer Institute (NCI) | Dec 2019 | |
| NCT03937219 | COSMIC-313 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | P3 | active not recruiting | 855 | Exelixis | Jun 2019 |
| NCT03235245 | EBIN | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | P2 | active not recruiting | 271 | European Organisation for Research and Treatment of Cancer - EORTC | Oct 2018 |
| NCT03520491 | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | P2 | active not recruiting | 52 | Memorial Sloan Kettering Cancer Center | Apr 2018 | |
| NCT03297606 | CAPTUR | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | recruiting | 720 | Canadian Cancer Trials Group | Mar 2018 |
| NCT03033914 | B | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | P1/P2 | active not recruiting | 82 | Memorial Sloan Kettering Cancer Center | Jan 2017 |
| NCT02873962 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | P2 | active not recruiting | 72 | Dana-Farber Cancer Institute | Nov 2016 | |
| NCT05111626 | FORTITUDE-102 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. | P3 | active not recruiting | 515 | Amgen | Mar 2022 |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | P2 | active not recruiting | 90 | National Cancer Institute (NCI) | Nov 2020 | |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | P1 | active not recruiting | 31 | City of Hope Medical Center | Nov 2021 | |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | P2 | recruiting | 150 | National Cancer Institute (NCI) | Dec 2022 | |
| NCT03811015 | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | P3 | active not recruiting | 636 | National Cancer Institute (NCI) | Aug 2019 | |
| NCT06064097 | NPC | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | P2 | recruiting | 50 | National Cancer Institute (NCI) | Jun 2024 |
| NCT06265285 | CCBW | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | P2 | recruiting | 50 | Mayo Clinic | Apr 2024 |
| NCT05721846 | CheckVAC | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer | P1 | active not recruiting | 20 | Inna Chen, MD | May 2023 |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Early P1 | recruiting | 20 | Icahn School of Medicine at Mount Sinai | Feb 2023 | |
| NCT05234307 | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | P1 | recruiting | 30 | Dwight Owen | Nov 2022 | |
| NCT05257590 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | P2 | recruiting | 95 | TaiRx, Inc. | May 2022 | |
| NCT04751370 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | P2 | active not recruiting | 31 | National Cancer Institute (NCI) | Feb 2022 | |
| NCT05163041 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | P1/P2 | active not recruiting | 200 | BicycleTx Limited | Nov 2021 | |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | P3 | active not recruiting | 244 | National Cancer Institute (NCI) | Oct 2021 | |
| NCT04953104 | ARID1A and/or KDM6A Mutation and CXCL13 Expression | P2 | active not recruiting | 6 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT04674683 | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | P3 | active not recruiting | 450 | HUYABIO International, LLC. | Aug 2021 | |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | P1 | active not recruiting | 63 | Patrick Wen, MD | Feb 2021 | |
| NCT05745233 | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites | N/A | enrolling by invitation | 30 | China Medical University Hospital | Jan 2021 | |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | P2 | active not recruiting | 37 | National Cancer Institute (NCI) | Dec 2020 | |
| NCT04477343 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | P1 | recruiting | 20 | University of Rochester | Nov 2020 | |
| NCT04109729 | Rad2Nivo | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer | P1 | active not recruiting | 39 | University of Utah | Sep 2020 |
| NCT04310007 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | P2 | active not recruiting | 117 | National Cancer Institute (NCI) | Jul 2020 | |
| NCT04091750 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | P2 | active not recruiting | 14 | Georgetown University | Mar 2020 | |
| NCT04043195 | NSCLC | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | P1/P2 | active not recruiting | 30 | Hatim Husain | Aug 2019 |
| NCT05696548 | NAVIGATION | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | P2 | active not recruiting | 51 | National Cancer Center Hospital East | Jul 2019 |
| NCT03604991 | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | P2/P3 | suspended | 278 | National Cancer Institute (NCI) | May 2019 | |
| NCT03650894 | HER | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | P2 | active not recruiting | 30 | Providence Health & Services | Apr 2019 |
| NCT03347838 | Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers | P2 | active not recruiting | 19 | University of Colorado, Denver | Jan 2019 | |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | P2 | active not recruiting | 30 | David Bond, MD | Jan 2019 | |
| NCT03637543 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | P2 | active not recruiting | 29 | Beth Israel Deaconess Medical Center | Oct 2018 | |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | P1/P2 | active not recruiting | 44 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2018 | |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | Early P1 | active not recruiting | 14 | H. Lee Moffitt Cancer Center and Research Institute | Jun 2018 | |
| NCT03247712 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | P1/P2 | active not recruiting | 22 | Providence Health & Services | Jan 2018 | |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | P2 | active not recruiting | 100 | Dana-Farber Cancer Institute | Dec 2017 | |
| NCT03015896 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | P1/P2 | active not recruiting | 36 | David Bond, MD | Feb 2017 | |
| NCT02919683 | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | P2 | active not recruiting | 30 | Dana-Farber Cancer Institute | Nov 2016 | |
| NCT02595944 | ANVIL | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | P3 | active not recruiting | 903 | National Cancer Institute (NCI) | Jul 2016 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | P2 | active not recruiting | 6,452 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | Early P1 | active not recruiting | 104 | M.D. Anderson Cancer Center | Nov 2014 | |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | P1/P2 | active not recruiting | 146 | National Cancer Institute (NCI) | Mar 2014 | |
| NCT07196384 | GLOW | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW | P1 | not yet recruiting | 15 | University Medical Center Groningen | Dec 2025 |
| NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | P2 | active not recruiting | 32 | M.D. Anderson Cancer Center | Jan 2019 | |
| NCT04413123 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | P2 | active not recruiting | 60 | Bradley A. McGregor, MD | Nov 2020 | |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | P3 | active not recruiting | 267 | National Cancer Institute (NCI) | Sep 2015 | |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | P2 | active not recruiting | 11 | National Cancer Institute (NCI) | Feb 2020 | |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | P2 | recruiting | 26 | Alliance for Clinical Trials in Oncology | Nov 2024 | |
| NCT04159818 | TONIC-2 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | P2 | recruiting | 52 | The Netherlands Cancer Institute | Feb 2020 |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | P2/P3 | active not recruiting | 384 | National Cancer Institute (NCI) | Oct 2019 | |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | P2 | active not recruiting | 6 | Emory University | May 2021 | |
| NCT04652960 | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | P1 | active not recruiting | 38 | National Cancer Institute (NCI) | Oct 2021 | |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | P2 | recruiting | 23 | University of California, Irvine | Nov 2024 | |
| NCT04966663 | ctDNA Lung RCT | Using ctDNA to Determine Therapies for Lung Cancer | P2 | recruiting | 66 | University Health Network, Toronto | Mar 2022 |
| NCT04495296 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | P1/P2 | recruiting | 320 | Suzhou Transcenta Therapeutics Co., Ltd. | Aug 2020 | |
| NCT05215470 | CLARA | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | P2 | active not recruiting | 100 | Hospital das Clínicas de Ribeirão Preto | Jan 2022 |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | P1 | active not recruiting | 123 | Replimune, Inc. | Dec 2020 | |
| NCT04396821 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | P1/P2 | active not recruiting | 150 | Suzhou Transcenta Therapeutics Co., Ltd. | May 2020 | |
| NCT04162015 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | P1 | active not recruiting | 22 | Memorial Sloan Kettering Cancer Center | Nov 2019 | |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | P2 | active not recruiting | 62 | National Cancer Institute (NCI) | Mar 2019 | |
| NCT03743662 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | P2 | active not recruiting | 39 | Memorial Sloan Kettering Cancer Center | Nov 2018 | |
| NCT02989636 | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | P1 | active not recruiting | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2017 | |
| NCT02293980 | MK-3795-001 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | P1 | active not recruiting | 110 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Nov 2014 |
| NCT06158919 | G/GEJ cancer | A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer | N/A | recruiting | 58 | Fudan University | Nov 2023 |
| NCT03233152 | GlitIpNi | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. | P1/P2 | active not recruiting | 110 | Universitair Ziekenhuis Brussel | Nov 2016 |
| NCT04624178 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | P2 | active not recruiting | 20 | Memorial Sloan Kettering Cancer Center | Nov 2020 | |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | P2 | active not recruiting | 15 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT03884998 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | P1 | active not recruiting | 27 | City of Hope Medical Center | Feb 2019 | |
| NCT05501054 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | P1/P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Feb 2023 | |
| NCT04991025 | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | P2 | recruiting | 60 | Memorial Sloan Kettering Cancer Center | Oct 2022 | |
| NCT05491616 | SANO-3 | Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study | P2 | active not recruiting | 77 | Erasmus Medical Center | Sep 2022 |
| NCT05089370 | DEC-C | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | P1/P2 | active not recruiting | 8 | University of Colorado, Denver | Jun 2022 |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | P2 | active not recruiting | 30 | Massachusetts General Hospital | May 2020 | |
| NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | P1 | active not recruiting | 36 | Replimune, Inc. | Oct 2019 | |
| NCT03728361 | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | P2 | active not recruiting | 55 | Dwight Owen | Dec 2018 | |
| NCT03607890 | L | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | P2 | active not recruiting | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2018 |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | P2 | active not recruiting | 69 | Memorial Sloan Kettering Cancer Center | Oct 2018 | |
| NCT03620578 | HO152 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL | P2 | active not recruiting | 97 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Aug 2018 |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | P2 | active not recruiting | 54 | National Cancer Institute (NCI) | Dec 2018 | |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | P1 | recruiting | 28 | Osel, Inc. | Jun 2024 | |
| NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | P2 | active not recruiting | 80 | Dan Zandberg | Dec 2019 | |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | P2 | active not recruiting | 31 | CatalYm GmbH | Sep 2023 | |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | P2 | active not recruiting | 82 | National Cancer Institute (NCI) | Jul 2015 | |
| NCT04561206 | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | P2 | recruiting | 31 | City of Hope Medical Center | Nov 2021 | |
| NCT06284564 | BOOST-RCC | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | P2 | active not recruiting | 10 | M.D. Anderson Cancer Center | Aug 2024 |
| NCT06532149 | EROS | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | recruiting | 80 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Aug 2024 |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | P1/P2 | active not recruiting | 100 | Bristol-Myers Squibb | Jun 2023 | |
| NCT04933903 | LOW | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | P2 | recruiting | 25 | Brown University | Oct 2021 |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | P2 | active not recruiting | 24 | Memorial Sloan Kettering Cancer Center | Sep 2019 | |
| NCT02914405 | MiniVan | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma | P1 | active not recruiting | 44 | University Hospital Southampton NHS Foundation Trust | May 2018 |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | P2 | active not recruiting | 46 | Brown University | Apr 2018 | |
| NCT03282344 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | P2 | active not recruiting | 88 | Memorial Sloan Kettering Cancer Center | Sep 2017 | |
| NCT02451982 | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | P2 | active not recruiting | 76 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2016 | |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | P1 | active not recruiting | 152 | National Cancer Institute (NCI) | Jul 2015 | |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | N/A | active not recruiting | 8,300 | National Cancer Institute (NCI) | Sep 2014 | |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | P1 | active not recruiting | 20 | City of Hope Medical Center | Dec 2019 | |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | P1 | active not recruiting | 12 | National Cancer Institute (NCI) | Nov 2019 | |
| NCT03071406 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | P2 | active not recruiting | 50 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2017 | |
| NCT02453620 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | P1 | active not recruiting | 57 | National Cancer Institute (NCI) | Feb 2016 | |
| NCT05672173 | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | P2 | active not recruiting | 9 | City of Hope Medical Center | Jun 2023 | |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | P2 | active not recruiting | 101 | National Cancer Institute (NCI) | Aug 2022 | |
| NCT05727410 | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma | P2 | recruiting | 50 | Myung-Ju Ahn | Nov 2022 | |
| NCT04013854 | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | P2 | active not recruiting | 67 | Abramson Cancer Center at Penn Medicine | Jan 2020 | |
| NCT03843294 | TAA-T | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | P1 | active not recruiting | 18 | Catherine Bollard | Jun 2019 |
| NCT03635892 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | P2 | active not recruiting | 60 | Memorial Sloan Kettering Cancer Center | Aug 2018 | |
| NCT03377023 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | P1/P2 | active not recruiting | 66 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2018 | |
| NCT02099058 | PK | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | P1 | active not recruiting | 237 | AbbVie | Jan 2014 |
| NCT04015778 | A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | P2 | active not recruiting | 316 | Guangdong Association of Clinical Trials | Aug 2019 | |
| NCT04079712 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | P2 | active not recruiting | 17 | National Cancer Institute (NCI) | Aug 2020 | |
| NCT02940301 | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | P2 | active not recruiting | 18 | Ohio State University Comprehensive Cancer Center | Dec 2016 | |
| NCT05601752 | SURPASS-3 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | P2 | active not recruiting | 66 | USWM CT, LLC | Jun 2023 |
| NCT05322577 | FORTITUDE-103 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | P1/P2 | active not recruiting | 72 | Amgen | May 2022 |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | P2 | active not recruiting | 13 | Dana-Farber Cancer Institute | Jun 2021 | |
| NCT03463408 | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Early P1 | active not recruiting | 14 | University of Rochester | Jul 2018 | |
| NCT05504642 | CERAD-IMMUNE | Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients | P2 | withdrawn | 0 | Universitätsklinikum Köln | Nov 2023 |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | P2 | active not recruiting | 18 | Memorial Sloan Kettering Cancer Center | Nov 2020 | |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | P1/P2 | active not recruiting | 51 | M.D. Anderson Cancer Center | Oct 2020 | |
| NCT04090710 | CYTOSHRINK | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | P2 | active not recruiting | 66 | Ontario Clinical Oncology Group (OCOG) | Jan 2020 |
| NCT03844256 | CRIMI | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study | P1/P2 | recruiting | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Jan 2019 |
| NCT02393794 | TNBC | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | P1/P2 | active not recruiting | 51 | Priyanka Sharma | Jul 2015 |
| NCT03695952 | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | — | active not recruiting | 100 | Asan Medical Center | Jul 2018 | |
| NCT03414684 | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | P2 | active not recruiting | 78 | Dana-Farber Cancer Institute | Jan 2018 | |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | P1/P2 | active not recruiting | 64 | Lantern Pharma Inc. | Jun 2023 | |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | P2 | active not recruiting | 82 | National Cancer Institute (NCI) | Apr 2018 | |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | P1 | active not recruiting | 28 | National Cancer Institute (NCI) | Oct 2017 | |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | P1/P2 | active not recruiting | 15 | Washington University School of Medicine | Nov 2020 | |
| NCT04039607 | CheckMate 9DW | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | P3 | active not recruiting | 732 | Bristol-Myers Squibb | Sep 2019 |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | P2 | active not recruiting | 82 | Academic and Community Cancer Research United | Oct 2017 | |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | P2 | active not recruiting | 29 | Dana-Farber Cancer Institute | Mar 2018 | |
| NCT04866654 | RAFTING | Radiation Free Chemotherapy for Early Hodgkin Lymphoma | P2 | recruiting | 160 | Medical University of Gdansk | Mar 2021 |
| NCT03502733 | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | P1 | active not recruiting | 64 | National Cancer Institute (NCI) | Aug 2018 | |
| NCT05867121 | A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 | P1 | active not recruiting | 102 | Genentech, Inc. | Oct 2023 | |
| NCT05262556 | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | P1 | active not recruiting | 15 | Amr Mohamed MD | Dec 2022 | |
| NCT05568095 | STAR-221 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | P3 | active not recruiting | 1,040 | Arcus Biosciences, Inc. | Nov 2022 |
| NCT06008925 | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | P1/P2 | recruiting | 43 | CNBG-Virogin Biotech (Shanghai) Ltd. | Nov 2022 | |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | P1/P2 | active not recruiting | 320 | BioAtla, Inc. | Aug 2022 | |
| NCT04803877 | SARC038 | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | P2 | active not recruiting | 48 | Sarcoma Alliance for Research through Collaboration | Jun 2021 |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | P2 | active not recruiting | 45 | Dana-Farber Cancer Institute | Aug 2020 | |
| NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | P2 | active not recruiting | 47 | Xiao X. Wei, MD | May 2020 | |
| NCT04021108 | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | P2 | active not recruiting | 80 | Weill Medical College of Cornell University | Jul 2019 | |
| NCT03443856 | VESTIGE | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | P2 | active not recruiting | 197 | European Organisation for Research and Treatment of Cancer - EORTC | Jul 2019 |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | P2 | active not recruiting | 15 | Emory University | Jun 2019 | |
| NCT04268888 | TACE-3 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC | P2/P3 | suspended | 522 | The Clatterbridge Cancer Centre NHS Foundation Trust | May 2019 |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | P1 | active not recruiting | 138 | Toray Industries, Inc | Apr 2019 | |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | P2 | active not recruiting | 140 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT03016871 | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL | P2 | active not recruiting | 78 | City of Hope Medical Center | Apr 2017 | |
| NCT02656706 | Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | P2 | active not recruiting | 22 | Brown University | Jul 2016 | |
| NCT03203473 | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | P2 | active not recruiting | 85 | Toni Choueiri, MD | Oct 2017 | |
| NCT05496192 | IV | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | P2 | withdrawn | 0 | Bristol-Myers Squibb | May 2023 |
| NCT06049576 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | P1 | active not recruiting | 31 | City of Hope Medical Center | Oct 2023 | |
| NCT05203913 | CNN-BC | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer | P2 | recruiting | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | May 2023 |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | P1/P2 | recruiting | 159 | Aulos Bioscience, Inc. | Apr 2022 | |
| NCT04008030 | CheckMate 8HW | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | P3 | active not recruiting | 839 | Bristol-Myers Squibb | Aug 2019 |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | P2 | withdrawn | 0 | Replimune, Inc. | Jan 2024 | |
| NCT04042753 | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | P2 | completed | 10 | Memorial Sloan Kettering Cancer Center | Jul 2019 | |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | P2 | unknown | 30 | Sheba Medical Center | Jun 2017 | |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | P2 | active not recruiting | 40 | Dana-Farber Cancer Institute | Mar 2016 | |
| NCT05964101 | GALAXY-1 | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | P2 | unknown | 25 | The First Affiliated Hospital of Guangzhou Medical University | Oct 2023 |
| NCT05480384 | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction | P2 | active not recruiting | 1 | Brown University | Jul 2023 | |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | P2 | recruiting | 57 | Yonsei University | Feb 2022 | |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | P2 | active not recruiting | 66 | National Cancer Institute LAO | Oct 2023 | |
| NCT03036098 | CheckMate901 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | P3 | active not recruiting | 1,314 | Bristol-Myers Squibb | Mar 2017 |
| NCT04151563 | CheckMate 79X | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | P1/P2 | withdrawn | 0 | Bristol-Myers Squibb | Apr 2021 |
| NCT04400539 | IMPALA | The IMmunotherapy Pleural 5-ALA PDT | P2 | recruiting | 20 | University Hospital, Lille | May 2022 |
| NCT03628209 | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma | P1 | active not recruiting | 21 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2019 | |
| NCT03355560 | Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy | P2 | completed | 39 | Trisha Wise-Draper | Dec 2017 | |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | P2 | terminated | 37 | M.D. Anderson Cancer Center | Jul 2019 | |
| NCT04295863 | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | P1 | recruiting | 264 | University of Chicago | Jun 2020 | |
| NCT04638439 | P1101 | The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection | P1 | completed | 20 | PharmaEssentia | Aug 2022 |
| NCT04913922 | AARON | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | P2 | unknown | 30 | Ludwig-Maximilians - University of Munich | May 2021 |
| NCT05767684 | Neoantigen Derived DCs as Cancer Treatment | P1 | unknown | 12 | National Health Research Institutes, Taiwan | Jun 2023 | |
| NCT04095208 | CONGRATS | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study | P2 | completed | 68 | Institut Bergonié | Feb 2020 |
| NCT04817254 | ICI | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | P2 | completed | 47 | National Cancer Institute (NCI) | Dec 2021 |
| NCT04603248 | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | N/A | completed | 50 | Yonsei University | Dec 2020 | |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | P2 | terminated | 15 | M.D. Anderson Cancer Center | May 2022 | |
| NCT04495257 | RCC | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | P1 | completed | 26 | Yale University | Sep 2020 |
| NCT07215962 | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% | — | active not recruiting | 300 | Bristol-Myers Squibb | Nov 2024 | |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | P1 | withdrawn | 0 | Case Comprehensive Cancer Center | Jun 2024 | |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | P1 | completed | 5 | China Medical University Hospital | Feb 2022 | |
| NCT03337919 | ANIMATE | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma | P2 | unknown | 78 | University College, London | Dec 2018 |
| NCT04623775 | NSCLC | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | P2 | active not recruiting | 468 | Bristol-Myers Squibb | Feb 2021 |
| NCT04785287 | BMS986218 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | P1/P2 | terminated | 13 | M.D. Anderson Cancer Center | Mar 2021 |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | P2 | completed | 67 | Bristol-Myers Squibb | Jul 2016 | |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | P2 | terminated | 225 | Iovance Biotherapeutics, Inc. | May 2019 | |
| NCT05715216 | OMP-313M32 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | P2 | active not recruiting | 20 | M.D. Anderson Cancer Center | Mar 2023 |
| NCT05926960 | PORTSIDE | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | P2 | terminated | 38 | Pfizer | Jun 2023 |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | P1 | withdrawn | 0 | Emory University | Jul 2020 | |
| NCT03689699 | MAGIC-8 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | P1/P2 | active not recruiting | 59 | Mark Stein | Oct 2018 |
| NCT02379520 | HESTIA | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | P1 | completed | 32 | Baylor College of Medicine | Sep 2015 |
| NCT06163820 | BETTER | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | P1/P2 | recruiting | 46 | Melanoma and Skin Cancer Trials Limited | May 2025 |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | P1 | withdrawn | 0 | Mayo Clinic | Oct 2025 | |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | P2 | completed | 14 | Memorial Sloan Kettering Cancer Center | May 2020 | |
| NCT07526961 | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland | — | completed | 240 | Bristol-Myers Squibb | Dec 2025 | |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | P3 | completed | 343 | AVEO Pharmaceuticals, Inc. | Sep 2021 | |
| NCT03141177 | CheckMate 9ER | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | P3 | active not recruiting | 701 | Bristol-Myers Squibb | Jul 2017 |
| NCT05393674 | Fedratinib in Combination With Nivolumab | P2 | completed | 30 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Jun 2022 | |
| NCT05343481 | Efficacy of VTP-300 in Chronic Hepatitis B Infection | P2 | completed | 121 | Barinthus Biotherapeutics | Sep 2022 | |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | P2 | completed | 20 | University of Washington | Jun 2020 | |
| NCT04552223 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | P2 | completed | 27 | Jose Lutzky, MD | Nov 2020 | |
| NCT05223816 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | P2 | recruiting | 97 | Virogin Biotech Canada Ltd | Jan 2024 | |
| NCT07529613 | T-DXd_HER2Low | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma | P1/P2 | completed | 30 | National Cancer Center Hospital East | Dec 2023 |
| NCT05887830 | Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial | P1/P2 | unknown | 96 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jun 2023 | |
| NCT05598853 | IT-IO | Intrathecal Double Checkpoint Inhibition | P1 | active not recruiting | 26 | University of Zurich | Nov 2022 |
| NCT05266612 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | P1 | recruiting | 12 | Virogin Biotech Canada Ltd | Nov 2022 | |
| NCT04535713 | GALLANT | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | P2 | recruiting | 260 | Sarcoma Oncology Research Center, LLC | Sep 2020 |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | P1/P2 | active not recruiting | 70 | Dan Zandberg | Jun 2020 | |
| NCT03854032 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | P2 | active not recruiting | 45 | Thomas Jefferson University | Apr 2019 | |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | P2 | active not recruiting | 25 | Yale University | Dec 2018 | |
| NCT04195139 | NUTMEG | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM | P2 | active not recruiting | 103 | University of Sydney | Feb 2018 |
| NCT03350126 | NIPICOL | iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | P2 | active not recruiting | 57 | GERCOR - Multidisciplinary Oncology Cooperative Group | Dec 2017 |
| NCT06235164 | The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer | — | unknown | 585 | Fujian Medical University | Jan 2019 | |
| NCT03585465 | Metro-PD1 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | P1/P2 | terminated | 63 | Centre Oscar Lambret | Mar 2019 |
| NCT03707808 | myDAvIpNi | Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | P1/P2 | recruiting | 18 | Universitair Ziekenhuis Brussel | Jan 2018 |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | P2/P3 | completed | 159 | National Cancer Institute (NCI) | Sep 2020 | |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | P1/P2 | unknown | 51 | Zhejiang University | Mar 2022 | |
| NCT04022980 | Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma | P1 | completed | 14 | Wake Forest University Health Sciences | Mar 2020 | |
| NCT04717154 | INSPIRE | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | P2 | completed | 69 | Radboud University Medical Center | Jan 2021 |
| NCT03405155 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | P2 | completed | 26 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Jan 2018 | |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | P1 | completed | 39 | City of Hope Medical Center | May 2020 | |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | P1/P2 | terminated | 8 | University of Wisconsin, Madison | Jan 2020 | |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | P1/P2 | completed | 270 | Dragonfly Therapeutics | Nov 2019 | |
| NCT03400332 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | P1/P2 | completed | 281 | Bristol-Myers Squibb | Feb 2018 | |
| NCT03245892 | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | P1 | completed | 27 | Memorial Sloan Kettering Cancer Center | Aug 2017 | |
| NCT05255601 | RELATIVITY-069 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | P1/P2 | completed | 5 | Bristol-Myers Squibb | Sep 2022 |
| NCT05821751 | PRINCESS | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors | N/A | unknown | 40 | Fondazione del Piemonte per l'Oncologia | Dec 2021 |
| NCT06097975 | NEO-GLITIPNI | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma | P1 | recruiting | 18 | Universitair Ziekenhuis Brussel | Mar 2024 |
| NCT05461235 | Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | P2 | unknown | 1 | China Medical University, China | Jul 2022 | |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | P2 | unknown | 5 | Suzhou Kintor Pharmaceutical Inc, | Aug 2021 | |
| NCT05354102 | FIH | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | P1 | unknown | 11 | Biomica Ltd. | May 2022 |
| NCT03638375 | ACTME | TIL and Anti-PD1 in Metastatic Melanoma | P1/P2 | unknown | 34 | Leiden University | Jul 2018 |
| NCT04702880 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | P2 | completed | 135 | Bristol-Myers Squibb | Mar 2021 | |
| NCT04205552 | NEOpredict | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients | P2 | completed | 90 | University Hospital, Essen | Mar 2020 |
| NCT04423029 | A Study of DF6002 Alone and in Combination With Nivolumab | P1 | completed | 170 | Dragonfly Therapeutics | Jul 2020 | |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | P2 | terminated | 10 | M.D. Anderson Cancer Center | Dec 2017 | |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | P2 | completed | 266 | Bristol-Myers Squibb | Feb 2021 | |
| NCT07141563 | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC | — | completed | 70 | Bristol-Myers Squibb | May 2025 | |
| NCT05337137 | RELATIVITY-106 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | P1/P2 | completed | 83 | Bristol-Myers Squibb | May 2022 |
| NCT05136677 | CheckMate 6DW | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | P2 | completed | 102 | Bristol-Myers Squibb | Jan 2022 |
| NCT07091695 | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | — | completed | 100 | Bristol-Myers Squibb | May 2025 | |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | P3 | completed | 256 | Amgen | Jul 2023 | |
| NCT05588297 | Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases | P2 | unknown | 12 | Shanghai Changzheng Hospital | Oct 2022 | |
| NCT04006262 | NEONIPIGA | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | P2 | active not recruiting | 32 | GERCOR - Multidisciplinary Oncology Cooperative Group | Oct 2019 |
| NCT02812667 | NSCLC | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | P1 | completed | 18 | Lyudmila Bazhenova, M.D. | Aug 2016 |
| NCT03469960 | DICIPLE | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | P3 | completed | 265 | Intergroupe Francophone de Cancerologie Thoracique | May 2018 |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | P3 | terminated | 102 | ImmunityBio, Inc. | May 2018 | |
| NCT04315155 | BENEFIT | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation | P1 | withdrawn | 0 | University of Utah | Oct 2020 |
| NCT03906071 | SAPPHIRE | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | P3 | completed | 577 | Mirati Therapeutics Inc. | Jul 2019 |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | P1/P2 | active not recruiting | 33 | Vyriad, Inc. | Apr 2019 | |
| NCT04887870 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | P2/P3 | completed | 52 | Mirati Therapeutics Inc. | Jun 2021 | |
| NCT02758717 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | P2 | active not recruiting | 46 | Academic and Community Cancer Research United | May 2016 | |
| NCT04477512 | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | P1 | completed | 18 | Washington University School of Medicine | Feb 2021 | |
| NCT06410534 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Sep 2025 | |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | P2 | terminated | 15 | Academic and Community Cancer Research United | Jan 2023 | |
| NCT05472623 | Neo-Kan | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab | P2 | withdrawn | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2023 |
| NCT04741438 | RAR-Immune | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype | P3 | unknown | 96 | Centre Leon Berard | Mar 2021 |
| NCT02499367 | TONIC | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | P2 | unknown | 84 | The Netherlands Cancer Institute | Aug 2015 |
| NCT05394740 | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | P1/P2 | completed | 30 | National Cancer Center Hospital East | Jun 2022 | |
| NCT04123379 | NSCLC | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | P2 | completed | 48 | Icahn School of Medicine at Mount Sinai | Mar 2020 |
| NCT03417037 | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer | P3 | withdrawn | 0 | Bristol-Myers Squibb | May 2018 | |
| NCT03146650 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | P2 | unknown | 25 | Northwestern University | May 2017 | |
| NCT04787991 | REVOLUTION | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | P1 | completed | 45 | Cancer Insight, LLC | Aug 2021 |
| NCT04465643 | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | P1 | completed | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2021 | |
| NCT06452329 | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer | — | completed | 260 | Bristol-Myers Squibb | Feb 2024 | |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | P2 | completed | 100 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | P1/P2 | completed | 68 | Bristol-Myers Squibb | Aug 2022 | |
| NCT05328908 | RELATIVITY-123 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | P3 | terminated | 770 | Bristol-Myers Squibb | Apr 2022 |
| NCT05219435 | VEXILLUM | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | P2 | completed | 25 | Spanish Oncology Genito-Urinary Group | Jul 2022 |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | — | unknown | 1,800 | CCTU- Cancer Theme | Jul 2020 | |
| NCT04019964 | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | P2 | completed | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2020 | |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | — | active not recruiting | 100 | Bristol-Myers Squibb | Oct 2024 | |
| NCT04876313 | NURE-Combo | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) | P2 | unknown | 29 | IRCCS San Raffaele | Jan 2022 |
| NCT04334759 | DREAM3R | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | P3 | completed | 214 | PrECOG, LLC. | Feb 2021 |
| NCT04591431 | ROME | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | P2 | unknown | 400 | Fondazione per la Medicina Personalizzata | Oct 2020 |
| NCT03711058 | MSS | Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | P1/P2 | completed | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2019 |
| NCT03452579 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | P2 | active not recruiting | 90 | David Peereboom | May 2018 | |
| NCT02977052 | OpACIN-neo | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | P2 | unknown | 186 | The Netherlands Cancer Institute | Nov 2016 |
| NCT02437279 | OpACIN | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients | P1 | unknown | 20 | The Netherlands Cancer Institute | Nov 2016 |
| NCT03383302 | STILE | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects | P1/P2 | completed | 29 | Royal Marsden NHS Foundation Trust | Feb 2018 |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | P2 | completed | 133 | National Cancer Institute (NCI) | Jul 2017 | |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | P1/P2 | suspended | 30 | Northwestern University | Nov 2018 | |
| NCT04062656 | IMAGINE | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG | P2 | unknown | 21 | University Hospital, Essen | Sep 2019 |
| NCT04526730 | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | P2 | completed | 17 | H. Lee Moffitt Cancer Center and Research Institute | Dec 2020 | |
| NCT06191796 | XL092 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | P1 | terminated | 25 | Exelixis | Jan 2024 |
| NCT05625412 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | P1 | completed | 70 | Bristol-Myers Squibb | Dec 2022 | |
| NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | P1 | completed | 31 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT04913025 | REFINE | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers | P2 | unknown | 160 | University College, London | May 2022 |
| NCT04879368 | INTEGRATEIIb | RegoNivo vs Standard of Care Chemotherapy in AGOC | P3 | completed | 462 | Australasian Gastro-Intestinal Trials Group | May 2021 |
| NCT03739619 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | P1/P2 | completed | 3 | Emory University | Nov 2018 | |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | P2 | completed | 74 | Swiss Cancer Institute | Dec 2017 | |
| NCT04988841 | PICASSO | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma | P2 | completed | 70 | Assistance Publique - Hôpitaux de Paris | Jan 2022 |
| NCT06499298 | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer | — | completed | 64 | Bristol-Myers Squibb | Dec 2024 | |
| NCT04021043 | BMS-986156 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | P1/P2 | completed | 51 | M.D. Anderson Cancer Center | Aug 2019 |
| NCT04493203 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | P2 | completed | 31 | Yana Najjar | Dec 2020 | |
| NCT06421311 | URADJ | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France | — | terminated | 176 | Bristol-Myers Squibb | Jul 2024 |
| NCT05002569 | RELATIVITY-098 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | P3 | terminated | 1,093 | Bristol-Myers Squibb | Oct 2021 |
| NCT07079644 | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | — | completed | 678 | Bristol-Myers Squibb | Nov 2024 | |
| NCT04250246 | NIBIT-ML1 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | P2 | unknown | 184 | Italian Network for Tumor Biotherapy Foundation | Mar 2020 |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | P1 | completed | 37 | National Cancer Center, Japan | May 2019 | |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | P4 | unknown | 50 | Assistance Publique Hopitaux De Marseille | Apr 2018 | |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | P3 | completed | 1,096 | Bristol-Myers Squibb | Oct 2014 | |
| NCT03807765 | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | P1 | completed | 14 | H. Lee Moffitt Cancer Center and Research Institute | Jan 2019 | |
| NCT04850755 | A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies | P1 | completed | 11 | National University Hospital, Singapore | Mar 2021 | |
| NCT04925284 | JEWEL-101 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | P1 | completed | 269 | Exelixis | Jun 2021 |
| NCT05660993 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | P2 | unknown | 50 | National Research Center for Hematology, Russia | Aug 2019 | |
| NCT06771674 | Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma | — | completed | 662 | Hookipa Biotech GmbH | Jun 2024 | |
| NCT05482451 | Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer | Early P1 | active not recruiting | 10 | China Medical University Hospital | Mar 2021 | |
| NCT04223648 | MEDI4736 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | Early P1 | withdrawn | 0 | Yale University | Aug 2020 |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | P1 | completed | 67 | Bristol-Myers Squibb | Aug 2021 | |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | P1/P2 | terminated | 19 | M.D. Anderson Cancer Center | Apr 2021 | |
| NCT03721757 | NICO | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer | P2 | completed | 21 | The Clatterbridge Cancer Centre NHS Foundation Trust | May 2019 |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Jul 2022 | |
| NCT04966676 | ATLAS | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer | P2 | terminated | 5 | University Health Network, Toronto | Jan 2022 |
| NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | P1/P2 | completed | 229 | Bristol-Myers Squibb | May 2018 | |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | P1/P2 | terminated | 175 | Bolt Biotherapeutics, Inc. | Feb 2020 | |
| NCT03557359 | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | P2 | completed | 35 | Fabio Iwamoto, MD | Jun 2018 | |
| NCT03770416 | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | P2 | completed | 18 | M.D. Anderson Cancer Center | Feb 2019 | |
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | P1/P2 | completed | 1,482 | Bristol-Myers Squibb | Nov 2013 | |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | P1/P2 | terminated | 13 | John Kirkwood | Oct 2021 | |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | P1/P2 | completed | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dec 2019 | |
| NCT06116461 | NIVOPTIMIZE | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response | P4 | unknown | 34 | Erasmus Medical Center | Jan 2022 |
| NCT04085250 | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy | P2 | unknown | 264 | Sun Yat-sen University | Nov 2019 | |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | P2 | terminated | 13 | NYU Langone Health | Sep 2019 | |
| NCT03382561 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | P2 | completed | 160 | National Cancer Institute (NCI) | May 2018 | |
| NCT04785820 | RO7121661 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | P2 | completed | 190 | Hoffmann-La Roche | Jun 2021 |
| NCT04177953 | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery | P2 | completed | 92 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Feb 2019 | |
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | P2 | completed | 164 | Michael B. Atkins, MD | Apr 2017 | |
| NCT03366272 | NIVEAU | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients | P2/P3 | completed | 348 | Universität des Saarlandes | Dec 2017 |
| NCT03143153 | CheckMate 648 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | P3 | completed | 970 | Bristol-Myers Squibb | Jun 2017 |
| NCT03338790 | CheckMate 9KD | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | P2 | completed | 292 | Bristol-Myers Squibb | Dec 2017 |
| NCT04620200 | MATISSE | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery | P2 | completed | 50 | The Netherlands Cancer Institute | Aug 2020 |
| NCT03387761 | NABUCCO | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | P1 | completed | 54 | The Netherlands Cancer Institute | Jan 2018 |
| NCT02985957 | CheckMate 650 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | P2 | completed | 351 | Bristol-Myers Squibb | Mar 2017 |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | P2 | terminated | 6 | Gregory Daniels | May 2019 | |
| NCT05739045 | Nivolumab Combined With SOX Used in the Perioperative Treatment | P2 | recruiting | 46 | Xiangdong Cheng | Nov 2022 | |
| NCT05150236 | ANZUP2001 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | P2 | unknown | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Apr 2022 |
| NCT03995017 | RiME | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma | P1/P2 | unknown | 34 | University of Kansas Medical Center | Jan 2020 |
| NCT04172402 | NGS as the First-line Treatment in Advanced Biliary Tract Cancer | P2 | completed | 48 | National Health Research Institutes, Taiwan | Dec 2019 | |
| NCT03879122 | A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | P2/P3 | unknown | 135 | Spanish Oncology Genito-Urinary Group | Feb 2019 | |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | P2 | withdrawn | 0 | Dana-Farber Cancer Institute | Dec 2018 | |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | P2 | completed | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | May 2018 | |
| NCT03172416 | PIPAC | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis | P1 | unknown | 21 | National University Hospital, Singapore | Apr 2017 |
| NCT03097939 | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | P2 | unknown | 113 | National Cancer Centre, Singapore | Mar 2017 | |
| NCT03458455 | TREATMENT | Improved Therapy Response Assessment in Metastatic Brain Tumors | — | unknown | 200 | Oslo University Hospital | Mar 2013 |
| NCT04871594 | TURANDOT | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer | P1 | completed | 15 | The Netherlands Cancer Institute | Aug 2021 |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | P2 | unknown | 29 | YULISU | Dec 2020 | |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | P1/P2 | unknown | 30 | St. Petersburg State Pavlov Medical University | Apr 2017 | |
| NCT03712202 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | P2 | active not recruiting | 155 | City of Hope Medical Center | Nov 2018 | |
| NCT03172624 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | P2 | completed | 64 | Memorial Sloan Kettering Cancer Center | May 2017 | |
| NCT03591731 | NIPINEC | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | P2 | completed | 185 | Intergroupe Francophone de Cancerologie Thoracique | Jan 2019 |
| NCT02998528 | CheckMate 816 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 505 | Bristol-Myers Squibb | Mar 2017 |
| NCT04247165 | LAPTOP | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. | P1/P2 | completed | 55 | Herlev Hospital | Jun 2020 |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1 | completed | 29 | M.D. Anderson Cancer Center | Oct 2018 | |
| NCT03442569 | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | P2 | completed | 56 | UNC Lineberger Comprehensive Cancer Center | Mar 2018 | |
| NCT05859477 | NIVOFGFR2 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | P2 | unknown | 23 | Kidney Cancer Research Bureau | Jun 2022 |
| NCT04823403 | HIPANIV | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | P1 | recruiting | 27 | Gustave Roussy, Cancer Campus, Grand Paris | Nov 2020 |
| NCT04263051 | Optim-UCPVax | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer | P2 | completed | 60 | Centre Hospitalier Universitaire de Besancon | Sep 2020 |
| NCT04133948 | DONIMI | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma | P1/P2 | completed | 44 | The Netherlands Cancer Institute | Jan 2020 |
| NCT04026412 | CheckMate73L | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery | P3 | completed | 925 | Bristol-Myers Squibb | Oct 2019 |
| NCT03981146 | ANICCA | A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | P2 | completed | 35 | University of Birmingham | Aug 2019 |
| NCT04267146 | NIVOGLIO | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma | P1/P2 | completed | 41 | Gustave Roussy, Cancer Campus, Grand Paris | Jul 2019 |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | P2 | terminated | 3 | Jonsson Comprehensive Cancer Center | Dec 2020 | |
| NCT05921760 | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | P1/P2 | terminated | 7 | Servier Bio-Innovation LLC | Oct 2023 | |
| NCT03838263 | IMMUNEBOOST | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer | P2 | completed | 62 | UNICANCER | Jul 2019 |
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | P1/P2 | completed | 1,163 | Bristol-Myers Squibb | Oct 2013 | |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | P1/P2 | completed | 34 | University of Michigan Rogel Cancer Center | May 2019 | |
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | P1 | completed | 10 | Memorial Sloan Kettering Cancer Center | Jul 2019 | |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | P2 | completed | 101 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT01658878 | CheckMate040 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | P1/P2 | completed | 657 | Bristol-Myers Squibb | Oct 2012 |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | P1 | completed | 26 | M.D. Anderson Cancer Center | Sep 2018 | |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | P1/P2 | completed | 356 | Bristol-Myers Squibb | Dec 2017 | |
| NCT02743494 | CheckMate 577 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer | P3 | completed | 794 | Bristol-Myers Squibb | Jul 2016 |
| NCT03377361 | CheckMate 9N9 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | P1/P2 | completed | 325 | Bristol-Myers Squibb | Jan 2018 |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | P1 | terminated | 15 | Molecular Templates, Inc. | Nov 2023 | |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | P2 | unknown | 20 | Tel-Aviv Sourasky Medical Center | May 2022 | |
| NCT03267498 | NPC | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | P2 | completed | 40 | Sue Yom | Feb 2018 |
| NCT04072198 | NIVACOR | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | P2 | completed | 73 | Gruppo Oncologico Italiano di Ricerca Clinica | Sep 2019 |
| NCT02477826 | CheckMate 227 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 2,747 | Bristol-Myers Squibb | Aug 2015 |
| NCT03727061 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | P1 | terminated | 5 | Roswell Park Cancer Institute | Jul 2019 | |
| NCT02060188 | CheckMate142 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | P2 | completed | 385 | Bristol-Myers Squibb | Mar 2014 |
| NCT03215706 | CheckMate 9LA | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | P3 | completed | 719 | Bristol-Myers Squibb | Aug 2017 |
| NCT02388906 | CheckMate 238 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma | P3 | completed | 906 | Bristol-Myers Squibb | Mar 2015 |
| NCT03404960 | Parpvax | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | P1/P2 | completed | 104 | University of Pennsylvania | Jan 2018 |
| NCT04581382 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | Early P1 | completed | 18 | Mayo Clinic | Dec 2020 | |
| NCT05043714 | NEBULA | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours | P1 | completed | 30 | Akamis Bio | Dec 2021 |
| NCT04187404 | Spencer | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | P1/P2 | terminated | 70 | Enterome | Jul 2020 |
| NCT06735781 | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | — | completed | 101 | Bristol-Myers Squibb | Sep 2024 | |
| NCT04981899 | NICE-40 | A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma | P1/P2 | unknown | 30 | St. Petersburg State Pavlov Medical University | Mar 2021 |
| NCT04125719 | PPD1 | PVSRIPO in Combination With Nivolumab in Melanoma | P1 | withdrawn | 0 | Darell Bigner | Jun 2020 |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | P1/P2 | completed | 79 | Famewave Ltd. | Mar 2021 | |
| NCT04525638 | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | P2 | unknown | 30 | Fundación de investigación HM | Jun 2020 | |
| NCT03704077 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | P2 | withdrawn | 0 | Bristol-Myers Squibb | Oct 2019 | |
| NCT03867799 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | P2 | active not recruiting | 25 | Royal Marsden NHS Foundation Trust | Mar 2019 | |
| NCT05144529 | TOP2101 | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | P2 | terminated | 19 | Eziafa Oduah, MD, PhD, MPH | Mar 2022 |
| NCT06590480 | RPL-EAP-001 | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma | — | no longer available | 0 | Replimune, Inc. | — |
| NCT03642067 | MSS | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | P2 | completed | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2019 |
| NCT02419495 | KPT-330 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | P1 | terminated | 221 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | P1/P2 | terminated | 36 | Bristol-Myers Squibb | Oct 2022 | |
| NCT03656718 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | P1/P2 | completed | 139 | Bristol-Myers Squibb | Oct 2018 | |
| NCT03107182 | OPTIMA-II | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | P2 | completed | 72 | University of Chicago | Jun 2017 |
| NCT03994601 | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | P1/P2 | completed | 219 | Bristol-Myers Squibb | Sep 2019 | |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | P1 | terminated | 79 | National Cancer Institute (NCI) | Oct 2015 | |
| NCT02196961 | ADMEC-O | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation | P2 | completed | 180 | Prof. Dr. med. Dirk Schadendorf | Jun 2014 |
| NCT05655715 | CheckPRO | Checkpoint Inhibitors and SBRT for MCRPC | P2 | completed | 90 | Herlev and Gentofte Hospital | Nov 2019 |
| NCT03692325 | Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia | P2 | completed | 33 | Dana-Farber Cancer Institute | Dec 2018 | |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | P1/P2 | terminated | 92 | Bristol-Myers Squibb | Mar 2018 | |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | P2 | terminated | 255 | Seagen Inc. | Jan 2019 | |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | P1/P2 | completed | 44 | Bristol-Myers Squibb | Jul 2020 | |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Early P1 | completed | 1 | H. Lee Moffitt Cancer Center and Research Institute | Jun 2023 | |
| NCT05298592 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | P1 | completed | 77 | Bristol-Myers Squibb | Mar 2022 | |
| NCT04401995 | CMP-001 | Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab | P2 | completed | 9 | Diwakar Davar | Sep 2020 |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | P2 | completed | 12 | National Cancer Institute (NCI) | Dec 2019 | |
| NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | P2 | completed | 20 | Dan Zandberg | May 2020 | |
| NCT06094296 | NSCLC | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | P2 | terminated | 1 | Bristol-Myers Squibb | Nov 2023 |
| NCT04256213 | COLIBRI | COL Immunotherapy Before Radiochimio + Ipilimumab | N/A | completed | 40 | ARCAGY/ GINECO GROUP | Jul 2020 |
| NCT05898828 | R | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Aug 2024 |
| NCT03890952 | Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma | P2 | completed | 40 | Ulrik Lassen | Oct 2018 | |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | P1/P2 | terminated | 23 | TriSalus Life Sciences, Inc. | Mar 2022 | |
| NCT04463368 | SCANDIUM II | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | P1 | completed | 18 | Vastra Gotaland Region | Mar 2021 |
| NCT04610671 | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | P1 | completed | 21 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2020 | |
| NCT03496662 | PDAC | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | P1/P2 | completed | 40 | Washington University School of Medicine | Aug 2018 |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | P2 | terminated | 4 | Providence Health & Services | Jun 2022 | |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | P2/P3 | terminated | 20 | Regeneron Pharmaceuticals | Feb 2021 | |
| NCT04891770 | SLGN | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | P2 | completed | 103 | Gilead Sciences | Aug 2021 |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | P2 | completed | 262 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Nov 2018 | |
| NCT05169957 | HAMMER I | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | P1 | completed | 2 | University of Michigan Rogel Cancer Center | Aug 2022 |
| NCT04935229 | PERIO | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | P1 | terminated | 67 | TriSalus Life Sciences, Inc. | Aug 2021 |
| NCT03850067 | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | P1 | completed | 90 | Celgene | Mar 2019 | |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | P1 | terminated | 21 | Navire Pharma Inc., a BridgeBio company | Oct 2022 | |
| NCT04170556 | GOING | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | P1/P2 | completed | 69 | Fundacion Clinic per a la Recerca Biomédica | Mar 2020 |
| NCT02966548 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | P1 | completed | 35 | Bristol-Myers Squibb | Jan 2017 | |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | P1/P2 | completed | 320 | Bristol-Myers Squibb | Aug 2012 | |
| NCT04050761 | ProNiHN | A Study of Nivolumab in Patients With Head and Neck Cancer. | — | completed | 502 | Bristol-Myers Squibb | Jun 2019 |
| NCT06003075 | Induction Chemo-Nivo in Unresectable Stage III NSCLC | P2 | terminated | 1 | Ralph G Zinner | Dec 2023 | |
| NCT03743766 | Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | P2 | completed | 42 | John Kirkwood | Mar 2019 | |
| NCT05088889 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | P1 | unknown | 10 | Sheba Medical Center | Jan 2022 | |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | P1/P2 | completed | 39 | Salma Sabbour | Sep 2018 | |
| NCT05265650 | Noelia | Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC | P1/P2 | unknown | 30 | Clinica Universidad de Navarra, Universidad de Navarra | Jun 2022 |
| NCT04575922 | Nivolumab+Ipilimumab+RT in MSS mCRC | P2 | unknown | 32 | Massachusetts General Hospital | Oct 2020 | |
| NCT03277924 | ImmunoSarc | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | P1/P2 | completed | 197 | Grupo Espanol de Investigacion en Sarcomas | May 2017 |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | P2/P3 | completed | 76 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT04100018 | CheckMate 7DX | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | P3 | completed | 1,030 | Bristol-Myers Squibb | Feb 2020 |
| NCT02017717 | CheckMate 143 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients | P3 | completed | 529 | Bristol-Myers Squibb | Feb 2014 |
| NCT03829722 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | P2 | completed | 26 | University of Michigan Rogel Cancer Center | Sep 2019 | |
| NCT02833233 | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | N/A | completed | 5 | Memorial Sloan Kettering Cancer Center | Jun 2016 | |
| NCT03475134 | TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) | P1 | completed | 18 | Centre Hospitalier Universitaire Vaudois | Feb 2018 | |
| NCT02872116 | CheckMate649 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | P3 | completed | 2,031 | Bristol-Myers Squibb | Oct 2016 |
| NCT05772624 | Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma | P2 | unknown | 16 | Hospital Universitario Dr. Jose E. Gonzalez | Feb 2023 | |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | P1 | terminated | 1 | Emory University | Oct 2022 | |
| NCT04782791 | Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer | P2 | unknown | 30 | Chinese PLA General Hospital | May 2022 | |
| NCT05236608 | ADIVO Lung | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | P1/P2 | unknown | 53 | National University Hospital, Singapore | Nov 2021 |
| NCT04146324 | An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia | — | completed | 150 | Bristol-Myers Squibb | Dec 2019 | |
| NCT03510871 | HCC | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | P2 | completed | 43 | National Health Research Institutes, Taiwan | Feb 2019 |
| NCT03700905 | IMSTAR-HN | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy | P3 | unknown | 276 | Universitätsklinikum Hamburg-Eppendorf | Aug 2018 |
| NCT02631447 | SECOMBIT | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | P2 | completed | 251 | Fondazione Melanoma Onlus | Nov 2016 |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | P1/P2 | completed | 110 | Hoffmann-La Roche | Feb 2022 | |
| NCT02927769 | CheckMate 744 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | P2 | completed | 72 | Bristol-Myers Squibb | Mar 2017 |
| NCT03970252 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | Early P1 | completed | 28 | Jonsson Comprehensive Cancer Center | Jul 2019 | |
| NCT04305249 | ERASER | Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies | P1 | terminated | 36 | Antengene Therapeutics Limited | Aug 2020 |
| NCT02664181 | PRECISE | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial | P2 | completed | 13 | Case Comprehensive Cancer Center | Jun 2017 |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | P1/P2 | completed | 48 | Compugen Ltd | Aug 2020 | |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | P1 | completed | 42 | Yale University | Jun 2018 | |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | P2 | completed | 67 | M.D. Anderson Cancer Center | Nov 2012 | |
| NCT02681302 | CPIT001 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence | P1/P2 | terminated | 46 | Hackensack Meridian Health | Jun 2016 |
| NCT03487666 | OXEL | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | P2 | completed | 45 | Georgetown University | May 2018 |
| NCT03818685 | BreastImmune03 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | P2 | unknown | 95 | Centre Leon Berard | Jul 2019 |
| NCT03639935 | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | P2 | completed | 32 | University of Michigan Rogel Cancer Center | Mar 2019 | |
| NCT02553642 | CA209-260 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | P2 | completed | 81 | Memorial Sloan Kettering Cancer Center | Sep 2015 |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | P1/P2 | completed | 88 | Vanderbilt-Ingram Cancer Center | Jul 2018 | |
| NCT03956680 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | P1 | completed | 54 | Bristol-Myers Squibb | Mar 2019 | |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | P3 | completed | 945 | Bristol-Myers Squibb | Jun 2013 | |
| NCT04967196 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | P1 | terminated | 6 | Mayo Clinic | Sep 2021 | |
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | P1/P2 | terminated | 14 | Enlivex Therapeutics RDO Ltd. | Nov 2022 | |
| NCT04382664 | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | P2 | completed | 156 | Ultimovacs ASA | May 2020 | |
| NCT02667587 | CheckMate548 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | P3 | completed | 716 | Bristol-Myers Squibb | May 2016 |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | — | completed | 327 | Bristol-Myers Squibb | Feb 2024 | |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | P1/P2 | terminated | 376 | Bristol-Myers Squibb | May 2017 | |
| NCT04907539 | RNF43 | A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) | P2 | completed | 25 | Redx Pharma Ltd | Nov 2021 |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | P2 | completed | 35 | Memorial Sloan Kettering Cancer Center | Aug 2017 | |
| NCT07436390 | MAK | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | N/A | completed | 132 | Institute of Oncology Ljubljana | Mar 2024 |
| NCT03715946 | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | P2 | completed | 40 | Robert L. Ferris, MD, PhD | Nov 2018 | |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | P1/P2 | unknown | 13 | Therapeutic Advances in Childhood Leukemia Consortium | Nov 2019 | |
| NCT04704154 | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | P2 | completed | 175 | Bayer | Feb 2021 | |
| NCT03570619 | IMPACT | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | P2 | completed | 56 | University of Michigan Rogel Cancer Center | Dec 2018 |
| NCT02754726 | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | P2 | completed | 35 | HonorHealth Research Institute | Apr 2016 | |
| NCT04282109 | NIVOTAX | Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) | P2 | completed | 141 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Jun 2020 |
| NCT03033576 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | P2 | completed | 94 | National Cancer Institute (NCI) | Oct 2017 | |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | P3 | completed | 783 | Bristol-Myers Squibb | Sep 2018 | |
| NCT05583188 | VIGOR | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC | P4 | terminated | 5 | Galvanize Therapeutics, Inc. | Feb 2023 |
| NCT05061017 | PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | P2 | completed | 13 | Diwakar Davar | Dec 2021 |
| NCT03388190 | METIMMOX | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin | P2 | completed | 80 | University Hospital, Akershus | May 2018 |
| NCT04124601 | CHINOREC | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer | P2 | completed | 80 | Johannes Laengle, MD, PhD | Jun 2020 |
| NCT03770299 | CheckMate 9TN | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | P2 | withdrawn | 0 | Bristol-Myers Squibb | Jan 2021 |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | P2 | terminated | 17 | Patrick Boland | Jun 2018 | |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | P2 | completed | 5 | Children's National Research Institute | Feb 2022 | |
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | P2 | completed | 76 | Matthew Galsky | Jul 2018 | |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | P1/P2 | terminated | 6 | Inge Marie Svane | Apr 2021 | |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | P2/P3 | unknown | 90 | Shanghai Zhongshan Hospital | Jun 2022 | |
| NCT05130684 | Neo-NTP-CRT | Neo-NTP-CRT for Locally Advanced ESCC | P2 | unknown | 43 | National Taiwan University Hospital | Feb 2021 |
| NCT03784040 | da VINci | Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | P1 | unknown | 40 | National University Hospital, Singapore | Feb 2019 |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | P1 | terminated | 19 | Dana-Farber Cancer Institute | Jan 2020 | |
| NCT03161379 | GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | P2 | completed | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2018 | |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | P2 | terminated | 12 | Roberto Pili | Jul 2018 | |
| NCT03892044 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | P1 | completed | 7 | David Bond, MD | Nov 2019 | |
| NCT05297565 | CheckMate-6GE | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection | P3 | completed | 14 | Bristol-Myers Squibb | Aug 2022 |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | P3 | completed | 743 | Bristol-Myers Squibb | Dec 2015 | |
| NCT03285321 | NSCLC | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | P2 | completed | 105 | Greg Durm, MD | Sep 2017 |
| NCT04698187 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | P2 | terminated | 44 | Regeneron Pharmaceuticals | Mar 2021 | |
| NCT03138512 | CheckMate 914 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney | P3 | completed | 1,641 | Bristol-Myers Squibb | Jul 2017 |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | P1 | terminated | 1 | Abramson Cancer Center at Penn Medicine | Aug 2020 | |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | P2 | completed | 19 | Dana-Farber Cancer Institute | Dec 2019 | |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | P1/P2 | suspended | 227 | Clovis Oncology, Inc. | Jul 2019 | |
| NCT03374839 | Nivo-TIL | Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients | P1/P2 | unknown | 11 | Nantes University Hospital | Feb 2018 |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | P1 | completed | 121 | Compugen Ltd | Sep 2018 | |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | Early P1 | completed | 15 | Fox Chase Cancer Center | May 2018 | |
| NCT06361563 | Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada | — | completed | 250 | Bristol-Myers Squibb | Sep 2023 | |
| NCT06361576 | Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada | — | completed | 700 | Bristol-Myers Squibb | Sep 2023 | |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | P2 | completed | 62 | Amsterdam UMC, location VUmc | Feb 2018 | |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | P1/P2 | completed | 101 | Bristol-Myers Squibb | Nov 2016 | |
| NCT05834348 | DELINOR | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | completed | 5,279 | Pfizer | Jun 2023 |
| NCT03511391 | CHEERS | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | P2 | completed | 99 | University Hospital, Ghent | Mar 2018 |
| NCT02635061 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | P1 | terminated | 17 | Celgene | Aug 2016 | |
| NCT05498480 | RELATIVITY-111 | Study of Relatlimab in Combination With Nivolumab in Chinese Participants | P1 | completed | 6 | Bristol-Myers Squibb | Jul 2022 |
| NCT04540705 | PIVOT IO 011 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | P1 | completed | 30 | Bristol-Myers Squibb | Sep 2020 |
| NCT03712943 | MMR | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | P1 | completed | 52 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2018 |
| NCT03662659 | GEJ | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | P2 | completed | 274 | Bristol-Myers Squibb | Oct 2018 |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | P1/P2 | completed | 37 | Bristol-Myers Squibb | Aug 2017 | |
| NCT04513522 | CheckMate 7C9 | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India | P4 | completed | 101 | Bristol-Myers Squibb | Dec 2020 |
| NCT05027204 | SCCHN | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | P1/P2 | unknown | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Mar 2022 |
| NCT07053202 | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma | N/A | completed | 140 | The First Hospital of Hebei Medical University | Oct 2021 | |
| NCT05224999 | Nivolumab for Recurrent/Metastatic Carcinosarcoma | P2 | unknown | 28 | Yonsei University | Nov 2019 | |
| NCT03993249 | MIBC | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | P2 | unknown | 78 | Hellenic GenitoUrinary Cancer Group | May 2019 |
| NCT03618641 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | P2 | completed | 34 | Diwakar Davar | Aug 2018 | |
| NCT03161756 | CHARLI | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | P1/P2 | unknown | 72 | Melanoma and Skin Cancer Trials Limited | Dec 2017 |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | P2 | completed | 26 | Centre hospitalier de l'Université de Montréal (CHUM) | Jun 2017 | |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | P1/P2 | completed | 50 | Sabine Mueller, MD, PhD | Nov 2016 | |
| NCT04060407 | CINDI | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | P1/P2 | withdrawn | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Jun 2021 |
| NCT04109066 | CheckMate 7FL | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | P3 | completed | 521 | Bristol-Myers Squibb | Nov 2019 |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | P1/P2 | completed | 95 | H. Lee Moffitt Cancer Center and Research Institute | Dec 2017 | |
| NCT02846376 | CPIT-002 | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant | P1 | terminated | 8 | Hackensack Meridian Health | Mar 2019 |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | P1/P2 | completed | 25 | Icahn School of Medicine at Mount Sinai | Jun 2020 | |
| NCT04350463 | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | P2 | completed | 92 | Celgene | Jul 2020 | |
| NCT04611165 | Nextrah | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC | P2 | completed | 50 | National Cancer Center, Korea | Nov 2019 |
| NCT03829111 | CBM588 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | P1 | completed | 30 | City of Hope Medical Center | May 2019 |
| NCT04340193 | CheckMate 74W | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | P3 | completed | 26 | Bristol-Myers Squibb | Sep 2020 |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | P2 | completed | 120 | Olivia Newton-John Cancer Research Institute | Aug 2017 | |
| NCT05169684 | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | P2 | terminated | 10 | Bristol-Myers Squibb | Feb 2022 | |
| NCT03682276 | PRIME-HCC | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | P1/P2 | unknown | 32 | Imperial College London | Mar 2019 |
| NCT02933255 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | P1/P2 | completed | 24 | National Cancer Institute (NCI) | Apr 2017 | |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | 0 | Fujian Cancer Hospital | Oct 2021 | |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | P2 | completed | 16 | Robin Kate Kelley | Apr 2018 | |
| NCT02613507 | CheckMate 078 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer | P3 | completed | 504 | Bristol-Myers Squibb | Dec 2015 |
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | P2 | completed | 316 | Goethe University | Nov 2017 | |
| NCT02992964 | Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | P1/P2 | terminated | 11 | The Hospital for Sick Children | May 2017 | |
| NCT03083691 | BIOLUMA | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | P2 | completed | 90 | Lung Cancer Group Cologne | Apr 2017 |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | P1/P2 | completed | 21 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2017 | |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | P2 | completed | 25 | Hospital Israelita Albert Einstein | Feb 2020 | |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | P1 | terminated | 6 | University of Michigan Rogel Cancer Center | Jun 2020 | |
| NCT04056910 | AG-120 | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | P2 | completed | 15 | Jason J. Luke, MD | Sep 2021 |
| NCT03012581 | AcSé | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | P2 | completed | 269 | UNICANCER | Jun 2017 |
| NCT06163170 | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | — | completed | 100 | Bristol-Myers Squibb | Aug 2023 | |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | P2 | terminated | 34 | Arkadiusz Z. Dudek, MD | Jun 2018 | |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | P1 | completed | 261 | Bristol-Myers Squibb | Jun 2019 | |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | P1/P2 | completed | 20 | University of Washington | Jan 2019 | |
| NCT04892043 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | P1 | terminated | 5 | SQZ Biotechnologies | Aug 2021 | |
| NCT03944915 | DEPEND | De-Escalation Therapy for Human Papillomavirus Negative Disease | P2 | completed | 35 | University of Chicago | Aug 2019 |
| NCT04149574 | CheckMate 7G8 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) | P3 | terminated | 13 | Bristol-Myers Squibb | Jan 2020 |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | P1/P2 | completed | 76 | Mereo BioPharma | Mar 2021 | |
| NCT03728179 | RACIN | RACIN in Patients With Advanced TIL-negative Solid Tumors | P1 | completed | 40 | Centre Hospitalier Universitaire Vaudois | Jan 2019 |
| NCT03425292 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | P1 | completed | 49 | Saint John's Cancer Institute | Mar 2018 | |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | P2 | completed | 26 | Case Comprehensive Cancer Center | Aug 2017 | |
| NCT05116917 | INFLUENCE | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. | P2 | terminated | 19 | Herlev Hospital | Nov 2021 |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | Early P1 | terminated | 2 | Northwestern University | Feb 2019 | |
| NCT03669523 | DENIVOS | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) | P2 | completed | 82 | Centre Hospitalier Annecy Genevois | Nov 2018 |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | P2 | completed | 46 | Spanish Lung Cancer Group | Apr 2017 | |
| NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | P2 | completed | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2019 | |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | P1 | terminated | 21 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Sep 2020 | |
| NCT04187833 | Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes | P2 | completed | 8 | Case Comprehensive Cancer Center | Jun 2020 | |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | P2 | completed | 150 | M.D. Anderson Cancer Center | Apr 2015 | |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS | P2 | withdrawn | 0 | Yale University | Feb 2020 | |
| NCT03569696 | NivoM | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy | P2 | unknown | 50 | Meirav Kedmi MD | Oct 2018 |
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | P2 | active not recruiting | 36 | Robert R. McWilliams, MD | Sep 2017 | |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | P1/P2 | completed | 96 | HUYABIO International, LLC. | Aug 2016 | |
| NCT03447470 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | P1 | completed | 46 | Redx Pharma Ltd | Mar 2019 | |
| NCT04203901 | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | P2 | terminated | 16 | CoImmune | Jul 2020 | |
| NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | P2 | completed | 10 | Jonsson Comprehensive Cancer Center | Apr 2019 | |
| NCT04270864 | PRIMO | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers | P1 | terminated | 25 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2020 |
| NCT02350764 | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | P2 | completed | 29 | Memorial Sloan Kettering Cancer Center | Jan 2015 | |
| NCT04046614 | NintNivo | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology | P1/P2 | completed | 56 | AIO-Studien-gGmbH | May 2018 |
| NCT03523572 | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | P1 | completed | 86 | Daiichi Sankyo | Aug 2018 | |
| NCT01716806 | HL | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | P2 | completed | 131 | Seagen Inc. | Oct 2012 |
| NCT03521570 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | P2 | completed | 62 | Emory University | Jun 2018 | |
| NCT03529890 | RACE IT | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder | P2 | unknown | 33 | Technical University of Munich | Feb 2019 |
| NCT05435053 | CHECKPOINT | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer | P2 | terminated | 9 | Ismail Gögenur | Sep 2022 |
| NCT03190265 | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | P2 | completed | 61 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dec 2017 | |
| NCT03630640 | NIVOLEP | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation | P2 | completed | 43 | Assistance Publique - Hôpitaux de Paris | Oct 2018 |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | P3 | terminated | 15 | National Cancer Institute (NCI) | Dec 2020 | |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | P2 | completed | 25 | UNC Lineberger Comprehensive Cancer Center | Sep 2018 | |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | P1/P2 | terminated | 72 | Aravive, Inc. | Feb 2021 | |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | P1 | terminated | 5 | Fate Therapeutics | May 2022 | |
| NCT03293784 | TICIMEL | TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma | P1 | completed | 33 | Institut Claudius Regaud | Oct 2017 |
| NCT02532231 | Nivolumab in AML in Remission at High Risk for Relapse | P2 | completed | 15 | M.D. Anderson Cancer Center | Oct 2015 | |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | P1 | terminated | 4 | Washington University School of Medicine | Oct 2018 | |
| NCT03668119 | CheckMate 848 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | P2 | completed | 212 | Bristol-Myers Squibb | Oct 2018 |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | P1/P2 | unknown | 10 | National University Hospital, Singapore | Aug 2021 | |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | P1/P2 | unknown | 72 | National Taiwan University Hospital | Feb 2019 | |
| NCT05081674 | BLISS | Brazilian Lung Immunotherapy Study | P2 | completed | 154 | Hospital Israelita Albert Einstein | Jan 2020 |
| NCT03451331 | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | P2 | completed | 49 | Matthew Galsky | May 2018 | |
| NCT02009449 | IVY | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | P1 | completed | 353 | Eli Lilly and Company | Nov 2013 |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | P1 | completed | 78 | Ikena Oncology | Dec 2019 | |
| NCT03697564 | Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer | P2 | completed | 2 | Hitendra Patel | Oct 2019 | |
| NCT04212026 | IRE | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | P2 | terminated | 8 | University Hospital, Basel, Switzerland | Jun 2020 |
| NCT03927105 | BMS-986227 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | P2 | completed | 4 | University of Michigan Rogel Cancer Center | Apr 2019 |
| NCT04021420 | SONIMEL01 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma | P1/P2 | unknown | 21 | Assistance Publique - Hôpitaux de Paris | Oct 2019 |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | P1 | completed | 22 | Mirati Therapeutics Inc. | Aug 2020 | |
| NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | P2 | completed | 100 | Parker Institute for Cancer Immunotherapy | Oct 2018 | |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | P2 | unknown | 52 | Suthee Rapisuwon | Jul 2018 | |
| NCT03576612 | GMCI | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | P1 | completed | 41 | Candel Therapeutics, Inc. | Feb 2018 |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | P1/P2 | unknown | 26 | David Minor, MD | Oct 2016 | |
| NCT03493932 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | P1 | completed | 21 | National Institute of Neurological Disorders and Stroke (NINDS) | Sep 2018 | |
| NCT03573947 | TOP1705 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | P2 | completed | 46 | Jeffrey Clarke | Oct 2018 |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | P1/P2 | completed | 332 | Bristol-Myers Squibb | Aug 2017 | |
| NCT03742986 | IBC | Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | P2 | completed | 8 | NYU Langone Health | May 2019 |
| NCT03980925 | GEP | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | P2 | completed | 37 | Grupo Espanol de Tumores Neuroendocrinos | Oct 2019 |
| NCT03215810 | TIL | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | P1 | completed | 20 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2017 |
| NCT04209114 | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer | P3 | completed | 114 | Bristol-Myers Squibb | Feb 2020 | |
| NCT04612530 | IRE | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | P1 | unknown | 18 | Amsterdam UMC, location VUmc | Sep 2020 |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | P2 | completed | 205 | Bristol-Myers Squibb | Dec 2017 | |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | P2 | terminated | 1 | Dana-Farber Cancer Institute | Jun 2021 | |
| NCT04594811 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | P1 | terminated | 10 | NeoImmuneTech | Jan 2021 | |
| NCT02829918 | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | P2 | completed | 54 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2016 | |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | P2 | completed | 25 | Mirati Therapeutics Inc. | Oct 2018 | |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | P1 | terminated | 6 | Jonsson Comprehensive Cancer Center | Jul 2019 | |
| NCT03920631 | MicroBLITZ | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas | P1 | withdrawn | 0 | Ahmed Galal, MD | Jul 2020 |
| NCT05039736 | TKI | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Feb 2023 |
| NCT03841201 | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | P2 | completed | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Jun 2019 | |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | P1 | withdrawn | 0 | Ikena Oncology | Mar 2023 | |
| NCT03514901 | To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. | P2 | unknown | 120 | Intergruppo Melanoma Italiano | Jun 2018 | |
| NCT04107103 | NivoPlus | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma | P2 | completed | 6 | AHS Cancer Control Alberta | Mar 2020 |
| NCT02899299 | CheckMate743 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | P3 | completed | 605 | Bristol-Myers Squibb | Nov 2016 |
| NCT03033446 | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma | P2 | completed | 40 | National Cancer Centre, Singapore | Dec 2016 | |
| NCT03001882 | CheckMate 592 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | P2 | completed | 230 | Bristol-Myers Squibb | Mar 2017 |
| NCT04322643 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | P2 | terminated | 4 | Case Comprehensive Cancer Center | Mar 2020 | |
| NCT04577638 | AIRING | Accelerated Radio-Immunotherapy for Lung Cancer | P2 | completed | 8 | Center Eugene Marquis | Mar 2021 |
| NCT04953962 | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | P2 | completed | 36 | CanBas Co. Ltd. | Dec 2021 | |
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | P2 | completed | 2 | University of Chicago | Dec 2021 | |
| NCT02737787 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | P1 | completed | 11 | Memorial Sloan Kettering Cancer Center | Apr 2016 | |
| NCT03436862 | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | P2 | completed | 37 | SCRI Development Innovations, LLC | May 2018 | |
| NCT01928576 | NA_00084192 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | P2 | completed | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2013 |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | P2 | completed | 164 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT03006705 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | P3 | completed | 800 | Ono Pharmaceutical Co., Ltd. | Jan 2017 | |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | P1/P2 | completed | 140 | National Cancer Institute (NCI) | Mar 2015 | |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | P1 | completed | 190 | Astellas Pharma Global Development, Inc. | Jul 2018 | |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | P1 | terminated | 9 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2020 | |
| NCT03732664 | ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer | P1 | completed | 27 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Oct 2018 | |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | P2 | completed | 20 | Barbara Ann Karmanos Cancer Institute | Apr 2018 | |
| NCT04721301 | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | P1 | completed | 50 | University Hospital Heidelberg | Jan 2017 | |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | P1/P2 | completed | 39 | Gritstone bio, Inc. | Jul 2019 | |
| NCT04749602 | Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | P2 | completed | 26 | Kidney Cancer Research Bureau | Aug 2020 | |
| NCT04112498 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | P1 | completed | 24 | Bristol-Myers Squibb | Oct 2019 | |
| NCT04778904 | VTP-300 | First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV | P1/P2 | completed | 55 | Barinthus Biotherapeutics | Dec 2020 |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | P1/P2 | completed | 67 | Medical University of South Carolina | Jan 2016 | |
| NCT04208958 | ConsortiumIO | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer | P1/P2 | completed | 56 | Vedanta Biosciences, Inc. | Jan 2020 |
| NCT03219775 | TITAN-TCC | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma | P2 | unknown | 169 | AIO-Studien-gGmbH | Jul 2017 |
| NCT03310619 | PLATFORM | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | P1/P2 | completed | 62 | Celgene | Dec 2017 |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Apr 2022 | |
| NCT04084951 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | P1 | completed | 30 | SQZ Biotechnologies | Jan 2020 | |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer | P2 | terminated | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Dec 2017 | |
| NCT03063450 | CONFIRM | CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma | P3 | completed | 332 | University of Southampton | Mar 2017 |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | P2 | withdrawn | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2019 | |
| NCT03542461 | EDEN | Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) | P3 | unknown | 125 | Gruppo Oncologico Italiano di Ricerca Clinica | Sep 2017 |
| NCT04901988 | DETECTION | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION | P2/P3 | terminated | 8 | The Christie NHS Foundation Trust | Nov 2021 |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | P1/P2 | withdrawn | 0 | University of Southern California | Jan 2020 | |
| NCT03792724 | INTRUST | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors | P1/P2 | unknown | 32 | Clinica Universidad de Navarra, Universidad de Navarra | Jan 2019 |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | P2 | completed | 53 | M.D. Anderson Cancer Center | Feb 2016 | |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | P1 | completed | 9 | Memorial Sloan Kettering Cancer Center | Apr 2019 | |
| NCT04311710 | CheckMate 76U | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types | P1 | terminated | 21 | Bristol-Myers Squibb | Jun 2020 |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Feb 2022 | |
| NCT03554317 | COMBAT-CRPC | COMbination of Bipolar Androgen Therapy and Nivolumab | P2 | completed | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2018 |
| NCT01176474 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | P1 | completed | 73 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2010 | |
| NCT04319224 | JTX-2011 | Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | P1/P2 | terminated | 4 | Jounce Therapeutics, Inc. | Mar 2020 |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | P2 | unknown | 12 | Momotaro-Gene Inc. | Aug 2019 | |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | P2 | terminated | 14 | National Cancer Institute (NCI) | Aug 2020 | |
| NCT05471674 | Neoadjuvant Anti-PD1 in HCC | P2 | completed | 20 | Dr Tan-to CHEUNG | Jul 2020 | |
| NCT04377048 | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | P2 | unknown | 38 | National Taiwan University Hospital | Jul 2020 | |
| NCT04306042 | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy | — | unknown | 1,000 | Guangdong Association of Clinical Trials | Mar 2020 | |
| NCT04091490 | Nivo-DHAP | Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) | P2 | completed | 40 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Feb 2020 |
| NCT04131621 | CheCUP | Nivolumab/Ipilimumab in Second Line CUP-syndrome | P2 | unknown | 194 | University Hospital Heidelberg | Dec 2019 |
| NCT04061863 | KORNELIA | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer | P1/P2 | unknown | 90 | Seoul National University Hospital | Aug 2019 |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | P2 | terminated | 22 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | P2 | withdrawn | 0 | University of Texas Southwestern Medical Center | Mar 2018 | |
| NCT03047928 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | P1/P2 | completed | 48 | Inge Marie Svane | Feb 2018 | |
| NCT03177239 | UNISoN | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | P2 | unknown | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Oct 2017 |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | P1 | unknown | 219 | Infinity Pharmaceuticals, Inc. | Dec 2015 | |
| NCT04801966 | TAILOR | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | N/A | terminated | 3 | Peter MacCallum Cancer Centre, Australia | Sep 2021 |
| NCT03453892 | ST-ICI | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | — | completed | 150 | University of Erlangen-Nürnberg Medical School | Apr 2017 |
| NCT03414983 | CheckMate 9X8 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | P2/P3 | completed | 196 | Bristol-Myers Squibb | Feb 2018 |
| NCT03418922 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | P1 | completed | 30 | Eisai Co., Ltd. | Jan 2018 | |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | P2 | completed | 1 | Bristol-Myers Squibb | Oct 2022 | |
| NCT02181738 | CheckMate 205 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | P2 | completed | 294 | Bristol-Myers Squibb | Aug 2014 |
| NCT04887194 | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | P1 | completed | 40 | Mirati Therapeutics Inc. | Apr 2021 | |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | P1 | completed | 32 | National Cancer Institute (NCI) | Apr 2015 | |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | P1/P2 | completed | 106 | Bristol-Myers Squibb | Nov 2014 | |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | P2 | completed | 3 | National Cancer Institute (NCI) | May 2018 | |
| NCT03894891 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | P2 | completed | 6 | Dana-Farber Cancer Institute | Jun 2019 | |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | P2 | completed | 4 | Masonic Cancer Center, University of Minnesota | May 2019 | |
| NCT03798639 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | P1 | completed | 7 | Claire Verschraegen | Jan 2019 | |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | P2 | withdrawn | 0 | Jonsson Comprehensive Cancer Center | Dec 2019 | |
| NCT03834233 | CA209-9JC | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | P2 | unknown | 24 | Instituto do Cancer do Estado de São Paulo | Sep 2019 |
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | N/A | unknown | 1 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jul 2022 | |
| NCT04310709 | RENOBATE | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma | P2 | completed | 42 | Asan Medical Center | Jun 2020 |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | P1 | withdrawn | 0 | Vanderbilt-Ingram Cancer Center | Nov 2018 | |
| NCT02866383 | CheckPAC | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | P2 | completed | 160 | Herlev Hospital | Nov 2016 |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | P1/P2 | terminated | 47 | Sumitomo Pharma America, Inc. | Dec 2017 | |
| NCT03317327 | REPORT | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors | P1/P2 | completed | 20 | Oslo University Hospital | Sep 2017 |
| NCT02663518 | TTI-621 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | P1 | terminated | 249 | Pfizer | Jan 2016 |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | P1 | completed | 33 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2016 | |
| NCT03162731 | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer | Early P1 | completed | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | May 2017 | |
| NCT03980041 | MARIO-275 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | P2 | completed | 49 | Infinity Pharmaceuticals, Inc. | Sep 2019 |
| NCT03958045 | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | P2 | completed | 33 | Zhonglin Hao | Sep 2019 | |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | P1 | completed | 37 | Fate Therapeutics | Feb 2019 | |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | P1/P2 | completed | 29 | Gritstone bio, Inc. | Feb 2019 | |
| NCT02439450 | HS-110 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | P1/P2 | completed | 121 | Heat Biologics | Apr 2015 |
| NCT02917772 | TITAN-RCC | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma | P2 | completed | 200 | AIO-Studien-gGmbH | Oct 2016 |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | P1 | completed | 14 | Rutgers, The State University of New Jersey | Oct 2017 | |
| NCT02488759 | CheckMate358 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | P1/P2 | completed | 578 | Bristol-Myers Squibb | Oct 2015 |
| NCT03729245 | TKI | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | P3 | terminated | 623 | Nektar Therapeutics | Dec 2018 |
| NCT03562507 | ERICA | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | P2 | terminated | 8 | University of Michigan Rogel Cancer Center | Apr 2019 |
| NCT02864251 | CheckMate722 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | P3 | completed | 367 | Bristol-Myers Squibb | Mar 2017 |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | P1 | completed | 16 | Bayer | Oct 2018 | |
| NCT03605719 | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | P1 | completed | 23 | Emory University | Oct 2018 | |
| NCT03437200 | CRUCIAL | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer | P2 | terminated | 8 | European Organisation for Research and Treatment of Cancer - EORTC | Jan 2019 |
| NCT03532451 | PrE0807 | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | P1 | completed | 43 | PrECOG, LLC. | Mar 2019 |
| NCT03959761 | ICONIC | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma | P1/P2 | completed | 22 | Hospices Civils de Lyon | Oct 2019 |
| NCT03835533 | PORTER | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | P1 | completed | 43 | Parker Institute for Cancer Immunotherapy | Jun 2019 |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | P1 | terminated | 17 | Mayo Clinic | Mar 2018 | |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | P2/P3 | withdrawn | 0 | Shi Ming | Oct 2019 | |
| NCT04098432 | CA209-9KH | STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma | P1/P2 | completed | 15 | University Hospital Hradec Kralove | Dec 2018 |
| NCT03893695 | HCC | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | P1/P2 | completed | 20 | Suzhou Kintor Pharmaceutical Inc, | May 2019 |
| NCT04057365 | BTC | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | P2 | terminated | 15 | Massachusetts General Hospital | Oct 2019 |
| NCT04410445 | PIVOT-12 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | P3 | terminated | 765 | Nektar Therapeutics | Jul 2020 |
| NCT02741570 | CheckMate 651 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | P3 | completed | 947 | Bristol-Myers Squibb | Oct 2016 |
| NCT04655157 | QUAD01 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | P1/P2 | terminated | 2 | Jason J. Luke, MD | May 2021 |
| NCT03586999 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | P1/P2 | completed | 18 | University of Colorado, Denver | Nov 2018 | |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | P2 | completed | 30 | M.D. Anderson Cancer Center | Sep 2017 | |
| NCT03238365 | Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck | Early P1 | completed | 50 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Aug 2017 | |
| NCT02947386 | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | P1 | completed | 7 | Roswell Park Cancer Institute | Jun 2017 | |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | P1 | completed | 38 | Tempest Therapeutics | Mar 2019 | |
| NCT04277442 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | P1 | completed | 1 | National Cancer Institute (NCI) | Mar 2020 | |
| NCT03015740 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | P1/P2 | completed | 42 | M.D. Anderson Cancer Center | Apr 2017 | |
| NCT03219671 | CKS | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | P2 | unknown | 20 | Alona Zer | Apr 2018 |
| NCT03843515 | NeoNivo | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction | P1 | unknown | 17 | Amsterdam UMC, location VUmc | Apr 2019 |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | P1/P2 | unknown | 90 | Takayuki Yoshino | Oct 2016 | |
| NCT02481830 | CheckMate331 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | P3 | completed | 569 | Bristol-Myers Squibb | Sep 2015 |
| NCT03519256 | CheckMate 9UT | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder | P2 | terminated | 142 | Bristol-Myers Squibb | Aug 2018 |
| NCT03606174 | L | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | P2 | terminated | 260 | Mirati Therapeutics Inc. | Sep 2018 |
| NCT03004833 | NIVAHL | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | P2 | completed | 110 | University of Cologne | Feb 2017 |
| NCT04132817 | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | P1 | completed | 12 | Bristol-Myers Squibb | Sep 2020 | |
| NCT03970382 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | P1 | suspended | 21 | PACT Pharma, Inc. | Jul 2019 | |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | P2 | completed | 36 | Jonsson Comprehensive Cancer Center | Dec 2016 | |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | P2 | terminated | 14 | Georgetown University | Jul 2017 | |
| NCT04620954 | ORION-02 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | P1/P2 | unknown | 31 | National Cancer Centre, Singapore | Oct 2020 |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | P1 | terminated | 2 | University of California, San Francisco | Aug 2020 | |
| NCT03987815 | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | P2 | unknown | 20 | Samsung Medical Center | Aug 2019 | |
| NCT04017897 | The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma | P2 | unknown | 52 | Yonsei University | Jul 2019 | |
| NCT03525925 | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | P1 | completed | 16 | Ohio State University Comprehensive Cancer Center | Jul 2018 | |
| NCT03351361 | eNERGY | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients | P3 | completed | 217 | Rennes University Hospital | Feb 2018 |
| NCT05468294 | Nivokin | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer | P1/P2 | unknown | 3 | Philogen S.p.A. | Mar 2017 |
| NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | P1 | completed | 19 | Washington University School of Medicine | Sep 2018 | |
| NCT03785925 | PIVOT-10 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | P2 | completed | 192 | Nektar Therapeutics | Apr 2019 |
| NCT03149120 | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | P2 | withdrawn | 0 | NYU Langone Health | Aug 2017 | |
| NCT04730349 | PIVOT IO 020 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | P1/P2 | terminated | 15 | Bristol-Myers Squibb | Jun 2021 |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | P1 | withdrawn | 0 | National Cancer Institute (NCI) | May 2021 | |
| NCT03620123 | OPTIM | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | P2 | completed | 54 | AIO-Studien-gGmbH | Jul 2018 |
| NCT03684811 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | P1/P2 | completed | 93 | Forma Therapeutics, Inc. | Nov 2018 | |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | Early P1 | withdrawn | 0 | Presage Biosciences | Sep 2021 | |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | P2 | unknown | 22 | National Cancer Center, Korea | Jan 2019 | |
| NCT03226756 | TopNIVO | Nivolumab in Recurrent and/or Metastatic SCCHN | P2 | completed | 351 | UNICANCER | Jul 2017 |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | P3 | completed | 541 | Bristol-Myers Squibb | Mar 2014 | |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | P1 | terminated | 10 | Augusta University | Jan 2020 | |
| NCT03507699 | Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer | P1 | completed | 19 | Sheba Medical Center | Dec 2018 | |
| NCT02857569 | NIVIPIT | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma | P1/P2 | completed | 90 | Gustave Roussy, Cancer Campus, Grand Paris | Dec 2016 |
| NCT03406715 | SCLC | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | P2 | terminated | 14 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2018 |
| NCT04050085 | SD-101 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | P1 | completed | 6 | University of California, Davis | Aug 2019 |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | P4 | completed | 1,041 | Bristol-Myers Squibb | Oct 2016 | |
| NCT03409198 | ICON | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | P2 | completed | 82 | Oslo University Hospital | Jan 2018 |
| NCT02935634 | FRACTION-GC | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | P2 | completed | 190 | Bristol-Myers Squibb | Nov 2016 |
| NCT03435640 | REVEAL | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | P1/P2 | terminated | 64 | Nektar Therapeutics | Mar 2018 |
| NCT02970981 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | P2 | completed | 18 | NYU Langone Health | Nov 2016 | |
| NCT03865082 | ILLUMINATE-206 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | P2 | active not recruiting | 30 | Idera Pharmaceuticals, Inc. | Oct 2019 |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | P2 | terminated | 7 | Abramson Cancer Center at Penn Medicine | Jul 2019 | |
| NCT02983045 | PIVOT-02 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | P1/P2 | completed | 557 | Nektar Therapeutics | Dec 2016 |
| NCT04118166 | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | P2 | completed | 30 | Kristen Ganjoo | Oct 2019 | |
| NCT02823574 | CheckMate 714 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | P2 | completed | 425 | Bristol-Myers Squibb | Nov 2016 |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | P2 | terminated | 7 | Abramson Cancer Center at Penn Medicine | Nov 2018 | |
| NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | Early P1 | terminated | 3 | Abramson Cancer Center at Penn Medicine | Jul 2020 | |
| NCT02154490 | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | — | completed | 1,864 | SWOG Cancer Research Network | Jul 2014 | |
| NCT02712905 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | P1/P2 | terminated | 116 | Incyte Corporation | May 2016 | |
| NCT03431948 | C4-MOSART | Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer | P1 | completed | 60 | University of Chicago | Mar 2018 |
| NCT04122625 | SMARTPLUS-106 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | P1/P2 | completed | 46 | Debiopharm International SA | Apr 2019 |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | P1/P2 | completed | 21 | Shanghai Chest Hospital | Nov 2020 | |
| NCT03917537 | WGA in Platinum-refractory HNSCC Underwent Nivolumab | — | unknown | 80 | Chang Gung Memorial Hospital | Apr 2018 | |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | P2 | terminated | 2 | Andrew Yee, MD | Feb 2020 | |
| NCT04126733 | Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | P2 | completed | 70 | Bayer | Oct 2019 | |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | Early P1 | terminated | 1 | Presage Biosciences | Oct 2021 | |
| NCT03949153 | CRIRIN | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis | P1/P2 | completed | 19 | University Hospital, Strasbourg, France | Aug 2019 |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | P2 | completed | 10 | NYU Langone Health | Feb 2018 | |
| NCT03396211 | A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer | P1 | completed | 30 | Elevar Therapeutics | Dec 2017 | |
| NCT03090737 | CheckMate 907 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer | P2 | completed | 129 | Bristol-Myers Squibb | Jun 2017 |
| NCT03168464 | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | P1/P2 | terminated | 15 | Weill Medical College of Cornell University | Oct 2017 | |
| NCT02726581 | CheckMate 602 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | P3 | completed | 170 | Bristol-Myers Squibb | Aug 2016 |
| NCT03298893 | NiCOL | Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL) | P1/P2 | completed | 21 | Institut Curie | Nov 2017 |
| NCT02659059 | CheckMate 568 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer | P2 | completed | 324 | Bristol-Myers Squibb | Feb 2016 |
| NCT03409848 | INTEGA | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma | P2 | completed | 97 | AIO-Studien-gGmbH | Mar 2018 |
| NCT03817125 | MCGRAW | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | P1 | completed | 14 | Parker Institute for Cancer Immunotherapy | Jan 2019 |
| NCT02617589 | CheckMate 498 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | P3 | completed | 560 | Bristol-Myers Squibb | Mar 2016 |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | P1 | terminated | 15 | National Cancer Institute (NCI) | Aug 2013 | |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | P2 | terminated | 10 | Barbara Ann Karmanos Cancer Institute | Nov 2019 | |
| NCT03040791 | ImmunoProst | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) | P2 | unknown | 38 | Hospital Moinhos de Vento | Jun 2018 |
| NCT03146468 | NIVALLO | Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation | P2 | unknown | 14 | Melbourne Health | May 2017 |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | P1/P2 | completed | 24 | Genocea Biosciences, Inc. | Aug 2018 | |
| NCT03214250 | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | P1/P2 | completed | 129 | Parker Institute for Cancer Immunotherapy | Jul 2017 | |
| NCT02764593 | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | P1 | completed | 40 | RTOG Foundation, Inc. | Jun 2016 | |
| NCT03304093 | CHIVA2 | Immunotherapy by Nivolumab for HIV+ Patients | P2 | completed | 30 | Intergroupe Francophone de Cancerologie Thoracique | Oct 2017 |
| NCT03444753 | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | P1 | terminated | 82 | Bristol-Myers Squibb | Apr 2018 | |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | P2 | completed | 37 | M.D. Anderson Cancer Center | Jun 2015 | |
| NCT03590210 | NiTraSarc | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas | P2 | completed | 92 | University Medicine Greifswald | Jun 2018 |
| NCT03121534 | Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation | P2 | terminated | 9 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT03461952 | NIMBLe | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | P2 | terminated | 4 | Canadian Cancer Trials Group | Mar 2019 |
| NCT02329847 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | P1/P2 | completed | 144 | Janssen Research & Development, LLC | Mar 2015 | |
| NCT02581631 | CheckMate 436 | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | P1/P2 | completed | 145 | Bristol-Myers Squibb | Feb 2016 |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | P2 | terminated | 14 | Wake Forest University Health Sciences | Nov 2018 | |
| NCT02046733 | STIMULI | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | P2 | completed | 222 | ETOP IBCSG Partners Foundation | Dec 2015 |
| NCT04955262 | NKTR-214 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | P1 | withdrawn | 0 | Nektar Therapeutics | Aug 2019 |
| NCT05714371 | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | — | completed | 618 | Novartis Pharmaceuticals | Oct 2021 | |
| NCT03417154 | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | P2 | completed | 12 | Masonic Cancer Center, University of Minnesota | Aug 2018 | |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | P1 | terminated | 15 | Celgene | Jul 2019 | |
| NCT02713867 | CheckMate 384 | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks | P3 | completed | 363 | Bristol-Myers Squibb | May 2016 |
| NCT03130959 | CheckMate 908 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | P2 | completed | 166 | Bristol-Myers Squibb | Jun 2017 |
| NCT03262779 | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | P2 | completed | 20 | Yale University | Jul 2017 | |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | P2 | unknown | 70 | The First Affiliated Hospital with Nanjing Medical University | Jan 2020 | |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | P1/P2 | withdrawn | 0 | HealthPartners Institute | Sep 2020 | |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | P2 | unknown | 8 | Kidney Cancer Research Bureau | Oct 2019 | |
| NCT04761744 | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | P2 | unknown | 48 | Korean Cancer Study Group | Jun 2019 | |
| NCT03169777 | CRC | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | P1/P2 | withdrawn | 0 | ImmunityBio, Inc. | Aug 2018 |
| NCT03169738 | NSCLC | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | P1/P2 | withdrawn | 0 | ImmunityBio, Inc. | Feb 2018 |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | P1/P2 | withdrawn | 0 | ImmunityBio, Inc. | Dec 2017 | |
| NCT03169764 | HNSCC | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | P1/P2 | withdrawn | 0 | ImmunityBio, Inc. | Dec 2017 |
| NCT05170685 | Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab | — | no longer available | 0 | Bristol-Myers Squibb | — | |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | Flame Biosciences | Aug 2021 | |
| NCT03251924 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | P1/P2 | terminated | 80 | Bristol-Myers Squibb | Sep 2017 | |
| NCT01673867 | CheckMate057 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | P3 | completed | 582 | Bristol-Myers Squibb | Nov 2012 |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | P1/P2 | terminated | 20 | Apollomics (Australia) Pty. Ltd. | Sep 2018 | |
| NCT03572582 | IMMUTACE | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma | P2 | completed | 49 | AIO-Studien-gGmbH | Jun 2018 |
| NCT04936399 | EAMS | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | — | completed | 87 | Bristol-Myers Squibb | Jun 2020 |
| NCT05611229 | Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | completed | 1,975 | Novartis Pharmaceuticals | Jun 2020 | |
| NCT03711188 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | P2 | completed | 16 | Immodulon Therapeutics Ltd | Oct 2018 | |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | P1/P2 | completed | 34 | Sarcoma Oncology Research Center, LLC | Aug 2017 | |
| NCT04570683 | Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas | Early P1 | unknown | 30 | Bispebjerg Hospital | Jan 2020 | |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | P2 | terminated | 19 | WindMIL Therapeutics | Oct 2019 | |
| NCT02426892 | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | P2 | completed | 33 | M.D. Anderson Cancer Center | Dec 2015 | |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | P2 | terminated | 5 | Dana-Farber Cancer Institute | Apr 2018 | |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | P2 | terminated | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2018 | |
| NCT04258150 | TRIPPLE-R | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | P2 | terminated | 26 | Herlev Hospital | Apr 2020 |
| NCT02996110 | FRACTION-RCC | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | P2 | completed | 182 | Bristol-Myers Squibb | Feb 2017 |
| NCT05535569 | EBV | Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer | P1/P2 | completed | 50 | Yonsei University | Jul 2017 |
| NCT03416244 | RAMONA | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer | P2 | completed | 66 | AIO-Studien-gGmbH | Feb 2018 |
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | P2 | terminated | 5 | Bristol-Myers Squibb | Sep 2020 | |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | P2 | completed | 17 | Medical University of South Carolina | May 2017 | |
| NCT02387996 | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | P2 | completed | 270 | Bristol-Myers Squibb | Mar 2015 | |
| NCT02538666 | CheckMate 451 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | P3 | completed | 907 | Bristol-Myers Squibb | Oct 2015 |
| NCT03126110 | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | P1/P2 | completed | 145 | Incyte Biosciences International Sàrl | Apr 2017 | |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | P2 | terminated | 161 | Mirati Therapeutics Inc. | Nov 2016 | |
| NCT03903640 | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | P2 | terminated | 2 | Washington University School of Medicine | Oct 2019 | |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | P1 | completed | 10 | Emory University | Dec 2017 | |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | P1/P2 | completed | 627 | Bristol-Myers Squibb | Apr 2016 | |
| NCT03663166 | NSCLC | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | P1/P2 | terminated | 19 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2018 |
| NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | P1/P2 | completed | 93 | Seagen Inc. | Oct 2015 | |
| NCT03132038 | NISCAHN | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | P2 | completed | 98 | UNICANCER | Mar 2017 |
| NCT05068609 | VOLUME-PRO | A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) | — | completed | 509 | Bristol-Myers Squibb | Aug 2020 |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | P1/P2 | completed | 235 | Bristol-Myers Squibb | Jun 2016 | |
| NCT02636036 | SPICE | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors | P1 | completed | 51 | Akamis Bio | Jan 2016 |
| NCT02982954 | CHECKMATE 920 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | P4 | completed | 211 | Bristol-Myers Squibb | Jan 2017 |
| NCT02601014 | STARVE-PC | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | P2 | completed | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2016 |
| NCT02066636 | CheckMate153 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen | P3 | completed | 1,428 | Bristol-Myers Squibb | Apr 2014 |
| NCT03299946 | HCC | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | P1 | completed | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2018 |
| NCT03832621 | MAYA | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | P2 | completed | 135 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Mar 2019 |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | P2 | unknown | 17 | Northwestern University | Jul 2017 | |
| NCT02593786 | CheckMate 077 | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors | P1/P2 | completed | 58 | Bristol-Myers Squibb | Jan 2016 |
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | P2 | completed | 8 | Dana-Farber Cancer Institute | Oct 2016 | |
| NCT04413838 | NIVISCO | Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection | P2 | unknown | 120 | Hospices Civils de Lyon | Jun 2020 |
| NCT03798314 | Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | P1 | completed | 3 | Mayo Clinic | Jan 2019 | |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | P3 | completed | 361 | Bristol-Myers Squibb | May 2014 | |
| NCT04430985 | IMMUNOX | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | P2 | withdrawn | 0 | Dorte Nielsen | Sep 2020 |
| NCT03800602 | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | P2 | completed | 29 | Emory University | Jan 2019 | |
| NCT04393220 | Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma | P2 | completed | 60 | Fuda Cancer Hospital, Guangzhou | May 2020 | |
| NCT04356508 | COVID-19 | COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 | P2 | unknown | 15 | Dr Gerry Gin Wai Kwok | Apr 2020 |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | P1 | completed | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2016 | |
| NCT02409368 | Checkmate 171 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | P2 | completed | 812 | Bristol-Myers Squibb | Apr 2015 |
| NCT03335540 | ADVISE | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | P1 | completed | 20 | Bristol-Myers Squibb | May 2018 |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | P1 | completed | 8 | Roswell Park Cancer Institute | Mar 2018 | |
| NCT03925246 | REVOLUMAB | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas | P2 | completed | 43 | Assistance Publique - Hôpitaux de Paris | Jul 2019 |
| NCT01642004 | NSCLC | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | P3 | completed | 272 | Bristol-Myers Squibb | Oct 2012 |
| NCT03580408 | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | P2 | completed | 64 | The Lymphoma Academic Research Organisation | Aug 2018 | |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | P1 | completed | 12 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2019 | |
| NCT03834623 | CC-122 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | P2 | completed | 23 | H. Lee Moffitt Cancer Center and Research Institute | May 2019 |
| NCT04503967 | OASIS | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer | P2 | unknown | 48 | Shanghai Zhongshan Hospital | Aug 2020 |
| NCT03246958 | Nivolumab Plus Ipilimumab in Thyroid Cancer | P2 | completed | 53 | Dana-Farber Cancer Institute | Oct 2017 | |
| NCT02799901 | NIRVANA | Nivolumab Plus Radiotherapy in Advanced Melanoma | P2 | completed | 72 | Centre Hospitalier Universitaire de Nice | Mar 2017 |
| NCT04075604 | CheckMate 7A8 | A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | P2 | completed | 23 | Bristol-Myers Squibb | Oct 2019 |
| NCT01454102 | BMS-936558 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | P1 | completed | 472 | Bristol-Myers Squibb | Dec 2011 |
| NCT02939300 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | P2 | completed | 18 | Massachusetts General Hospital | Feb 2018 | |
| NCT02626962 | GEM1402 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | P2 | completed | 52 | Grupo Español Multidisciplinar de Melanoma | Apr 2016 |
| NCT01668784 | BMS-936558 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | P3 | completed | 821 | Bristol-Myers Squibb | Oct 2012 |
| NCT03469713 | NIVES | Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma | P2 | completed | 69 | Gruppo Oncologico Italiano di Ricerca Clinica | Jul 2017 |
| NCT03294304 | MIBC | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | P2 | completed | 43 | Masonic Cancer Center, University of Minnesota | Jan 2018 |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Nov 2017 | |
| NCT03636477 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | P1 | completed | 21 | Alaunos Therapeutics | Jun 2018 | |
| NCT03316274 | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma | Early P1 | completed | 12 | University of California, San Francisco | May 2018 | |
| NCT03371992 | NO3DEXPL | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC | Early P1 | unknown | 25 | Nilogen Oncosystems | Mar 2018 |
| NCT03013335 | NIVOREN | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen | P2 | completed | 730 | UNICANCER | Jan 2016 |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | P2 | completed | 167 | Prof. Dr. med. Dirk Schadendorf | Sep 2015 | |
| NCT02832167 | CheckMate 627 | An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread | P2 | completed | 239 | Bristol-Myers Squibb | Feb 2016 |
| NCT03952325 | CONTESSA TRIO | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | P2 | terminated | 294 | Odonate Therapeutics, Inc. | Jul 2019 |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | P1/P2 | completed | 28 | AVEO Pharmaceuticals, Inc. | Mar 2017 | |
| NCT04434560 | Neoadjuvant Immunotherapy in Brain Metastases | P2 | terminated | 1 | Sarah Sammons, MD | Nov 2020 | |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | P1 | completed | 71 | National Cancer Institute (NCI) | May 2013 | |
| NCT03195491 | CheckMate870 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia | P3 | completed | 400 | Bristol-Myers Squibb | Dec 2017 |
| NCT03101566 | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | P2 | completed | 75 | University of Michigan Rogel Cancer Center | Sep 2017 | |
| NCT01472081 | RCC | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | P1 | completed | 194 | Bristol-Myers Squibb | Feb 2012 |
| NCT04299880 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | P1 | completed | 7 | Sumitomo Pharma America, Inc. | Feb 2020 | |
| NCT04023617 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | P2 | unknown | 72 | Peking University Cancer Hospital & Institute | Jul 2019 | |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | P3 | completed | 387 | Bristol-Myers Squibb | Apr 2016 | |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma | P2 | terminated | 7 | University of Texas Southwestern Medical Center | Jun 2016 | |
| NCT02596035 | CheckMate 374 | An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma | P4 | completed | 197 | Bristol-Myers Squibb | Jan 2016 |
| NCT01721772 | CheckMate 066 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | P3 | completed | 418 | Bristol-Myers Squibb | Jan 2013 |
| NCT03646461 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | P2 | terminated | 5 | University of California, San Diego | Oct 2018 | |
| NCT06440187 | HN17-11 | Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 | P2 | completed | 38 | Seoul National University Hospital | Jun 2018 |
| NCT01721759 | BMS-936558 | Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens | P2 | completed | 117 | Bristol-Myers Squibb | Nov 2012 |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | P1 | withdrawn | 0 | SCRI Development Innovations, LLC | Apr 2020 | |
| NCT01354431 | MDX-1106 | BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | P2 | completed | 168 | Bristol-Myers Squibb | May 2011 |
| NCT03647839 | MODULATE | Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer | P2 | completed | 90 | Australasian Gastro-Intestinal Trials Group | Sep 2018 |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | P1 | completed | 6 | Icahn School of Medicine at Mount Sinai | May 2018 | |
| NCT04771715 | PD-1 | Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer | — | unknown | 100 | Peking Union Medical College Hospital | May 2019 |
| NCT03879811 | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | P2 | withdrawn | 0 | Memorial Sloan Kettering Cancer Center | Mar 2019 | |
| NCT03307603 | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | P1/P2 | withdrawn | 0 | Case Comprehensive Cancer Center | Dec 2018 | |
| NCT03656627 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | P1 | terminated | 7 | Alliance Foundation Trials, LLC. | Jun 2019 | |
| NCT02419417 | BET | Study of BMS-986158 in Subjects With Select Advanced Cancers | P1/P2 | completed | 83 | Bristol-Myers Squibb | Jun 2015 |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | P1/P2 | terminated | 8 | Edward Kim | Oct 2018 | |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | P2 | terminated | 11 | Abramson Cancer Center at Penn Medicine | Feb 2019 | |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | P1 | terminated | 6 | Jonsson Comprehensive Cancer Center | Jun 2018 | |
| NCT04149275 | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | P2 | withdrawn | 0 | University of Alabama at Birmingham | Feb 2021 | |
| NCT03823625 | SQUINT | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) | P2 | unknown | 112 | Fondazione Ricerca Traslazionale | Sep 2017 |
| NCT01927419 | CheckMate 069 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | P2 | completed | 142 | Bristol-Myers Squibb | Aug 2013 |
| NCT03271047 | MSS | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | P2 | completed | 75 | Pfizer | Oct 2017 |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | P2 | completed | 13 | Megan Daly, MD | Dec 2016 | |
| NCT02899078 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | P1/P2 | completed | 31 | University of California, Davis | Nov 2016 | |
| NCT03138499 | CheckMate 812 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, | P3 | terminated | 23 | Bristol-Myers Squibb | Jun 2017 |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Feb 2021 | |
| NCT03353675 | NSCLC | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | P2 | completed | 44 | Transgene | Jan 2018 |
| NCT02960906 | BIONIKK | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | P2 | completed | 200 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | May 2017 |
| NCT03003637 | IMCISION | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | P1/P2 | completed | 33 | The Netherlands Cancer Institute | Feb 2017 |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | P2 | terminated | 64 | Novartis Pharmaceuticals | Feb 2015 | |
| NCT03071094 | HCC | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | P1/P2 | terminated | 14 | Transgene | Jul 2017 |
| NCT03068455 | CheckMate 915 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma | P3 | completed | 1,844 | Bristol-Myers Squibb | Apr 2017 |
| NCT03782064 | DC | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | P2 | terminated | 5 | Beth Israel Deaconess Medical Center | Feb 2019 |
| NCT03453164 | CIRCUIT | Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) | P1/P2 | completed | 41 | Fukushima Medical University | Mar 2018 |
| NCT02959554 | NIVOSWITCH | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control | P2 | terminated | 49 | AIO-Studien-gGmbH | Dec 2016 |
| NCT03347123 | ECHO-208 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | P1/P2 | terminated | 11 | Incyte Corporation | Mar 2018 |
| NCT02467361 | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | P1 | completed | 104 | Sumitomo Pharma America, Inc. | Aug 2015 | |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | P2 | completed | 20 | National Cancer Institute (NCI) | May 2015 | |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | P2 | terminated | 5 | Baptist Health South Florida | Dec 2018 | |
| NCT04042506 | SBRT as a Vaccination for Metastatic Melanoma | P2 | withdrawn | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2019 | |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | P1/P2 | terminated | 7 | Oncovir, Inc. | Sep 2018 | |
| NCT02702492 | PANAMA | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | P1 | terminated | 60 | Karyopharm Therapeutics Inc | Jun 2016 |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | P2 | terminated | 3 | John Hays | Oct 2018 | |
| NCT02684253 | SBRT | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | P2 | completed | 65 | Memorial Sloan Kettering Cancer Center | Feb 2016 |
| NCT02949843 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | P2 | terminated | 19 | Wake Forest University Health Sciences | Mar 2017 | |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | P2 | terminated | 47 | NewLink Genetics Corporation | Jun 2014 | |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | P2 | terminated | 6 | University Hospital Tuebingen | Apr 2018 | |
| NCT02983006 | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | P1 | completed | 12 | NYU Langone Health | Oct 2016 | |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | P1 | terminated | 3 | Washington University School of Medicine | Oct 2018 | |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | P2 | unknown | 60 | Assaf-Harofeh Medical Center | Dec 2017 | |
| NCT03044626 | FORCE | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC | P2 | completed | 101 | AIO-Studien-gGmbH | Feb 2017 |
| NCT03963518 | SURROGATE-ICI | Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI) | — | completed | 631 | Institut Bergonié | Jan 2017 |
| NCT02856451 | Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab | — | completed | 486 | Bristol-Myers Squibb | Dec 2015 | |
| NCT03661632 | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | P1 | completed | 27 | Bristol-Myers Squibb | Sep 2018 | |
| NCT02038946 | FL | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | P2 | completed | 116 | Bristol-Myers Squibb | Mar 2014 |
| NCT03792750 | A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors | P1/P2 | completed | 12 | Bristol-Myers Squibb | Dec 2018 | |
| NCT03406871 | REGONIVO | Regorafenib and Nivolumab Simultaneous Combination Therapy | P1 | completed | 50 | Kohei Shitara | Jan 2018 |
| NCT03878524 | SMMART | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | P1 | terminated | 2 | OHSU Knight Cancer Institute | Apr 2020 |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | Early P1 | terminated | 6 | Yale University | Feb 2018 | |
| NCT02857426 | CheckMate 647 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | P2 | completed | 66 | Bristol-Myers Squibb | Oct 2016 |
| NCT03250273 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | P2 | completed | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2017 | |
| NCT03065179 | RADVAX | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients | P2 | completed | 29 | University of Texas Southwestern Medical Center | Mar 2017 |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | P1/P2 | completed | 140 | Apexigen America, Inc. | Jul 2017 | |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer | P2 | terminated | 4 | Brown University | Nov 2018 | |
| NCT02831933 | ENSIGN | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma | P2 | terminated | 11 | Eric Bernicker, MD | Feb 2017 |
| NCT03380130 | NASIR-HCC | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC | P2 | completed | 41 | Clinica Universidad de Navarra, Universidad de Navarra | Sep 2017 |
| NCT02737475 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | P1/P2 | completed | 166 | Bristol-Myers Squibb | Jun 2016 | |
| NCT02837029 | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | P1 | completed | 27 | Northwestern University | Jul 2016 | |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT03354962 | BOOSTER MELANOMA | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | P1/P2 | terminated | 6 | Institut Claudius Regaud | Oct 2018 |
| NCT02569242 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | P3 | completed | 419 | Ono Pharmaceutical Co., Ltd. | Dec 2015 | |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | P2 | terminated | 6 | Weill Medical College of Cornell University | Nov 2016 | |
| NCT02038933 | DLBCL | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | P2 | completed | 121 | Bristol-Myers Squibb | Mar 2014 |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | P2 | completed | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Nov 2017 | |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | P1/P2 | terminated | 12 | University of Chicago | Aug 2018 | |
| NCT04343144 | CORIMUNO-NIVO | Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort. | P2 | unknown | 92 | Assistance Publique - Hôpitaux de Paris | Apr 2020 |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | P1 | withdrawn | 0 | Sherif Farag | Oct 2019 | |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | P2 | terminated | 7 | University of Utah | Jan 2018 | |
| NCT02320058 | CheckMate204 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself | P2 | completed | 119 | Bristol-Myers Squibb | Mar 2015 |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | Early P1 | completed | 11 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2016 | |
| NCT03824704 | ARIES | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | P2 | terminated | 1 | pharmaand GmbH | Aug 2019 |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | P1/P2 | terminated | 6 | Washington University School of Medicine | May 2019 | |
| NCT02213289 | PANGEA-IMBBP | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | P2 | completed | 80 | University of Chicago | Jan 2015 |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | P2 | completed | 138 | Bristol-Myers Squibb | Apr 2013 | |
| NCT03597282 | NEO-PV-01 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | P1 | terminated | 22 | BioNTech US Inc. | Oct 2018 |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | P1/P2 | completed | 9 | Georgetown University | Nov 2017 | |
| NCT03203876 | A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | P1 | completed | 10 | Bristol-Myers Squibb | Jul 2017 | |
| NCT03061188 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | P1 | completed | 15 | Northwestern University | May 2017 | |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | P1 | terminated | 19 | National Cancer Institute (NCI) | May 2016 | |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | P1/P2 | withdrawn | 0 | H. Lee Moffitt Cancer Center and Research Institute | Jul 2018 | |
| NCT02852083 | ModuLung | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC | P2 | unknown | 86 | University Hospital Regensburg | Jan 2016 |
| NCT03023904 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | P2 | withdrawn | 0 | Vanderbilt-Ingram Cancer Center | Dec 2017 | |
| NCT02659540 | Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | P1 | completed | 20 | Ludwig Institute for Cancer Research | Oct 2016 | |
| NCT04707547 | RFA | Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy | P4 | completed | 5 | Taipei Medical University WanFang Hospital | Oct 2019 |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | P1 | terminated | 2 | Medical College of Wisconsin | Sep 2018 | |
| NCT02628574 | Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | P1 | completed | 109 | Leap Therapeutics, Inc. | Jan 2016 | |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | P2 | terminated | 21 | University of Washington | Jun 2017 | |
| NCT02973113 | PREVALE | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | P1 | completed | 8 | Baylor College of Medicine | Feb 2016 |
| NCT02423343 | LY2157299 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | P1/P2 | completed | 41 | Eli Lilly and Company | Jan 2015 |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | P1/P2 | completed | 105 | Bristol-Myers Squibb | Jun 2017 | |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | P3 | completed | 20 | Bristol-Myers Squibb | Nov 2017 | |
| NCT03296137 | Adoptive Cell Therapy Across Cancer Diagnoses | P1/P2 | completed | 25 | Inge Marie Svane | Oct 2017 | |
| NCT02904226 | ICONIC | JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | P1/P2 | completed | 242 | Jounce Therapeutics, Inc. | Aug 2016 |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | P1 | terminated | 7 | SignalRX Pharmaceuticals, Inc. | Mar 2017 | |
| NCT03815942 | ADVANCE | VAccination in Early and ADvanced Prostate caNCEr | P1/P2 | terminated | 23 | University of Oxford | Dec 2018 |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | P1/P2 | completed | 13 | University of Michigan Rogel Cancer Center | Mar 2017 | |
| NCT02985554 | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies | P1 | terminated | 3 | University of Chicago | Mar 2017 | |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | P1 | terminated | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2019 | |
| NCT02327078 | ECHO-204 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | P1/P2 | completed | 307 | Incyte Corporation | Nov 2014 |
| NCT03599362 | SBRT | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | P2 | terminated | 7 | NYU Langone Health | Jul 2018 |
| NCT03993626 | CAROSELL | A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer | P1/P2 | unknown | 55 | Celleron Therapeutics Ltd. | May 2018 |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | P1 | withdrawn | 0 | National Cancer Centre, Singapore | Dec 2019 | |
| NCT02612779 | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | P2 | completed | 74 | Bristol-Myers Squibb | Feb 2016 | |
| NCT02575222 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | P1 | completed | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2016 | |
| NCT03808168 | Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia | P2 | withdrawn | 0 | University of Texas Southwestern Medical Center | Jan 2019 | |
| NCT03287674 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | P1/P2 | completed | 7 | Inge Marie Svane | Oct 2017 | |
| NCT02897765 | NEO-PV-01 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | P1 | completed | 34 | BioNTech US Inc. | Oct 2016 |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | P2 | terminated | 2 | Elizabeth Davis | Jan 2019 | |
| NCT03511222 | X-82 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | P1 | terminated | 16 | Washington University School of Medicine | Sep 2018 |
| NCT04659551 | GIADA | Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | P2 | completed | 43 | Istituto Oncologico Veneto IRCCS | Oct 2017 |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | P2 | completed | 47 | National Cancer Institute (NCI) | May 2016 | |
| NCT03758729 | Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. | P2 | withdrawn | 0 | Samsung Medical Center | May 2020 | |
| NCT02464657 | MDS | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | P1/P2 | completed | 44 | M.D. Anderson Cancer Center | Jul 2015 |
| NCT02341625 | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | P1/P2 | terminated | 126 | Bristol-Myers Squibb | Jun 2015 | |
| NCT03652142 | Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma | — | unknown | 50 | Attikon Hospital | May 2018 | |
| NCT02771626 | NSCLC | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | P1/P2 | terminated | 118 | Calithera Biosciences, Inc | Aug 2016 |
| NCT03100006 | ORION-01 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | P1/P2 | terminated | 13 | National Cancer Centre, Singapore | Feb 2017 |
| NCT02574078 | CheckMate370 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | P1/P2 | completed | 341 | Bristol-Myers Squibb | Nov 2015 |
| NCT02848443 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | P1 | completed | 78 | Institut de Recherches Internationales Servier | May 2016 | |
| NCT02901145 | Nivolumab in Relapsed Pediatric Solid Tumors | P1/P2 | unknown | 30 | Hadassah Medical Organization | Nov 2016 | |
| NCT02946671 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | P1 | completed | 16 | Osaka University | Mar 2016 | |
| NCT02434081 | NICOLAS | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma | P2 | completed | 94 | ETOP IBCSG Partners Foundation | Nov 2015 |
| NCT03343652 | NB001 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma | P1/P2 | completed | 30 | St. Petersburg State Pavlov Medical University | May 2017 |
| NCT02859324 | HCC | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | P1/P2 | completed | 21 | Celgene | Sep 2016 |
| NCT05802290 | NIVACTOR | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN | P3 | completed | 124 | Gruppo Oncologico del Nord-Ovest | Nov 2017 |
| NCT02118337 | AMP-514 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | P1/P2 | completed | 97 | MedImmune LLC | May 2014 |
| NCT03382912 | Cypress 2 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer | P2 | terminated | 52 | Eli Lilly and Company | Mar 2018 |
| NCT03767439 | Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | P2 | withdrawn | 0 | Columbia University | Jul 2019 | |
| NCT03575598 | SNOW | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | Early P1 | completed | 10 | University Health Network, Toronto | Aug 2018 |
| NCT03982121 | ISILI | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | P1 | withdrawn | 0 | Gustave Roussy, Cancer Campus, Grand Paris | Jun 2019 |
| NCT03597009 | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | P1/P2 | terminated | 1 | UNC Lineberger Comprehensive Cancer Center | Mar 2019 | |
| NCT02599402 | CheckMate 401 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | P3 | completed | 533 | Bristol-Myers Squibb | Dec 2015 |
| NCT02840994 | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | P1 | completed | 24 | Bavarian Nordic | Dec 2016 | |
| NCT02460068 | NIBIT-M2 | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis | P3 | unknown | 168 | Italian Network for Tumor Biotherapy Foundation | Dec 2012 |
| NCT02750514 | FRACTION-Lung | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | P2 | terminated | 295 | Bristol-Myers Squibb | May 2016 |
| NCT03259529 | BeGeRN | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | P1/P2 | completed | 30 | St. Petersburg State Pavlov Medical University | Mar 2017 |
| NCT03634800 | RISE-M | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) | P2 | terminated | 6 | Weill Medical College of Cornell University | Oct 2018 |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | P1 | terminated | 11 | NYU Langone Health | Apr 2018 | |
| NCT03224871 | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | Early P1 | completed | 3 | University of California, Davis | Aug 2017 | |
| NCT03539198 | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | — | terminated | 19 | Mayo Clinic | Jul 2018 | |
| NCT03048474 | INITIATE | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | P2 | completed | 36 | The Netherlands Cancer Institute | Sep 2016 |
| NCT02529072 | AVERT | Nivolumab With DC Vaccines for Recurrent Brain Tumors | P1 | completed | 6 | Gary Archer Ph.D. | Jan 2016 |
| NCT03343665 | Nivo40 | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma | P1/P2 | completed | 30 | St. Petersburg State Pavlov Medical University | Aug 2017 |
| NCT04007588 | BMS-986205 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | P2 | withdrawn | 0 | Dana-Farber Cancer Institute | Sep 2019 |
| NCT03745807 | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | P1 | completed | 3 | Bristol-Myers Squibb | Apr 2019 | |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | P1/P2 | completed | 295 | Bristol-Myers Squibb | Oct 2015 | |
| NCT01714739 | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | P1/P2 | completed | 337 | Bristol-Myers Squibb | Oct 2012 | |
| NCT03518320 | Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer | P1 | terminated | 13 | Taris Biomedical LLC | Jan 2019 | |
| NCT03363776 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | P1/P2 | terminated | 10 | Bristol-Myers Squibb | Dec 2017 | |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | P2 | terminated | 31 | National Cancer Centre, Singapore | Apr 2017 | |
| NCT02526017 | FPA008-003 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | P1 | completed | 313 | Five Prime Therapeutics, Inc. | Sep 2015 |
| NCT03301636 | NLG2107 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | P2 | terminated | 21 | NewLink Genetics Corporation | Dec 2017 |
| NCT02955251 | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | P1 | completed | 61 | AbbVie | Nov 2016 | |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | P3 | completed | 106 | Bristol-Myers Squibb | Oct 2016 | |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | P1 | terminated | 36 | Gilead Sciences | Sep 2016 | |
| NCT03158272 | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | P1 | completed | 19 | Bristol-Myers Squibb | May 2017 | |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | P3 | completed | 74 | Bristol-Myers Squibb | Dec 2017 | |
| NCT02944396 | NSCLC | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | P1 | completed | 25 | AbbVie | Dec 2016 |
| NCT03048136 | CheckMate 955 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | P3 | withdrawn | 0 | Bristol-Myers Squibb | Mar 2018 |
| NCT03241173 | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | P1/P2 | completed | 52 | Incyte Biosciences International Sàrl | Oct 2017 | |
| NCT04123925 | NICOLE | Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study | P2 | completed | 22 | National Cancer Institute, Naples | Jun 2018 |
| NCT02999295 | A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer | P1/P2 | completed | 46 | National Cancer Center, Japan | Jan 2017 | |
| NCT03316586 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | P2 | completed | 18 | Dana-Farber Cancer Institute | Nov 2017 | |
| NCT02864381 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | completed | 144 | Gilead Sciences | Sep 2016 | |
| NCT03256136 | Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC | P2 | completed | 9 | Massachusetts General Hospital | Nov 2017 | |
| NCT03939975 | Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | P2 | completed | 50 | Sun Yat-sen University | Jun 2019 | |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | P2 | completed | 3 | National Cancer Institute (NCI) | Feb 2017 | |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | P4 | completed | 100 | Bristol-Myers Squibb | Mar 2018 | |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | P2 | terminated | 3 | Fox Chase Cancer Center | Jan 2018 | |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | P1/P2 | terminated | 42 | AbbVie | Mar 2017 | |
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | P1/P2 | completed | 131 | NewLink Genetics Corporation | Jul 2014 | |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | P1 | terminated | 6 | Assistance Publique Hopitaux De Marseille | Jun 2018 | |
| NCT03382886 | NUANCE | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma | P1 | terminated | 1 | University of Utah | Apr 2018 |
| NCT03726281 | Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors | P2 | withdrawn | 0 | Hospital Beatriz Ângelo | Oct 2018 | |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | P2 | withdrawn | 0 | The University of Hong Kong | Jun 2018 | |
| NCT02716272 | MAPS2 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | P2 | completed | 125 | Intergroupe Francophone de Cancerologie Thoracique | Mar 2016 |
| NCT02614456 | Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors | P1 | completed | 26 | Fox Chase Cancer Center | Dec 2015 | |
| NCT02483247 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | P1 | completed | 165 | Sumitomo Pharma America, Inc. | Sep 2015 | |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | P2 | terminated | 5 | ExcellaBio LLC | Feb 2018 | |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | P2 | terminated | 12 | Mayo Clinic | May 2017 | |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | P1/P2 | terminated | 232 | Bristol-Myers Squibb | Sep 2014 | |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | P2 | terminated | 3 | Nasser Hanna, M.D. | Jan 2017 | |
| NCT03119428 | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | P1 | terminated | 33 | OncoMed Pharmaceuticals, Inc. | May 2017 | |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | P1 | terminated | 6 | Vanderbilt-Ingram Cancer Center | Jun 2018 | |
| NCT02775292 | NYM | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | P1 | completed | 1 | Jonsson Comprehensive Cancer Center | Jan 2017 |
| NCT03203304 | SBRT | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | P1 | terminated | 14 | University of Chicago | Aug 2017 |
| NCT03121417 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | P2 | withdrawn | 0 | Emory University | Jul 2017 | |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | P2 | completed | 20 | Parker Institute for Cancer Immunotherapy | Jun 2016 | |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | P2 | terminated | 3 | Northwestern University | Sep 2017 | |
| NCT02941744 | ipniv | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases | P1/P2 | completed | 56 | Universitair Ziekenhuis Brussel | Mar 2016 |
| NCT02599649 | MDS | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | P2 | terminated | 10 | M.D. Anderson Cancer Center | Mar 2016 |
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | P3 | terminated | 20 | RTOG Foundation, Inc. | Oct 2016 | |
| NCT02156804 | BMS-936558 | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | P2 | completed | 1,009 | Bristol-Myers Squibb | Oct 2014 |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | P1 | completed | 35 | Bristol-Myers Squibb | Feb 2014 | |
| NCT03259516 | Nivolumab With Chemotherapy in Refractory MDS | P1/P2 | terminated | 2 | St. Petersburg State Pavlov Medical University | May 2017 | |
| NCT02476123 | KW-0761 | Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors | P1 | completed | 118 | Kyowa Kirin Co., Ltd. | Jun 2015 |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | P1/P2 | completed | 175 | Celldex Therapeutics | Jan 2015 | |
| NCT03192943 | A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors | P1 | completed | 11 | Bristol-Myers Squibb | Jun 2017 | |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | P1 | terminated | 41 | Calithera Biosciences, Inc | Aug 2016 | |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | P2 | terminated | 1 | Yvonne Efebera | Mar 2018 | |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | P2 | terminated | 10 | Northwestern University | Mar 2016 | |
| NCT01621490 | PD-1 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | P1 | completed | 170 | Bristol-Myers Squibb | Sep 2012 |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | P1/P2 | completed | 114 | Kyowa Kirin, Inc. | Feb 2016 | |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | P1/P2 | terminated | 12 | Janssen Research & Development, LLC | Jan 2018 | |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | P2 | terminated | 132 | Celldex Therapeutics | Nov 2014 | |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | P2 | terminated | 16 | St. Petersburg State Pavlov Medical University | Jun 2017 | |
| NCT02864316 | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure | P2 | terminated | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dec 2016 | |
| NCT03132493 | NIVEX | Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient | — | completed | 676 | Spanish Lung Cancer Group | Jun 2017 |
| NCT02309177 | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | P1 | completed | 114 | Celgene | Jan 2015 | |
| NCT02446860 | ADAPTeR | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) | P2 | terminated | 15 | Royal Marsden NHS Foundation Trust | Apr 2015 |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | P1 | terminated | 1 | Northwestern University | Aug 2017 | |
| NCT03351231 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer | P1/P2 | terminated | 7 | Bristol-Myers Squibb | Nov 2017 | |
| NCT02846792 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | P1/P2 | terminated | 5 | University of Washington | Jun 2017 | |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | P1/P2 | terminated | 9 | X4 Pharmaceuticals | Dec 2016 | |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | P1/P2 | completed | 41 | Biogen | Oct 2014 | |
| NCT02142218 | Checkmate 168 | Expanded Access Program With Nivolumab to Treat Melanoma | — | no longer available | 0 | Bristol-Myers Squibb | Jun 2014 |
| NCT02621515 | CA209-322 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases | P2 | terminated | 7 | University Medical Center Groningen | Aug 2016 |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | P3 | terminated | 2 | Incyte Corporation | Dec 2017 | |
| NCT03106610 | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | P1 | terminated | 1 | M.D. Anderson Cancer Center | Jul 2017 | |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | P1 | terminated | 22 | Millennium Pharmaceuticals, Inc. | Jun 2016 | |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Apr 2018 | |
| NCT03342352 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | P3 | withdrawn | 0 | Incyte Corporation | Dec 2017 | |
| NCT03386838 | An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | P3 | withdrawn | 0 | Bristol-Myers Squibb | Mar 2018 | |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | P2 | terminated | 8 | M.D. Anderson Cancer Center | May 2015 | |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | P2 | withdrawn | 0 | Medical University of South Carolina | Apr 2018 | |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | P2 | terminated | 10 | howard safran | Feb 2016 | |
| NCT01998126 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | P1 | completed | 14 | University of Utah | Dec 2013 | |
| NCT03023527 | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | P1 | terminated | 6 | PETHEMA Foundation | Jan 2017 | |
| NCT02967133 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | P2 | terminated | 7 | Alliance Foundation Trials, LLC. | Dec 2016 | |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | P1/P2 | terminated | 25 | Bristol-Myers Squibb | Aug 2016 | |
| NCT02960854 | A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock. | P1 | completed | 38 | Bristol-Myers Squibb | Dec 2016 | |
| NCT02626065 | PAIR | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies | P4 | completed | 32 | Hospices Civils de Lyon | Apr 2015 |
| NCT02423954 | NivoPlus | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | P1/P2 | terminated | 33 | Western Regional Medical Center | Apr 2015 |
| NCT03165409 | Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | — | completed | 1,828 | Bristol-Myers Squibb | Feb 2017 | |
| NCT02991196 | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer | P1 | terminated | 4 | Daiichi Sankyo | Dec 2016 | |
| NCT02860546 | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | P2 | completed | 18 | Taiho Oncology, Inc. | Aug 2016 | |
| NCT02497508 | NivoMes | Nivolumab in Patients With Recurrent Malignant Mesothelioma | P2 | completed | 33 | The Netherlands Cancer Institute | Jul 2015 |
| NCT02243371 | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | P2 | completed | 93 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2015 | |
| NCT03126643 | Expanded Access to Nivolumab (Opdivo) | — | approved for marketing | 0 | Bristol-Myers Squibb | — | |
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | P1 | completed | 1 | Celgene | Sep 2016 | |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | Gradalis, Inc. | Mar 2016 | |
| NCT02550249 | Neo-nivo | Neoadjuvant Nivolumab in Glioblastoma | P2 | completed | 29 | Clinica Universidad de Navarra, Universidad de Navarra | Jun 2015 |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | P1/P2 | withdrawn | 0 | Symphogen A/S | Nov 2016 | |
| NCT02648633 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | P1 | terminated | 4 | University of Virginia | May 2016 | |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | P1/P2 | withdrawn | 0 | University of Pittsburgh | Oct 2016 | |
| NCT02472977 | CXCessoR4 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | P1/P2 | terminated | 61 | Bristol-Myers Squibb | Jul 2015 |
| NCT02950038 | NSCLC | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Dec 2016 |
| NCT02534506 | Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | P1 | completed | 18 | Bristol-Myers Squibb | Nov 2015 | |
| NCT02962804 | RCC | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | P2 | withdrawn | 0 | University of Kansas Medical Center | — |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | P1 | terminated | 18 | Celgene | Oct 2014 | |
| NCT02518958 | PRIMETIME | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | P1 | completed | 12 | EpicentRx, Inc. | Jul 2015 |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | P2 | withdrawn | 0 | California Pacific Medical Center Research Institute | Oct 2014 | |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | P1 | withdrawn | 0 | University of Pittsburgh | Aug 2015 | |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | P2 | completed | 45 | National Cancer Institute (NCI) | Jul 2015 | |
| NCT02475382 | CheckMate 169 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen | — | no longer available | 0 | Bristol-Myers Squibb | — |
| NCT01629758 | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | P1 | completed | 33 | Bristol-Myers Squibb | Jun 2012 | |
| NCT02186249 | CheckMate218 | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | — | no longer available | 0 | Bristol-Myers Squibb | — |
Nivolumab clinical trials: frequently asked questions
- How many Nivolumab clinical trials are there?
- 1624 Nivolumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 266 are actively recruiting participants. 596 are marked completed.
- Are Nivolumab clinical trials recruiting in 2026?
- Yes — 266 Nivolumab trials are actively recruiting in 2026, with 4858 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Nivolumab being studied for?
- Nivolumab is being studied for Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Non Small Cell Lung Cancer and 2364 more. The trials are grouped by indication on this page.
- What phase is Nivolumab in?
- Nivolumab clinical trials span 15 Phase 4, 137 Phase 3, 732 Phase 2, 325 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Nivolumab clinical trials?
- The lead sponsor across the most Nivolumab trials is Bristol-Myers Squibb, with 541 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nivolumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: